pmcid,first_author,title,year,type,sentence,question,answer,abstract_hash
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,- Background: Refractory angina (RA) is a chronic condition characterized by the presence of debilitating angina symptoms due to established reversible ischemia in the presence of obstructive coronary artery disease (CAD).,What is refractory angina characterized by? (pmcid=10982321),Refractory angina is characterized by the presence of debilitating angina symptoms due to established reversible ischemia in the presence of obstructive coronary artery disease (CAD).,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"Treatments for this condition have undergone major developments in recent decades; however, the treatment for RA remains a challenge for medicine.",What major developments have treatments for refractory angina undergone in recent decades? (pmcid=10982321),Treatments for refractory angina have undergone major developments in recent decades.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"In this sense, the Coronary Sinus Reducer System (CSRS) stands as the last line of therapy for ineligible patients for revascularization with reversible ischemia.",What does the Coronary Sinus Reducer System (CSRS) stand as for ineligible patients for revascularization with reversible ischemia? (pmcid=10982321),The Coronary Sinus Reducer System (CSRS) stands as the last line of therapy for ineligible patients for revascularization with reversible ischemia.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,The purpose of this report is to evaluate the potential burden on the National Health Service (NHS) and measure the health effects in terms of both quantity (life years) and quality-of-life aspects related to the reducer.,What is the purpose of the report (pmcid=10982321)?,The purpose of the report is to evaluate the potential burden on the National Health Service (NHS) and measure the health effects in terms of both quantity (life years) and quality-of-life aspects related to the reducer device.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,Methods: Two different economic evaluation models were developed as part of the analysis.,What type of economic evaluation models were developed as part of the analysis (pmcid=10982321)?,Two different economic evaluation models were developed as part of the analysis.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,The budget impact was developed to estimate the potential burden on the NHS from incremental uptake of the use of the reducer in the target population.,What was the purpose of developing the budget impact model in the study (pmcid=10982321)?,The purpose of developing the budget impact model in the study was to estimate the potential burden on the NHS from incremental uptake of the use of the reducer device in patients with refractory angina.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"The utility cost analysis compares and evaluates the quality of life and health resource use and costs between the two alternatives, based on the research of Gallone et al.",What research was the utility cost analysis based on (pmcid=10982321)?,The utility cost analysis was based on the research of Gallone et al.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,A deterministic and probabilistic sensitivity analysis was carried out to characterize the uncertainty around the parameters of the model.,Was a sensitivity analysis carried out to characterize the uncertainty around the parameters of the model (pmcid=10982321)?,Yes.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"Results: In the budget impact analysis (BIA), the reducer is shown to be more expensive in the first 2 years of the model, due to the gradual uptake in the market and the cost of the device.",What is shown to be more expensive in the first 2 years of the model in the budget impact analysis? (pmcid=10982321),The reducer device is shown to be more expensive in the first 2 years of the model in the budget impact analysis.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"Starting from the third year, assuming maintenance of effectiveness, there are savings in terms of resource absorption in direct healthcare costs arising from hospitalizations, emergency department accesses, coronarography, and visits avoided.",What type of costs are saved in terms of resource absorption in direct healthcare costs starting from the third year (pmcid=10982321)?,"Hospitalizations, emergency department accesses, coronarography, and visits",
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"Conclusion: The BIA and cost-effectiveness model show that the reducer device, despite an increase in resources absorbed in the first years of implementation and use, has the potential to result in increased quality of life in patients with RA.",What do the budget impact model and cost-effectiveness model show about the reducer device in patients with refractory angina (pmcid=10982321)?,The budget impact model and cost-effectiveness model show that the reducer device has the potential to result in increased quality of life in patients with refractory angina.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,These costs are largely offset in the short term by the improved clinical outcomes achievable leading to savings from the third year onward in the BIA and a dominance ratio in the cost–utility analysis.,What are the cost savings achieved in the budget impact model for the reducer device in patients with refractory angina (pmcid=10982321)?,"The cost savings achieved in the budget impact model for the reducer device in patients with refractory angina are largely offset in the short term by the improved clinical outcomes achievable, leading to savings from the third year onward.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,- Background: Recent developments improved outcomes in patients with autoimmune diseases.,What recent developments improved outcomes in patients with autoimmune diseases? (pmcid=10169960),Recent developments improved outcomes in patients with autoimmune diseases.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"Biologics were approved as first-line treatment in selected naïve patients with plaque psoriasis (PsO), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).",What were biologics approved as first-line treatment for in selected naïve patients? (pmcid=10169960),"Biologics were approved as first-line treatment for plaque psoriasis (PsO), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA) in selected naïve patients.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"Among them, secukinumab was most recently approved for treatment of active nr-axSpA in adults.",What was secukinumab most recently approved for the treatment of in adults (pmcid=10169960)?,Secukinumab was most recently approved for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adults.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"In this work, we assessed the budget impact of new secukinumab treatment options in the Italian market.",What did the work assess in the Italian market (pmcid=10169960)?,The work assessed the budget impact of new secukinumab treatment options in the Italian market.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,Methods: A cross-indication budget impact model was designed to estimate the effects of adding secukinumab in the Italian market from the National Health System perspective over a 3-year period.,What was the perspective of the budget impact model analysis (pmcid=10169960)?,The perspective of the budget impact model analysis in pmcid 10169960 was from the National Health System perspective.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"The model included all adults with PsO, PsA, AS and nr-axSpA, treated with biologics or biosimilars.",Who were included in the model for the budget impact analysis (pmcid=10169960)?,"All adults with Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis, treated with biologics or biosimilars.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"It compared costs between two scenarios, secukinumab availability or absence, for the four diseases combined and taken individually.",What costs were compared in the study for the four diseases combined and taken individually (pmcid=10169960)?,"The study compared costs between two scenarios, secukinumab availability or absence, for the four diseases combined and taken individually.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,A sensitivity analyses was conducted.,Was a sensitivity analysis conducted (pmcid=10169960)?,Yes.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"Results: There were 68,121 adult patients treated with biologics in 2021 and 68,341 in 2023.",How many adult patients were treated with biologics in 2021 and 2023? (pmcid=10169960),"68,121 adult patients were treated with biologics in 2021 and 68,341 in 2023.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,The budget impact analysis (BIA) on all indications showed a cost reduction of €33.7 million (− 1.5%) over 3 years with the introduction of secukinumab.,What cost reduction was observed over 3 years with the introduction of secukinumab in the budget impact analysis (pmcid=10169960)?,€33.7 million,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"PsA patients had the highest saving (− €34.9 million), followed by PsO patients (− €7.8 million).",How much savings did PsA patients have in the study conducted by Cortesi PA? (pmcid=10169960),PsA patients had a savings of €34.9 million in the study conducted by Cortesi PA.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,Cost saving in PsO patients was balanced by increased budget reported in AS patients (+ €8.0 million).,How was the budget impact of Secukinumab in Italy distributed among Psoriasis and Ankylosing Spondylitis patients (pmcid=10169960)?,"The budget impact of Secukinumab in Italy was distributed as cost saving in Psoriasis patients and an increased budget in Ankylosing Spondylitis patients. Specifically, there was a cost saving of €8.0 million in Psoriasis patients, while there was an increased budget of €8.0 million in Ankylosing Spondylitis patients.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"In nr-axSpA patients, secukinumab reported no significant budget increase (+ 1.0%).",What was the budget increase reported for secukinumab in nr-axSpA patients (pmcid=10169960)?,"In nr-axSpA patients, secukinumab reported no significant budget increase (+ 1.0%).",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"Conclusion: This BIA accounted for the new indication of secukinumab in nr-axSpA patients, reporting no significant changes in the required budget and adding an effective treatment option.",What indication of secukinumab was accounted for in the budget impact model (pmcid=10169960)?,The budget impact model accounted for the new indication of secukinumab in non-radiographic axial spondyloarthritis (nr-axSpA) patients.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"Considering all indications, secukinumab is a sustainable treatment option.",Is secukinumab considered a sustainable treatment option for all indications (pmcid=10169960)?,"Yes, considering all indications, secukinumab is considered a sustainable treatment option according to the information provided in the context.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,Supplementary Information: The online version contains supplementary material available at 10.1007/s41669-023-00404-3.,What supplementary material is available in the online version of the article (pmcid=10169960)?,"The supplementary material available in the online version of the article with pmcid 10169960 includes additional information related to the budget impact model of Secukinumab for the treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis in Italy.",
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,- Aims:: The budgetary consequences of increasing dronedarone utilization for treatment of atrial fibrillation were evaluated from a US payer perspective.,What were the budgetary consequences evaluated in the study (pmcid=10402749)?,The budgetary consequences evaluated in the study were the increasing utilization of dronedarone for the treatment of atrial fibrillation from a US payer perspective.,
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,"Materials & methods:: A budget impact model over a 5-year time horizon was developed, including drug-related costs and risks for long-term clinical outcomes (LTCOs).",What time horizon was considered in the budget impact model developed for dronedarone compared with other rhythm control strategies (pmcid=10402749)?,The budget impact model considered a 5-year time horizon.,
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,"Treatments included antiarrhythmic drugs (AADs; dronedarone, amiodarone, sotalol, propafenone, dofetilide, flecainide), rate control medications, and ablation.",What treatments were included in the study (pmcid=10402749)?,"The treatments included in the study were antiarrhythmic drugs (AADs) such as dronedarone, amiodarone, sotalol, propafenone, dofetilide, and flecainide, as well as rate control medications and ablation.",
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,Direct comparisons and temporal and non-temporal combination scenarios investigating treatment order were analyzed as costs per patient per month (PPPM).,What was analyzed as costs per patient per month in the study (pmcid=10402749)?,Direct comparisons and temporal and non-temporal combination scenarios were analyzed as costs per patient per month (PPPM) in the study.,
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,"Results:: By projected year 5, costs PPPM for dronedarone versus other AADs decreased by $37.69 due to fewer LTCOs, treatment with dronedarone versus ablation or rate control medications + ablation resulted in cost savings ($359.94 and $370.54, respectively), and AADs placed before ablation decreased PPPM costs by $242 compared with ablation before AADs.",What were the projected cost savings for treatment with dronedarone versus ablation or rate control medications + ablation by year 5 (pmcid=10402749)?,"By year 5, the projected cost savings for treatment with dronedarone versus ablation or rate control medications + ablation were $359.94 and $370.54, respectively.",
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,Conclusion:: Increased dronedarone utilization demonstrated incremental cost reductions over time.,Did increased dronedarone utilization result in incremental cost reductions over time (pmcid=10402749)?,"Yes, increased dronedarone utilization resulted in incremental cost reductions over time according to the study with pmcid=10402749.",
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,"- Background and Objective: In Germany, influenza vaccination is mainly advised for persons aged 60 years and over and individuals with health risks.",What age group is influenza vaccination mainly advised for in Germany (pmcid=10570167)?,"In Germany, influenza vaccination is mainly advised for persons aged 60 years and over.",
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,"Since 2021, an inactivated, quadrivalent high-dose influenza vaccine (IIV4-HD) has been recommended for persons aged 60 years and over.",What vaccine has been recommended for persons aged 60 years and over since 2021 (pmcid=10570167)?,"An inactivated, quadrivalent high-dose influenza vaccine (IIV4-HD)",
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,The aim of this study was to calculate the impact of vaccinating the German population aged 60 years and over with IIV4-HD compared to standard-dose influenza vaccines (IIV4-SD) with regard to health outcomes and costs.,What was the aim of this study (pmcid=10570167)?,The aim of the study with pmcid=10570167 was to calculate the impact of vaccinating the German population aged 60 years and over with a Quadrivalent High-Dose Inactivated Influenza Vaccine (IIV4-HD) compared to standard-dose influenza vaccines (IIV4-SD) with regard to health outcomes and costs.,
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Methods: An age-stratified deterministic compartment model was built to simulate the course of influenza infection for the German population in the season 2019/20.,What season was simulated in the age-stratified deterministic compartment model for the German population? (pmcid=10570167),The season simulated in the age-stratified deterministic compartment model for the German population was the season 2019/20.,
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Probabilities for health outcomes and cost data were searched from the literature and were used to compare the influenza-related health and economic effects for different scenarios.,What were the probabilities for health outcomes and cost data used for in the study (pmcid=10570167)?,The probabilities for health outcomes and cost data were used to compare the influenza-related health and economic effects for different scenarios in the study with pmcid=10570167.,
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Perspectives were those of the statutory health insurance and the society.,What were the perspectives considered in the study (pmcid=10570167)?,The perspectives considered in the study were those of the statutory health insurance and the society.,
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Deterministic sensitivity analyses were conducted.,Were deterministic sensitivity analyses conducted in the study? (pmcid=10570167),"Yes, deterministic sensitivity analyses were conducted in the study.",
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,"Results: From the statutory health insurance perspective, vaccinating the German population aged 60 years and over with IIV4-HD would have prevented 277,026 infections (− 1.1%) with an increase of overall direct costs of €224 million (+ 40.1%) compared with IIV4-SD.","How many infections would have been prevented by vaccinating the German population aged 60 years and over with IIV4-HD compared to IIV4-SD, from the statutory health insurance perspective? (pmcid=10570167)","277,026 infections",
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,"A separate analysis showed that increased vaccination of 75% (World Health Organization recommendation for older age groups) in persons aged 60 years and over using IIV4-SD only would prevent 1,289,648 infections (− 5.1%) and would save costs from a statutory health insurance perspective of €103 million (− 13.2%) compared with IIV4-HD at actual vaccination rates.",How many infections would be prevented by increased vaccination of 75% in persons aged 60 years and over using IIV4-SD only? (pmcid=10570167),"1,289,648 infections",
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Conclusions: The modeling approach offers important insights into the epidemiological and budgetary impact of different vaccination scenarios.,What insights does the modeling approach offer into the epidemiological and budgetary impact of different vaccination scenarios? (pmcid=10570167),The modeling approach offers important insights into the epidemiological and budgetary impact of different vaccination scenarios.,
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Achieving a higher vaccination coverage with IIV4-SD in persons aged 60 years and over would result in lower costs and fewer influenza infections compared with the scenario with IIV4-HD and actual vaccination rates.,What would be the result of achieving a higher vaccination coverage with IIV4-SD in persons aged 60 years and over compared to the scenario with IIV4-HD and actual vaccination rates (pmcid=10570167)?,Lower costs and fewer influenza infections,
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Supplementary Information: The online version contains supplementary material available at 10.1007/s40273-023-01299-y.,What supplementary material is available in the online version of the article (pmcid=10570167)?,"The supplementary material available in the online version of the article with pmcid=10570167 includes additional information related to the study, such as data, tables, figures, or additional analysis.",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"- Background: In South Africa, diabetes prevalence is expected to reach 5.4 million by 2030.",What is the expected diabetes prevalence in South Africa by 2030 (pmcid=10442735)?,The expected diabetes prevalence in South Africa by 2030 is 5.4 million.,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"In South Africa, diabetes-related complications severely impact not only patient health and quality of life but also the economy.",How do diabetes-related complications impact both patient health and the economy in South Africa (pmcid=10442735)?,"Diabetes-related complications in South Africa severely impact both patient health and quality of life, as well as the economy.",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,Objective: The Diabetes Nurse Educator (DNE) study assessed the benefit of adding the MyDiaCare program to standard of care for managing patients with type 1 and type 2 diabetes in South Africa.,What benefit did the Diabetes Nurse Educator (DNE) study assess by adding the MyDiaCare program to standard of care for managing patients with type 1 and type 2 diabetes in South Africa (pmcid: 10442735)?,The Diabetes Nurse Educator (DNE) study assessed the benefit of adding the MyDiaCare program to standard of care for managing patients with type 1 and type 2 diabetes in South Africa.,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,An economic study was also performed to estimate the budget impact of adding MyDiaCare to standard of care for patients with type 2 diabetes older than 19 years treated in the South African private health care sector.,What was the purpose of the economic study conducted in the South African private health care sector (pmcid=10442735)?,The purpose of the economic study conducted in the South African private health care sector was to estimate the budget impact of adding MyDiaCare to the standard of care for patients with type 2 diabetes older than 19 years.,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Methods: The real-world DNE study was designed as an observational, retrospective, multicenter, single-group study.",What type of study design was used in the real-world DNE study (pmcid=10442735)?,"The real-world DNE study used an observational, retrospective, multicenter, single-group study design.",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,Eligible patients were older than 18 years and had at least 6 months of participation in the MyDiaCare program.,How long did eligible patients have to participate in the MyDiaCare program? (pmcid=10442735),Eligible patients had to have at least 6 months of participation in the MyDiaCare program.,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,The MyDiaCare program combines a patient mobile app and a health care professional platform with face-to-face visits with a DNE.,What does the MyDiaCare program combine according to the abstract sentence? (pmcid=10442735),The MyDiaCare program combines a patient mobile app and a health care professional platform with face-to-face visits with a Diabetes Nurse Educator (DNE).,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"The benefit of MyDiaCare was assessed by the changes in glycated hemoglobin (HbA1c) levels, the proportion of patients achieving clinical and biological targets, adherence to care plans, and satisfaction after 6 months of participating in the MyDiaCare program.",What was assessed to determine the benefit of MyDiaCare after 6 months of participation in the program (pmcid=10442735)?,"The benefit of MyDiaCare was assessed by the changes in glycated hemoglobin (HbA1c) levels, the proportion of patients achieving clinical and biological targets, adherence to care plans, and satisfaction after 6 months of participating in the MyDiaCare program.",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,A budget impact model was performed using data from the DNE study and another South African cohort of the DISCOVERY study to estimate the economic impact of MyDiaCare.,What data was used to estimate the economic impact of MyDiaCare in the budget impact model (pmcid=10442735)?,Data from the DNE study and another South African cohort of the DISCOVERY study was used to estimate the economic impact of MyDiaCare in the budget impact model.,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Results: Between November 25, 2019, and June 30, 2020, a total of 117 patients (8 with type 1 diabetes and 109 with type 2 diabetes) were enrolled in 2 centers.","How many patients were enrolled in the study between November 25, 2019, and June 30, 2020 (pmcid=10442735)?","117 patients were enrolled in the study between November 25, 2019, and June 30, 2020 (pmcid=10442735).",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"After 6 months of MyDiaCare, a clinically relevant decrease in mean HbA1c levels of 0.6% from 7.8% to 7.2% was observed.",What was the observed decrease in mean HbA1c levels after 6 months of MyDiaCare (pmcid=10442735)?,0.6%,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Furthermore, 54% (43/79) of patients reached or maintained their HbA1c targets at 6 months.",Did 54% of patients reach or maintain their HbA1c targets at 6 months (pmcid=10442735)?,"Yes, 54% of patients reached or maintained their HbA1c targets at 6 months according to the information provided in the context.",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Most patients achieved their targets for blood pressure (53/79, 67% for systolic and 70/79, 89% for diastolic blood pressure) and lipid parameters (49/71, 69% for low-density-lipoprotein [LDL] cholesterol, 41/71, 58% for high-density-lipoprotein [HDL] cholesterol, and 59/71, 83% for total cholesterol), but fewer patients achieved their targets for triglycerides (32/70, 46%), waist circumference (12/68, 18%), and body weight (13/76, 17%).",What percentage of patients achieved their target for low-density-lipoprotein (LDL) cholesterol in the study (pmcid=10442735)?,69%,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,The mean overall adherence to the MyDiaCare care plan was 93%.,What was the mean overall adherence to the MyDiaCare care plan? (pmcid=10442735),The mean overall adherence to the MyDiaCare care plan was 93%.,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Most patients (87/117, 74%) were satisfied with the MyDiaCare program.",Were most patients satisfied with the MyDiaCare program (pmcid=10442735)?,"Yes, most patients (74%) were satisfied with the MyDiaCare program according to the study associated with pmcid=10442735.",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"The net budget impact per patient with type 2 diabetes, older than 19 years, treated in the private sector using MyDiaCare was estimated to be approximately South African Rands (ZAR) 71,023 (US $4089) during the first year of introducing MyDiaCare.","What was the estimated net budget impact per patient with type 2 diabetes, older than 19 years, treated in the private sector using MyDiaCare during the first year of introducing MyDiaCare? (pmcid: 10442735)","The estimated net budget impact per patient with type 2 diabetes, older than 19 years, treated in the private sector using MyDiaCare during the first year of introducing MyDiaCare was approximately South African Rands (ZAR) 71,023 (US $4089).",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Conclusions: The results of using MyDiaCare program, which combines digital tools for patients and health care professionals with DNE support, suggest that it may be a clinically effective and cost-saving solution for diabetes management in the South African private health care sector.",Was the MyDiaCare program found to be a cost-saving solution for diabetes management in the South African private health care sector (pmcid=10442735)?,"Yes, the MyDiaCare program was found to be a cost-saving solution for diabetes management in the South African private health care sector, according to the study associated with pmcid 10442735.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"- Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, progressive autoimmune disease causing peripheral nervous system dysfunction.",What is chronic inflammatory demyelinating polyneuropathy (CIDP) and what does it cause? (pmcid=9910243),"Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, progressive autoimmune disease that causes peripheral nervous system dysfunction.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Guidelines recommend immunoglobulin (IG) therapy as an immunomodulatory agent in CIDP.,What do guidelines recommend as an immunomodulatory agent in CIDP? (pmcid=9910243),Immunoglobulin (IG) therapy,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Drawbacks and unmet needs with intravenous immunoglobulin (IVIG) include adverse effects and wear-off effects, along with the burden of administration based on site of care.",What are some drawbacks and unmet needs associated with intravenous immunoglobulin (IVIG) (pmcid=9910243)?,"Some drawbacks and unmet needs associated with intravenous immunoglobulin (IVIG) include adverse effects, wear-off effects, and the burden of administration based on site of care.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Subcutaneous administration of Hizentra, a subcutaneous immunoglobulin (SCIG) reduces patient burden by allowing self-administration outside the hospital setting and has fewer adverse events (AEs).",How does subcutaneous administration of Hizentra reduce patient burden and adverse events? (pmcid=9910243),Subcutaneous administration of Hizentra reduces patient burden by allowing self-administration outside the hospital setting and has fewer adverse events (AEs).,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Objective: We aimed to compare the expected cost of treatment and the budget impact of Hizentra compared with IVIG for maintenance treatment of CIDP in the United States.,What was the objective of the study comparing Hizentra with IVIG for maintenance treatment of CIDP in the United States? (pmcid=9910243),The objective of the study was to compare the expected cost of treatment and the budget impact of Hizentra compared with IVIG for maintenance treatment of CIDP in the United States.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Methods: A decision tree model was developed to estimate the expected budget impact of maintenance treatment with Hizentra for US stakeholders.,What type of model was developed to estimate the expected budget impact of maintenance treatment with Hizentra for US stakeholders? (pmcid=9910243),A decision tree model was developed.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"The model adopts primarily a US integrated delivery network perspective and, secondarily, a commercial perspective over a 1-year time horizon.",What perspective does the budget impact model of maintenance treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) adopt primarily (pmcid=9910243)?,The budget impact model primarily adopts a US integrated delivery network perspective.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Pharmacy costs were based on a payment mix of average sales price (73%), wholesale acquisition cost (2%), and average wholesale price (25%).",What were the pharmacy costs based on in the budget impact model for maintenance treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) relative to Intravenous Immunoglobulin in the United States (pmcid=9910243)?,"The pharmacy costs were based on a payment mix of average sales price (73%), wholesale acquisition cost (2%), and average wholesale price (25%).",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Costs in the model reflect 2022 US dollars.,What do the costs in the model reflect (pmcid=9910243)?,Costs in the model reflect 2022 US dollars.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"In accordance with the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines and recommendations for budget impact modeling, no discounting was performed.",Was discounting performed in accordance with ISPOR guidelines and recommendations for budget impact modeling (pmcid=9910243)?,"No, discounting was not performed in accordance with ISPOR guidelines and recommendations for budget impact modeling in the study with pmcid=9910243.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,The PATH clinical study of Hizentra maintenance in CIDP was used to determine clinical inputs for relapse rates at initial assessment (24 weeks) and at 52 weeks for Hizentra.,What clinical study was used to determine relapse rates for Hizentra maintenance in CIDP (pmcid=9910243)?,The PATH clinical study was used to determine relapse rates for Hizentra maintenance in CIDP.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,The ICE clinical study of Gamunex maintenance in CIDP was the basis of relapse rates for Gamunex (and other IVIGs).,What was the basis of relapse rates for Gamunex (and other IVIGs) in the ICE clinical study? (pmcid=9910243),The basis of relapse rates for Gamunex (and other IVIGs) in the ICE clinical study was the Gamunex maintenance in CIDP.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Literature-based estimates were obtained for infusion costs by site of care, costs of IVIG infusion-related complications, and significant IVIG AE rates.","What estimates were obtained for infusion costs, costs of IVIG infusion-related complications, and significant IVIG AE rates? (pmcid=9910243)","Literature-based estimates were obtained for infusion costs by site of care, costs of IVIG infusion-related complications, and significant IVIG AE rates.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Hizentra AE rates from the US Hizentra prescribing information were assessed but were not included in the model as the AEs in CIDP were mild, easily treated, and self-limited.",What were the adverse event rates for Hizentra assessed in the model (pmcid=9910243)?,"The adverse event rates for Hizentra were assessed from the US Hizentra prescribing information, but they were not included in the model as the adverse events in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) were mild, easily treated, and self-limited.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Sensitivity analyses and scenario analyses were conducted to evaluate variations from the base case.,What type of analyses were conducted to evaluate variations from the base case in the study (pmcid=9910243)?,Sensitivity analyses and scenario analyses were conducted to evaluate variations from the base case in the study (pmcid=9910243).,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Results: The model showed that a Hizentra starting dose of 0.2 g/kg is expected to result in annual cost savings of US$32,447 per patient compared with IVIG.",What are the expected annual cost savings per patient with Hizentra compared to IVIG? (pmcid=9910243),"The expected annual cost savings per patient with Hizentra compared to IVIG is US$32,447.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"For a hypothetical 25-million-member plan, the budget impact of a 10% market share shift from IVIG to Hizentra is expected to result in savings of US$2,296,235.",What is the expected savings for a hypothetical 25-million-member plan with a 10% market share shift from IVIG to Hizentra? (pmcid=9910243),"The expected savings for a hypothetical 25-million-member plan with a 10% market share shift from IVIG to Hizentra is US$2,296,235.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Conclusion: This analysis projects that Hizentra is likely associated with favorable economic benefit compared with IVIG in managing CIDP.,What economic benefit is projected for Hizentra compared to IVIG in managing CIDP? (pmcid=9910243),Hizentra is likely associated with favorable economic benefit compared with IVIG in managing CIDP.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Supplementary Information: The online version contains supplementary material available at 10.1007/s41669-023-00386-2.,What supplementary material is available in the online version of the article (pmcid=9910243)?,The supplementary material available in the online version of the article with pmcid=9910243 includes additional information related to the budget impact model of maintenance treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) relative to Intravenous Immunoglobulin in the United States.,
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,- Purpose: Serum or urine protein electrophoresis (SPEP or UPEP) and immunofixation electrophoresis (SIFE or UIFE) are routinely used to detect M-proteins in MM patients.,What are the routine tests used to detect M-proteins in MM patients (pmcid=11849414)?,Serum or urine protein electrophoresis (SPEP or UPEP) and immunofixation electrophoresis (SIFE or UIFE),4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"However, SPEP and SIFE are not sensitive enough to measure M-protein levels that are low but still clinically significant.",What is the limitation of SPEP and SIFE in measuring M-protein levels (pmcid=11849414)?,The limitation of SPEP and SIFE in measuring M-protein levels is that they are not sensitive enough to measure M-protein levels that are low but still clinically significant.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"This study aimed to evaluate the potential cost savings associated with using the EXENT GAM Assay, a serum-based quantitative-immunoprecipitation mass spectrometry (QIP-MS) diagnostic test instead of SIFE to guide the timing of minimal residual disease (MRD) testing for patients with multiple myeloma (MM).",What diagnostic test was evaluated in the study (pmcid=11849414)?,"The EXENT GAM Assay, a serum-based quantitative-immunoprecipitation mass spectrometry (QIP-MS) diagnostic test.",4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,Patients and Methods: A simple 2-year budget impact model was created in Excel using data from MM clinical trials and fee schedules.,What data was used to create the budget impact model in Excel (pmcid=11849414)?,Data from MM clinical trials and fee schedules.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,Patients are tested with either QIP-MS or SIFE at predetermined timepoints.,What are patients tested with at predetermined timepoints in the study (pmcid=11849414)?,Patients are tested with either QIP-MS or SIFE at predetermined timepoints.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"If patients test negative, they will receive MRD testing.",What will patients receive if they test negative? (pmcid=11849414),Patients will receive MRD testing.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,The result of the MRD test will determine if the preceding serum-based test was a true negative result (MRD test is negative) or a false negative result (MRD test is positive).,What will the result of the MRD test determine (pmcid=11849414)?,The result of the MRD test will determine if the preceding serum-based test was a true negative result or a false negative result.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,Patients receiving autologous stem cell transplant (henceforth referred to as transplant) and those not receiving transplant are both eligible for one MRD test per year.,What are the eligibility criteria for patients to receive one MRD test per year (pmcid=11849414)?,Patients receiving autologous stem cell transplant and those not receiving transplant are both eligible for one MRD test per year.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,MRD testing for transplant-eligible patients occurs prior to transplant and one year following transplant.,When does MRD testing occur for transplant-eligible patients (pmcid=11849414)?,MRD testing for transplant-eligible patients occurs prior to transplant and one year following transplant.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"Results: Across a hypothetical population of 5154 mm patients receiving 1st-line treatment in France, using QIP-MS instead of SIFE prior to MRD testing leads to 1973 fewer false negative results and 744 more false positive results (due, in part, to the detection of residual IgG).",What is the hypothetical population size of multiple myeloma patients receiving 1st-line treatment in France in the study (pmcid=11849414)?,The hypothetical population size of multiple myeloma patients receiving 1st-line treatment in France in the study (pmcid=11849414) is 5154.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"Net savings per QIP-MS test would be €260 or total savings of €2,481,832.",What are the total savings per QIP-MS test according to the abstract sentence provided (pmcid=11849414)?,The total savings per QIP-MS test according to the abstract sentence provided is €260.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,Conclusion: This study suggests that the use of QIP-MS prior to MRD testing may be cost-saving for testing French patients with MM.,What does this study suggest about the use of QIP-MS prior to MRD testing for French patients with MM (pmcid=11849414)?,This study suggests that the use of QIP-MS prior to MRD testing may be cost-saving for testing French patients with MM.,4ae7b04289a67daab4a015e7c41bacf7
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,- Background: Low-dose aspirin and rivaroxaban are the cornerstone treatment for cardiovascular prevention in patients with peripheral artery disease (PAD) and/or stable coronary artery disease (SCAD).,What are the cornerstone treatments for cardiovascular prevention in patients with peripheral artery disease (PAD) and/or stable coronary artery disease (SCAD) according to the abstract sentence provided (pmcid=11871816)?,Low-dose aspirin and rivaroxaban,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,The combination of rivaroxaban with aspirin imposes a synergistic effect on the inhibition of factor-induced platelet aggregation.,What effect does the combination of rivaroxaban with aspirin have on factor-induced platelet aggregation (pmcid=11871816)?,The combination of rivaroxaban with aspirin imposes a synergistic effect on the inhibition of factor-induced platelet aggregation.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"The present work aimed at comparing the cost-utility and cost-effectiveness of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban alone (5 mg twice daily) with aspirin alone in patients with peripheral artery disease (PAD) or coronary artery disease (CAD) and related subgroups.",What was the aim of the present work (pmcid=11871816)?,"The aim of the present work was to compare the cost-utility and cost-effectiveness of rivaroxaban plus aspirin, rivaroxaban alone, and aspirin alone in patients with peripheral artery disease or coronary artery disease and related subgroups.",ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,Methods: This pharmacoeconomic study was performed based on the insurance organization and utilized a state-transition decision Markov model.,What type of model was utilized in this pharmacoeconomic study (pmcid=11871816)?,State-transition decision Markov model,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"From the COMPASS trial, Clinical efficacy and Clinical events were collected.",What data was collected from the COMPASS trial (pmcid=11871816)?,Clinical efficacy and Clinical events were collected from the COMPASS trial.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,Health outcomes and cost were assessed over a 20-year time horizon (lifetime).,What time horizon was used to assess health outcomes and cost in the study (pmcid=11871816)?,Health outcomes and cost were assessed over a 20-year time horizon (lifetime).,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,The direct costs of medical services were included in the analysis.,What costs were included in the analysis (pmcid=11871816)?,The direct costs of medical services were included in the analysis.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,The results were stated based on Incremental Cost-Utility (ICUR) and Incremental Cost Effectiveness Ratio (ICER).,What were the results based on in the study conducted by Goudarzi Z (pmcid=11871816)?,The results were based on Incremental Cost-Utility (ICUR) and Incremental Cost Effectiveness Ratio (ICER) in the study conducted by Goudarzi Z.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,Uncertainty was assessed utilizing deterministic and probabilistic sensitivity analyses.,What type of sensitivity analyses were utilized to assess uncertainty in the study (pmcid=11871816)?,Deterministic and probabilistic sensitivity analyses were utilized to assess uncertainty in the study (pmcid=11871816).,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"Discount rates of .058 and .03 were included for cost and effectiveness data, respectively.",What discount rates were included for cost and effectiveness data in the analysis (pmcid=11871816)?,Discount rates of .058 and .03 were included for cost and effectiveness data in the analysis (pmcid=11871816).,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,The budget impact based on the Markov model was estimated as the financial burden resulting from the insurance coverage of rivaroxaban.,What was estimated as the financial burden resulting from the insurance coverage of rivaroxaban (pmcid=11871816)?,The budget impact based on the Markov model was estimated as the financial burden resulting from the insurance coverage of rivaroxaban.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"Results: In the total of CAD and PAD patients, treatment with rivaroxaban plus aspirin and rivaroxaban alone were more expensive than the aspirin alone, but also more effective, resulting in ICUR being $4594/QALY and $13601/QALY respectively, and for ICER being $3348/LYG and $9901/LYG.",What were the incremental cost-effectiveness ratios for treatment with rivaroxaban plus aspirin and rivaroxaban alone compared to aspirin alone in patients with coronary and peripheral artery diseases (pmcid=11871816)?,"The incremental cost-effectiveness ratios for treatment with rivaroxaban plus aspirin compared to aspirin alone were $4594 per quality-adjusted life year (QALY) and $3348 per life year gained (LYG). For treatment with rivaroxaban alone compared to aspirin alone, the incremental cost-effectiveness ratios were $13601 per QALY and $9901 per LYG.",ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,In PAD patients rivaroxaban plus aspirin had higher effectiveness than aspirin alone that ICUR and ICER being $11929/QALY and $9896/LYG respectively.,What were the incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) values for rivaroxaban plus aspirin compared to aspirin alone in PAD patients (pmcid=11871816)?,The incremental cost-effectiveness ratio (ICER) was $9896/LYG and the incremental cost-utility ratio (ICUR) was $11929/QALY for rivaroxaban plus aspirin compared to aspirin alone in PAD patients.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"In CAD patients, treatment with rivaroxaban plus aspirin was expensive and less effective than aspirin alone.",What was the cost-effectiveness and budget impact analysis comparing rivaroxaban with or without aspirin to aspirin alone in patients with coronary and peripheral artery diseases in Iran (pmcid=11871816)?,The cost-effectiveness and budget impact analysis comparing rivaroxaban with or without aspirin to aspirin alone in patients with coronary and peripheral artery diseases in Iran found that treatment with rivaroxaban plus aspirin was expensive and less effective than aspirin alone.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"The estimated annual budget impact was $28,253,135 for the rivaroxaban plus aspirin and $292,593,909 for the rivaroxaban alone in the total of CAD and PAD patients.",What were the estimated annual budget impacts for rivaroxaban plus aspirin and rivaroxaban alone in patients with coronary and peripheral artery diseases in Iran (pmcid=11871816)?,"The estimated annual budget impact was $28,253,135 for rivaroxaban plus aspirin and $292,593,909 for rivaroxaban alone in patients with coronary and peripheral artery diseases in Iran.",ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,Conclusions: This study showed that rivaroxaban plus aspirin is a cost-effective alternative in PAD and total of CAD and PAD patients.,What did this study show about the cost-effectiveness of rivaroxaban plus aspirin in patients with coronary and peripheral artery diseases (pmcid=11871816)?,This study showed that rivaroxaban plus aspirin is a cost-effective alternative in patients with peripheral artery disease (PAD) and in the total of patients with coronary artery disease (CAD) and PAD.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"In CAD patients, rivaroxaban plus aspirin and rivaroxaban alone were not cost-effective.",Was rivaroxaban plus aspirin or rivaroxaban alone cost-effective in CAD patients? (pmcid=11871816),"In CAD patients, rivaroxaban plus aspirin and rivaroxaban alone were not cost-effective.",ddc198ccb56f3d98e6906adc3f6f99cf
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"- Background: Lennox-Gastaut syndrome (LGS) is a severe encephalopathic disease that leads to a decrease in the quality of life, physical injury, psychosocial impairment, and a significant increase in treatment costs.",What is the background information provided in the abstract regarding Lennox-Gastaut syndrome (LGS) (pmcid=11881394)?,"The background information provided in the abstract regarding Lennox-Gastaut syndrome (LGS) is that it is a severe encephalopathic disease that leads to a decrease in the quality of life, physical injury, psychosocial impairment, and a significant increase in treatment costs.",f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,Cannabidiol (CBD) is approved for the adjunctive treatment of tonic-colonic seizures in LGS.,What is cannabidiol approved for in the adjunctive treatment of Lennox Gastaut syndrome (pmcid=11881394)?,Cannabidiol (CBD) is approved for the adjunctive treatment of tonic-colonic seizures in Lennox Gastaut syndrome (LGS).,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,This study aimed to determine the cost-effectiveness of CBD compared to the usual treatment in patients with LGS syndrome.,What did the study aim to determine in patients with Lennox Gastaut syndrome (pmcid=11881394)?,The study aimed to determine the cost-effectiveness of cannabidiol (CBD) compared to the usual treatment in patients with Lennox Gastaut syndrome.,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,Methods: We developed a lifetime-horizon Markov model to compare the cost-effectiveness of adjunctive CBD versus usual care.,What type of model was developed to compare the cost-effectiveness of adjunctive CBD versus usual care (pmcid=11881394)?,Markov model,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"Additionally, we performed a budget impact analysis over a 5-year time horizon.",What type of analysis was performed over a 5-year time horizon (pmcid=11881394)?,Budget impact analysis,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"The findings were presented as the incremental cost-effectiveness ratio (ICER) for CEA, with a willingness to pay threshold of $18,261 per QALY gained, and as the difference in the overall budget ($) between the scenarios with and without CBD for budget impact assessment.",What was the incremental cost-effectiveness ratio (ICER) calculated for in this study (pmcid=11881394)?,The incremental cost-effectiveness ratio (ICER) was calculated for cost-effectiveness analysis (CEA) in this study (pmcid=11881394).,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"Results: In the base case scenario, CBD was cost-effective compared with usual care $6573 per QALY.",What was the cost-effectiveness of cannabidiol compared to usual care in the base case scenario (pmcid=11881394)?,"In the base case scenario, cannabidiol (CBD) was cost-effective compared to usual care at $6573 per QALY.",f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,Sensitivity analyses substantiated these results.,What did the sensitivity analyses substantiate in the study on the value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome (pmcid=11881394)?,The sensitivity analyses substantiated the results of the study on the value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome.,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"From a healthcare perspective, there is a 77% probability that CBD is cost-effective at a willingness to pay of $18,261 per quality-adjusted life-year (QALY).","What is the probability that CBD is cost-effective at a willingness to pay of $18,261 per quality-adjusted life-year, from a healthcare perspective (pmcid=11881394)?",77%,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"Overall, the market access of CBD was associated to an increased budget of about $3,459,846 (+ 33%) in the next 5 years simulated.",What was the increased budget associated with the market access of CBD in the next 5 years simulated (pmcid=11881394)?,"The increased budget associated with the market access of CBD in the next 5 years simulated was about $3,459,846 (+33%).",f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"Conclusions: Compared to usual care, CBD seems to be cost-effective in LGS patients and sustainable, with less than 34% overall budget increased in the next 5 years.",What is the overall budget increase expected in the next 5 years when comparing CBD to usual care in LGS patients (pmcid=11881394)?,Less than 34% overall budget increase,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,Future studies need to confirm our results in the real word setting and in other countries.,What do future studies need to confirm in the real world setting and in other countries (pmcid=11881394)?,Future studies need to confirm the value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome in the real world setting and in other countries.,f72ca8a5314e56cf03a3e5f7079df43c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"- Background: Retinal diseases are major contributors to disability, significantly affecting patients’ quality of life.",What are major contributors to disability according to the abstract sentence provided (pmcid=11884430)?,Retinal diseases,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) represent a significant disease and economic burden in Colombia.,What represents a significant disease and economic burden in Colombia (pmcid=11884430)?,Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD),b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Assessing the economic evaluation of available treatments is essential for the efficient allocation of healthcare resources.,What is essential for the efficient allocation of healthcare resources (pmcid=11884430)?,Assessing the economic evaluation of available treatments is essential for the efficient allocation of healthcare resources.,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Objective: To estimate the cost-effectiveness and budget impact of using faricimab for the treatment of patients with DME and nAMD within the Colombian health system.,What is the objective of the study conducted by Samacá-Samacá D regarding the use of faricimab in the treatment of patients with DME and nAMD in Colombia (pmcid=11884430)?,The objective of the study conducted by Samacá-Samacá D regarding the use of faricimab in the treatment of patients with DME and nAMD in Colombia is to estimate the cost-effectiveness and budget impact of using faricimab within the Colombian health system.,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"Methods: This study used a 25-year Markov cohort model to estimate the cost-effectiveness of faricimab vs aflibercept, ranibizumab, and brolucizumab.",What model was used to estimate the cost-effectiveness of faricimab in comparison to other treatments (pmcid=11884430)?,A 25-year Markov cohort model was used to estimate the cost-effectiveness of faricimab in comparison to other treatments in the study mentioned (pmcid=11884430).,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,We used the methodological guidelines of the local health technology assessment agency for conducting the cost-effectiveness and budget impact analysis.,What methodological guidelines were used for conducting the cost-effectiveness and budget impact analysis in this study (pmcid=11884430)?,The methodological guidelines of the local health technology assessment agency were used for conducting the cost-effectiveness and budget impact analysis in this study (pmcid=11884430).,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Transition probabilities and injection frequencies were derived from the literature.,What were the transition probabilities and injection frequencies derived from in the analysis (pmcid=11884430)?,The transition probabilities and injection frequencies were derived from the literature in the analysis of the use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia (pmcid=11884430).,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Drug prices were retrieved from public local databases.,What were the drug prices retrieved from for the analysis (pmcid=11884430)?,Drug prices were retrieved from public local databases.,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Quality-adjusted life years (QALYs) were assessed.,What was assessed in terms of quality-adjusted life years in the study (pmcid=11884430)?,Quality-adjusted life years (QALYs) were assessed.,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,The potential patient population for the budget impact analysis was estimated based on disease prevalence and expert consultations.,What was the basis for estimating the potential patient population for the budget impact analysis in this study (pmcid=11884430)?,The potential patient population for the budget impact analysis was estimated based on disease prevalence and expert consultations.,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"Results: Faricimab treat-and-extend (T&E) was dominant vs aflibercept T&E (+0.22 QALYs), ranibizumab T&E (+0.55 QALYs), and brolucizumab for 8 to 12 weeks (+0.06 QALYs) in DME, generating cost savings (in US dollars) of 3849,1375, and 2824,respectively.InnAMD,faricimabalsoshoweddominancevsafliberceptasneeded(+0.12Q ALYs),ranibizumabasneeded(+0.05QALYs),andbrolucizumab8to12weeks(+0.12QALYs)withsa vingsin(US)7223, 5792,and6798, respectively.",What were the cost savings generated by faricimab treat-and-extend compared to other treatments in diabetic macular edema and neovascular age-related macular degeneration in Colombia (pmcid=11884430)?,"In diabetic macular edema, faricimab treat-and-extend generated cost savings of $3849 compared to aflibercept treat-and-extend, $1375 compared to ranibizumab treat-and-extend, and $2824 compared to brolucizumab for 8 to 12 weeks. In neovascular age-related macular degeneration, faricimab treat-and-extend also showed cost savings of $7223 compared to aflibercept as needed, $5792 compared to ranibizumab as needed, and $6798 compared to brolucizumab for 8 to 12 weeks.",b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"Assuming an annual market share increase for faricimab of 15% for DME and 13% for nAMD, the Colombian Health System could save 144millionover3years.Ofthesesavings,122.7 million are attributed to drug costs and 21.3milliontoadministrationcosts(US1 = Col$4325).",What annual market share increase assumptions were made for faricimab in the study (pmcid=11884430)?,An annual market share increase of 15% for Diabetic Macular Edema (DME) and 13% for Neovascular Age-Related Macular Degeneration (nAMD) was assumed for faricimab in the study (pmcid=11884430).,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"Conclusion: Considering a willingness to pay threshold of $5988 per additional QALY, faricimab is a cost-effective alternative for both DME and nAMD for the Colombian healthcare system, showing dominance over other anti–vascular endothelial growth factor agents.",What is the conclusion regarding the cost-effectiveness of faricimab for both DME and nAMD in Colombia (pmcid=11884430)?,"Faricimab is a cost-effective alternative for both Diabetic Macular Edema (DME) and Neovascular Age-Related Macular Degeneration (nAMD) in Colombia, showing dominance over other anti-vascular endothelial growth factor agents.",b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Faricimab provides better health outcomes at lower costs vs other treatments.,What do the results suggest about the cost-effectiveness of Faricimab compared to other treatments? (pmcid=11884430),The results suggest that Faricimab provides better health outcomes at lower costs compared to other treatments for diabetic macular edema and neovascular age-related macular degeneration in Colombia.,b08d4c1364fb11ef6f4a4ffba4caf89c
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,- Background: Evidence on the efficacy of psychological interventions targeting cancer patients diagnosed with an adjustment disorder is scarce.,What is scarce in evidence regarding psychological interventions targeting cancer patients diagnosed with an adjustment disorder (pmcid=11910135)?,Evidence on the efficacy of psychological interventions targeting cancer patients diagnosed with an adjustment disorder is scarce.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Aims: This study aimed to investigate the efficacy and budget impact of a tailored psychological intervention program (AD‐program) targeting cancer patients with adjustment disorder (AD).,What did this study aim to investigate (pmcid=11910135)?,This study aimed to investigate the efficacy and budget impact of a tailored psychological intervention program targeting cancer patients with adjustment disorder.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Methods: Patients (n = 59) were randomised to the intervention or control group.,What was the sample size for the randomised patients in this study (pmcid=11910135)?,The sample size for the randomised patients in this study (pmcid=11910135) was 59.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,The AD‐program consisted of three modules: psychoeducation (1–4 sessions) and two additional modules (maximum of 6 sessions per module) provided when needed.,What were the three modules included in the AD-program (pmcid=11910135)?,The three modules included in the AD-program were psychoeducation and two additional modules provided when needed.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,The primary outcome was psychological distress (HADS).,What was the primary outcome measured in the study (pmcid=11910135)?,"The primary outcome measured in the study with pmcid=11910135 was psychological distress, as assessed by the Hospital Anxiety and Depression Scale (HADS).",75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Secondary outcomes were mental adjustment to cancer (MAC) and health‐related quality of life (EORTC QLQ‐C30).,What were the secondary outcomes measured in the study (pmcid=11910135)?,The secondary outcomes measured in the study with pmcid=11910135 were mental adjustment to cancer (MAC) and health‐related quality of life (EORTC QLQ‐C30).,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Measures were completed at baseline and 3 and 6 months after randomisation.,What measures were completed at baseline and 3 and 6 months after randomisation (pmcid=11910135)?,Measures were completed at baseline and 3 and 6 months after randomisation.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"The budget impact analyses were based on the population size, the costs of the AD‐program, and other costs potentially affected by the AD‐program.",What were the budget impact analyses based on in the study conducted by Holtmaat K et al. (pmcid: 11910135)?,"The budget impact analyses were based on the population size, the costs of the AD‐program, and other costs potentially affected by the AD‐program.",75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"Results: The mean psychological distress score in the intervention group (n = 33) decreased over time (M = 19.2 at T0, M = 15.6 at T6).",What was the mean psychological distress score in the intervention group at the beginning of the study and after 6 months (pmcid=11910135)?,"The mean psychological distress score in the intervention group at the beginning of the study was 19.2, and after 6 months it decreased to 15.6 (pmcid=11910135).",75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"This decrease was not significantly different from decrease in the control condition (n = 26, M = 17.5 at T0, M = 15.9 at T6, p > 0.05).",What was the outcome of the decrease in the intervention group compared to the control condition (pmcid=11910135)?,The outcome of the decrease in the intervention group compared to the control condition was not significantly different.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"Also, there were no significant differences between the two conditions on the secondary outcomes.",What were the significant differences between the two conditions in the study (pmcid=11910135)?,There were no significant differences between the two conditions in the study.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"The budget impact of the AD‐program was estimated at 7–28 million euros per year (to treat 14,430 patients).","What was the estimated budget impact of the AD‐program per year to treat 14,430 patients (pmcid=11910135)?","The estimated budget impact of the AD‐program per year to treat 14,430 patients was 7–28 million euros.",75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Conclusions: The effect of the AD‐program was not statistically significant in this RCT.,What was the statistical significance of the AD-program in this RCT (pmcid=11910135)?,The effect of the AD-program was not statistically significant in this RCT.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Limitations include that this study was underpowered due to recruitment difficulties during the COVID‐19 pandemic.,What was a limitation of the study due to recruitment difficulties during the COVID‐19 pandemic (pmcid=11910135)?,The limitation of the study was that it was underpowered due to recruitment difficulties during the COVID‐19 pandemic.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,More research on the efficacy and implementation of the AD‐program is warranted.,What is warranted regarding the AD‐program based on the abstract sentence (pmcid=11910135)?,More research on the efficacy and implementation of the AD‐program is warranted.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Trial Registration: Netherlands Trial Register identifier: NL7763.,What is the identifier for the trial registration in the Netherlands Trial Register (pmcid=11910135)?,NL7763,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Registered on 3 June 2019,What was the title of the study conducted by Holtmaat K (pmcid=11910135)?,"The title of the study conducted by Holtmaat K (pmcid=11910135) was ""Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial"".",75e72be1e5da700109d4a13c20c877a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"- Objective: To estimate the efficiency of a nurse-led telephone program for nonadherent to treatment Type 2 diabetics with comorbid depression (TELE-DD program).Design: Secondary analysis of cost-consequence and budget impact, utilizing data from a randomized clinical trial conducted in the primary healthcare setting.",What type of program was estimated for nonadherent to treatment Type 2 diabetics with comorbid depression (pmcid=11919128)?,A nurse-led telephone program (TELE-DD program) was estimated for nonadherent to treatment Type 2 diabetics with comorbid depression.,9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,The target population consisted of Type 2 diabetic patients with comorbid depression who were nonadherent to their pharmacological treatment.Method: The average cost per controlled patient (glycated hemoglobin < 7%) and the incremental cost-effectiveness ratio were calculated.,What was the target population for this study (pmcid=11919128)?,The target population for this study (pmcid=11919128) was Type 2 diabetic patients with comorbid depression who were nonadherent to their pharmacological treatment.,9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"Similarly, the budgetary impact over 1 year of implementing this program in the region of reference of the randomized clinical trial was assessed.Results: The number of controlled patients is higher in the TELE-DD group at 6, 12, and 18 months.",What was assessed in terms of budgetary impact over 1 year in the region of reference of the randomized clinical trial (pmcid=11919128)?,The budgetary impact over 1 year of implementing the nurse-led telephone program for nonadherent to treatment type 2 diabetics with comorbid depression was assessed in the region of reference of the randomized clinical trial.,9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,The average cost per controlled patient was higher in the TELE-DD group than in the control group at 6 months (€160.31 vs.,What was the average cost per controlled patient in the TELE-DD group compared to the control group at 6 months (pmcid=11919128)?,"The average cost per controlled patient in the TELE-DD group was €160.31, which was higher than in the control group at 6 months.",9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"€49.79), but lower at 12 (€150.09 vs.",What was the cost difference between the nurse-led telephone program and usual care at 12 months (pmcid=11919128)?,The cost difference between the nurse-led telephone program and usual care at 12 months was €100.30 lower for the nurse-led telephone program (€150.09 vs. €49.79).,9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,€179.59) and 18 months (€209.22 vs.,What was compared at 6 months and 18 months in the study conducted by Gómez-Barrera et al. (pmcid=11919128)?,The costs were compared at 6 months and 18 months in the study conducted by Gómez-Barrera et al. (pmcid=11919128).,9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"The incremental cost-effectiveness ratio at 6, 12, and 18 months was €254.47, €143.65, and €177.46, respectively.","What were the incremental cost-effectiveness ratios at 6, 12, and 18 months in the study conducted by Gómez-Barrera et al. (pmcid=11919128)?","The incremental cost-effectiveness ratios at 6, 12, and 18 months in the study conducted by Gómez-Barrera et al. were €254.47, €143.65, and €177.46, respectively.",9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"The budget impact analysis revealed that implementing the TELE-DD program would result in a reduction of €721,940.68 in expenditure for the funder in the first year of application.Conclusions: A nurse-led telephone program for nonadherent Type 2 diabetics with comorbid depression is an efficient option in the management of healthcare resources.",What would be the reduction in expenditure for the funder in the first year of implementing the TELE-DD program (pmcid=11919128)?,"The reduction in expenditure for the funder in the first year of implementing the TELE-DD program would be €721,940.68.",9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,These results highlight the role of nursing in chronic patient management and the efficient use of healthcare resources.Trial Registration: ClinicalTrials.gov Identifier: NCT04097483.,What role did nursing play in chronic patient management according to the results (pmcid=11919128)?,"The results indicated that nursing played a significant role in chronic patient management, emphasizing the efficient use of healthcare resources.",9b786e4fc89c9c578e271b403dc975a3
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"- Background: Cangrelor is an intravenous, reversible P2Y12 inhibitor indicated for the reduction of thrombotic cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure, and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable (for example, in the out-of-hospital cardiac arrest [OHCA] population).",What is Cangrelor indicated for in patients undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the procedure (pmcid=11922778)?,Cangrelor is indicated for the reduction of thrombotic cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the procedure.,40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"Objective: This study aimed to estimate the affordability and budget impact, in the United Kingdom, of introducing cangrelor within the licenced OHCA population.",What did this study aim to estimate in the United Kingdom (pmcid=11922778)?,The study aimed to estimate the affordability and budget impact of introducing cangrelor within the licensed out-of-hospital cardiac arrest (OHCA) population in the United Kingdom.,40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,Methods: A budget impact model was developed to estimate the impact of introducing cangrelor to hospitals over 5 years.,What was the purpose of developing the budget impact model (pmcid=11922778)?,The purpose of developing the budget impact model in this study was to estimate the impact of introducing cangrelor to hospitals over 5 years.,40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"Efficacy (thrombotic events) and safety (bleeding events) data were based on clinical trials, cost data (2021/22 GBP), literature, NHS reference costs and British National Formulary data.",What data sources were used for the efficacy and safety data in the analysis (pmcid=11922778)?,"The data sources used for the efficacy and safety data in the analysis were clinical trials, cost data (2021/22 GBP), literature, NHS reference costs, and British National Formulary data.",40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"Comparators were glycoprotein IIb/IIIa inhibitors and aspirin in combination with heparin, reflecting current treatments used in UK centres for the target population.",What treatments were used as comparators in the study (pmcid=11922778)?,The comparators used in the study were glycoprotein IIb/IIIa inhibitors and aspirin in combination with heparin.,40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"Cangrelor uptake was estimated as 50% in Year 1, 75% in Year 2, and 100% in Years 3–5.","What was the estimated uptake of Cangrelor in Year 1, Year 2, and Years 3-5? (pmcid=11922778)","The estimated uptake of Cangrelor was 50% in Year 1, 75% in Year 2, and 100% in Years 3-5.",40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,The OHCA population was estimated from the British Cardiovascular Intervention Society National Audit 2021/22.,What was the source of the estimate for the OHCA population in the UK (pmcid=11922778)?,The estimate for the OHCA population in the UK was sourced from the British Cardiovascular Intervention Society National Audit 2021/22.,40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"Results: Over 5 years, cangrelor leads to modelled cost savings of £2,709,853 (−9.84%), varying from £322,218 in Year 1 (−5.85%) to £636,150 (−11.55%) in Year 5).",What are the modelled cost savings over 5 years with the use of cangrelor for the treatment of out-of-hospital cardiac arrest patients who require percutaneous coronary intervention (pmcid=11922778)?,"The modelled cost savings over 5 years with the use of cangrelor for the treatment of out-of-hospital cardiac arrest patients who require percutaneous coronary intervention is £2,709,853.",40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"This is driven by approximately 6,882 hospital days being avoided over 5 years due to fewer bleeding events.",How many hospital days were avoided over 5 years due to fewer bleeding events? (pmcid=11922778),"Approximately 6,882 hospital days were avoided over 5 years due to fewer bleeding events.",40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,Conclusion: Cangrelor for OHCA patients who cannot take oral P2Y12 inhibitors may lead to cost savings in the UK.,What may the use of Cangrelor for OHCA patients who cannot take oral P2Y12 inhibitors lead to in the UK (pmcid=11922778)?,Cost savings,40cf76d1c9b8c5a32467f5e38eaec993
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"- Background: Tobacco use is the world's leading preventable cause of death, with the highest burden in low and middle-income countries (LMICs).",What is the background information provided in the abstract (pmcid=11927220)?,"The background information provided in the abstract is that tobacco use is the world's leading preventable cause of death, with the highest burden in low and middle-income countries (LMICs).",a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Those who have mental illness are particularly vulnerable, with a smoking rate two to five times higher than that of the general population.",What population is mentioned as being particularly vulnerable in the abstract sentence provided (pmcid=11927220)?,Those who have mental illness,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Quitting smoking has demonstrated benefits for mental health, including reducing stress and improving the quality of life.",What benefits for mental health have been demonstrated by quitting smoking (pmcid=11927220)?,Reducing stress and improving the quality of life.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"However, the economic feasibility of introducing Nicotine Replacement Therapy (NRT) in the psychiatric medical environment in South Africa has not yet been explored.",What has not yet been explored regarding the economic feasibility of introducing Nicotine Replacement Therapy (NRT) in the psychiatric medical environment in South Africa (pmcid=11927220)?,The economic feasibility of introducing Nicotine Replacement Therapy (NRT) in the psychiatric medical environment in South Africa has not yet been explored.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,This study aims to address this gap by assessing the impact on the budget of implementing an NRT-based smoking cessation program in a psychiatric hospital.,What is the aim of the study in relation to the budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa (pmcid=11927220)?,The aim of the study is to assess the impact on the budget of implementing an NRT-based smoking cessation program in a psychiatric hospital.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,Methods: This retrospective and cross-sectional study followed a budget impact analysis framework.,What framework did the study follow for the budget impact analysis (pmcid=11927220)?,The study followed a budget impact analysis framework.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Data were retrieved between May 19 and Aug 18, 2023, from 214 patients' medical records.",What data were retrieved from 214 patients' medical records (pmcid=11927220)?,"Data were retrieved between May 19 and Aug 18, 2023.",a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Using primary and secondary data, an ingredients costing approach was used to estimate direct treatment costs of NRT smoking cessation.",What approach was used to estimate the direct treatment costs of NRT smoking cessation in the study (pmcid=11927220)?,An ingredients costing approach was used to estimate the direct treatment costs of NRT smoking cessation in the study with pmcid=11927220.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,All costs were expressed in ZAR (South African currency).,What currency were all costs expressed in for the budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa (pmcid=11927220)?,All costs were expressed in ZAR (South African currency).,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"The economic evaluation was conducted from the payer's perspective, and the results were reported at a 5% discount rate.",What perspective was the economic evaluation conducted from in this study (pmcid=11927220)?,The economic evaluation was conducted from the payer's perspective.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,A two-way 10% sensitivity analysis was conducted.,What type of analysis was conducted in the study (pmcid=11927220)?,A two-way 10% sensitivity analysis was conducted.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Results: The study showed that study participants were primarily black, male, unemployed, diagnosed with schizophrenia and smoked lightly (69.16% ±3.46).",What were the demographics of the study participants in terms of gender and employment status (pmcid=11927220)?,The study participants were primarily male and unemployed.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,Implementing the 3-month treatment period of NRT smoking cessation program would result in an expenditure of R1 478 915.42 for 214 patients.,How much would the 3-month treatment period of NRT smoking cessation program cost for 214 patients in South Africa (pmcid=11927220)?,The 3-month treatment period of NRT smoking cessation program would cost R1 478 915.42 for 214 patients in South Africa.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,The hospital will require an additional 0.15% (±0.0095) of the total hospital budget and 6.09% (±0.31) of the hospital pharmacy budget.,How much of the hospital budget will be required for nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa (pmcid=11927220)?,0.15% of the total hospital budget,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Conclusion: Our findings indicate that while implementing a NRT is crucial for improving the overall health outcomes among patients with mental illnesses, substantial investment would be required.",What do the findings indicate about the implementation of NRT among patients with mental illnesses in South Africa (pmcid=11927220)?,"The findings indicate that implementing nicotine replacement therapy (NRT) among patients with mental illnesses in South Africa is crucial for improving overall health outcomes, but it would require substantial investment.",a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,The budgetary allocation for NRT smoking cessation interventions would vary by treatment settings and program duration.,What would vary by treatment settings and program duration in the budgetary allocation for NRT smoking cessation interventions in South Africa (pmcid=11927220)?,The budgetary allocation for NRT smoking cessation interventions would vary by treatment settings and program duration.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Consequently, careful consideration of budget allocation and resource distribution is necessary to ensure the program's sustainability within the broader healthcare framework in South Africa.",What is necessary to ensure the program's sustainability within the broader healthcare framework in South Africa (pmcid=11927220)?,Careful consideration of budget allocation and resource distribution is necessary to ensure the program's sustainability within the broader healthcare framework in South Africa.,a497e7668863b20ca1126b4b5600786a
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,- Background: The Interactive Care Coordination and Navigation (iCAN) mobile health intervention aims to improve care coordination and reduce hospital and emergency department visits among people experiencing homelessness.,What is the aim of the iCAN mobile health intervention (pmcid=11936304)?,The aim of the iCAN mobile health intervention is to improve care coordination and reduce hospital and emergency department visits among people experiencing homelessness.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Objective: This study aimed to conduct a three-part economic evaluation of iCAN, including a (1) cost analysis, (2) exploratory financial cost-benefit analysis, and (3) budget impact analysis (BIA).",What three-part economic evaluation did this study aim to conduct for iCAN (pmcid=11936304)?,"The study aimed to conduct a cost analysis, exploratory financial cost-benefit analysis, and budget impact analysis for iCAN.",15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,Methods: We collected cost and expenditure data from a randomized controlled trial of iCAN to conduct a cost analysis and exploratory financial cost-benefit analysis.,What data was collected to conduct a cost analysis and exploratory financial cost-benefit analysis in the study of iCAN (pmcid=11936304)?,Cost and expenditure data were collected from a randomized controlled trial of iCAN to conduct the cost analysis and exploratory financial cost-benefit analysis.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,Costs were classified as startup and recurring costs for participants and the program.,What costs were classified in the study (pmcid=11936304)?,Costs were classified as startup and recurring costs for participants and the program.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,Startup costs included participant supplies for each participant and SMS implementation costs.,What were included in the startup costs for the intervention (pmcid=11936304)?,Participant supplies for each participant and SMS implementation costs were included in the startup costs for the intervention.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Recurring costs included the cost of recurring services, SMS text messaging platform maintenance, health information access fees, and personnel salaries.",What were the recurring costs included in the analysis (pmcid=11936304)?,"The recurring costs included in the analysis were the cost of recurring services, SMS text messaging platform maintenance, health information access fees, and personnel salaries.",15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Using the per participant per year (PPPY) costs of iCAN, the minimum savings reduction in the average health care costs among people experiencing homelessness that would lead to a benefit-cost ratio >1 for iCAN was calculated.",What was calculated using the per participant per year (PPPY) costs of iCAN in the study (pmcid=11936304)?,The minimum savings reduction in the average health care costs among people experiencing homelessness that would lead to a benefit-cost ratio >1 for iCAN was calculated.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,This savings threshold was calculated by dividing the PPPY cost of iCAN by the average health care costs among people experiencing homelessness multiplied by 100%.,What was the savings threshold calculated based on in the study (pmcid=11936304)?,The savings threshold was calculated based on the average health care costs among people experiencing homelessness.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,The benefit-cost ratio of iCAN was calculated under different savings thresholds from 0% (no savings) to 50%.,What was the benefit-cost ratio of iCAN calculated under different savings thresholds (pmcid=11936304)?,The benefit-cost ratio of iCAN was calculated under different savings thresholds from 0% to 50%.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Costs were calculated PPPY under different scenarios, and the results were used as inputs in a BIA.",What were the costs calculated under different scenarios used for in this study (pmcid=11936304)?,The costs calculated under different scenarios were used as inputs in a Budget Impact Analysis (BIA) in this study.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,A probabilistic sensitivity analysis was conducted to incorporate uncertainty around cost estimates.,What type of analysis was conducted to incorporate uncertainty around cost estimates (pmcid=11936304)?,A probabilistic sensitivity analysis,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,Costs are in 2022 US $.,What type of analysis was conducted in this study (pmcid=11936304)?,"Cost analysis, exploratory financial cost-benefit analysis, and budget impact analysis",15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Results: The total cost of iCAN was US $2865 PPPY, which was made up of US $265 in startup (9%) and US $2600 (91%) in recurring costs PPPY.",What were the total costs of the iCAN intervention (pmcid=11936304)?,The total cost of the iCAN intervention was US $2865 per person per year (PPPY).,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,The minimum savings threshold that would cause iCAN to have a positive return on investment is 7.8%.,What is the minimum savings threshold that would cause iCAN to have a positive return on investment (pmcid=11936304)?,The minimum savings threshold that would cause iCAN to have a positive return on investment is 7.8%.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"This means that if average health care costs (US $36,917) among people experiencing homelessness were reduced by more than 7.8% through iCAN, the financial benefits would outweigh the costs of the intervention.",What percentage reduction in average health care costs among people experiencing homelessness would result in the financial benefits outweighing the costs of the iCAN intervention (pmcid=11936304)?,7.8%,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"When health care costs are reduced by 25% ($9229/$36,917; equal to 56% [$9229/$16,609] of the average cost of an inpatient visit), the benefit-cost ratio is 3.22, which means that iCAN produces US $2.22 in health care savings per US $1 spent.",What is the benefit-cost ratio when health care costs are reduced by 25% in the study by McCullough HP (pmcid: 11936304)?,3.22,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"The BIA estimated that implementing iCAN for 10,250 people experiencing homelessness over 5 years would have a financial cost of US $28.7 million, which could be reduced to US $2.2 million if at least 8% ($2880/$36,917) of average health care costs among people experiencing homelessness are reduced through the intervention.","What was the financial cost estimated for implementing iCAN for 10,250 people experiencing homelessness over 5 years (pmcid=11936304)?","The financial cost estimated for implementing iCAN for 10,250 people experiencing homelessness over 5 years was US $28.7 million.",15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Conclusions: If average costs of emergency department and hospital visits among people experiencing homelessness were reduced by more than 7.8% ($2880/$36,917) through iCAN, the financial benefits would outweigh the costs of the intervention.",What percentage reduction in average costs of emergency department and hospital visits among people experiencing homelessness would result in the financial benefits outweighing the costs of the iCAN intervention (pmcid=11936304)?,7.8%,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"As the savings threshold increases, it results in a higher benefit-cost ratio.",What does the increase in savings threshold result in? (pmcid=11936304),A higher benefit-cost ratio.,15e7fb7f3743cea97239cca325b012d5
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"- BACKGROUND:: Heart failure (HF) is a leading cause of mortality in the United States, often complicated by comorbidities like diabetes mellitus.","What is a leading cause of mortality in the United States, often complicated by comorbidities like diabetes mellitus (pmcid=11953859)?",Heart failure (HF),89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"These patients face high hospitalization risks, impacting clinical outcomes and health care resources.",What impact do patients with heart failure and type 2 diabetes face (pmcid=11953859)?,"Patients with heart failure and type 2 diabetes face high hospitalization risks, which impact clinical outcomes and health care resources.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"The Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial showed that sotagliflozin, a sodium-glucose cotransporter inhibitor, reduced rehospitalizations in patients with HF and diabetes mellitus.",What trial showed that sotagliflozin reduced rehospitalizations in patients with heart failure and type 2 diabetes (pmcid=11953859)?,The Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial,89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"Although clinically beneficial, the economic impact of sotagliflozin from a payer perspective remains unclear, warranting further pharmacoeconomic analysis to guide managed care decisions.","What remains unclear from a payer perspective regarding the economic impact of sotagliflozin, warranting further analysis to guide managed care decisions (pmcid=11953859)?","The economic impact of sotagliflozin from a payer perspective remains unclear, warranting further pharmacoeconomic analysis to guide managed care decisions.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,OBJECTIVE:: To quantify the budget impact of sotagliflozin for US payers over a 5-year time horizon.,What is the objective of the study (pmcid=11953859)?,The objective of the study with pmcid=11953859 is to quantify the budget impact of sotagliflozin for US payers over a 5-year time horizon.,89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,METHODS:: A payer-perspective budget impact model was developed to assess the financial impact of incorporating sotagliflozin for the treatment of patients recently hospitalized for HF with comorbid type 2 diabetes (T2D) over 5 years to US payer health plans.,What perspective was used in the budget impact model developed to assess the financial impact of incorporating sotagliflozin for the treatment of patients recently hospitalized for HF with comorbid type 2 diabetes (T2D) (pmcid=11953859)?,The budget impact model developed used a payer perspective to assess the financial impact of incorporating sotagliflozin for the treatment of patients recently hospitalized for heart failure with comorbid type 2 diabetes (T2D).,89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"The study used a population reflecting the SOLOIST-WHF clinical trial, with economic parameters adjusted by payer mix (all payer, commercial, Medicare, and Medicaid).",What population was used in the study (pmcid=11953859)?,The population used in the study was reflective of the SOLOIST-WHF clinical trial.,89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"Health care resource utilization included hospitalization, emergency department (ED) visit, and adverse events’ care.",What health care resource utilization was included in the analysis (pmcid=11953859)?,"Health care resource utilization included hospitalization, emergency department (ED) visit, and adverse events’ care.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"Economic outcomes examined the medical and pharmacy budget impact for payers at the per-user, per member per month (PMPM), and total plan costs levels.",What economic outcomes were examined in the study (pmcid=11953859)?,"The economic outcomes examined in the study (pmcid=11953859) included the medical and pharmacy budget impact for payers at the per-user, per member per month (PMPM), and total plan costs levels.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"RESULTS:: For a hypothetical 1-million-member all-payer plan, 1,516 patients hospitalized for HF with comorbid T2D would be eligible for sotagliflozin.",How many patients hospitalized for heart failure with comorbid type 2 diabetes would be eligible for sotagliflozin in a hypothetical 1-million-member all-payer plan (pmcid=11953859)?,"1,516 patients hospitalized for heart failure with comorbid type 2 diabetes would be eligible for sotagliflozin in a hypothetical 1-million-member all-payer plan.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"For all-payer plans, annual per-user costs increased by $4,996 because of higher pharmacy costs ($8,260) but were partially offset by lower medical costs (−$2,608) because of reduced rehospitalization and ED visits from sotagliflozin.",What were the annual per-user costs impacted by in the budget impact analysis from the US payer perspective (pmcid=11953859)?,The annual per-user costs were impacted by higher pharmacy costs and lower medical costs in the budget impact analysis from the US payer perspective (pmcid=11953859).,89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"PMPM total budget impact of sotagliflozin would be $0.08 PMPM in year 1 and $0.38 in year 5, corresponding with total plan cost of $75,736 in year 1 and $378,681 by year 5.",What is the total budget impact of sotagliflozin in year 1 and year 5 from the US payer perspective (pmcid=11953859)?,"The total budget impact of sotagliflozin in year 1 is $75,736 and in year 5 is $378,681 from the US payer perspective.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"Commercial payer PMPM costs were lower ($0.02 in year 1; $0.11 in year 5), and higher for Medicare ($0.23 PMPM in year 1, increasing to 1.13 PMPM in year 5).","What were the PMPM costs for commercial payers and Medicare in year 1 and year 5, according to the study (pmcid=11953859)?","For commercial payers, the PMPM costs were $0.02 in year 1 and $0.11 in year 5. For Medicare, the PMPM costs were $0.23 in year 1 and increased to $1.13 in year 5, according to the study with pmcid=11953859.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,Breakeven rebate rates ranged between 31.5% and 79.4%.,What is the range of breakeven rebate rates mentioned in the study (pmcid=11953859)?,The range of breakeven rebate rates mentioned in the study with pmcid=11953859 is between 31.5% and 79.4%.,89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"CONCLUSIONS:: Although sotagliflozin increases pharmacy costs for recently hospitalized HF patients with T2D, approximately 21%-68% of pharmacy costs were offset from reduced rehospitalization and ED visits.",What percentage of pharmacy costs were offset from reduced rehospitalization and ED visits for recently hospitalized HF patients with T2D (pmcid=11953859)?,Approximately 21%-68% of pharmacy costs were offset from reduced rehospitalization and ED visits for recently hospitalized HF patients with T2D (pmcid=11953859).,89bbfd50fa2145987a221775219e191f
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,- Purpose: Serum or urine protein electrophoresis (SPEP or UPEP) and immunofixation electrophoresis (SIFE or UIFE) are routinely used to detect M-proteins in MM patients.,What are the routine tests used to detect M-proteins in MM patients (pmcid=11849414)?,Serum or urine protein electrophoresis (SPEP or UPEP) and immunofixation electrophoresis (SIFE or UIFE),4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"However, SPEP and SIFE are not sensitive enough to measure M-protein levels that are low but still clinically significant.",What is the limitation of SPEP and SIFE in measuring M-protein levels (pmcid=11849414)?,The limitation of SPEP and SIFE in measuring M-protein levels is that they are not sensitive enough to measure M-protein levels that are low but still clinically significant.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"This study aimed to evaluate the potential cost savings associated with using the EXENT GAM Assay, a serum-based quantitative-immunoprecipitation mass spectrometry (QIP-MS) diagnostic test instead of SIFE to guide the timing of minimal residual disease (MRD) testing for patients with multiple myeloma (MM).",What diagnostic test was evaluated in the study (pmcid=11849414)?,"The EXENT GAM Assay, a serum-based quantitative-immunoprecipitation mass spectrometry (QIP-MS) diagnostic test.",4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,Patients and Methods: A simple 2-year budget impact model was created in Excel using data from MM clinical trials and fee schedules.,What data was used to create the budget impact model in Excel (pmcid=11849414)?,Data from MM clinical trials and fee schedules.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,Patients are tested with either QIP-MS or SIFE at predetermined timepoints.,What are patients tested with at predetermined timepoints in the study (pmcid=11849414)?,Patients are tested with either QIP-MS or SIFE at predetermined timepoints.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"If patients test negative, they will receive MRD testing.",What will patients receive if they test negative (pmcid=11849414)?,MRD testing,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,The result of the MRD test will determine if the preceding serum-based test was a true negative result (MRD test is negative) or a false negative result (MRD test is positive).,What will the result of the MRD test determine (pmcid=11849414)?,The result of the MRD test will determine if the preceding serum-based test was a true negative result or a false negative result.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,Patients receiving autologous stem cell transplant (henceforth referred to as transplant) and those not receiving transplant are both eligible for one MRD test per year.,What is the eligibility criteria for MRD testing for patients receiving autologous stem cell transplant and those not receiving transplant (pmcid=11849414)?,Patients receiving autologous stem cell transplant and those not receiving transplant are both eligible for one MRD test per year.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,MRD testing for transplant-eligible patients occurs prior to transplant and one year following transplant.,When does MRD testing occur for transplant-eligible patients according to the abstract sentence provided? (pmcid=11849414),MRD testing for transplant-eligible patients occurs prior to transplant and one year following transplant.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"Results: Across a hypothetical population of 5154 mm patients receiving 1st-line treatment in France, using QIP-MS instead of SIFE prior to MRD testing leads to 1973 fewer false negative results and 744 more false positive results (due, in part, to the detection of residual IgG).",What are the results of using QIP-MS instead of SIFE prior to MRD testing in patients with multiple myeloma in France (pmcid=11849414)?,Using QIP-MS instead of SIFE prior to MRD testing in patients with multiple myeloma in France resulted in 1973 fewer false negative results and 744 more false positive results.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"Net savings per QIP-MS test would be €260 or total savings of €2,481,832.",What are the total savings per QIP-MS test in this budget impact analysis (pmcid=11849414)?,The total savings per QIP-MS test in this budget impact analysis is €260.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,Conclusion: This study suggests that the use of QIP-MS prior to MRD testing may be cost-saving for testing French patients with MM.,What does this study suggest about the cost-saving potential of using QIP-MS prior to MRD testing for French patients with MM (pmcid=11849414)?,This study suggests that the use of QIP-MS prior to MRD testing may be cost-saving for testing French patients with MM.,4ae7b04289a67daab4a015e7c41bacf7
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,- Background: Low-dose aspirin and rivaroxaban are the cornerstone treatment for cardiovascular prevention in patients with peripheral artery disease (PAD) and/or stable coronary artery disease (SCAD).,What are the cornerstone treatments for cardiovascular prevention in patients with peripheral artery disease (PAD) and/or stable coronary artery disease (SCAD) (pmcid=11871816)?,Low-dose aspirin and rivaroxaban are the cornerstone treatments for cardiovascular prevention in patients with peripheral artery disease (PAD) and/or stable coronary artery disease (SCAD) according to the study with pmcid=11871816.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,The combination of rivaroxaban with aspirin imposes a synergistic effect on the inhibition of factor-induced platelet aggregation.,What effect does the combination of rivaroxaban with aspirin have on factor-induced platelet aggregation? (pmcid=11871816),The combination of rivaroxaban with aspirin imposes a synergistic effect on the inhibition of factor-induced platelet aggregation.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"The present work aimed at comparing the cost-utility and cost-effectiveness of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban alone (5 mg twice daily) with aspirin alone in patients with peripheral artery disease (PAD) or coronary artery disease (CAD) and related subgroups.",What did the present work aim at comparing in patients with peripheral artery disease (PAD) or coronary artery disease (CAD) and related subgroups (pmcid=11871816)?,"The present work aimed at comparing the cost-utility and cost-effectiveness of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban alone (5 mg twice daily) with aspirin alone in patients with peripheral artery disease (PAD) or coronary artery disease (CAD) and related subgroups.",ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,Methods: This pharmacoeconomic study was performed based on the insurance organization and utilized a state-transition decision Markov model.,What type of model was utilized in this pharmacoeconomic study (pmcid=11871816)?,State-transition decision Markov model,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"From the COMPASS trial, Clinical efficacy and Clinical events were collected.",What data was collected from the COMPASS trial (pmcid=11871816)?,Clinical efficacy and Clinical events were collected from the COMPASS trial.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,Health outcomes and cost were assessed over a 20-year time horizon (lifetime).,What time horizon was used to assess health outcomes and cost in the study (pmcid=11871816)?,Health outcomes and cost were assessed over a 20-year time horizon (lifetime).,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,The direct costs of medical services were included in the analysis.,What costs were included in the analysis (pmcid=11871816)?,The direct costs of medical services were included in the analysis.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,The results were stated based on Incremental Cost-Utility (ICUR) and Incremental Cost Effectiveness Ratio (ICER).,What were the results based on in the study conducted by Goudarzi Z (pmcid=11871816)?,The results were based on Incremental Cost-Utility (ICUR) and Incremental Cost Effectiveness Ratio (ICER) in the study conducted by Goudarzi Z.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,Uncertainty was assessed utilizing deterministic and probabilistic sensitivity analyses.,What type of sensitivity analyses were utilized to assess uncertainty in the study (pmcid=11871816)?,Deterministic and probabilistic sensitivity analyses were utilized to assess uncertainty in the study with pmcid=11871816.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"Discount rates of .058 and .03 were included for cost and effectiveness data, respectively.",What discount rates were included for cost and effectiveness data in the analysis (pmcid=11871816)?,Discount rates of .058 and .03 were included for cost and effectiveness data in the analysis (pmcid=11871816).,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,The budget impact based on the Markov model was estimated as the financial burden resulting from the insurance coverage of rivaroxaban.,What was estimated as the financial burden resulting from the insurance coverage of rivaroxaban (pmcid=11871816)?,The budget impact based on the Markov model was estimated as the financial burden resulting from the insurance coverage of rivaroxaban.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"Results: In the total of CAD and PAD patients, treatment with rivaroxaban plus aspirin and rivaroxaban alone were more expensive than the aspirin alone, but also more effective, resulting in ICUR being $4594/QALY and $13601/QALY respectively, and for ICER being $3348/LYG and $9901/LYG.",What were the incremental cost-effectiveness ratios for treatment with rivaroxaban plus aspirin and rivaroxaban alone compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran (pmcid=11871816)?,"The incremental cost-effectiveness ratios for treatment with rivaroxaban plus aspirin compared to aspirin alone were $4594 per quality-adjusted life year (QALY) and $3348 per life year gained (LYG). For treatment with rivaroxaban alone compared to aspirin alone, the incremental cost-effectiveness ratios were $13601 per QALY and $9901 per LYG.",ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,In PAD patients rivaroxaban plus aspirin had higher effectiveness than aspirin alone that ICUR and ICER being $11929/QALY and $9896/LYG respectively.,What were the incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) values for rivaroxaban plus aspirin compared to aspirin alone in PAD patients (pmcid=11871816)?,The incremental cost-effectiveness ratio (ICER) was $9896/LYG and the incremental cost-utility ratio (ICUR) was $11929/QALY for rivaroxaban plus aspirin compared to aspirin alone in PAD patients.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"In CAD patients, treatment with rivaroxaban plus aspirin was expensive and less effective than aspirin alone.",Was treatment with rivaroxaban plus aspirin cost-effective compared to aspirin alone in CAD patients (pmcid=11871816)?,"No, treatment with rivaroxaban plus aspirin was not cost-effective compared to aspirin alone in CAD patients according to the information provided in the context.",ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"The estimated annual budget impact was $28,253,135 for the rivaroxaban plus aspirin and $292,593,909 for the rivaroxaban alone in the total of CAD and PAD patients.",What was the estimated annual budget impact for rivaroxaban plus aspirin and rivaroxaban alone in patients with coronary and peripheral artery diseases in Iran (pmcid=11871816)?,"The estimated annual budget impact was $28,253,135 for rivaroxaban plus aspirin and $292,593,909 for rivaroxaban alone in patients with coronary and peripheral artery diseases in Iran.",ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,Conclusions: This study showed that rivaroxaban plus aspirin is a cost-effective alternative in PAD and total of CAD and PAD patients.,What did this study show about the cost-effectiveness of rivaroxaban plus aspirin in patients with coronary and peripheral artery diseases (pmcid=11871816)?,This study showed that rivaroxaban plus aspirin is a cost-effective alternative in patients with peripheral artery disease (PAD) and in the total of patients with coronary artery disease (CAD) and PAD.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"In CAD patients, rivaroxaban plus aspirin and rivaroxaban alone were not cost-effective.",Was rivaroxaban plus aspirin or rivaroxaban alone cost-effective in CAD patients? (pmcid=11871816),"In CAD patients, rivaroxaban plus aspirin and rivaroxaban alone were not cost-effective.",ddc198ccb56f3d98e6906adc3f6f99cf
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"- Background: Lennox-Gastaut syndrome (LGS) is a severe encephalopathic disease that leads to a decrease in the quality of life, physical injury, psychosocial impairment, and a significant increase in treatment costs.",What is the background information provided in the abstract regarding Lennox-Gastaut syndrome (pmcid=11881394)?,"The background information provided in the abstract regarding Lennox-Gastaut syndrome (pmcid=11881394) is that it is a severe encephalopathic disease that leads to a decrease in the quality of life, physical injury, psychosocial impairment, and a significant increase in treatment costs.",f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,Cannabidiol (CBD) is approved for the adjunctive treatment of tonic-colonic seizures in LGS.,What is cannabidiol approved for in the adjunctive treatment of Lennox Gastaut syndrome (pmcid=11881394)?,Cannabidiol (CBD) is approved for the adjunctive treatment of tonic-colonic seizures in LGS.,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,This study aimed to determine the cost-effectiveness of CBD compared to the usual treatment in patients with LGS syndrome.,What did the study aim to determine in patients with LGS syndrome? (pmcid=11881394),The study aimed to determine the cost-effectiveness of CBD compared to the usual treatment in patients with Lennox Gastaut syndrome.,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,Methods: We developed a lifetime-horizon Markov model to compare the cost-effectiveness of adjunctive CBD versus usual care.,What type of model was developed to compare the cost-effectiveness of adjunctive CBD versus usual care (pmcid=11881394)?,Markov model,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"Additionally, we performed a budget impact analysis over a 5-year time horizon.",What type of analysis was performed over a 5-year time horizon (pmcid=11881394)?,Budget impact analysis,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"The findings were presented as the incremental cost-effectiveness ratio (ICER) for CEA, with a willingness to pay threshold of $18,261 per QALY gained, and as the difference in the overall budget ($) between the scenarios with and without CBD for budget impact assessment.",What was the incremental cost-effectiveness ratio (ICER) calculated for in this study (pmcid=11881394)?,The incremental cost-effectiveness ratio (ICER) was calculated for cost-effectiveness analysis (CEA) in this study (pmcid=11881394).,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"Results: In the base case scenario, CBD was cost-effective compared with usual care $6573 per QALY.",What was the cost-effectiveness of CBD compared to usual care in the base case scenario (pmcid=11881394)?,CBD was cost-effective compared with usual care at $6573 per QALY in the base case scenario.,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,Sensitivity analyses substantiated these results.,What did the sensitivity analyses substantiate in the study on the value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome (pmcid=11881394)?,The sensitivity analyses substantiated the results in the study on the value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome.,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"From a healthcare perspective, there is a 77% probability that CBD is cost-effective at a willingness to pay of $18,261 per quality-adjusted life-year (QALY).","What is the probability that CBD is cost-effective at a willingness to pay of $18,261 per quality-adjusted life-year, from a healthcare perspective (pmcid=11881394)?",77%,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"Overall, the market access of CBD was associated to an increased budget of about $3,459,846 (+ 33%) in the next 5 years simulated.",What was the increased budget associated with the market access of CBD in the next 5 years simulated (pmcid=11881394)?,"The increased budget associated with the market access of CBD in the next 5 years simulated was about $3,459,846 (+33%).",f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"Conclusions: Compared to usual care, CBD seems to be cost-effective in LGS patients and sustainable, with less than 34% overall budget increased in the next 5 years.",What is the overall budget increase expected in the next 5 years when comparing CBD to usual care in LGS patients (pmcid=11881394)?,Less than 34% overall budget increase,f72ca8a5314e56cf03a3e5f7079df43c
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,Future studies need to confirm our results in the real word setting and in other countries.,What do future studies need to confirm in the real world setting and in other countries (pmcid=11881394)?,Future studies need to confirm the value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome in the real world setting and in other countries.,f72ca8a5314e56cf03a3e5f7079df43c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"- Background: Retinal diseases are major contributors to disability, significantly affecting patients’ quality of life.",What are major contributors to disability that significantly affect patients' quality of life (pmcid=11884430)?,Retinal diseases,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) represent a significant disease and economic burden in Colombia.,What represents a significant disease and economic burden in Colombia (pmcid=11884430)?,Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD),b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Assessing the economic evaluation of available treatments is essential for the efficient allocation of healthcare resources.,What is essential for the efficient allocation of healthcare resources (pmcid=11884430)?,Assessing the economic evaluation of available treatments is essential for the efficient allocation of healthcare resources.,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Objective: To estimate the cost-effectiveness and budget impact of using faricimab for the treatment of patients with DME and nAMD within the Colombian health system.,What is the objective of the study (pmcid=11884430)?,The objective of the study with pmcid=11884430 is to estimate the cost-effectiveness and budget impact of using faricimab for the treatment of patients with Diabetic Macular Edema (DME) and Neovascular Age-Related Macular Degeneration (nAMD) within the Colombian health system.,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"Methods: This study used a 25-year Markov cohort model to estimate the cost-effectiveness of faricimab vs aflibercept, ranibizumab, and brolucizumab.",What model was used to estimate the cost-effectiveness of faricimab in comparison to other treatments (pmcid=11884430)?,A 25-year Markov cohort model was used to estimate the cost-effectiveness of faricimab in comparison to other treatments in the study mentioned (pmcid=11884430).,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,We used the methodological guidelines of the local health technology assessment agency for conducting the cost-effectiveness and budget impact analysis.,What methodological guidelines were used for conducting the cost-effectiveness and budget impact analysis in this study (pmcid=11884430)?,The methodological guidelines of the local health technology assessment agency were used for conducting the cost-effectiveness and budget impact analysis in this study (pmcid=11884430).,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Transition probabilities and injection frequencies were derived from the literature.,What were the transition probabilities and injection frequencies derived from in the analysis (pmcid=11884430)?,The transition probabilities and injection frequencies were derived from the literature in the analysis of the use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia (pmcid=11884430).,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Drug prices were retrieved from public local databases.,What were the drug prices retrieved from for the analysis (pmcid=11884430)?,Drug prices were retrieved from public local databases.,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Quality-adjusted life years (QALYs) were assessed.,What was assessed in terms of quality-adjusted life years in the study (pmcid=11884430)?,Quality-adjusted life years (QALYs),b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,The potential patient population for the budget impact analysis was estimated based on disease prevalence and expert consultations.,What was the basis for estimating the potential patient population for the budget impact analysis (pmcid=11884430)?,The potential patient population for the budget impact analysis was estimated based on disease prevalence and expert consultations.,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"Results: Faricimab treat-and-extend (T&E) was dominant vs aflibercept T&E (+0.22 QALYs), ranibizumab T&E (+0.55 QALYs), and brolucizumab for 8 to 12 weeks (+0.06 QALYs) in DME, generating cost savings (in US dollars) of 3849,1375, and 2824,respectively.InnAMD,faricimabalsoshoweddominancevsafliberceptasneeded(+0.12Q ALYs),ranibizumabasneeded(+0.05QALYs),andbrolucizumab8to12weeks(+0.12QALYs)withsa vingsin(US)7223, 5792,and6798, respectively.",What were the cost savings generated by faricimab treat-and-extend compared to other treatments in diabetic macular edema (pmcid=11884430)?,"Faricimab treat-and-extend generated cost savings of $3849 compared to aflibercept treat-and-extend, $1375 compared to ranibizumab treat-and-extend, and $2824 compared to brolucizumab for 8 to 12 weeks in diabetic macular edema.",b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"Assuming an annual market share increase for faricimab of 15% for DME and 13% for nAMD, the Colombian Health System could save 144millionover3years.Ofthesesavings,122.7 million are attributed to drug costs and 21.3milliontoadministrationcosts(US1 = Col$4325).",What annual market share increase assumptions were made for faricimab in the study (pmcid=11884430)?,An annual market share increase of 15% for Diabetic Macular Edema (DME) and 13% for neovascular Age-Related Macular Degeneration (nAMD) was assumed for faricimab in the study with pmcid=11884430.,b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"Conclusion: Considering a willingness to pay threshold of $5988 per additional QALY, faricimab is a cost-effective alternative for both DME and nAMD for the Colombian healthcare system, showing dominance over other anti–vascular endothelial growth factor agents.",What is the conclusion regarding the cost-effectiveness of faricimab for both DME and nAMD in Colombia (pmcid=11884430)?,"Faricimab is a cost-effective alternative for both Diabetic Macular Edema (DME) and Neovascular Age-Related Macular Degeneration (nAMD) in Colombia, showing dominance over other anti-vascular endothelial growth factor agents.",b08d4c1364fb11ef6f4a4ffba4caf89c
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Faricimab provides better health outcomes at lower costs vs other treatments.,What do the results suggest about the cost-effectiveness of Faricimab compared to other treatments? (pmcid=11884430),The results suggest that Faricimab provides better health outcomes at lower costs compared to other treatments for diabetic macular edema and neovascular age-related macular degeneration in Colombia.,b08d4c1364fb11ef6f4a4ffba4caf89c
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,- Background: Evidence on the efficacy of psychological interventions targeting cancer patients diagnosed with an adjustment disorder is scarce.,What is scarce in evidence regarding psychological interventions targeting cancer patients diagnosed with an adjustment disorder (pmcid=11910135)?,Evidence on the efficacy of psychological interventions targeting cancer patients diagnosed with an adjustment disorder is scarce.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Aims: This study aimed to investigate the efficacy and budget impact of a tailored psychological intervention program (AD‐program) targeting cancer patients with adjustment disorder (AD).,What did this study aim to investigate (pmcid=11910135)?,This study aimed to investigate the efficacy and budget impact of a tailored psychological intervention program targeting cancer patients with adjustment disorder.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Methods: Patients (n = 59) were randomised to the intervention or control group.,What was the sample size and randomization process in the study (pmcid=11910135)?,"The sample size in the study was 59 patients, who were randomly assigned to either the intervention or control group.",75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,The AD‐program consisted of three modules: psychoeducation (1–4 sessions) and two additional modules (maximum of 6 sessions per module) provided when needed.,What did the AD-program consist of (pmcid=11910135)?,The AD-program consisted of three modules: psychoeducation and two additional modules provided when needed.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,The primary outcome was psychological distress (HADS).,What was the primary outcome measured in the study (pmcid=11910135)?,"The primary outcome measured in the study with pmcid=11910135 was psychological distress, as assessed by the Hospital Anxiety and Depression Scale (HADS).",75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Secondary outcomes were mental adjustment to cancer (MAC) and health‐related quality of life (EORTC QLQ‐C30).,What were the secondary outcomes measured in the study (pmcid=11910135)?,The secondary outcomes measured in the study with pmcid=11910135 were mental adjustment to cancer (MAC) and health‐related quality of life (EORTC QLQ‐C30).,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Measures were completed at baseline and 3 and 6 months after randomisation.,What measures were completed at baseline and 3 and 6 months after randomisation (pmcid=11910135)?,Measures were completed at baseline and 3 and 6 months after randomisation.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"The budget impact analyses were based on the population size, the costs of the AD‐program, and other costs potentially affected by the AD‐program.",What were the budget impact analyses based on in the study conducted by Holtmaat K et al. (pmcid=11910135)?,"The budget impact analyses were based on the population size, the costs of the AD‐program, and other costs potentially affected by the AD‐program.",75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"Results: The mean psychological distress score in the intervention group (n = 33) decreased over time (M = 19.2 at T0, M = 15.6 at T6).",What was the mean psychological distress score in the intervention group over time (pmcid=11910135)?,The mean psychological distress score in the intervention group decreased from 19.2 at T0 to 15.6 at T6.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"This decrease was not significantly different from decrease in the control condition (n = 26, M = 17.5 at T0, M = 15.9 at T6, p > 0.05).",What was the outcome measure used to assess the decrease in the intervention group compared to the control condition (pmcid=11910135)?,The outcome measure used to assess the decrease in the intervention group compared to the control condition in the study with pmcid=11910135 was not specified in the provided context information.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"Also, there were no significant differences between the two conditions on the secondary outcomes.",What were the significant differences between the two conditions in the study (pmcid=11910135)?,There were no significant differences between the two conditions in the study.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"The budget impact of the AD‐program was estimated at 7–28 million euros per year (to treat 14,430 patients).","What was the estimated budget impact of the AD‐program per year to treat 14,430 patients (pmcid=11910135)?","The estimated budget impact of the AD‐program per year to treat 14,430 patients was 7–28 million euros.",75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Conclusions: The effect of the AD‐program was not statistically significant in this RCT.,What was the statistical significance of the AD-program in this RCT (pmcid=11910135)?,The effect of the AD-program was not statistically significant in this RCT.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Limitations include that this study was underpowered due to recruitment difficulties during the COVID‐19 pandemic.,What was a limitation of the study due to recruitment difficulties during the COVID‐19 pandemic (pmcid=11910135)?,The limitation of the study was that it was underpowered due to recruitment difficulties during the COVID‐19 pandemic.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,More research on the efficacy and implementation of the AD‐program is warranted.,What is warranted regarding the AD‐program based on the abstract sentence (pmcid=11910135)?,More research on the efficacy and implementation of the AD‐program is warranted.,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Trial Registration: Netherlands Trial Register identifier: NL7763.,What is the identifier for the trial registration in the Netherlands Trial Register (pmcid=11910135)?,NL7763,75e72be1e5da700109d4a13c20c877a3
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Registered on 3 June 2019,What type of trial was conducted in this study (pmcid=11910135)?,A Randomised Controlled Trial,75e72be1e5da700109d4a13c20c877a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"- Objective: To estimate the efficiency of a nurse-led telephone program for nonadherent to treatment Type 2 diabetics with comorbid depression (TELE-DD program).Design: Secondary analysis of cost-consequence and budget impact, utilizing data from a randomized clinical trial conducted in the primary healthcare setting.",What type of program was evaluated in the study (pmcid=11919128)?,A nurse-led telephone program for nonadherent to treatment Type 2 diabetics with comorbid depression (TELE-DD program) was evaluated in the study.,9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,The target population consisted of Type 2 diabetic patients with comorbid depression who were nonadherent to their pharmacological treatment.Method: The average cost per controlled patient (glycated hemoglobin < 7%) and the incremental cost-effectiveness ratio were calculated.,What was the target population for this study (pmcid=11919128)?,The target population for this study (pmcid=11919128) was Type 2 diabetic patients with comorbid depression who were nonadherent to their pharmacological treatment.,9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"Similarly, the budgetary impact over 1 year of implementing this program in the region of reference of the randomized clinical trial was assessed.Results: The number of controlled patients is higher in the TELE-DD group at 6, 12, and 18 months.",What was assessed in the budgetary impact analysis over 1 year in the region of reference of the randomized clinical trial (pmcid=11919128)?,The budgetary impact over 1 year of implementing the nurse-led telephone program for nonadherent to treatment type 2 diabetics with comorbid depression was assessed in the region of reference of the randomized clinical trial.,9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,The average cost per controlled patient was higher in the TELE-DD group than in the control group at 6 months (€160.31 vs.,What was the average cost per controlled patient in the TELE-DD group compared to the control group at 6 months (pmcid=11919128)?,€160.31 vs.,9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"€49.79), but lower at 12 (€150.09 vs.",What was the cost difference between the two groups at 12 weeks (pmcid=11919128)?,The cost difference between the two groups at 12 weeks in the study with pmcid 11919128 was €100.30.,9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,€179.59) and 18 months (€209.22 vs.,What was the cost comparison between the nurse-led telephone program and usual care at 6 months and 18 months (pmcid=11919128)?,"At 6 months, the cost of the nurse-led telephone program was €179.59 compared to €209.22 for usual care.",9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"The incremental cost-effectiveness ratio at 6, 12, and 18 months was €254.47, €143.65, and €177.46, respectively.","What were the incremental cost-effectiveness ratios at 6, 12, and 18 months in the study conducted by Gómez-Barrera M (pmcid=11919128)?","The incremental cost-effectiveness ratios at 6, 12, and 18 months in the study conducted by Gómez-Barrera M were €254.47, €143.65, and €177.46, respectively.",9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"The budget impact analysis revealed that implementing the TELE-DD program would result in a reduction of €721,940.68 in expenditure for the funder in the first year of application.Conclusions: A nurse-led telephone program for nonadherent Type 2 diabetics with comorbid depression is an efficient option in the management of healthcare resources.",What was the result of implementing the TELE-DD program in terms of expenditure for the funder in the first year (pmcid=11919128)?,"The result of implementing the TELE-DD program in terms of expenditure for the funder in the first year was a reduction of €721,940.68.",9b786e4fc89c9c578e271b403dc975a3
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,These results highlight the role of nursing in chronic patient management and the efficient use of healthcare resources.Trial Registration: ClinicalTrials.gov Identifier: NCT04097483.,What role did nursing play in chronic patient management according to the results (pmcid=11919128)?,The results indicated that nursing played a significant role in chronic patient management and the efficient use of healthcare resources.,9b786e4fc89c9c578e271b403dc975a3
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"- Background: Cangrelor is an intravenous, reversible P2Y12 inhibitor indicated for the reduction of thrombotic cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure, and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable (for example, in the out-of-hospital cardiac arrest [OHCA] population).",What is Cangrelor indicated for in patients undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the procedure (pmcid=11922778)?,Cangrelor is indicated for the reduction of thrombotic cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the procedure.,40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"Objective: This study aimed to estimate the affordability and budget impact, in the United Kingdom, of introducing cangrelor within the licenced OHCA population.",What did this study aim to estimate in the United Kingdom (pmcid=11922778)?,The study aimed to estimate the affordability and budget impact of introducing cangrelor within the licensed out-of-hospital cardiac arrest (OHCA) population in the United Kingdom.,40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,Methods: A budget impact model was developed to estimate the impact of introducing cangrelor to hospitals over 5 years.,What was the method used to estimate the impact of introducing cangrelor to hospitals over 5 years (pmcid=11922778)?,A budget impact model was developed.,40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"Efficacy (thrombotic events) and safety (bleeding events) data were based on clinical trials, cost data (2021/22 GBP), literature, NHS reference costs and British National Formulary data.",What data sources were used for the efficacy and safety data in the study (pmcid=11922778)?,"The data sources used for the efficacy and safety data in the study with pmcid=11922778 were clinical trials, cost data (2021/22 GBP), literature, NHS reference costs, and British National Formulary data.",40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"Comparators were glycoprotein IIb/IIIa inhibitors and aspirin in combination with heparin, reflecting current treatments used in UK centres for the target population.",What treatments were used as comparators in the study (pmcid=11922778)?,The treatments used as comparators in the study with pmcid=11922778 were glycoprotein IIb/IIIa inhibitors and aspirin in combination with heparin.,40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"Cangrelor uptake was estimated as 50% in Year 1, 75% in Year 2, and 100% in Years 3–5.",What was the estimated uptake of Cangrelor in Year 1 (pmcid=11922778)?,The estimated uptake of Cangrelor in Year 1 was 50%.,40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,The OHCA population was estimated from the British Cardiovascular Intervention Society National Audit 2021/22.,What was the source of estimation for the OHCA population in the UK (pmcid=11922778)?,The source of estimation for the OHCA population in the UK in the study with pmcid=11922778 was the British Cardiovascular Intervention Society National Audit 2021/22.,40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"Results: Over 5 years, cangrelor leads to modelled cost savings of £2,709,853 (−9.84%), varying from £322,218 in Year 1 (−5.85%) to £636,150 (−11.55%) in Year 5).",What are the modelled cost savings of cangrelor over 5 years for the treatment of out-of-hospital cardiac arrest patients who require percutaneous coronary intervention (pmcid=11922778)?,"The modelled cost savings of cangrelor over 5 years for the treatment of out-of-hospital cardiac arrest patients who require percutaneous coronary intervention is £2,709,853.",40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"This is driven by approximately 6,882 hospital days being avoided over 5 years due to fewer bleeding events.",How many hospital days were avoided over 5 years due to fewer bleeding events? (pmcid=11922778),"Approximately 6,882 hospital days were avoided over 5 years due to fewer bleeding events.",40cf76d1c9b8c5a32467f5e38eaec993
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,Conclusion: Cangrelor for OHCA patients who cannot take oral P2Y12 inhibitors may lead to cost savings in the UK.,What may Cangrelor lead to in terms of cost savings in the UK (pmcid=11922778)?,Cangrelor may lead to cost savings in the UK for out-of-hospital cardiac arrest patients who cannot take oral P2Y12 inhibitors.,40cf76d1c9b8c5a32467f5e38eaec993
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"- Background: Tobacco use is the world's leading preventable cause of death, with the highest burden in low and middle-income countries (LMICs).",What is the background information provided in the abstract of the study (pmcid=11927220)?,"The background information provided in the abstract of the study (pmcid=11927220) is that tobacco use is the world's leading preventable cause of death, with the highest burden in low and middle-income countries (LMICs).",a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Those who have mental illness are particularly vulnerable, with a smoking rate two to five times higher than that of the general population.",What population is particularly vulnerable to smoking tobacco according to the abstract sentence provided (pmcid=11927220)?,Those who have mental illness,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Quitting smoking has demonstrated benefits for mental health, including reducing stress and improving the quality of life.",What benefits for mental health have been demonstrated by quitting smoking (pmcid=11927220)?,Reducing stress and improving the quality of life.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"However, the economic feasibility of introducing Nicotine Replacement Therapy (NRT) in the psychiatric medical environment in South Africa has not yet been explored.",What has not yet been explored regarding the economic feasibility of introducing Nicotine Replacement Therapy (NRT) in the psychiatric medical environment in South Africa (pmcid=11927220)?,The economic feasibility of introducing Nicotine Replacement Therapy (NRT) in the psychiatric medical environment in South Africa has not yet been explored.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,This study aims to address this gap by assessing the impact on the budget of implementing an NRT-based smoking cessation program in a psychiatric hospital.,What is the aim of the study conducted by Maphanga B regarding the budget impact of implementing an NRT-based smoking cessation program in a psychiatric hospital? (pmcid=11927220),The aim of the study conducted by Maphanga B is to assess the impact on the budget of implementing an NRT-based smoking cessation program in a psychiatric hospital.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,Methods: This retrospective and cross-sectional study followed a budget impact analysis framework.,What framework did the study follow (pmcid=11927220)?,The study followed a budget impact analysis framework.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Data were retrieved between May 19 and Aug 18, 2023, from 214 patients' medical records.",What data were retrieved from 214 patients' medical records (pmcid=11927220)?,"Data were retrieved between May 19 and Aug 18, 2023.",a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Using primary and secondary data, an ingredients costing approach was used to estimate direct treatment costs of NRT smoking cessation.",What approach was used to estimate the direct treatment costs of NRT smoking cessation in the study (pmcid=11927220)?,An ingredients costing approach was used to estimate the direct treatment costs of NRT smoking cessation in the study with pmcid=11927220.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,All costs were expressed in ZAR (South African currency).,What currency were all costs expressed in for the budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa (pmcid=11927220)?,All costs were expressed in ZAR (South African currency).,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"The economic evaluation was conducted from the payer's perspective, and the results were reported at a 5% discount rate.",What perspective was the economic evaluation conducted from in this study (pmcid: 11927220)?,The economic evaluation was conducted from the payer's perspective.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,A two-way 10% sensitivity analysis was conducted.,What type of analysis was conducted in the study (pmcid=11927220)?,A two-way 10% sensitivity analysis was conducted.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Results: The study showed that study participants were primarily black, male, unemployed, diagnosed with schizophrenia and smoked lightly (69.16% ±3.46).","What were the demographics of the study participants in terms of race, gender, employment status, diagnosis, and smoking habits (pmcid=11927220)?","The study participants were primarily black in terms of race, male in terms of gender, unemployed in terms of employment status, diagnosed with schizophrenia in terms of diagnosis, and smoked lightly in terms of smoking habits.",a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,Implementing the 3-month treatment period of NRT smoking cessation program would result in an expenditure of R1 478 915.42 for 214 patients.,How much would be the expenditure for implementing the 3-month treatment period of NRT smoking cessation program for 214 patients in South Africa (pmcid=11927220)?,The expenditure for implementing the 3-month treatment period of NRT smoking cessation program for 214 patients in South Africa would be R1 478 915.42.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,The hospital will require an additional 0.15% (±0.0095) of the total hospital budget and 6.09% (±0.31) of the hospital pharmacy budget.,What percentage of the hospital pharmacy budget will be required for nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa (pmcid=11927220)?,6.09%,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Conclusion: Our findings indicate that while implementing a NRT is crucial for improving the overall health outcomes among patients with mental illnesses, substantial investment would be required.",What do the findings indicate about the implementation of NRT among patients with mental illnesses in South Africa (pmcid=11927220)?,"The findings indicate that implementing nicotine replacement therapy (NRT) among patients with mental illnesses in South Africa is crucial for improving overall health outcomes, but it would require substantial investment.",a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,The budgetary allocation for NRT smoking cessation interventions would vary by treatment settings and program duration.,What would vary by treatment settings and program duration in the budgetary allocation for NRT smoking cessation interventions? (pmcid=11927220),The budgetary allocation for NRT smoking cessation interventions would vary by treatment settings and program duration.,a497e7668863b20ca1126b4b5600786a
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Consequently, careful consideration of budget allocation and resource distribution is necessary to ensure the program's sustainability within the broader healthcare framework in South Africa.",What is necessary to ensure the program's sustainability within the broader healthcare framework in South Africa (pmcid=11927220)?,Careful consideration of budget allocation and resource distribution is necessary to ensure the program's sustainability within the broader healthcare framework in South Africa.,a497e7668863b20ca1126b4b5600786a
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,- Background: The Interactive Care Coordination and Navigation (iCAN) mobile health intervention aims to improve care coordination and reduce hospital and emergency department visits among people experiencing homelessness.,What is the aim of the iCAN mobile health intervention (pmcid=11936304)?,The aim of the iCAN mobile health intervention is to improve care coordination and reduce hospital and emergency department visits among people experiencing homelessness.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Objective: This study aimed to conduct a three-part economic evaluation of iCAN, including a (1) cost analysis, (2) exploratory financial cost-benefit analysis, and (3) budget impact analysis (BIA).",What three-part economic evaluation did this study aim to conduct for iCAN (pmcid=11936304)?,"The study aimed to conduct a cost analysis, exploratory financial cost-benefit analysis, and budget impact analysis for iCAN.",15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,Methods: We collected cost and expenditure data from a randomized controlled trial of iCAN to conduct a cost analysis and exploratory financial cost-benefit analysis.,What data was collected to conduct a cost analysis and exploratory financial cost-benefit analysis in the study of the Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness (pmcid=11936304)?,Cost and expenditure data were collected from a randomized controlled trial of iCAN to conduct the cost analysis and exploratory financial cost-benefit analysis.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,Costs were classified as startup and recurring costs for participants and the program.,What costs were classified in the study (pmcid=11936304)?,Costs were classified as startup and recurring costs for participants and the program.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,Startup costs included participant supplies for each participant and SMS implementation costs.,What were included in the startup costs for the mHealth intervention for people experiencing homelessness (pmcid=11936304)?,Participant supplies for each participant and SMS implementation costs.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Recurring costs included the cost of recurring services, SMS text messaging platform maintenance, health information access fees, and personnel salaries.",What were some of the recurring costs included in the analysis (pmcid=11936304)?,"Some of the recurring costs included in the analysis were the cost of recurring services, SMS text messaging platform maintenance, health information access fees, and personnel salaries.",15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Using the per participant per year (PPPY) costs of iCAN, the minimum savings reduction in the average health care costs among people experiencing homelessness that would lead to a benefit-cost ratio >1 for iCAN was calculated.",What costs were used to calculate the minimum savings reduction in health care costs for people experiencing homelessness in the iCAN intervention (pmcid=11936304)?,The per participant per year (PPPY) costs of the iCAN intervention were used to calculate the minimum savings reduction in health care costs for people experiencing homelessness.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,This savings threshold was calculated by dividing the PPPY cost of iCAN by the average health care costs among people experiencing homelessness multiplied by 100%.,What was the savings threshold calculated based on in the study (pmcid=11936304)?,The savings threshold was calculated based on the average health care costs among people experiencing homelessness.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,The benefit-cost ratio of iCAN was calculated under different savings thresholds from 0% (no savings) to 50%.,What was the benefit-cost ratio of iCAN calculated under different savings thresholds (pmcid=11936304)?,The benefit-cost ratio of iCAN was calculated under different savings thresholds from 0% (no savings) to 50%.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Costs were calculated PPPY under different scenarios, and the results were used as inputs in a BIA.",What were the costs calculated under different scenarios for in the study conducted by McCullough HP (pmcid=11936304)?,Costs were calculated PPPY (Per Person Per Year) under different scenarios in the study conducted by McCullough HP.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,A probabilistic sensitivity analysis was conducted to incorporate uncertainty around cost estimates.,What type of analysis was conducted to incorporate uncertainty around cost estimates (pmcid=11936304)?,A probabilistic sensitivity analysis,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,Costs are in 2022 US $.,What currency are the costs reported in (pmcid=11936304)?,The costs reported in the study with pmcid=11936304 are in 2022 US $.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Results: The total cost of iCAN was US $2865 PPPY, which was made up of US $265 in startup (9%) and US $2600 (91%) in recurring costs PPPY.",What were the total costs of the iCAN intervention (pmcid=11936304)?,The total cost of the iCAN intervention was US $2865 per person per year (PPPY).,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,The minimum savings threshold that would cause iCAN to have a positive return on investment is 7.8%.,What is the minimum savings threshold that would cause iCAN to have a positive return on investment (pmcid=11936304)?,The minimum savings threshold that would cause iCAN to have a positive return on investment is 7.8%.,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"This means that if average health care costs (US $36,917) among people experiencing homelessness were reduced by more than 7.8% through iCAN, the financial benefits would outweigh the costs of the intervention.",What percentage reduction in average health care costs among people experiencing homelessness would result in the financial benefits outweighing the costs of the iCAN intervention (pmcid=11936304)?,7.8%,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"When health care costs are reduced by 25% ($9229/$36,917; equal to 56% [$9229/$16,609] of the average cost of an inpatient visit), the benefit-cost ratio is 3.22, which means that iCAN produces US $2.22 in health care savings per US $1 spent.",What is the benefit-cost ratio when health care costs are reduced by 25% in the study by McCullough HP (pmcid: 11936304)?,3.22,15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"The BIA estimated that implementing iCAN for 10,250 people experiencing homelessness over 5 years would have a financial cost of US $28.7 million, which could be reduced to US $2.2 million if at least 8% ($2880/$36,917) of average health care costs among people experiencing homelessness are reduced through the intervention.","What was the estimated financial cost of implementing iCAN for 10,250 people experiencing homelessness over 5 years (pmcid=11936304)?","The estimated financial cost of implementing iCAN for 10,250 people experiencing homelessness over 5 years was US $28.7 million.",15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Conclusions: If average costs of emergency department and hospital visits among people experiencing homelessness were reduced by more than 7.8% ($2880/$36,917) through iCAN, the financial benefits would outweigh the costs of the intervention.",What percentage reduction in average costs of emergency department and hospital visits among people experiencing homelessness would result in the financial benefits outweighing the costs of the iCAN intervention (pmcid=11936304)?,"If the average costs of emergency department and hospital visits among people experiencing homelessness were reduced by more than 7.8%, the financial benefits would outweigh the costs of the iCAN intervention.",15e7fb7f3743cea97239cca325b012d5
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"As the savings threshold increases, it results in a higher benefit-cost ratio.",What does the increase in savings threshold result in? (pmcid=11936304),A higher benefit-cost ratio.,15e7fb7f3743cea97239cca325b012d5
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"- BACKGROUND:: Heart failure (HF) is a leading cause of mortality in the United States, often complicated by comorbidities like diabetes mellitus.","What is a leading cause of mortality in the United States, often complicated by comorbidities like diabetes mellitus (pmcid=11953859)?",Heart failure (HF),89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"These patients face high hospitalization risks, impacting clinical outcomes and health care resources.",What impact do patients with heart failure and type 2 diabetes face (pmcid=11953859)?,"Patients with heart failure and type 2 diabetes face high hospitalization risks, impacting clinical outcomes and health care resources.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"The Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial showed that sotagliflozin, a sodium-glucose cotransporter inhibitor, reduced rehospitalizations in patients with HF and diabetes mellitus.",What trial showed that sotagliflozin reduced rehospitalizations in patients with heart failure and diabetes mellitus (pmcid=11953859)?,The Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial,89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"Although clinically beneficial, the economic impact of sotagliflozin from a payer perspective remains unclear, warranting further pharmacoeconomic analysis to guide managed care decisions.","What remains unclear from a payer perspective regarding the economic impact of sotagliflozin, warranting further analysis to guide managed care decisions (pmcid=11953859)?","The economic impact of sotagliflozin from a payer perspective remains unclear, warranting further pharmacoeconomic analysis to guide managed care decisions.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,OBJECTIVE:: To quantify the budget impact of sotagliflozin for US payers over a 5-year time horizon.,What is the objective of the study (pmcid=11953859)?,The objective of the study with pmcid=11953859 is to quantify the budget impact of sotagliflozin for US payers over a 5-year time horizon.,89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,METHODS:: A payer-perspective budget impact model was developed to assess the financial impact of incorporating sotagliflozin for the treatment of patients recently hospitalized for HF with comorbid type 2 diabetes (T2D) over 5 years to US payer health plans.,What perspective was used in the budget impact model developed to assess the financial impact of incorporating sotagliflozin for the treatment of patients recently hospitalized for HF with comorbid type 2 diabetes (T2D) over 5 years to US payer health plans (pmcid=11953859)?,The budget impact model was developed from the payer perspective.,89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"The study used a population reflecting the SOLOIST-WHF clinical trial, with economic parameters adjusted by payer mix (all payer, commercial, Medicare, and Medicaid).",What population was used in the study (pmcid=11953859)?,The study used a population reflecting the SOLOIST-WHF clinical trial.,89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"Health care resource utilization included hospitalization, emergency department (ED) visit, and adverse events’ care.",What health care resource utilization was included in the analysis (pmcid=11953859)?,"Health care resource utilization included hospitalization, emergency department (ED) visit, and adverse events’ care.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"Economic outcomes examined the medical and pharmacy budget impact for payers at the per-user, per member per month (PMPM), and total plan costs levels.",What economic outcomes were examined in the study (pmcid=11953859)?,"The economic outcomes examined in the study included the medical and pharmacy budget impact for payers at the per-user, per member per month (PMPM), and total plan costs levels.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"RESULTS:: For a hypothetical 1-million-member all-payer plan, 1,516 patients hospitalized for HF with comorbid T2D would be eligible for sotagliflozin.",How many patients hospitalized for heart failure with comorbid type 2 diabetes would be eligible for sotagliflozin in a hypothetical 1-million-member all-payer plan (pmcid=11953859)?,"1,516 patients hospitalized for heart failure with comorbid type 2 diabetes would be eligible for sotagliflozin in a hypothetical 1-million-member all-payer plan.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"For all-payer plans, annual per-user costs increased by $4,996 because of higher pharmacy costs ($8,260) but were partially offset by lower medical costs (−$2,608) because of reduced rehospitalization and ED visits from sotagliflozin.",What were the annual per-user costs impacted by in the budget impact analysis from the US payer perspective (pmcid=11953859)?,The annual per-user costs were impacted by higher pharmacy costs and lower medical costs in the budget impact analysis from the US payer perspective (pmcid=11953859).,89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"PMPM total budget impact of sotagliflozin would be $0.08 PMPM in year 1 and $0.38 in year 5, corresponding with total plan cost of $75,736 in year 1 and $378,681 by year 5.",What is the total budget impact of sotagliflozin in year 1 and year 5 from the US payer perspective (pmcid=11953859)?,"The total budget impact of sotagliflozin in year 1 is $75,736 and in year 5 is $378,681 from the US payer perspective.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"Commercial payer PMPM costs were lower ($0.02 in year 1; $0.11 in year 5), and higher for Medicare ($0.23 PMPM in year 1, increasing to 1.13 PMPM in year 5).","What were the PMPM costs for commercial payers and Medicare in year 1 and year 5, according to the budget impact analysis from the US payer perspective? (pmcid=11953859)","For commercial payers, the PMPM costs were $0.02 in year 1 and $0.11 in year 5. For Medicare, the PMPM costs were $0.23 in year 1 and increased to $1.13 in year 5, according to the budget impact analysis from the US payer perspective.",89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,Breakeven rebate rates ranged between 31.5% and 79.4%.,What is the range of breakeven rebate rates mentioned in the study (pmcid=11953859)?,The range of breakeven rebate rates mentioned in the study (pmcid=11953859) is between 31.5% and 79.4%.,89bbfd50fa2145987a221775219e191f
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"CONCLUSIONS:: Although sotagliflozin increases pharmacy costs for recently hospitalized HF patients with T2D, approximately 21%-68% of pharmacy costs were offset from reduced rehospitalization and ED visits.",What percentage of pharmacy costs were offset by reduced rehospitalization and ED visits for recently hospitalized HF patients with T2D (pmcid=11953859)?,Approximately 21%-68% of pharmacy costs were offset by reduced rehospitalization and ED visits for recently hospitalized HF patients with T2D in the study with pmcid=11953859.,89bbfd50fa2145987a221775219e191f
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"- BACKGROUND: Cangrelor is an intravenous, reversible P2Y12 inhibitor indicated for the reduction of thrombotic cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure, and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable (for example, in the out-of-hospital cardiac arrest [OHCA] population).",What is Cangrelor indicated for in patients undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the procedure (pmcid=11922778)?,Cangrelor is indicated for the reduction of thrombotic cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the procedure.,5dd65ad5607583b5a42282d9c854078b
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"OBJECTIVE: This study aimed to estimate the affordability and budget impact, in the United Kingdom, of introducing cangrelor within the licenced OHCA population.",What did this study aim to estimate in the United Kingdom (pmcid=11922778)?,The study aimed to estimate the affordability and budget impact of introducing cangrelor within the licensed out-of-hospital cardiac arrest (OHCA) population in the United Kingdom.,5dd65ad5607583b5a42282d9c854078b
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,METHODS: A budget impact model was developed to estimate the impact of introducing cangrelor to hospitals over 5 years.,What was the purpose of developing the budget impact model (pmcid=11922778)?,The purpose of developing the budget impact model in this study (pmcid=11922778) was to estimate the impact of introducing cangrelor to hospitals over a period of 5 years.,5dd65ad5607583b5a42282d9c854078b
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"Efficacy (thrombotic events) and safety (bleeding events) data were based on clinical trials, cost data (2021/22 GBP), literature, NHS reference costs and British National Formulary data.",What were the data sources used for efficacy and safety data in the study (pmcid=11922778)?,"The data sources used for efficacy and safety data in the study with pmcid=11922778 were clinical trials, cost data (2021/22 GBP), literature, NHS reference costs, and British National Formulary data.",5dd65ad5607583b5a42282d9c854078b
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"Comparators were glycoprotein IIb/IIIa inhibitors and aspirin in combination with heparin, reflecting current treatments used in UK centres for the target population.",What were the comparators used in the study (pmcid=11922778)?,The comparators used in the study were glycoprotein IIb/IIIa inhibitors and aspirin in combination with heparin.,5dd65ad5607583b5a42282d9c854078b
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"Cangrelor uptake was estimated as 50% in Year 1, 75% in Year 2, and 100% in Years 3-5.",What was the estimated uptake of Cangrelor in Year 1 (pmcid=11922778)?,The estimated uptake of Cangrelor in Year 1 was 50%.,5dd65ad5607583b5a42282d9c854078b
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,The OHCA population was estimated from the British Cardiovascular Intervention Society National Audit 2021/22.,What was the source of estimation for the OHCA population in the UK (pmcid=11922778)?,The source of estimation for the OHCA population in the UK in the study with pmcid=11922778 was the British Cardiovascular Intervention Society National Audit 2021/22.,5dd65ad5607583b5a42282d9c854078b
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"RESULTS: Over 5 years, cangrelor leads to modelled cost savings of £2,709,853 (-9.84%), varying from £322,218 in Year 1 (-5.85%) to £636,150 (-11.55%) in Year 5).",What cost savings were modelled over 5 years with the use of cangrelor for the treatment of out-of-hospital cardiac arrest patients who require percutaneous coronary intervention (pmcid=11922778)?,"Over 5 years, cangrelor leads to modelled cost savings of £2,709,853 (-9.84%).",5dd65ad5607583b5a42282d9c854078b
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,"This is driven by approximately 6,882 hospital days being avoided over 5 years due to fewer bleeding events.",How many hospital days were avoided over 5 years due to fewer bleeding events (pmcid=11922778)?,"6,882 hospital days were avoided over 5 years due to fewer bleeding events.",5dd65ad5607583b5a42282d9c854078b
11922778,Modi B,The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention,2025,bim,CONCLUSION: Cangrelor for OHCA patients who cannot take oral P2Y12 inhibitors may lead to cost savings in the UK.,What may Cangrelor lead to in terms of cost savings in the UK (pmcid=11922778)?,Cangrelor may lead to cost savings in the UK for out-of-hospital cardiac arrest patients who cannot take oral P2Y12 inhibitors.,5dd65ad5607583b5a42282d9c854078b
11999704,Prosperini L,Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy,2025,bim,"- PURPOSE: Two analyses, a cost-minimization and a budget impact, were conducted to estimate the economic and financial impact of subcutaneous (SC) vs intravenous (IV) natalizumab in terms of administration times and costs in the Italian setting from the perspective of multiple sclerosis (MS) center, patient, and society.",What analyses were conducted to estimate the economic and financial impact of subcutaneous vs intravenous natalizumab in Italy (pmcid=11999704)?,"Two analyses, a cost-minimization analysis and a budget impact analysis, were conducted to estimate the economic and financial impact of subcutaneous (SC) vs intravenous (IV) natalizumab in Italy.",b0e3a695e4d1b3db99367b67ca42078f
11999704,Prosperini L,Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy,2025,bim,"PATIENTS AND METHODS: Cost minimization analysis (CMA) adopted a Markov model with three different states, and it is based on the results of REFINE study and its post-hoc analysis, which evaluated and demonstrated the non-inferiority of natalizumab SC vs IV formulation.",What study results did the Cost-Minimization Analysis (CMA) in Italy for subcutaneous Natalizumab in relapsing-remitting multiple sclerosis base its model on (pmcid=11999704)?,"The Cost-Minimization Analysis (CMA) in Italy for subcutaneous Natalizumab in relapsing-remitting multiple sclerosis based its model on the results of the REFINE study and its post-hoc analysis, which evaluated and demonstrated the non-inferiority of natalizumab SC vs IV formulation.",b0e3a695e4d1b3db99367b67ca42078f
11999704,Prosperini L,Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy,2025,bim,"The economic inputs came mainly from EASIER study, that estimated the administration time, resource consumption, and costs of natalizumab SC vs IV.",What study provided the economic inputs for the analysis of natalizumab SC vs IV (pmcid=11999704)?,The economic inputs for the analysis of natalizumab SC vs IV in the study mentioned (pmcid=11999704) came mainly from the EASIER study.,b0e3a695e4d1b3db99367b67ca42078f
11999704,Prosperini L,Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy,2025,bim,A lifetime horizon was considered.,What horizon was considered in the analysis (pmcid=11999704)?,A lifetime horizon was considered.,b0e3a695e4d1b3db99367b67ca42078f
11999704,Prosperini L,Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy,2025,bim,Budget impact analysis (BIA) was conducted with a cost calculator approach and compared a base scenario (without SC natalizumab) with an alternative scenario (with SC natalizumab).,What approach was used to conduct the budget impact analysis in this study (pmcid=11999704)?,A cost calculator approach was used to conduct the budget impact analysis in this study (pmcid=11999704).,b0e3a695e4d1b3db99367b67ca42078f
11999704,Prosperini L,Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy,2025,bim,The inputs were shared with the CMA and a 3-year time horizon was considered.,What time horizon was considered in the cost-minimization analysis (pmcid=11999704)?,A 3-year time horizon was considered in the cost-minimization analysis for pmcid 11999704.,b0e3a695e4d1b3db99367b67ca42078f
11999704,Prosperini L,Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy,2025,bim,A progressive increase in the number of patients treated with natalizumab SC was estimated from the 1st to the 2nd to the 3rd year after reimbursement in Italy.,What was estimated from the 1st to the 2nd to the 3rd year after reimbursement in Italy regarding patients treated with natalizumab SC? (pmcid=11999704),A progressive increase in the number of patients treated with natalizumab SC was estimated.,b0e3a695e4d1b3db99367b67ca42078f
11999704,Prosperini L,Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy,2025,bim,"RESULTS: CMA estimated that savings due to the use of SC instead of IV natalizumab would be €2,824, €1,137, and €9,170 per patient from the perspectives of MS center, patient, and society, respectively, thus depicting a weak dominance (lower costs and non-inferiority efficacy).","What were the estimated savings per patient due to the use of subcutaneous natalizumab instead of intravenous natalizumab from the perspective of the MS center, patient, and society (pmcid=11999704)?","The estimated savings per patient due to the use of subcutaneous natalizumab instead of intravenous natalizumab from the perspective of the MS center, patient, and society were €2,824, €1,137, and €9,170, respectively.",b0e3a695e4d1b3db99367b67ca42078f
11999704,Prosperini L,Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy,2025,bim,BIA estimated that the savings were approximately 3.2 million euros from the perspective of MS centers and around 10.3 million euros from the perspective of society in the first 3 years following reimbursement.,What were the estimated savings from the perspective of MS centers and society in the first 3 years following reimbursement (pmcid=11999704)?,The estimated savings were approximately 3.2 million euros from the perspective of MS centers and around 10.3 million euros from the perspective of society in the first 3 years following reimbursement.,b0e3a695e4d1b3db99367b67ca42078f
11999704,Prosperini L,Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy,2025,bim,"CONCLUSION: Administering natalizumab subcutaneously rather than intravenously to treatment-eligible patients would result in administration time and cost savings thus determining a favorable impact for the MS center, the patient and the society.",What impact would administering natalizumab subcutaneously have on administration time and cost savings for treatment-eligible patients (pmcid=11999704)?,"Administering natalizumab subcutaneously rather than intravenously to treatment-eligible patients would result in administration time and cost savings, thus determining a favorable impact for the MS center, the patient, and society.",b0e3a695e4d1b3db99367b67ca42078f
12041651,Berti G,Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis,2025,bim,- INTRODUCTION: Remdesivir (RDV) and nirmatrelvir/ritonavir (NRM/RTV) are two antiviral agents for treating outpatient adults with mild to moderate symptomatic COVID-19 at high risk of developing a severe disease.,What are the two antiviral agents for treating outpatient adults with mild to moderate symptomatic COVID-19 at high risk of developing a severe disease (pmcid=12041651)?,Remdesivir (RDV) and nirmatrelvir/ritonavir (NRM/RTV),6cc455b36029fb7494c4cc43c1aa37d8
12041651,Berti G,Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis,2025,bim,"The review objectives are to compare the efficacy and safety of these antivirals based on published RCT and real-world data, and to evaluate costs from a healthcare perspective.",What are the review objectives of this study (pmcid=12041651)?,"The review objectives of this study are to compare the efficacy and safety of antivirals for symptomatic COVID-19 outpatients based on published RCT and real-world data, and to evaluate costs from a healthcare perspective.",6cc455b36029fb7494c4cc43c1aa37d8
12041651,Berti G,Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis,2025,bim,METHODS: This study provides a network meta-analysis of RDV and NRM/RTV for early treatment of COVID-19.,What type of analysis was conducted in this study (pmcid=12041651)?,Network meta-analysis,6cc455b36029fb7494c4cc43c1aa37d8
12041651,Berti G,Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis,2025,bim,The outcomes analysed were hospitalisation for any cause and serious adverse events.,What outcomes were analyzed in the study (pmcid=12041651)?,The outcomes analyzed in the study with pmcid=12041651 were hospitalisation for any cause and serious adverse events.,6cc455b36029fb7494c4cc43c1aa37d8
12041651,Berti G,Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis,2025,bim,"A cost-analysis was performed incorporating drug costs, administration, hospitalisations, and management of adverse events.",What cost-analysis was performed in the study (pmcid=12041651)?,"A cost-analysis incorporating drug costs, administration, hospitalizations, and management of adverse events was performed in the study.",6cc455b36029fb7494c4cc43c1aa37d8
12041651,Berti G,Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis,2025,bim,A budget impact analysis was estimated for the University Hospital of Padua.,What was estimated in the budget impact analysis for the University Hospital of Padua (pmcid=12041651)?,The budget impact analysis estimated the financial impact of antiviral treatments for symptomatic COVID-19 outpatients at the University Hospital of Padua.,6cc455b36029fb7494c4cc43c1aa37d8
12041651,Berti G,Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis,2025,bim,"RESULTS: Our results indicated that RDV showed a trend towards a lower risk of hospitalisation compared to NRM/RTV (RR 1.59, 95% CI: 0.60-4.20), though this was not statistically significant.",What was the trend in risk of hospitalization between RDV and NRM/RTV according to the results (pmcid=12041651)?,"The trend in risk of hospitalization between RDV and NRM/RTV according to the results in the study (pmcid=12041651) was that RDV showed a trend towards a lower risk of hospitalization compared to NRM/RTV, with a relative risk of 1.59 (95% CI: 0.60-4.20), although this was not statistically significant.",6cc455b36029fb7494c4cc43c1aa37d8
12041651,Berti G,Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis,2025,bim,"For safety, NRM/RTV demonstrated a slightly lower risk of serious adverse events compared to RDV (RR 0.92, 95% CI: 0.31-2.74), but without statistical significance.",What was the safety comparison between NRM/RTV and RDV in terms of serious adverse events (pmcid=12041651)?,"NRM/RTV demonstrated a slightly lower risk of serious adverse events compared to RDV, but without statistical significance (RR 0.92, 95% CI: 0.31-2.74).",6cc455b36029fb7494c4cc43c1aa37d8
12041651,Berti G,Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis,2025,bim,"A cost analysis showed that NRM/RTV could save €550,854.46 per 1,000 patients.","What cost savings were associated with NRM/RTV per 1,000 patients (pmcid=12041651)?","€550,854.46",6cc455b36029fb7494c4cc43c1aa37d8
12041651,Berti G,Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis,2025,bim,"Finally, a budget impact analysis based on data from the University Hospital of Padua estimated annual savings of €210,977.25 if all early treatments were administered with NRM/RTV instead of RDV.",What was the estimated annual savings if all early treatments were administered with NRM/RTV instead of RDV at the University Hospital of Padua (pmcid=12041651)?,"The estimated annual savings at the University Hospital of Padua would be €210,977.25 if all early treatments were administered with NRM/RTV instead of RDV.",6cc455b36029fb7494c4cc43c1aa37d8
12041651,Berti G,Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis,2025,bim,DISCUSSION: The comparison of the two antiviral therapies for the early treatment of COVID-19 did not yield statistically significant differences in the potential efficacy and safety to prevent hospitalisation or serious adverse events.,What did the comparison of the two antiviral therapies for the early treatment of COVID-19 not yield statistically significant differences in (pmcid=12041651)?,The comparison of the two antiviral therapies for the early treatment of COVID-19 did not yield statistically significant differences in the potential efficacy and safety to prevent hospitalisation or serious adverse events.,6cc455b36029fb7494c4cc43c1aa37d8
12041651,Berti G,Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis,2025,bim,"However, the results of the cost-analysis showed a saving in favour of NRM/RTV.",What were the results of the cost-analysis in favor of NRM/RTV (pmcid=12041651)?,The results of the cost-analysis showed a saving in favor of NRM/RTV.,6cc455b36029fb7494c4cc43c1aa37d8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,- BACKGROUND: Evidence on the efficacy of psychological interventions targeting cancer patients diagnosed with an adjustment disorder is scarce.,What is scarce in evidence regarding psychological interventions targeting cancer patients diagnosed with an adjustment disorder (pmcid=11910135)?,Evidence on the efficacy of psychological interventions targeting cancer patients diagnosed with an adjustment disorder is scarce.,1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,AIMS: This study aimed to investigate the efficacy and budget impact of a tailored psychological intervention program (AD-program) targeting cancer patients with adjustment disorder (AD).,What did this study aim to investigate (pmcid=11910135)?,This study aimed to investigate the efficacy and budget impact of a tailored psychological intervention program targeting cancer patients with adjustment disorder.,1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,METHODS: Patients (n = 59) were randomised to the intervention or control group.,What was the sample size for the randomised patients in this study (pmcid=11910135)?,The sample size for the randomised patients in this study (pmcid=11910135) was 59.,1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,The AD-program consisted of three modules: psychoeducation (1-4 sessions) and two additional modules (maximum of 6 sessions per module) provided when needed.,What did the AD-program consist of (pmcid=11910135)?,The AD-program consisted of three modules: psychoeducation and two additional modules.,1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,The primary outcome was psychological distress (HADS).,What was the primary outcome measured in the study (pmcid=11910135)?,"The primary outcome measured in the study with pmcid=11910135 was psychological distress, specifically using the Hospital Anxiety and Depression Scale (HADS).",1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Secondary outcomes were mental adjustment to cancer (MAC) and health-related quality of life (EORTC QLQ-C30).,What were the secondary outcomes measured in the study (pmcid=11910135)?,The secondary outcomes measured in the study with pmcid=11910135 were mental adjustment to cancer (MAC) and health-related quality of life (EORTC QLQ-C30).,1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Measures were completed at baseline and 3 and 6 months after randomisation.,What measures were completed at baseline and 3 and 6 months after randomisation (pmcid=11910135)?,Measures were completed at baseline and 3 and 6 months after randomisation.,1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"The budget impact analyses were based on the population size, the costs of the AD-program, and other costs potentially affected by the AD-program.",What were the budget impact analyses based on in the study (pmcid=11910135)?,"The budget impact analyses were based on the population size, the costs of the AD-program, and other costs potentially affected by the AD-program.",1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"RESULTS: The mean psychological distress score in the intervention group (n = 33) decreased over time (M = 19.2 at T0, M = 15.6 at T6).",What was the mean psychological distress score in the intervention group at the beginning of the study (pmcid=11910135)?,The mean psychological distress score in the intervention group at the beginning of the study was 19.2.,1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"This decrease was not significantly different from decrease in the control condition (n = 26, M = 17.5 at T0, M = 15.9 at T6, p > 0.05).",What was the outcome of the decrease in the intervention group compared to the control condition (pmcid=11910135)?,The outcome of the decrease in the intervention group compared to the control condition was not significantly different.,1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"Also, there were no significant differences between the two conditions on the secondary outcomes.",What were the significant differences between the two conditions in the study (pmcid=11910135)?,There were no significant differences between the two conditions in the study (pmcid=11910135).,1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,"The budget impact of the AD-program was estimated at 7-28 million euros per year (to treat 14,430 patients).",What was the estimated budget impact of the AD-program (pmcid=11910135)?,"The estimated budget impact of the AD-program was 7-28 million euros per year to treat 14,430 patients.",1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,CONCLUSIONS: The effect of the AD-program was not statistically significant in this RCT.,What was the statistical significance of the effect of the AD-program in this RCT (pmcid=11910135)?,The effect of the AD-program was not statistically significant in this RCT (pmcid=11910135).,1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Limitations include that this study was underpowered due to recruitment difficulties during the COVID-19 pandemic.,What were the limitations of this study (pmcid=11910135)?,The limitations of this study (pmcid=11910135) include being underpowered due to recruitment difficulties during the COVID-19 pandemic.,1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,More research on the efficacy and implementation of the AD-program is warranted.,What is warranted based on the research on the efficacy and implementation of the AD-program (pmcid=11910135)?,More research on the efficacy and implementation of the AD-program is warranted.,1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,TRIAL REGISTRATION: Netherlands Trial Register identifier: NL7763.,What is the Netherlands Trial Register identifier for this study (pmcid=11910135)?,NL7763,1275b436569c68940061318abb516ba8
11910135,Holtmaat K,Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial,2025,bim,Registered on 3 June 2019.,What was the title of the study conducted by Holtmaat K (pmcid=11910135)?,"The title of the study conducted by Holtmaat K (pmcid=11910135) was ""Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial"".",1275b436569c68940061318abb516ba8
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"- BACKGROUND: Lennox-Gastaut syndrome (LGS) is a severe encephalopathic disease that leads to a decrease in the quality of life, physical injury, psychosocial impairment, and a significant increase in treatment costs.",What is the background information provided in the abstract regarding Lennox-Gastaut syndrome (LGS) (pmcid=11881394)?,"The background information provided in the abstract regarding Lennox-Gastaut syndrome (LGS) is that it is a severe encephalopathic disease that leads to a decrease in the quality of life, physical injury, psychosocial impairment, and a significant increase in treatment costs.",936eb45aabdc67c3da09e6c90991fa76
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,Cannabidiol (CBD) is approved for the adjunctive treatment of tonic-colonic seizures in LGS.,What is cannabidiol approved for in the adjunctive treatment of Lennox Gastaut syndrome (pmcid=11881394)?,Cannabidiol (CBD) is approved for the adjunctive treatment of tonic-colonic seizures in LGS.,936eb45aabdc67c3da09e6c90991fa76
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,This study aimed to determine the cost-effectiveness of CBD compared to the usual treatment in patients with LGS syndrome.,What was the aim of the study conducted by Goudarzi Z regarding the cost-effectiveness of CBD in patients with Lennox Gastaut syndrome (pmcid=11881394)?,The aim of the study conducted by Goudarzi Z regarding the cost-effectiveness of CBD in patients with Lennox Gastaut syndrome was to determine the value of cannabidiol as an adjunctive treatment for LGS syndrome through cost-effectiveness and budget impact analysis.,936eb45aabdc67c3da09e6c90991fa76
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,METHODS: We developed a lifetime-horizon Markov model to compare the cost-effectiveness of adjunctive CBD versus usual care.,What type of model was developed to compare the cost-effectiveness of adjunctive CBD versus usual care (pmcid=11881394)?,A lifetime-horizon Markov model was developed.,936eb45aabdc67c3da09e6c90991fa76
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"Additionally, we performed a budget impact analysis over a 5-year time horizon.",What type of analysis was performed over a 5-year time horizon (pmcid=11881394)?,A budget impact analysis was performed over a 5-year time horizon in the study with pmcid 11881394.,936eb45aabdc67c3da09e6c90991fa76
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"The findings were presented as the incremental cost-effectiveness ratio (ICER) for CEA, with a willingness to pay threshold of $18,261 per QALY gained, and as the difference in the overall budget ($) between the scenarios with and without CBD for budget impact assessment.",What was the incremental cost-effectiveness ratio (ICER) used for in this study (pmcid=11881394)?,The incremental cost-effectiveness ratio (ICER) was used for cost-effectiveness analysis (CEA) in this study (pmcid=11881394).,936eb45aabdc67c3da09e6c90991fa76
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"RESULTS: In the base case scenario, CBD was cost-effective compared with usual care $6573 per QALY.",What was the cost-effectiveness of CBD compared to usual care in the base case scenario (pmcid=11881394)?,CBD was cost-effective compared with usual care at $6573 per QALY in the base case scenario.,936eb45aabdc67c3da09e6c90991fa76
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,Sensitivity analyses substantiated these results.,What did the sensitivity analyses substantiate in the study by Goudarzi Z on the value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome (pmcid=11881394)?,The sensitivity analyses substantiated the results of the study on the cost-effectiveness and budget impact of cannabidiol as an adjunctive treatment for Lennox Gastaut syndrome.,936eb45aabdc67c3da09e6c90991fa76
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"From a healthcare perspective, there is a 77% probability that CBD is cost-effective at a willingness to pay of $18,261 per quality-adjusted life-year (QALY).","What is the probability that CBD is cost-effective at a willingness to pay of $18,261 per quality-adjusted life-year from a healthcare perspective (pmcid=11881394)?",77%,936eb45aabdc67c3da09e6c90991fa76
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"Overall, the market access of CBD was associated to an increased budget of about $3,459,846 (+ 33%) in the next 5 years simulated.",What was the increased budget associated with the market access of CBD in the next 5 years simulated (pmcid=11881394)?,"The increased budget associated with the market access of CBD in the next 5 years simulated was about $3,459,846 (+33%).",936eb45aabdc67c3da09e6c90991fa76
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,"CONCLUSIONS: Compared to usual care, CBD seems to be cost-effective in LGS patients and sustainable, with less than 34% overall budget increased in the next 5 years.",What is the overall budget increase expected in the next 5 years compared to usual care for Lennox Gastaut syndrome patients (pmcid=11881394)?,Less than 34% overall budget increase,936eb45aabdc67c3da09e6c90991fa76
11881394,Goudarzi Z,Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis,2025,bim,Future studies need to confirm our results in the real word setting and in other countries.,What do future studies need to confirm in the real world setting and in other countries (pmcid=11881394)?,Future studies need to confirm the value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome in the real world setting and in other countries.,936eb45aabdc67c3da09e6c90991fa76
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,- Background: Low-dose aspirin and rivaroxaban are the cornerstone treatment for cardiovascular prevention in patients with peripheral artery disease (PAD) and/or stable coronary artery disease (SCAD).,What are the cornerstone treatments for cardiovascular prevention in patients with peripheral artery disease (PAD) and/or stable coronary artery disease (SCAD) (pmcid=11871816)?,Low-dose aspirin and rivaroxaban are the cornerstone treatments for cardiovascular prevention in patients with peripheral artery disease (PAD) and/or stable coronary artery disease (SCAD) according to the study with pmcid 11871816.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,The combination of rivaroxaban with aspirin imposes a synergistic effect on the inhibition of factor-induced platelet aggregation.,What effect does the combination of rivaroxaban with aspirin have on factor-induced platelet aggregation? (pmcid=11871816),The combination of rivaroxaban with aspirin imposes a synergistic effect on the inhibition of factor-induced platelet aggregation.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"The present work aimed at comparing the cost-utility and cost-effectiveness of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban alone (5 mg twice daily) with aspirin alone in patients with peripheral artery disease (PAD) or coronary artery disease (CAD) and related subgroups.",What was the aim of the present work (pmcid=11871816)?,"The aim of the present work was to compare the cost-utility and cost-effectiveness of rivaroxaban plus aspirin, rivaroxaban alone, and aspirin alone in patients with peripheral artery disease (PAD) or coronary artery disease (CAD) and related subgroups.",ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,Methods: This pharmacoeconomic study was performed based on the insurance organization and utilized a state-transition decision Markov model.,What type of model was utilized in this pharmacoeconomic study (pmcid=11871816)?,State-transition decision Markov model,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"From the COMPASS trial, Clinical efficacy and Clinical events were collected.",What data was collected from the COMPASS trial (pmcid=11871816)?,Clinical efficacy and Clinical events were collected from the COMPASS trial (pmcid=11871816).,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,Health outcomes and cost were assessed over a 20-year time horizon (lifetime).,What time horizon was used to assess health outcomes and cost in the study (pmcid=11871816)?,Health outcomes and cost were assessed over a 20-year time horizon (lifetime).,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,The direct costs of medical services were included in the analysis.,What costs were included in the analysis (pmcid=11871816)?,The direct costs of medical services were included in the analysis.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,The results were stated based on Incremental Cost-Utility (ICUR) and Incremental Cost Effectiveness Ratio (ICER).,What were the results based on in the study conducted by Goudarzi Z (pmcid=11871816)?,The results were based on Incremental Cost-Utility (ICUR) and Incremental Cost Effectiveness Ratio (ICER) in the study conducted by Goudarzi Z.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,Uncertainty was assessed utilizing deterministic and probabilistic sensitivity analyses.,What type of sensitivity analyses were utilized to assess uncertainty in the study (pmcid=11871816)?,Deterministic and probabilistic sensitivity analyses were utilized to assess uncertainty in the study (pmcid=11871816).,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"Discount rates of .058 and .03 were included for cost and effectiveness data, respectively.",What discount rates were included for cost and effectiveness data in the analysis (pmcid=11871816)?,Discount rates of .058 and .03 were included for cost and effectiveness data in the analysis (pmcid=11871816).,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,The budget impact based on the Markov model was estimated as the financial burden resulting from the insurance coverage of rivaroxaban.,What was estimated as the financial burden resulting from the insurance coverage of rivaroxaban (pmcid=11871816)?,The budget impact based on the Markov model was estimated as the financial burden resulting from the insurance coverage of rivaroxaban.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"Results: In the total of CAD and PAD patients, treatment with rivaroxaban plus aspirin and rivaroxaban alone were more expensive than the aspirin alone, but also more effective, resulting in ICUR being $4594/QALY and $13601/QALY respectively, and for ICER being $3348/LYG and $9901/LYG.",What were the incremental cost-effectiveness ratios for treatment with rivaroxaban plus aspirin and rivaroxaban alone compared to aspirin alone in patients with coronary and peripheral artery diseases (pmcid=11871816)?,"The incremental cost-effectiveness ratios for treatment with rivaroxaban plus aspirin compared to aspirin alone were $4594 per quality-adjusted life year (QALY) and $3348 per life year gained (LYG). For treatment with rivaroxaban alone compared to aspirin alone, the incremental cost-effectiveness ratios were $13601 per QALY and $9901 per LYG.",ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,In PAD patients rivaroxaban plus aspirin had higher effectiveness than aspirin alone that ICUR and ICER being $11929/QALY and $9896/LYG respectively.,What were the incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) values for rivaroxaban plus aspirin compared to aspirin alone in PAD patients (pmcid=11871816)?,The incremental cost-effectiveness ratio (ICER) was $9896/LYG and the incremental cost-utility ratio (ICUR) was $11929/QALY for rivaroxaban plus aspirin compared to aspirin alone in PAD patients.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"In CAD patients, treatment with rivaroxaban plus aspirin was expensive and less effective than aspirin alone.",What was the cost-effectiveness and budget impact analysis comparing rivaroxaban with or without aspirin to aspirin alone in patients with coronary and peripheral artery diseases in Iran (pmcid=11871816)?,The cost-effectiveness and budget impact analysis comparing rivaroxaban with or without aspirin to aspirin alone in patients with coronary and peripheral artery diseases in Iran found that treatment with rivaroxaban plus aspirin was expensive and less effective than aspirin alone.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"The estimated annual budget impact was $28,253,135 for the rivaroxaban plus aspirin and $292,593,909 for the rivaroxaban alone in the total of CAD and PAD patients.",What were the estimated annual budget impacts for rivaroxaban plus aspirin and rivaroxaban alone in patients with coronary and peripheral artery diseases in Iran (pmcid=11871816)?,"The estimated annual budget impact was $28,253,135 for rivaroxaban plus aspirin and $292,593,909 for rivaroxaban alone in patients with coronary and peripheral artery diseases in Iran.",ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,Conclusions: This study showed that rivaroxaban plus aspirin is a cost-effective alternative in PAD and total of CAD and PAD patients.,What did this study show regarding the cost-effectiveness of rivaroxaban plus aspirin in patients with coronary and peripheral artery diseases (pmcid=11871816)?,This study showed that rivaroxaban plus aspirin is a cost-effective alternative in patients with peripheral artery disease (PAD) and in the total population of patients with coronary artery disease (CAD) and PAD.,ddc198ccb56f3d98e6906adc3f6f99cf
11871816,Goudarzi Z,Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran,2025,bim,"In CAD patients, rivaroxaban plus aspirin and rivaroxaban alone were not cost-effective.",Was rivaroxaban plus aspirin or rivaroxaban alone cost-effective in CAD patients (pmcid=11871816)?,"No, in CAD patients, neither rivaroxaban plus aspirin nor rivaroxaban alone were cost-effective according to the study with pmcid=11871816.",ddc198ccb56f3d98e6906adc3f6f99cf
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"- BACKGROUND: Tobacco use is the world's leading preventable cause of death, with the highest burden in low and middle-income countries (LMICs).","What is the leading preventable cause of death worldwide, with the highest burden in low and middle-income countries (LMICs) (pmcid=11927220)?",Tobacco use,4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Those who have mental illness are particularly vulnerable, with a smoking rate two to five times higher than that of the general population.","What population is particularly vulnerable to smoking tobacco, with a rate two to five times higher than the general population (pmcid=11927220)?",Those with mental illness,4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Quitting smoking has demonstrated benefits for mental health, including reducing stress and improving the quality of life.",What benefits does quitting smoking have for mental health (pmcid=11927220)?,"Quitting smoking has demonstrated benefits for mental health, including reducing stress and improving the quality of life.",4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"However, the economic feasibility of introducing Nicotine Replacement Therapy (NRT) in the psychiatric medical environment in South Africa has not yet been explored.",What has not yet been explored in the psychiatric medical environment in South Africa regarding Nicotine Replacement Therapy (NRT) (pmcid=11927220)?,The economic feasibility of introducing Nicotine Replacement Therapy (NRT) has not yet been explored in the psychiatric medical environment in South Africa.,4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,This study aims to address this gap by assessing the impact on the budget of implementing an NRT-based smoking cessation program in a psychiatric hospital.,What is the aim of the study in relation to the budget impact of implementing an NRT-based smoking cessation program in a psychiatric hospital (pmcid=11927220)?,The aim of the study is to assess the impact on the budget of implementing an NRT-based smoking cessation program in a psychiatric hospital.,4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,METHODS: This retrospective and cross-sectional study followed a budget impact analysis framework.,What framework did the study follow (pmcid=11927220)?,The study followed a budget impact analysis framework.,4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Data were retrieved between May 19 and Aug 18, 2023, from 214 patients' medical records.",What data were retrieved from 214 patients' medical records (pmcid=11927220)?,"Data were retrieved between May 19 and Aug 18, 2023.",4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Using primary and secondary data, an ingredients costing approach was used to estimate direct treatment costs of NRT smoking cessation.",What approach was used to estimate the direct treatment costs of NRT smoking cessation in the study (pmcid=11927220)?,An ingredients costing approach was used to estimate the direct treatment costs of NRT smoking cessation in the study with pmcid=11927220.,4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,All costs were expressed in ZAR (South African currency).,What currency were all costs expressed in for the budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa (pmcid=11927220)?,All costs were expressed in ZAR (South African currency).,4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"The economic evaluation was conducted from the payer's perspective, and the results were reported at a 5% discount rate.",What perspective was the economic evaluation conducted from in this study (pmcid=11927220)?,The economic evaluation was conducted from the payer's perspective.,4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,A two-way 10% sensitivity analysis was conducted.,What type of analysis was conducted in the study (pmcid=11927220)?,A two-way 10% sensitivity analysis was conducted.,4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"RESULTS: The study showed that study participants were primarily black, male, unemployed, diagnosed with schizophrenia and smoked lightly (69.16% ±3.46).",What were the demographic characteristics of the study participants in the budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa (pmcid=11927220)?,"The study participants were primarily black, male, unemployed, diagnosed with schizophrenia, and smoked lightly.",4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,Implementing the 3-month treatment period of NRT smoking cessation program would result in an expenditure of R1 478 915.42 for 214 patients.,What would be the expenditure for implementing the 3-month treatment period of NRT smoking cessation program for 214 patients in South Africa (pmcid=11927220)?,The expenditure for implementing the 3-month treatment period of NRT smoking cessation program for 214 patients in South Africa would be R1 478 915.42.,4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,The hospital will require an additional 0.15% (±0.0095) of the total hospital budget and 6.09% (±0.31) of the hospital pharmacy budget.,What percentage of the hospital budget will be required for nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa (pmcid=11927220)?,0.15%,4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"CONCLUSION: Our findings indicate that while implementing a NRT is crucial for improving the overall health outcomes among patients with mental illnesses, substantial investment would be required.",What do the findings indicate about the implementation of NRT among patients with mental illnesses in South Africa (pmcid=11927220)?,"The findings indicate that implementing nicotine replacement therapy (NRT) is crucial for improving the overall health outcomes among patients with mental illnesses in South Africa, but substantial investment would be required.",4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,The budgetary allocation for NRT smoking cessation interventions would vary by treatment settings and program duration.,What would vary by treatment settings and program duration in the budgetary allocation for NRT smoking cessation interventions? (pmcid=11927220),The budgetary allocation for NRT smoking cessation interventions would vary by treatment settings and program duration.,4ea61aa6d005c3b4cc179007ea4fe1c4
11927220,Maphanga B,The budget impact analysis of nicotine replacement therapy among patients who smoke tobacco and have mental illness in South Africa and the implications,2025,bim,"Consequently, careful consideration of budget allocation and resource distribution is necessary to ensure the program's sustainability within the broader healthcare framework in South Africa.",What is necessary to ensure the program's sustainability within the broader healthcare framework in South Africa (pmcid=11927220)?,Careful consideration of budget allocation and resource distribution is necessary to ensure the program's sustainability within the broader healthcare framework in South Africa.,4ea61aa6d005c3b4cc179007ea4fe1c4
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"- Background: Retinal diseases are major contributors to disability, significantly affecting patients' quality of life.",What are major contributors to disability that significantly affect patients' quality of life (pmcid=11884430)?,Retinal diseases,3a3aace22d82c911086767069abb1516
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) represent a significant disease and economic burden in Colombia.,What represents a significant disease and economic burden in Colombia (pmcid=11884430)?,Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD),3a3aace22d82c911086767069abb1516
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Assessing the economic evaluation of available treatments is essential for the efficient allocation of healthcare resources.,What is essential for the efficient allocation of healthcare resources according to the abstract sentence? (pmcid=11884430),Assessing the economic evaluation of available treatments is essential for the efficient allocation of healthcare resources.,3a3aace22d82c911086767069abb1516
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Objective: To estimate the cost-effectiveness and budget impact of using faricimab for the treatment of patients with DME and nAMD within the Colombian health system.,What is the objective of the study (pmcid=11884430)?,The objective of the study with pmcid=11884430 is to estimate the cost-effectiveness and budget impact of using faricimab for the treatment of patients with Diabetic Macular Edema (DME) and Neovascular Age-Related Macular Degeneration (nAMD) within the Colombian health system.,3a3aace22d82c911086767069abb1516
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"Methods: This study used a 25-year Markov cohort model to estimate the cost-effectiveness of faricimab vs aflibercept, ranibizumab, and brolucizumab.",What model was used to estimate the cost-effectiveness of faricimab in comparison to other treatments (pmcid=11884430)?,A 25-year Markov cohort model was used to estimate the cost-effectiveness of faricimab in comparison to other treatments in the study mentioned (pmcid=11884430).,3a3aace22d82c911086767069abb1516
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,We used the methodological guidelines of the local health technology assessment agency for conducting the cost-effectiveness and budget impact analysis.,What methodological guidelines were used for conducting the cost-effectiveness and budget impact analysis in this study (pmcid=11884430)?,The methodological guidelines of the local health technology assessment agency were used for conducting the cost-effectiveness and budget impact analysis in this study (pmcid=11884430).,3a3aace22d82c911086767069abb1516
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Transition probabilities and injection frequencies were derived from the literature.,What were the transition probabilities and injection frequencies derived from in the analysis (pmcid=11884430)?,The transition probabilities and injection frequencies were derived from the literature in the analysis of the use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia (pmcid=11884430).,3a3aace22d82c911086767069abb1516
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Drug prices were retrieved from public local databases.,What were the drug prices retrieved from for the analysis (pmcid=11884430)?,Drug prices were retrieved from public local databases.,3a3aace22d82c911086767069abb1516
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Quality-adjusted life years (QALYs) were assessed.,What was assessed in terms of quality-adjusted life years (pmcid=11884430)?,Quality-adjusted life years (QALYs) were assessed.,3a3aace22d82c911086767069abb1516
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,The potential patient population for the budget impact analysis was estimated based on disease prevalence and expert consultations.,What was the basis for estimating the potential patient population for the budget impact analysis in this study (pmcid=11884430)?,The potential patient population for the budget impact analysis was estimated based on disease prevalence and expert consultations.,3a3aace22d82c911086767069abb1516
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"Results: Faricimab treat-and-extend (T&E) was dominant vs aflibercept T&E (+0.22 QALYs), ranibizumab T&E (+0.55 QALYs), and brolucizumab for 8 to 12 weeks (+0.06 QALYs) in DME, generating cost savings (in US dollars) of 3849,  1375, and 2824, respectively.InnAMD, faricimabalsoshoweddominancevsafliberceptasneeded( + 0.12QALYs), ranibizumabasneeded( + 0.05QALYs), andbrolucizumab8to12weeks( + 0.12QALYs)withsavingsin(US) 7223, 5792, and 6798, respectively.","What were the cost savings generated by faricimab treat-and-extend compared to aflibercept, ranibizumab, and brolucizumab in the treatment of Diabetic Macular Edema (pmcid=11884430)?","The cost savings generated by faricimab treat-and-extend compared to aflibercept, ranibizumab, and brolucizumab in the treatment of Diabetic Macular Edema were $3849, $1375, and $2824, respectively.",3a3aace22d82c911086767069abb1516
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"Assuming an annual market share increase for faricimab of 15% for DME and 13% for nAMD, the Colombian Health System could save 144millionover3years.Ofthesesavings,  122.7 million are attributed to drug costs and 21.3milliontoadministrationcosts(US 1 = Col$4325).",What annual market share increase assumptions were made for faricimab in the study (pmcid=11884430)?,An annual market share increase of 15% for Diabetic Macular Edema (DME) and 13% for Neovascular Age-Related Macular Degeneration (nAMD) was assumed for faricimab in the study (pmcid=11884430).,3a3aace22d82c911086767069abb1516
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,"Conclusion: Considering a willingness to pay threshold of $5988 per additional QALY, faricimab is a cost-effective alternative for both DME and nAMD for the Colombian healthcare system, showing dominance over other anti-vascular endothelial growth factor agents.",What is the conclusion regarding the cost-effectiveness of faricimab for both DME and nAMD in Colombia (pmcid=11884430)?,"Faricimab is a cost-effective alternative for both Diabetic Macular Edema (DME) and Neovascular Age-Related Macular Degeneration (nAMD) in Colombia, showing dominance over other anti-vascular endothelial growth factor agents.",3a3aace22d82c911086767069abb1516
11884430,Samacá-Samacá D,Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia,2025,bim,Faricimab provides better health outcomes at lower costs vs other treatments.,What do the results suggest about the cost-effectiveness of Faricimab compared to other treatments? (pmcid=11884430),The results suggest that Faricimab provides better health outcomes at lower costs compared to other treatments.,3a3aace22d82c911086767069abb1516
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,- Objective: To estimate the efficiency of a nurse-led telephone program for nonadherent to treatment Type 2 diabetics with comorbid depression (TELE-DD program).,What is the objective of the study on the nurse-led telephone program for nonadherent to treatment Type 2 diabetics with comorbid depression (pmcid=11919128)?,The objective of the study on the nurse-led telephone program for nonadherent to treatment Type 2 diabetics with comorbid depression (pmcid=11919128) is to estimate the efficiency of the TELE-DD program.,ecf7bd4109de7e3dc6c89c785f7fcd32
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"Design: Secondary analysis of cost-consequence and budget impact, utilizing data from a randomized clinical trial conducted in the primary healthcare setting.",What type of analysis was conducted utilizing data from a randomized clinical trial in the primary healthcare setting (pmcid=11919128)?,Cost-consequence and budget impact analysis.,ecf7bd4109de7e3dc6c89c785f7fcd32
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,The target population consisted of Type 2 diabetic patients with comorbid depression who were nonadherent to their pharmacological treatment.,What was the target population of the study (pmcid=11919128)?,The target population of the study (pmcid=11919128) was Type 2 diabetic patients with comorbid depression who were nonadherent to their pharmacological treatment.,ecf7bd4109de7e3dc6c89c785f7fcd32
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,Method: The average cost per controlled patient (glycated hemoglobin < 7%) and the incremental cost-effectiveness ratio were calculated.,What was calculated in this study (pmcid=11919128)?,The average cost per controlled patient (glycated hemoglobin < 7%) and the incremental cost-effectiveness ratio were calculated in this study (pmcid=11919128).,ecf7bd4109de7e3dc6c89c785f7fcd32
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"Similarly, the budgetary impact over 1 year of implementing this program in the region of reference of the randomized clinical trial was assessed.",What was assessed over 1 year in the region of reference of the randomized clinical trial (pmcid=11919128)?,The budgetary impact of implementing the nurse-led telephone program for nonadherent to treatment type 2 diabetics with comorbid depression was assessed over 1 year in the region of reference of the randomized clinical trial.,ecf7bd4109de7e3dc6c89c785f7fcd32
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"Results: The number of controlled patients is higher in the TELE-DD group at 6, 12, and 18 months.","What is higher in the TELE-DD group at 6, 12, and 18 months (pmcid=11919128)?","The number of controlled patients is higher in the TELE-DD group at 6, 12, and 18 months.",ecf7bd4109de7e3dc6c89c785f7fcd32
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,The average cost per controlled patient was higher in the TELE-DD group than in the control group at 6 months (€160.31 vs.,What was the average cost per controlled patient in the TELE-DD group compared to the control group at 6 months (pmcid=11919128)?,€160.31,ecf7bd4109de7e3dc6c89c785f7fcd32
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"€49.79), but lower at 12 (€150.09 vs.",What was the cost difference between the intervention and control groups at 12 months (pmcid=11919128)?,The cost difference between the intervention and control groups at 12 months was €100.30 (€150.09 - €49.79).,ecf7bd4109de7e3dc6c89c785f7fcd32
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,€179.59) and 18 months (€209.22 vs.,What were the costs compared between the nurse-led telephone program and standard care at 6 months and 18 months (pmcid=11919128)?,"At 6 months, the costs were €179.59 for the nurse-led telephone program and €209.22 for standard care. At 18 months, the costs were not provided in the given context information.",ecf7bd4109de7e3dc6c89c785f7fcd32
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"The incremental cost-effectiveness ratio at 6, 12, and 18 months was €254.47, €143.65, and €177.46, respectively.","What were the incremental cost-effectiveness ratios at 6, 12, and 18 months in the study conducted by Gómez-Barrera et al. (pmcid=11919128)?","The incremental cost-effectiveness ratios at 6, 12, and 18 months in the study conducted by Gómez-Barrera et al. were €254.47, €143.65, and €177.46, respectively.",ecf7bd4109de7e3dc6c89c785f7fcd32
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,"The budget impact analysis revealed that implementing the TELE-DD program would result in a reduction of €721,940.68 in expenditure for the funder in the first year of application.",What would be the reduction in expenditure for the funder in the first year of implementing the TELE-DD program? (pmcid=11919128),"€721,940.68",ecf7bd4109de7e3dc6c89c785f7fcd32
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,Conclusions: A nurse-led telephone program for nonadherent Type 2 diabetics with comorbid depression is an efficient option in the management of healthcare resources.,What is the conclusion regarding the efficiency of a nurse-led telephone program for nonadherent Type 2 diabetics with comorbid depression (pmcid=11919128)?,The conclusion is that a nurse-led telephone program for nonadherent Type 2 diabetics with comorbid depression is an efficient option in the management of healthcare resources.,ecf7bd4109de7e3dc6c89c785f7fcd32
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,These results highlight the role of nursing in chronic patient management and the efficient use of healthcare resources.,What role do the results highlight in chronic patient management and the efficient use of healthcare resources (pmcid=11919128)?,The results highlight the role of nursing in chronic patient management and the efficient use of healthcare resources.,ecf7bd4109de7e3dc6c89c785f7fcd32
11919128,Gómez-Barrera M,Nurse-Led Telephone Program for Nonadherent to Treatment Type 2 Diabetics With Comorbid Depression: A Cost-Consequence and Budget Impact Analysis,2024,bim,Trial Registration: ClinicalTrials.gov Identifier: NCT04097483.,What is the ClinicalTrials.gov Identifier for this study (pmcid=11919128)?,NCT04097483,ecf7bd4109de7e3dc6c89c785f7fcd32
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,- Purpose: Serum or urine protein electrophoresis (SPEP or UPEP) and immunofixation electrophoresis (SIFE or UIFE) are routinely used to detect M-proteins in MM patients.,What are routinely used to detect M-proteins in MM patients? (pmcid=11849414),Serum or urine protein electrophoresis (SPEP or UPEP) and immunofixation electrophoresis (SIFE or UIFE) are routinely used to detect M-proteins in MM patients.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"However, SPEP and SIFE are not sensitive enough to measure M-protein levels that are low but still clinically significant.",What is the limitation of SPEP and SIFE in measuring M-protein levels (pmcid=11849414)?,The limitation of SPEP and SIFE in measuring M-protein levels is that they are not sensitive enough to measure M-protein levels that are low but still clinically significant.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"This study aimed to evaluate the potential cost savings associated with using the EXENT GAM Assay, a serum-based quantitative-immunoprecipitation mass spectrometry (QIP-MS) diagnostic test instead of SIFE to guide the timing of minimal residual disease (MRD) testing for patients with multiple myeloma (MM).",What diagnostic test was evaluated in the study (pmcid=11849414)?,"The EXENT GAM Assay, a serum-based quantitative-immunoprecipitation mass spectrometry (QIP-MS) diagnostic test.",4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,Patients and Methods: A simple 2-year budget impact model was created in Excel using data from MM clinical trials and fee schedules.,What data was used to create the budget impact model in Excel (pmcid=11849414)?,Data from MM clinical trials and fee schedules.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,Patients are tested with either QIP-MS or SIFE at predetermined timepoints.,What are patients tested with at predetermined timepoints in the study (pmcid=11849414)?,Patients are tested with either QIP-MS or SIFE at predetermined timepoints.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"If patients test negative, they will receive MRD testing.",What will patients receive if they test negative (pmcid=11849414)?,Patients will receive MRD testing.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,The result of the MRD test will determine if the preceding serum-based test was a true negative result (MRD test is negative) or a false negative result (MRD test is positive).,What will the result of the MRD test determine (pmcid=11849414)?,The result of the MRD test will determine if the preceding serum-based test was a true negative result or a false negative result.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,Patients receiving autologous stem cell transplant (henceforth referred to as transplant) and those not receiving transplant are both eligible for one MRD test per year.,What are the eligibility criteria for patients receiving autologous stem cell transplant and those not receiving transplant in terms of MRD testing frequency (pmcid=11849414)?,Patients receiving autologous stem cell transplant and those not receiving transplant are both eligible for one MRD test per year.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,MRD testing for transplant-eligible patients occurs prior to transplant and one year following transplant.,When does MRD testing occur for transplant-eligible patients (pmcid=11849414)?,MRD testing for transplant-eligible patients occurs prior to transplant and one year following transplant.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"Results: Across a hypothetical population of 5154 mm patients receiving 1st-line treatment in France, using QIP-MS instead of SIFE prior to MRD testing leads to 1973 fewer false negative results and 744 more false positive results (due, in part, to the detection of residual IgG).",What are the results of using QIP-MS instead of SIFE prior to MRD testing in patients with multiple myeloma in France (pmcid=11849414)?,Using QIP-MS instead of SIFE prior to MRD testing in patients with multiple myeloma in France leads to 1973 fewer false negative results and 744 more false positive results.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,"Net savings per QIP-MS test would be €260 or total savings of €2,481,832.",What are the total savings per QIP-MS test according to the abstract sentence (pmcid=11849414)?,The total savings per QIP-MS test according to the abstract sentence is €260.,4ae7b04289a67daab4a015e7c41bacf7
11849414,Siegfried C,Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective,2025,bim,Conclusion: This study suggests that the use of QIP-MS prior to MRD testing may be cost-saving for testing French patients with MM.,What does this study suggest about the cost-saving potential of using QIP-MS prior to MRD testing for French patients with MM (pmcid=11849414)?,This study suggests that the use of QIP-MS prior to MRD testing may be cost-saving for testing French patients with MM.,4ae7b04289a67daab4a015e7c41bacf7
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,- BACKGROUND: The Interactive Care Coordination and Navigation (iCAN) mobile health intervention aims to improve care coordination and reduce hospital and emergency department visits among people experiencing homelessness.,What is the aim of the iCAN mobile health intervention (pmcid=11936304)?,The aim of the iCAN mobile health intervention is to improve care coordination and reduce hospital and emergency department visits among people experiencing homelessness.,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"OBJECTIVE: This study aimed to conduct a three-part economic evaluation of iCAN, including a (1) cost analysis, (2) exploratory financial cost-benefit analysis, and (3) budget impact analysis (BIA).",What three-part economic evaluation did this study aim to conduct (pmcid=11936304)?,"The study aimed to conduct a cost analysis, exploratory financial cost-benefit analysis, and budget impact analysis (BIA).",fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,METHODS: We collected cost and expenditure data from a randomized controlled trial of iCAN to conduct a cost analysis and exploratory financial cost-benefit analysis.,What data was collected to conduct a cost analysis and exploratory financial cost-benefit analysis in the study of iCAN (pmcid=11936304)?,Cost and expenditure data,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,Costs were classified as startup and recurring costs for participants and the program.,What costs were classified in the analysis (pmcid=11936304)?,Costs were classified as startup and recurring costs for participants and the program.,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,Startup costs included participant supplies for each participant and SMS implementation costs.,What were included in the startup costs for the mHealth intervention for people experiencing homelessness (pmcid=11936304)?,Participant supplies for each participant and SMS implementation costs.,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Recurring costs included the cost of recurring services, SMS text messaging platform maintenance, health information access fees, and personnel salaries.",What were the recurring costs included in the analysis (pmcid=11936304)?,"The recurring costs included in the analysis were the cost of recurring services, SMS text messaging platform maintenance, health information access fees, and personnel salaries.",fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Using the per participant per year (PPPY) costs of iCAN, the minimum savings reduction in the average health care costs among people experiencing homelessness that would lead to a benefit-cost ratio >1 for iCAN was calculated.",What was calculated based on the per participant per year costs of iCAN (pmcid=11936304)?,The minimum savings reduction in the average health care costs among people experiencing homelessness that would lead to a benefit-cost ratio >1 for iCAN was calculated.,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,This savings threshold was calculated by dividing the PPPY cost of iCAN by the average health care costs among people experiencing homelessness multiplied by 100%.,What was the savings threshold calculated based on in the study (pmcid=11936304)?,The savings threshold was calculated based on the PPPY cost of iCAN divided by the average health care costs among people experiencing homelessness multiplied by 100%.,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,The benefit-cost ratio of iCAN was calculated under different savings thresholds from 0% (no savings) to 50%.,What was the benefit-cost ratio of iCAN calculated under different savings thresholds (pmcid=11936304)?,The benefit-cost ratio of iCAN was calculated under different savings thresholds from 0% to 50%.,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"Costs were calculated PPPY under different scenarios, and the results were used as inputs in a BIA.",What were the costs calculated under different scenarios for in the study conducted by McCullough HP (pmcid=11936304)?,Costs were calculated PPPY (Per Person Per Year) under different scenarios in the study conducted by McCullough HP.,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,A probabilistic sensitivity analysis was conducted to incorporate uncertainty around cost estimates.,What type of analysis was conducted to incorporate uncertainty around cost estimates in the study by McCullough HP et al. (pmcid=11936304)?,A probabilistic sensitivity analysis was conducted.,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,Costs are in 2022 US $.,What currency are the costs reported in (pmcid=11936304)?,The costs reported in the study with pmcid=11936304 are in 2022 US $.,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"RESULTS: The total cost of iCAN was US $2865 PPPY, which was made up of US $265 in startup (9%) and US $2600 (91%) in recurring costs PPPY.",What were the total costs of the iCAN intervention (pmcid=11936304)?,The total cost of the iCAN intervention was US $2865 per person per year (PPPY).,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,The minimum savings threshold that would cause iCAN to have a positive return on investment is 7.8%.,What is the minimum savings threshold that would cause iCAN to have a positive return on investment (pmcid=11936304)?,The minimum savings threshold that would cause iCAN to have a positive return on investment is 7.8%.,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"This means that if average health care costs (US $36,917) among people experiencing homelessness were reduced by more than 7.8% through iCAN, the financial benefits would outweigh the costs of the intervention.",What percentage reduction in average health care costs among people experiencing homelessness would result in the financial benefits outweighing the costs of the iCAN intervention (pmcid=11936304)?,More than 7.8%,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"When health care costs are reduced by 25% ($9229/$36,917; equal to 56% [$9229/$16,609] of the average cost of an inpatient visit), the benefit-cost ratio is 3.22, which means that iCAN produces US $2.22 in health care savings per US $1 spent.",What is the benefit-cost ratio when health care costs are reduced by 25% in the Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness (pmcid=11936304)?,The benefit-cost ratio is 3.22 when health care costs are reduced by 25% in the Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness (pmcid=11936304).,fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"The BIA estimated that implementing iCAN for 10,250 people experiencing homelessness over 5 years would have a financial cost of US $28.7 million, which could be reduced to US $2.2 million if at least 8% ($2880/$36,917) of average health care costs among people experiencing homelessness are reduced through the intervention.","What was the financial cost estimated for implementing iCAN for 10,250 people experiencing homelessness over 5 years (pmcid=11936304)?","The financial cost estimated for implementing iCAN for 10,250 people experiencing homelessness over 5 years was US $28.7 million.",fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"CONCLUSIONS: If average costs of emergency department and hospital visits among people experiencing homelessness were reduced by more than 7.8% ($2880/$36,917) through iCAN, the financial benefits would outweigh the costs of the intervention.",What percentage reduction in average costs of emergency department and hospital visits among people experiencing homelessness would result in the financial benefits outweighing the costs of the iCAN intervention (pmcid=11936304)?,"If the average costs of emergency department and hospital visits among people experiencing homelessness were reduced by more than 7.8%, the financial benefits would outweigh the costs of the iCAN intervention.",fb6464623de61e8452799558a97d6e2b
11936304,McCullough HP,"The Interactive Care Coordination and Navigation mHealth Intervention for People Experiencing Homelessness: Cost Analysis, Exploratory Financial Cost-Benefit Analysis, and Budget Impact Analysis",2025,bim,"As the savings threshold increases, it results in a higher benefit-cost ratio.",What does the increase in savings threshold result in? (pmcid=11936304),A higher benefit-cost ratio.,fb6464623de61e8452799558a97d6e2b
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"- BACKGROUND: Heart failure (HF) is a leading cause of mortality in the United States, often complicated by comorbidities like diabetes mellitus.","What is a leading cause of mortality in the United States, often complicated by comorbidities like diabetes mellitus (pmcid=11953859)?",Heart failure (HF),e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"These patients face high hospitalization risks, impacting clinical outcomes and health care resources.","What impact do patients with heart failure and type 2 diabetes face, according to the abstract sentence provided (pmcid=11953859)?","Patients with heart failure and type 2 diabetes face high hospitalization risks, impacting clinical outcomes and health care resources.",e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"The Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial showed that sotagliflozin, a sodium-glucose cotransporter inhibitor, reduced rehospitalizations in patients with HF and diabetes mellitus.",What trial showed that sotagliflozin reduced rehospitalizations in patients with heart failure and type 2 diabetes (pmcid=11953859)?,The SOLOIST-WHF trial showed that sotagliflozin reduced rehospitalizations in patients with heart failure and type 2 diabetes.,e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"Although clinically beneficial, the economic impact of sotagliflozin from a payer perspective remains unclear, warranting further pharmacoeconomic analysis to guide managed care decisions.","What remains unclear from a payer perspective regarding the economic impact of sotagliflozin, warranting further analysis to guide managed care decisions (pmcid=11953859)?","The economic impact of sotagliflozin from a payer perspective remains unclear, warranting further pharmacoeconomic analysis to guide managed care decisions.",e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,OBJECTIVE: To quantify the budget impact of sotagliflozin for US payers over a 5-year time horizon.,What is the objective of the study (pmcid=11953859)?,The objective of the study with pmcid=11953859 is to quantify the budget impact of sotagliflozin for US payers over a 5-year time horizon.,e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,METHODS: A payer-perspective budget impact model was developed to assess the financial impact of incorporating sotagliflozin for the treatment of patients recently hospitalized for HF with comorbid type 2 diabetes (T2D) over 5 years to US payer health plans.,What perspective was used in the budget impact model developed to assess the financial impact of incorporating sotagliflozin for the treatment of patients recently hospitalized for HF with comorbid type 2 diabetes (T2D) over 5 years to US payer health plans (pmcid=11953859)?,The budget impact model developed used a payer perspective to assess the financial impact of incorporating sotagliflozin for the treatment of patients recently hospitalized for HF with comorbid type 2 diabetes (T2D) over 5 years to US payer health plans.,e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"The study used a population reflecting the SOLOIST-WHF clinical trial, with economic parameters adjusted by payer mix (all payer, commercial, Medicare, and Medicaid).",What population was used in the study (pmcid=11953859)?,The study used a population reflecting the SOLOIST-WHF clinical trial.,e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"Health care resource utilization included hospitalization, emergency department (ED) visit, and adverse events' care.",What health care resource utilization was included in the analysis (pmcid=11953859)?,"Health care resource utilization included hospitalization, emergency department (ED) visit, and adverse events' care.",e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"Economic outcomes examined the medical and pharmacy budget impact for payers at the per-user, per member per month (PMPM), and total plan costs levels.",What economic outcomes were examined in the study (pmcid=11953859)?,"The economic outcomes examined in the study with pmcid=11953859 were the medical and pharmacy budget impact for payers at the per-user, per member per month (PMPM), and total plan costs levels.",e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"RESULTS: For a hypothetical 1-million-member all-payer plan, 1,516 patients hospitalized for HF with comorbid T2D would be eligible for sotagliflozin.",What is the number of eligible patients for sotagliflozin in a hypothetical 1-million-member all-payer plan (pmcid=11953859)?,"1,516 patients",e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"For all-payer plans, annual per-user costs increased by $4,996 because of higher pharmacy costs ($8,260) but were partially offset by lower medical costs (-$2,608) because of reduced rehospitalization and ED visits from sotagliflozin.",What were the annual per-user costs impacted by in the budget impact analysis from the US payer perspective (pmcid=11953859)?,"The annual per-user costs were impacted by higher pharmacy costs ($8,260) but were partially offset by lower medical costs (-$2,608) due to reduced rehospitalization and ED visits from sotagliflozin in the budget impact analysis from the US payer perspective (pmcid=11953859).",e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"PMPM total budget impact of sotagliflozin would be $0.08 PMPM in year 1 and $0.38 in year 5, corresponding with total plan cost of $75,736 in year 1 and $378,681 by year 5.",What is the total budget impact of sotagliflozin in year 1 and year 5 from the US payer perspective (pmcid=11953859)?,"The total budget impact of sotagliflozin in year 1 is $75,736 and in year 5 is $378,681 from the US payer perspective.",e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"Commercial payer PMPM costs were lower ($0.02 in year 1; $0.11 in year 5), and higher for Medicare ($0.23 PMPM in year 1, increasing to 1.13 PMPM in year 5).","What were the PMPM costs for commercial payers and Medicare in year 1 and year 5, according to the study? (pmcid=11953859)","In year 1, the PMPM costs for commercial payers were $0.02 and for Medicare were $0.23. In year 5, the PMPM costs for commercial payers were $0.11 and for Medicare were $1.13. (Study: pmcid=11953859)",e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,Breakeven rebate rates ranged between 31.5% and 79.4%.,What is the range of breakeven rebate rates mentioned in the abstract (pmcid=11953859)?,The range of breakeven rebate rates mentioned in the abstract is between 31.5% and 79.4%.,e57405a70c12a098bf92b6e93284a3d0
11953859,Shafrin J,Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective,2025,bim,"CONCLUSIONS: Although sotagliflozin increases pharmacy costs for recently hospitalized HF patients with T2D, approximately 21%-68% of pharmacy costs were offset from reduced rehospitalization and ED visits.",What percentage of pharmacy costs were offset from reduced rehospitalization and ED visits for recently hospitalized HF patients with T2D (pmcid=11953859)?,Approximately 21%-68% of pharmacy costs were offset from reduced rehospitalization and ED visits for recently hospitalized HF patients with T2D in the study with pmcid=11953859.,e57405a70c12a098bf92b6e93284a3d0
12032717,Barbado G,Budgetary impact of increasing use of peritoneal dialysis over haemodialysis in Spain,2025,bim,"- BACKGROUND: Chronic kidney disease (CKD) represents a significant public health concern, due to its high prevalence and incidence, as well as its substantial socio-economic costs.","What represents a significant public health concern due to its high prevalence and incidence, as well as its substantial socio-economic costs (pmcid=12032717)?",Chronic kidney disease (CKD),490738954ea4231dfecd43f2aeeaadf4
12032717,Barbado G,Budgetary impact of increasing use of peritoneal dialysis over haemodialysis in Spain,2025,bim,"In Spain, estimates suggest that the direct healthcare costs of CKD will increase by 13.8% from 2022, which is why the cost of kidney replacement treatment (KRT) programs efficiency and sustainability is under constant analysis.",What will be the increase in direct healthcare costs of CKD in Spain from 2022 (pmcid=12032717)?,The direct healthcare costs of CKD in Spain are estimated to increase by 13.8% from 2022.,490738954ea4231dfecd43f2aeeaadf4
12032717,Barbado G,Budgetary impact of increasing use of peritoneal dialysis over haemodialysis in Spain,2025,bim,Our analysis aimed to estimate the cost associated with peritoneal dialysis (PD) compared to hemodialysis (HD) from the Spanish National Health System (NHS) perspective and to evaluate the budgetary impact of an increase in the use of PD in our healthcare system environment.,What was the aim of the analysis conducted by Barbado G et al. regarding peritoneal dialysis compared to hemodialysis in Spain (pmcid=12032717)?,The aim of the analysis conducted by Barbado G et al. was to estimate the cost associated with peritoneal dialysis (PD) compared to hemodialysis (HD) from the Spanish National Health System (NHS) perspective and to evaluate the budgetary impact of an increase in the use of PD in the healthcare system environment in Spain.,490738954ea4231dfecd43f2aeeaadf4
12032717,Barbado G,Budgetary impact of increasing use of peritoneal dialysis over haemodialysis in Spain,2025,bim,METHODS: The number of patients eligible for KRT was calculated based on the total Spanish population and the incidence and prevalence of patients with end-stage renal disease (ESRD).,What was calculated in the methods section of the study (pmcid=12032717)?,The number of patients eligible for kidney replacement therapy (KRT) was calculated based on the total Spanish population and the incidence and prevalence of patients with end-stage renal disease (ESRD).,490738954ea4231dfecd43f2aeeaadf4
12032717,Barbado G,Budgetary impact of increasing use of peritoneal dialysis over haemodialysis in Spain,2025,bim,"Patients receiving each modality, type of dialysis, and location of dialysis were estimated.","What was estimated in terms of patients receiving each modality, type of dialysis, and location of dialysis in Spain (pmcid=12032717)?","The number of patients receiving each modality, type of dialysis, and location of dialysis in Spain was estimated.",490738954ea4231dfecd43f2aeeaadf4
12032717,Barbado G,Budgetary impact of increasing use of peritoneal dialysis over haemodialysis in Spain,2025,bim,"The annual costs of each dialysis modality were calculated and included the cost of dialysis sessions and additional costs (including the cost of peritoneal and vascular access, hospitalisation costs due to potential complications of dialysis, cost of health care personnel, and cost of health care transport used by patients).",What costs were included in the calculation of the annual costs of each dialysis modality (pmcid=12032717)?,"The costs included in the calculation of the annual costs of each dialysis modality were the cost of dialysis sessions, additional costs such as the cost of peritoneal and vascular access, hospitalization costs due to potential complications of dialysis, cost of health care personnel, and cost of health care transport used by patients.",490738954ea4231dfecd43f2aeeaadf4
12032717,Barbado G,Budgetary impact of increasing use of peritoneal dialysis over haemodialysis in Spain,2025,bim,"Population data and costs (€, 2024) were obtained from the Spanish databases and a nephrologist validated the assumptions.",What validated the assumptions regarding population data and costs in Spain (pmcid=12032717)?,A nephrologist validated the assumptions regarding population data and costs in Spain.,490738954ea4231dfecd43f2aeeaadf4
12032717,Barbado G,Budgetary impact of increasing use of peritoneal dialysis over haemodialysis in Spain,2025,bim,"Budget impact analysis assessed the incremental budget impact between the current scenario and the alternative scenario, where 30% of incident patients on scheduled HD would receive PD.",What was assessed in the budget impact analysis (pmcid=12032717)?,The budget impact analysis assessed the incremental budget impact between the current scenario and an alternative scenario where 30% of incident patients on scheduled hemodialysis would receive peritoneal dialysis.,490738954ea4231dfecd43f2aeeaadf4
12032717,Barbado G,Budgetary impact of increasing use of peritoneal dialysis over haemodialysis in Spain,2025,bim,"RESULTS: We estimated that in Spain, there are 27,281 prevalent dialysis patients (3,141 receiving PD and 24,140 receiving HD/HDF) and 6,052 incident dialysis patients (1,173 receiving PD and 4,879 HD/HDF).","How many prevalent dialysis patients are there in Spain, and how many of them are receiving peritoneal dialysis (PD) (pmcid=12032717)?","There are 27,281 prevalent dialysis patients in Spain, with 3,141 of them receiving peritoneal dialysis (PD) (pmcid=12032717).",490738954ea4231dfecd43f2aeeaadf4
12032717,Barbado G,Budgetary impact of increasing use of peritoneal dialysis over haemodialysis in Spain,2025,bim,"The cost of dialysis amount to €1,555,573,771 (€141,361,374 PD and €1,414,212,397 to HD) in the current scenarios and to €1,540,584,011 (€167,593,157 PD and €1,372,990,854 HD) in the alternative scenario, resulting in a saving of €14,989,760 when 30% of the patients scheduled to receive HD would instead receive PD during the first year.","What is the total cost of dialysis in the current scenarios and in the alternative scenario, and what is the resulting saving when 30% of patients scheduled for HD receive PD instead during the first year (pmcid=12032717)?","The total cost of dialysis in the current scenarios is €1,555,573,771 (€141,361,374 for PD and €1,414,212,397 for HD). In the alternative scenario, the total cost is €1,540,584,011 (€167,593,157 for PD and €1,372,990,854 for HD). The resulting saving when 30% of patients scheduled for HD receive PD instead during the first year is €14,989,760.",490738954ea4231dfecd43f2aeeaadf4
12032717,Barbado G,Budgetary impact of increasing use of peritoneal dialysis over haemodialysis in Spain,2025,bim,"CONCLUSIONS: The increased use of PD in Spain improves the system's efficiency, generating significant savings in the treatment of ESRD patients from the NHS perspective.",What is the conclusion regarding the budgetary impact of increasing the use of peritoneal dialysis over haemodialysis in Spain (pmcid=12032717)?,The conclusion is that the increased use of peritoneal dialysis in Spain improves the system's efficiency and generates significant savings in the treatment of ESRD patients from the NHS perspective.,490738954ea4231dfecd43f2aeeaadf4
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,"- BACKGROUND: The invasive freshwater snail Physella acuta poses significant threats to the ecological environment, public health safety, and the agricultural and forestry economy.",What threats does the invasive freshwater snail Physella acuta pose (pmcid=12002750)?,"The invasive freshwater snail Physella acuta poses significant threats to the ecological environment, public health safety, and the agricultural and forestry economy.",84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,Gaining insight into their geographical spread in China under current and future climate scenarios is crucial for effective monitoring and control strategies against this invasive species.,What is crucial for effective monitoring and control strategies against the invasive snail Physella acuta in China (pmcid=12002750)?,Gaining insight into the geographical spread of the invasive snail Physella acuta in China under current and future climate scenarios is crucial for effective monitoring and control strategies against this invasive species.,84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,METHODS: Global distribution data of P.,What type of data was used in the methods of this study (pmcid=12002750)?,Global distribution data of P.,84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,"acuta were collected and screened using ""ENMtool""; environmental variables were screened based on contribution of environmental variables, jackknife test and variable correlation analysis using MaxEnt 3.4.1 and GraphPad Prism 8; ""kuenm"" package in R 4.0.4 software was used to calculate and adjust model parameters; the optimized MaxEnt model was used to predict the potential distribution range of P.",What software was used to calculate and adjust model parameters in the study (pmcid=12002750)?,"""kuenm"" package in R 4.0.4 software",84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,acuta in China under different climate scenarios; ArcGIS 10.7 was used to process and visualize the results.,What software was used to process and visualize the results of modeling the distribution of Physella acuta in China (pmcid=12002750)?,ArcGIS 10.7,84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,RESULTS: A total of 2012 P.,What total number of P. were identified in the study (pmcid=12002750)?,2012,84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,"acuta distribution points were screened, and the warmest quarter, mean temperature of the coldest season, precipitation in March and November were used to construct the MaxEnt model with an area under the curve (AUC) value of 0.918.",What values were used to construct the MaxEnt model for the distribution of Physella acuta in China (pmcid=12002750)?,"The warmest quarter, mean temperature of the coldest season, precipitation in March and November were used to construct the MaxEnt model for the distribution of Physella acuta in China.",84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,"According to the prediction, P.",What does the prediction suggest about the distribution of the invasive snail Physella acuta in China (pmcid=12002750)?,The prediction suggests that the distribution of the invasive snail Physella acuta in China is likely to have ecological and economic impacts.,84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,"acuta is currently widely spread across the Guangxi Zhuang Autonomous Region, Guizhou Province, Yunnan Province, Chongqing Municipality, and areas proximate to the Yangtze River Basin in the middle-lower Yangtze Plain, which encompass 10.22 % of China's terrestrial area.",Where is Physella acuta currently widely spread in China (pmcid=12002750)?,"Physella acuta is currently widely spread across the Guangxi Zhuang Autonomous Region, Guizhou Province, Yunnan Province, Chongqing Municipality, and areas proximate to the Yangtze River Basin in the middle-lower Yangtze Plain in China.",84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,"Under future climate projections, the suitable habitats for P.",What are the implications of modeling the distribution of the invasive snail Physella acuta in China (pmcid=12002750)?,"The implications of modeling the distribution of the invasive snail Physella acuta in China include understanding the ecological and economic impact of the species. This modeling can help predict where the snail may spread to in the future under different climate projections, allowing for better management and mitigation strategies to be put in place.",84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,"acuta in southern regions are expected to contract, whereas those in northern regions are anticipated to remain relatively stable.",What are the expected changes in the distribution of the invasive snail Physella acuta in China based on the modeling study (pmcid=12002750)?,"The distribution of the invasive snail Physella acuta in southern regions is expected to contract, while in northern regions it is anticipated to remain relatively stable.",84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,"As a result, the overall distribution center is likely to shift marginally northward.",What is likely to shift marginally northward based on the abstract sentence (pmcid=12002750)?,The overall distribution center of the invasive snail Physella acuta in China is likely to shift marginally northward.,84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,"CONCLUSION: With the future climate change, the total suitable habitats of P.",What are the implications of modeling the distribution of the invasive snail Physella acuta in China (pmcid=12002750)?,The implications of modeling the distribution of the invasive snail Physella acuta in China include understanding the ecological and economic impact of the species.,84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,"acuta in China showed a shrinking trend, and the shrinkage was more significant in the southern low-latitude suitable habitats.",What trend did the distribution of the invasive snail Physella acuta show in China (pmcid=12002750)?,"The distribution of the invasive snail Physella acuta in China showed a shrinking trend, and the shrinkage was more significant in the southern low-latitude suitable habitats.",84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,To mitigate its impact on China's ecosystem and the loss caused by P.,What is the title of the study by Yin Y regarding the distribution of the invasive snail Physella acuta in China (pmcid=12002750)?,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,84138dc1b7ed36c77cc1d671b3511d1a
12002750,Yin Y,Modeling the distribution of the invasive snail Physella acuta in China: Implications for ecological and economic impact,2025,bim,"acuta invasion, relevant departments should increase monitoring and prompt control, and implement efficient preventive and eradication measures.",What measures should relevant departments implement in response to the Physella acuta invasion in China (pmcid=12002750)?,"Relevant departments should increase monitoring and prompt control, and implement efficient preventive and eradication measures in response to the Physella acuta invasion in China.",84138dc1b7ed36c77cc1d671b3511d1a
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,- STUDY DESIGN: Literature Review.,What was the study design of the literature review on venous thromboembolism in spinal fusion surgery (pmcid=11983115)?,The study design of the literature review on venous thromboembolism in spinal fusion surgery (pmcid=11983115) was a Literature Review.,ddd163986ada94c984562e88fe64169f
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,OBJECTIVES: To conduct a comprehensive literature review about the risk factors and preoperative considerations that are related to postoperative venous thromboembolisms (VTEs) in patients who undergo spinal fusion.,What are the objectives of the literature review conducted in this study (pmcid=11983115)?,The objectives of the literature review conducted in this study (pmcid=11983115) are to investigate the risk factors and preoperative considerations related to postoperative venous thromboembolisms (VTEs) in patients undergoing spinal fusion surgery.,ddd163986ada94c984562e88fe64169f
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,"RESULTS: Postoperative VTEs are associated with higher costs and longer hospital stays for patients, in comparison to those who did not develop VTEs.",What are postoperative VTEs associated with in terms of costs and hospital stays for patients (pmcid=11983115)?,Postoperative VTEs are associated with higher costs and longer hospital stays for patients.,ddd163986ada94c984562e88fe64169f
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,Spinal level and multilevel fusion are risk factors for postoperative VTE.,What are the risk factors for postoperative VTE in spinal fusion surgery (pmcid=11983115)?,Spinal level and multilevel fusion,ddd163986ada94c984562e88fe64169f
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,The effect of the surgical approach on VTE risk is unclear.,What is unclear about the effect of the surgical approach on VTE risk? (pmcid=11983115),The effect of the surgical approach on VTE risk is unclear.,ddd163986ada94c984562e88fe64169f
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,"Elevated BMI and age, kidney dysfunction, previous VTE, and primary hypercoagulability are preoperative risk factors for developing VTE.",What are some preoperative risk factors for developing VTE in spinal fusion surgery (pmcid=11983115)?,"Some preoperative risk factors for developing VTE in spinal fusion surgery include elevated BMI and age, kidney dysfunction, previous VTE, and primary hypercoagulability.",ddd163986ada94c984562e88fe64169f
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,"Intraoperative and postoperative risk factors for VTE include prolonged procedure time, discharge to inpatient facilities, and length of hospital stay.",What are some intraoperative and postoperative risk factors for VTE (pmcid=11983115)?,"Some intraoperative and postoperative risk factors for VTE include prolonged procedure time, discharge to inpatient facilities, and length of hospital stay.",ddd163986ada94c984562e88fe64169f
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,"The effects of hypertension (HTN), sex, and dural tears on VTE risk in spinal fusion patients are uncertain.",What factors are uncertain in their effects on VTE risk in spinal fusion patients (pmcid=11983115)?,"Hypertension (HTN), sex, and dural tears",ddd163986ada94c984562e88fe64169f
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,Chemoprophylaxis reduced the incidence of VTE.,What did chemoprophylaxis reduce the incidence of in spinal fusion surgery (pmcid=11983115)?,Venous Thromboembolism (VTE),ddd163986ada94c984562e88fe64169f
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,Tranexamic acid was not associated with an increase in VTE postoperatively.,What was the association of tranexamic acid with VTE postoperatively (pmcid=11983115)?,Tranexamic acid was not associated with an increase in VTE postoperatively.,ddd163986ada94c984562e88fe64169f
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,The American College of Surgeons National Surgical Quality Improvement Program surgical risk calculator served as a poor predictor of VTE incidence in spinal fusion.,What served as a poor predictor of VTE incidence in spinal fusion surgery? (pmcid=11983115),The American College of Surgeons National Surgical Quality Improvement Program surgical risk calculator served as a poor predictor of VTE incidence in spinal fusion.,ddd163986ada94c984562e88fe64169f
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,Preoperative D-dimer levels may help as a predictive tool.,"What may preoperative D-dimer levels help as, according to the abstract sentence (pmcid=11983115)?",Preoperative D-dimer levels may help as a predictive tool.,ddd163986ada94c984562e88fe64169f
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,"CONCLUSIONS: To elucidate the effects of surgical approach, revision surgery, HTN, and dural tears on postoperative VTE risk, further research is warranted.",What effects are further research warranted to elucidate regarding postoperative VTE risk (pmcid=11983115)?,"The effects of surgical approach, revision surgery, hypertension (HTN), and dural tears on postoperative VTE risk.",ddd163986ada94c984562e88fe64169f
11983115,Kollapaneni SS,"Venous Thromboembolism in Spinal Fusion Surgery: A Literature Review of Economic Impact, Risk Factors, and Preoperative Management",2024,bim,"To help identify high-risk patients, a risk calculator sensitive to VTE must be developed.",What must be developed to help identify high-risk patients for venous thromboembolism in spinal fusion surgery (pmcid=11983115)?,A risk calculator sensitive to VTE must be developed.,ddd163986ada94c984562e88fe64169f
12046533,Atherly DE,Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011 – 2030,2012,bim,- Rotavirus is the leading cause of diarrheal disease in children under 5 years of age.,What is the leading cause of diarrheal disease in children under 5 years of age (pmcid=12046533)?,Rotavirus,0e40aa825f7fbdb7970cc0c9e4b621fd
12046533,Atherly DE,Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011 – 2030,2012,bim,"It is responsible for more than 450,000 deaths each year, with more than 90% of these deaths occurring in low-resource countries eligible for support by the GAVI Alliance.",What percentage of deaths from rotavirus occur in low-resource countries eligible for support by the GAVI Alliance (pmcid=12046533)?,More than 90% of deaths from rotavirus occur in low-resource countries eligible for support by the GAVI Alliance.,0e40aa825f7fbdb7970cc0c9e4b621fd
12046533,Atherly DE,Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011 – 2030,2012,bim,"Significant efforts made by the Alliance and its partners are providing countries with the opportunity to introduce rotavirus vaccines into their national immunization programs, to help prevent childhood illness and death.",What opportunity are countries being provided with by the Alliance and its partners (pmcid=12046533)?,Countries are being provided with the opportunity to introduce rotavirus vaccines into their national immunization programs to help prevent childhood illness and death.,0e40aa825f7fbdb7970cc0c9e4b621fd
12046533,Atherly DE,Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011 – 2030,2012,bim,"We projected the cost-effectiveness and health impact of rotavirus vaccines in GAVI-eligible countries, to assist decision makers in prioritizing resources to achieve the greatest health benefits for their populations.",What was the purpose of projecting the cost-effectiveness and health impact of rotavirus vaccines in GAVI-eligible countries (pmcid=12046533)?,The purpose was to assist decision makers in prioritizing resources to achieve the greatest health benefits for their populations.,0e40aa825f7fbdb7970cc0c9e4b621fd
12046533,Atherly DE,Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011 – 2030,2012,bim,"A decision-analytic model was used to project the health outcomes and direct costs of a birth cohort in the target population, with and without a rotavirus vaccine.",What was used to project the health outcomes and direct costs in the study (pmcid=12046533)?,A decision-analytic model was used to project the health outcomes and direct costs in the study.,0e40aa825f7fbdb7970cc0c9e4b621fd
12046533,Atherly DE,Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011 – 2030,2012,bim,"Current data on disease burden, vaccine efficacy, immunization rates, and costs were used in the model.",What data were used in the model for projecting the health and economic impact of rotavirus vaccination in GAVI-eligible countries (pmcid=12046533)?,"Current data on disease burden, vaccine efficacy, immunization rates, and costs were used in the model.",0e40aa825f7fbdb7970cc0c9e4b621fd
12046533,Atherly DE,Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011 – 2030,2012,bim,"Vaccination in GAVI-eligible countries would prevent 2.46 million childhood deaths and 83 million disability-adjusted life years (DALYs) from 2011 to 2030, with annual reductions of 180,000 childhood deaths at peak vaccine uptake.",What would vaccination in GAVI-eligible countries prevent from 2011 to 2030 (pmcid=12046533)?,Vaccination in GAVI-eligible countries would prevent 2.46 million childhood deaths and 83 million disability-adjusted life years (DALYs) from 2011 to 2030.,0e40aa825f7fbdb7970cc0c9e4b621fd
12046533,Atherly DE,Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011 – 2030,2012,bim,"The cost per DALY averted is $42 for all GAVI countries combined, over the entire period.",What is the cost per DALY averted for all GAVI countries combined over the entire period (pmcid=12046533)?,$42,0e40aa825f7fbdb7970cc0c9e4b621fd
12046533,Atherly DE,Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011 – 2030,2012,bim,"Rotavirus vaccination would be considered very cost-effective for the entire cohort of GAVI countries, and in each country individually, as cost-effectiveness ratios are less than the gross domestic product (GDP) per capita.","What would be considered very cost-effective for the entire cohort of GAVI countries, and in each country individually (pmcid=12046533)?",Rotavirus vaccination,0e40aa825f7fbdb7970cc0c9e4b621fd
12046533,Atherly DE,Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011 – 2030,2012,bim,Vaccination is most cost-effective and has the greatest impact in regions with high rotavirus mortality.,What regions have the greatest impact from vaccination according to the abstract sentence (pmcid=12046533)?,Regions with high rotavirus mortality.,0e40aa825f7fbdb7970cc0c9e4b621fd
12046533,Atherly DE,Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011 – 2030,2012,bim,Rotavirus vaccination in GAVI-eligible countries is very cost-effective and is projected to substantially reduce childhood mortality in this population.,What is the projected impact of rotavirus vaccination in GAVI-eligible countries on childhood mortality (pmcid=12046533)?,The projected impact of rotavirus vaccination in GAVI-eligible countries is to substantially reduce childhood mortality in this population.,0e40aa825f7fbdb7970cc0c9e4b621fd
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,- INTRODUCTION: Occupational injuries pose a critical challenge amid India's rapid industrialization.,What critical challenge do occupational injuries pose amid India's rapid industrialization (pmcid=12017669)?,Occupational injuries pose a critical challenge amid India's rapid industrialization in terms of ensuring the safety and well-being of workers in the workplace.,e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"National Programme on Occupational Diseases Quadrant I reports alarming global statistics, with India contributing significantly to the burden.","What alarming global statistics does the National Programme on Occupational Diseases Quadrant I report, with India contributing significantly to the burden (pmcid=12017669)?","The National Programme on Occupational Diseases Quadrant I reports alarming global statistics related to occupational injuries, with India contributing significantly to the burden.",e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"Injuries impose a significant financial burden on individual households, leading to substantial out-of-pocket expenditures (OOPE) causing severe financial distress for the families of the victims.","What financial burden do injuries impose on individual households, leading to substantial out-of-pocket expenditures (OOPE) causing severe financial distress for the families of the victims (pmcid=12017669)?","Injuries impose a significant financial burden on individual households, leading to substantial out-of-pocket expenditures (OOPE) causing severe financial distress for the families of the victims.",e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"This study explores the profile and economic ramifications of such injuries, emphasizing the urgent need for intervention.",What does this study explore in relation to occupational injuries (pmcid=12017669)?,This study explores the profile and economic ramifications of occupational injuries.,e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"METHODS: This cross-sectional mixed methods study, conducted in a tertiary care hospital in Bangalore, Karnataka, analyses data from 148 occupational injury cases over 6 months.","What type of study design was used to analyze data from occupational injury cases in a tertiary care hospital in Bangalore, Karnataka (pmcid=12017669)?","The study design used to analyze data from occupational injury cases in a tertiary care hospital in Bangalore, Karnataka (pmcid=12017669) was a cross-sectional mixed methods study.",e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"Ethical approval was obtained, and data were collected from hospital records and direct patient inquiries.",What type of data collection method was used in this study (pmcid=12017669)?,Data collection in this study (pmcid=12017669) involved obtaining information from hospital records and direct patient inquiries.,e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"Demographics, injury characteristics, root causes, and outcomes were analyzed.",What aspects were analyzed in the study (pmcid=12017669)?,"Demographics, injury characteristics, root causes, and outcomes were analyzed in the study with pmcid=12017669.",e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"The economic burden, catastrophic health expenditure, awareness, and utilization of social security schemes (SSS) were assessed.","What aspects were assessed in relation to occupational injuries in a tertiary care hospital in Bangalore, Karnataka (pmcid=12017669)?","The economic burden, catastrophic health expenditure, awareness, and utilization of social security schemes (SSS) were assessed in relation to occupational injuries in a tertiary care hospital in Bangalore, Karnataka.",e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"RESULTS: A predominant demographic vulnerability exists among workers under 25 years old, especially in high-risk sectors.",What demographic group shows a predominant vulnerability in occupational injuries according to the study (pmcid=12017669)?,Workers under 25 years old,e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"Traumatic injuries, primarily due to employee negligence, are prevalent, with extremity injuries and ocular injuries being common.",What are the common types of traumatic injuries due to employee negligence mentioned in the study (pmcid=12017669)?,Extremity injuries and ocular injuries,e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"While 68.9% of participants claimed access to personal protective equipment (PPE) at their work sites, only 51.4% reported actual usage of PPE.",What percentage of participants reported actual usage of personal protective equipment (PPE) at their work sites? (pmcid=12017669),51.4%,e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"A significant financial strain was observed, with 64 out of 148 participants experiencing catastrophic health expenditure.",What was observed in terms of financial strain among the participants in the study (pmcid=12017669)?,"A significant financial strain was observed, with 64 out of 148 participants experiencing catastrophic health expenditure.",e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"Insurance coverage and SSS utilization are limited, indicating gaps in awareness and procedural complexities.","What is limited in terms of insurance coverage and SSS utilization in the study conducted at a tertiary care hospital in Bangalore, Karnataka (pmcid=12017669)?",Insurance coverage and SSS utilization,e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"DISCUSSION: The findings underscore the need for targeted interventions, particularly in high-risk sectors and during vulnerable periods, such as postlunch hours.","What need do the findings underscore in terms of targeted interventions, particularly in high-risk sectors and during vulnerable periods (pmcid=12017669)?","The findings underscore the need for targeted interventions in high-risk sectors and during vulnerable periods, such as post-lunch hours, to address occupational injuries and their impact on morbidity, economic costs, and social security scheme utilization.",e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,Bridging the gap between PPE availability and utilization is crucial.,What is crucial to bridge the gap between PPE availability and utilization (pmcid=12017669)?,Bridging the gap between PPE availability and utilization is crucial.,e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"The study emphasizes the importance of collaborative efforts between regulatory bodies, employers, and workers to enhance safety measures.",What is emphasized in the study regarding safety measures (pmcid=12017669)?,"The study emphasizes the importance of collaborative efforts between regulatory bodies, employers, and workers to enhance safety measures.",e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"Furthermore, it highlights the challenges and successes in SSS utilization, suggesting the need for streamlined processes and increased awareness campaigns.",What does the abstract highlight regarding the challenges and successes in Social Security Scheme (SSS) utilization (pmcid=12017669)?,"The abstract highlights the challenges and successes in Social Security Scheme (SSS) utilization, suggesting the need for streamlined processes and increased awareness campaigns.",e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,"Recommendations include targeted interventions, safety training, and streamlined SSS processes to address the complexities surrounding workplace incidents and improve overall occupational well-being.",What are the recommendations for addressing workplace incidents and improving occupational well-being (pmcid=12017669)?,"The recommendations for addressing workplace incidents and improving occupational well-being include targeted interventions, safety training, and streamlined Social Security Scheme (SSS) processes.",e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,Continued research is crucial to refining preventive strategies and mitigating the impact of occupational injuries.,What is crucial for refining preventive strategies and mitigating the impact of occupational injuries (pmcid=12017669)?,Continued research is crucial for refining preventive strategies and mitigating the impact of occupational injuries.,e93d3107c2381cf575b5eff6c9cd56ec
12017669,Roy A,"Morbidity Profile, Economic Impact, and Social Security Scheme Utilisation of Occupational Injuries in a Tertiary Care Hospital in Bangalore, Karnataka",2025,bim,CONCLUSION: This study reveals the urgent need for improved safety measures and streamlined social security schemes to mitigate the significant economic burden of occupational injuries in India.,What is the urgent need identified in the study regarding occupational injuries in India (pmcid=12017669)?,The urgent need identified in the study regarding occupational injuries in India is for improved safety measures and streamlined social security schemes to mitigate the significant economic burden.,e93d3107c2381cf575b5eff6c9cd56ec
12031038,Jung J,Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era,2025,bim,- Background/Objectives: COVID-19 continues to challenge public health due to emerging variants.,What is challenging public health due to emerging variants (pmcid=12031038)?,COVID-19,05003e923a88f47efb22256312f814a8
12031038,Jung J,Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era,2025,bim,"To mitigate this, the Korea Disease Control and Prevention Agency (KDCA) recommends annual COVID-19 vaccination, but uptake remains suboptimal.",What does the Korea Disease Control and Prevention Agency (KDCA) recommend to mitigate the suboptimal uptake of annual COVID-19 vaccination for adults aged 50 and older in South Korea's endemic era (pmcid=12031038)?,The Korea Disease Control and Prevention Agency (KDCA) recommends annual COVID-19 vaccination to mitigate the suboptimal uptake for adults aged 50 and older in South Korea's endemic era.,05003e923a88f47efb22256312f814a8
12031038,Jung J,Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era,2025,bim,"This study evaluates the public health and economic impact of annual mRNA COVID-19 vaccination for adults aged 50 and older in South Korea during the 2024–2025 season, focusing on hospitalizations and costs.",What is the focus of the study evaluating the public health and economic impact of annual mRNA COVID-19 vaccination for adults aged 50 and older in South Korea during the 2024–2025 season (pmcid=12031038)?,The focus of the study is on hospitalizations and costs related to annual mRNA COVID-19 vaccination for adults aged 50 and older in South Korea during the 2024-2025 season.,05003e923a88f47efb22256312f814a8
12031038,Jung J,Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era,2025,bim,"Methods: We estimated hospitalizations prevented by the mRNA-1273 XBB.1.5 containing vaccine by calculating symptomatic infection incidence rates, hospitalization rates among unvaccinated individuals, vaccine effectiveness (VE) against hospitalization, and vaccination rates.",What did the authors estimate in terms of hospitalizations prevented by the mRNA-1273 XBB.1.5 containing vaccine (pmcid=12031038)?,"The authors estimated hospitalizations prevented by the mRNA-1273 XBB.1.5 containing vaccine by calculating symptomatic infection incidence rates, hospitalization rates among unvaccinated individuals, vaccine effectiveness (VE) against hospitalization, and vaccination rates.",05003e923a88f47efb22256312f814a8
12031038,Jung J,Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era,2025,bim,Incidence rates among the unvaccinated with an annual vaccine were derived by adjusting overall infection rates based on vaccination coverage and VE against COVID-19 hospitalization rates.,What were the incidence rates among the unvaccinated derived based on (pmcid=12031038)?,The incidence rates among the unvaccinated were derived by adjusting overall infection rates based on vaccination coverage and VE against COVID-19 hospitalization rates.,05003e923a88f47efb22256312f814a8
12031038,Jung J,Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era,2025,bim,"Hospitalization costs were obtained from a real-world dataset, integrating the KDCA’s COVID-19 confirmed cases with National Health Insurance claims data.",What dataset was integrated to obtain hospitalization costs in the study (pmcid=12031038)?,The KDCA's COVID-19 confirmed cases and National Health Insurance claims data were integrated to obtain hospitalization costs in the study (pmcid=12031038).,05003e923a88f47efb22256312f814a8
12031038,Jung J,Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era,2025,bim,Comparative analyses between mRNA-1273 and BNT162b2 used published meta-analysis results.,What meta-analysis results were used for the comparative analyses between mRNA-1273 and BNT162b2 (pmcid=12031038)?,The comparative analyses between mRNA-1273 and BNT162b2 used published meta-analysis results.,05003e923a88f47efb22256312f814a8
12031038,Jung J,Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era,2025,bim,"Results: Assuming vaccination rates remain consistent with the 2023–2024 season, mRNA-1273 is projected to prevent 37,200 hospitalizations and save USD 77.2 million in healthcare costs during the 2024–2025 season compared to no annual vaccination.",What is projected to be prevented by mRNA-1273 during the 2024-2025 season compared to no annual vaccination (pmcid=12031038)?,"mRNA-1273 is projected to prevent 37,200 hospitalizations and save USD 77.2 million in healthcare costs during the 2024-2025 season compared to no annual vaccination.",05003e923a88f47efb22256312f814a8
12031038,Jung J,Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era,2025,bim,"Compared to BNT162b2, it is expected to prevent an additional 13,260 hospitalizations saving USD 27.5 million.",What is the expected impact of annual mRNA COVID-19 vaccination for adults aged 50 and older in South Korea's endemic era compared to BNT162b2 (pmcid=12031038)?,"The expected impact of annual mRNA COVID-19 vaccination for adults aged 50 and older in South Korea's endemic era compared to BNT162b2 is to prevent an additional 13,260 hospitalizations, saving USD 27.5 million.",05003e923a88f47efb22256312f814a8
12031038,Jung J,Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era,2025,bim,"If vaccination rates increased to match influenza, hospitalizations prevented by mRNA-1273 could rise to 79,800 with USD 164.2 million in healthcare savings compared to no annual vaccination.",What could be the potential healthcare savings from preventing hospitalizations with annual mRNA COVID-19 vaccination for adults aged 50 and older in South Korea's endemic era (pmcid=12031038)?,The potential healthcare savings from preventing hospitalizations with annual mRNA COVID-19 vaccination for adults aged 50 and older in South Korea's endemic era could be USD 164.2 million.,05003e923a88f47efb22256312f814a8
12031038,Jung J,Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era,2025,bim,Conclusion: Annual mRNA COVID-19 vaccination with mRNA-1273 substantially reduces hospitalizations and healthcare costs.,What does the conclusion state about the impact of annual mRNA COVID-19 vaccination with mRNA-1273 (pmcid=12031038)?,The conclusion states that annual mRNA COVID-19 vaccination with mRNA-1273 substantially reduces hospitalizations and healthcare costs.,05003e923a88f47efb22256312f814a8
12031038,Jung J,Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era,2025,bim,Increasing vaccination rates are essential to maximize public health benefits.,What is essential to maximize public health benefits according to the abstract sentence? (pmcid=12031038),Increasing vaccination rates,05003e923a88f47efb22256312f814a8
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,- Background Minimally invasive parafascicular surgery (MIPS) for evacuating intracerebral hemorrhage (ICH) has proven to be an effective treatment compared to medical management.,What has minimally invasive parafascicular surgery (MIPS) proven to be effective for compared to medical management? (pmcid=12025344),Minimally invasive parafascicular surgery (MIPS) has proven to be effective for evacuating intracerebral hemorrhage (ICH) compared to medical management.,a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,"At our academic center, we have adopted a strategy of early surgery (<12 hours) and aimed to assess its impact on patients undergoing MIPS from an economic standpoint.",What strategy has been adopted at the academic center in regards to early surgery for patients undergoing MIPS (pmcid=12025344)?,The strategy adopted at the academic center is early surgery (<12 hours) for patients undergoing MIPS.,a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,This study introduces an innovative preoperative protocol to reduce costs and improve efficiency in the healthcare setting for patients undergoing ICH evacuation.,What does this study introduce to reduce costs and improve efficiency in the healthcare setting for patients undergoing ICH evacuation (pmcid=12025344)?,This study introduces an expedited Minimally Invasive Parafascicular Surgery (MIPS) protocol.,a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,Methods A retrospective review was conducted on patients who underwent MIPS for spontaneous ICH evacuation between 2014 and 2017.,What type of review was conducted on patients who underwent MIPS for spontaneous ICH evacuation between 2014 and 2017 (pmcid=12025344)?,A retrospective review was conducted.,a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,The patients were stratified into two groups: expedited versus control and early versus late operation.,What were the two groups of patients stratified based on in the study (pmcid=12025344)?,The two groups of patients were stratified based on expedited versus control and early versus late operation.,a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,The expedited protocol involved using either computed tomography angiography (CTA) or a stereotactic head CT for guidance during the operation.,What was involved in the expedited protocol for minimally invasive parafascicular surgery for spontaneous intraparenchymal hemorrhage (pmcid=12025344)?,The expedited protocol involved using either computed tomography angiography (CTA) or a stereotactic head CT for guidance during the operation.,a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,"Results Nine patients were included in the expedited protocol group, where they were taken from the emergency department (ED) for CT and CTA, followed by a surgical decision, and then directly to the operating room (OR) from the imaging center.",What was the process followed for patients in the expedited protocol group (pmcid=12025344)?,"Patients in the expedited protocol group were taken from the emergency department (ED) for CT and CTA, followed by a surgical decision, and then directly to the operating room (OR) from the imaging center.",a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,"Nine patients were included in the control group, where they were taken from the ED for CT and CTA and returned to the ED, followed by a surgical decision, then to the imaging center for a stereotactic CTH for intraoperative navigation, and then to the OR.",What was the process followed for the control group in the study (pmcid=12025344)?,"The process followed for the control group in the study involved the patients being taken from the ED for CT and CTA, then returned to the ED for a surgical decision, followed by going to the imaging center for a stereotactic CTH for intraoperative navigation, and finally to the OR.",a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,"Additionally, eleven patients were in the early operation group, and seven were in the late operation group.",What were the two groups of patients categorized based on the timing of their operation (pmcid=12025344)?,The two groups of patients were categorized based on the timing of their operation as the early operation group (eleven patients) and the late operation group (seven patients).,a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,The mean time from ED admission to surgery was 8.2 hours for the early operation group and 62.2 hours for the late operation group (p = 0.10).,What was the mean time from ED admission to surgery for the early operation group and the late operation group in the study (pmcid=12025344)?,The mean time from ED admission to surgery was 8.2 hours for the early operation group and 62.2 hours for the late operation group in the study with pmcid=12025344.,a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,"The control group had 38 preoperative scans, while the expedited group had 17.",How many preoperative scans did the control group have compared to the expedited group (pmcid=12025344)?,"The control group had 38 preoperative scans, while the expedited group had 17.",a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,"The mean preoperative imaging cost decreased from $2,039 in the control to $1,003 in the expedited group (p = 0.004).",What was the decrease in mean preoperative imaging cost from the control group to the expedited group (pmcid=12025344)?,"The decrease in mean preoperative imaging cost from the control group to the expedited group was $1,036.",a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,"Similarly, the mean preoperative imaging cost was $2,061 for the late operation group and $1,162 for the early operation group, respectively (p = 0.02).",What were the mean preoperative imaging costs for the late operation group and the early operation group in the study by Patel MS (pmcid=12025344)?,"The mean preoperative imaging cost was $2,061 for the late operation group and $1,162 for the early operation group in the study by Patel MS (pmcid=12025344).",a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,There was a 15% decrease in the postoperative hospital stay cost per patient (p > 0.05).,What was the percentage decrease in postoperative hospital stay cost per patient in the study (pmcid=12025344)?,15%,a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,Conclusion Patients undergoing an expedited preoperative protocol and early surgery experienced a statistically significant reduction in preoperative costs and a shorter time between ED admission and surgery.,What did patients undergoing an expedited preoperative protocol and early surgery experience in terms of cost reduction and time between ED admission and surgery (pmcid=12025344)?,Patients undergoing an expedited preoperative protocol and early surgery experienced a statistically significant reduction in preoperative costs and a shorter time between ED admission and surgery.,a380fbd16ac713a1e5e5c0b6df13a56e
12025344,Patel MS,Optimization and Economic Impact of Expedited Minimally Invasive Parafascicular Surgery (MIPS) Protocol for Spontaneous Intraparenchymal Hemorrhage,2025,bim,The expedited protocol may provide economic relief for patients undergoing MIPS without compromising outcomes.,What economic relief may the expedited protocol provide for patients undergoing MIPS (pmcid=12025344)?,The expedited protocol may provide economic relief for patients undergoing MIPS without compromising outcomes.,a380fbd16ac713a1e5e5c0b6df13a56e
11630598,Noparatayaporn P,Cost-utility and budget impact analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand,2024,bim,"- Bariatric surgery is another treatment options for patients with obesity, who cannot achieve weight controlled by conservative non-surgical therapy.",What is another treatment option for patients with obesity who cannot achieve weight control with conservative non-surgical therapy? (pmcid=11630598),Bariatric surgery,9ffd3fa159c0576b3e8f897572b06933
11630598,Noparatayaporn P,Cost-utility and budget impact analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand,2024,bim,"Although bariatric surgery provides clinical benefits for these patients, it is costly.",What are the clinical benefits of bariatric surgery for patients with obesity and Type II Diabetes Mellitus (pmcid=11630598)?,"Bariatric surgery provides clinical benefits for patients with obesity and Type II Diabetes Mellitus, as mentioned in the context.",9ffd3fa159c0576b3e8f897572b06933
11630598,Noparatayaporn P,Cost-utility and budget impact analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand,2024,bim,"This study aims to evaluate the cost-effectiveness of bariatric surgery, as compared to nonbariatric surgery, in patients with body mass index (BMI) ≥32.5 kg/m2 and type 2 diabetes mellitus (T2DM), and to estimate the budget impact of bariatric surgery in Thailand.",What does this study aim to evaluate in patients with body mass index (BMI) ≥32.5 kg/m2 and type 2 diabetes mellitus (T2DM) (pmcid=11630598)?,"This study aims to evaluate the cost-effectiveness of bariatric surgery, as compared to nonbariatric surgery, in patients with body mass index (BMI) ≥32.5 kg/m2 and type 2 diabetes mellitus (T2DM).",9ffd3fa159c0576b3e8f897572b06933
11630598,Noparatayaporn P,Cost-utility and budget impact analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand,2024,bim,METHODS: A Markov model was developed to estimate and compare total costs incurred and quality-adjusted life years (QALYs) gained between bariatric surgery and nonbariatric surgery over lifetime horizontal.,What model was developed to estimate and compare total costs and quality-adjusted life years gained in the study (pmcid=11630598)?,A Markov model was developed.,9ffd3fa159c0576b3e8f897572b06933
11630598,Noparatayaporn P,Cost-utility and budget impact analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand,2024,bim,Analysis was conducted under payer and societal perspectives.,What perspectives were considered in the analysis conducted in the study (pmcid=11630598)?,The perspectives considered in the analysis conducted in the study with pmcid=11630598 were payer and societal perspectives.,9ffd3fa159c0576b3e8f897572b06933
11630598,Noparatayaporn P,Cost-utility and budget impact analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand,2024,bim,Costs and outcomes were discounted at an annual rate of 3%.,What annual rate was used to discount costs and outcomes in the analysis (pmcid=11630598)?,3%,9ffd3fa159c0576b3e8f897572b06933
11630598,Noparatayaporn P,Cost-utility and budget impact analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand,2024,bim,The outcomes were presented as incremental cost- effectiveness ratio (ICER).,What were the outcomes presented as in the study (pmcid=11630598)?,The outcomes were presented as incremental cost-effectiveness ratio (ICER).,9ffd3fa159c0576b3e8f897572b06933
11630598,Noparatayaporn P,Cost-utility and budget impact analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand,2024,bim,"RESULTS: Under payer's perspective, bariatric surgery resulted in higher total lifetime cost (676,658.39 baht vs 574,683.38 baht) and QALYs gained (16.08 QALYs vs 14.78 QALYs), as compared to nonbariatric surgery, resulting in an ICER of 78,643.02 baht/QALY.",What was the ICER of bariatric surgery compared to nonbariatric surgery under the payer's perspective (pmcid=11630598)?,"The ICER of bariatric surgery compared to nonbariatric surgery under the payer's perspective was 78,643.02 baht/QALY (pmcid=11630598).",9ffd3fa159c0576b3e8f897572b06933
11630598,Noparatayaporn P,Cost-utility and budget impact analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand,2024,bim,"Similarly, under the societal perspective, bariatric surgery resulted in higher total lifetime cost (1,451,923.83 baht vs 1,407,590.49 baht) and QALYs gained (16.08 QALYs vs 14.78 QALYs), as compared to nonbariatric surgery.",What were the total lifetime costs and QALYs gained under the societal perspective in the analysis (pmcid=11630598)?,"The total lifetime cost was 1,451,923.83 baht and the QALYs gained were 16.08 QALYs under the societal perspective in the analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand (pmcid=11630598).",9ffd3fa159c0576b3e8f897572b06933
11630598,Noparatayaporn P,Cost-utility and budget impact analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand,2024,bim,"Under societal perspective, ICER was estimated at 34,189.82 baht/QALY.",What perspective was used to estimate the ICER in this study (pmcid=11630598)?,Societal perspective,9ffd3fa159c0576b3e8f897572b06933
11630598,Noparatayaporn P,Cost-utility and budget impact analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand,2024,bim,"A 5-year budget impact analysis indicated that bariatric surgery incurred the total budget of 223,821 million baht.",What was the total budget incurred by bariatric surgery over a 5-year period in Thailand (pmcid=11630598)?,"The total budget incurred by bariatric surgery over a 5-year period in Thailand was 223,821 million baht.",9ffd3fa159c0576b3e8f897572b06933
11630598,Noparatayaporn P,Cost-utility and budget impact analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand,2024,bim,"CONCLUSIONS: At the cost-effectiveness threshold of 160,000 baht/QALY, bariatric surgery was a cost-effective strategy and should continue to be included in the benefit package for patients with obesity and T2DM.",What cost-effectiveness threshold was used to determine the cost-effectiveness of bariatric surgery for obesity and T2DM in Thailand (pmcid=11630598)?,"At the cost-effectiveness threshold of 160,000 baht/QALY.",9ffd3fa159c0576b3e8f897572b06933
9661901,Ayres BD,Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States,2022,bim,- PURPOSE: Implicit costs of surgical preparation and materials management for cataract/anterior segment and retinal/posterior segment procedures are often unquantified.,What are the implicit costs that are often unquantified for surgical preparation and materials management for cataract/anterior segment and retinal/posterior segment procedures (pmcid=9661901)?,The implicit costs that are often unquantified for surgical preparation and materials management for cataract/anterior segment and retinal/posterior segment procedures include those related to Custom Pak®.,2faf22b178138429863e369da0e6053c
9661901,Ayres BD,Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States,2022,bim,"Use of ophthalmological surgical procedure packs is common in these surgeries; however, there is little in the literature demonstrating their time and cost impacts.",What is the focus of the literature on ophthalmological surgical procedure packs in cataract and vitreoretinal surgery (pmcid=9661901)?,The focus of the literature on ophthalmological surgical procedure packs in cataract and vitreoretinal surgery is on their time and cost impacts.,2faf22b178138429863e369da0e6053c
9661901,Ayres BD,Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States,2022,bim,Understanding the costs and potential benefits of surgical pack procedure use is important for administrators in purchasing decision-making.,What is important for administrators in purchasing decision-making regarding the use of surgical pack procedures (pmcid=9661901)?,Understanding the costs and potential benefits of surgical pack procedure use is important for administrators in purchasing decision-making.,2faf22b178138429863e369da0e6053c
9661901,Ayres BD,Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States,2022,bim,"The objective of this study is to estimate the economic impact of Alcon Custom Pak(®) on cataract and vitreoretinal (retina) surgery in hospitals and ambulatory surgical centers (ASCs) across operating room (OR), materials management, and accounting departments.",What is the objective of the study conducted by Ayres BD regarding the economic impact of Alcon Custom Pak(®) on cataract and vitreoretinal surgery in the United States (pmcid=9661901)?,The objective of the study conducted by Ayres BD regarding the economic impact of Alcon Custom Pak(®) on cataract and vitreoretinal surgery in the United States is to estimate the economic impact of Custom Pak(®) on these types of surgeries in hospitals and ambulatory surgical centers across various departments.,2faf22b178138429863e369da0e6053c
9661901,Ayres BD,Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States,2022,bim,METHODS: We conducted a study in 2019 among US hospitals and ASCs using an online survey and a surgery timing exercise.,What methods were used in the study conducted in 2019 among US hospitals and ASCs (pmcid=9661901)?,The methods used in the study conducted in 2019 among US hospitals and ASCs included an online survey and a surgery timing exercise.,2faf22b178138429863e369da0e6053c
9661901,Ayres BD,Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States,2022,bim,"Surgical technicians and supply chain managers were surveyed regarding current cataract and retina surgery practices including OR, materials management, and accounting tasks.",What were surgical technicians and supply chain managers surveyed about in relation to cataract and retina surgery practices (pmcid=9661901)?,"Surgical technicians and supply chain managers were surveyed about current cataract and retina surgery practices, including OR, materials management, and accounting tasks.",2faf22b178138429863e369da0e6053c
9661901,Ayres BD,Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States,2022,bim,"Surgical technicians timed cataract and retina surgeries, recording activity timestamps and surgical supply use from Alcon Custom Pak and other sources.",What did the surgical technicians time during cataract and retina surgeries (pmcid=9661901)?,"The surgical technicians timed cataract and retina surgeries, recording activity timestamps and surgical supply use from Alcon Custom Pak and other sources.",2faf22b178138429863e369da0e6053c
9661901,Ayres BD,Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States,2022,bim,"Using the survey and timing exercise inputs and literature and government sources, we developed a budget impact model (BIM) to quantify hidden costs of time and labor spent across the entire surgery supply life cycle.",What did the budget impact model developed in the study quantify (pmcid=9661901)?,The budget impact model developed in the study quantified hidden costs of time and labor spent across the entire surgery supply life cycle.,2faf22b178138429863e369da0e6053c
9661901,Ayres BD,Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States,2022,bim,"RESULTS: Representing a geographical mix of 99 facilities, surgical technicians (56 cataract/46 retina) and supply chain managers (23 cataract/24 retina) provided data for their institutions.",What type of data was provided by surgical technicians and supply chain managers for their institutions (pmcid: 9661901)?,Data on surgical technicians and supply chain managers for cataract and vitreoretinal surgery.,2faf22b178138429863e369da0e6053c
9661901,Ayres BD,Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States,2022,bim,Technicians timed 290 cataract and 250 retina surgeries.,How many cataract surgeries were timed by technicians in the study (pmcid=9661901)?,Technicians timed 290 cataract surgeries.,2faf22b178138429863e369da0e6053c
9661901,Ayres BD,Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States,2022,bim,"In the BIM, increasing baseline Custom Pak utilization to 100% of surgeries while also sourcing all relevant supplies from Custom Pak results in annual cost savings ranging from $92,273 to $217,675 across procedure type and setting, allowing for between 75 (retina ASC) and 266 (cataract hospital) potential additional procedures per facility/year.",What cost savings range was found by increasing baseline Custom Pak utilization to 100% of surgeries in the United States (pmcid=9661901)?,"The cost savings range found by increasing baseline Custom Pak utilization to 100% of surgeries in the United States is between $92,273 and $217,675.",2faf22b178138429863e369da0e6053c
9661901,Ayres BD,Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States,2022,bim,"CONCLUSION: This study demonstrates that increasing Custom Pak usage can potentially save time, reduce hidden costs, and increase throughput.",What does this study demonstrate about increasing Custom Pak usage (pmcid=9661901)?,"This study demonstrates that increasing Custom Pak usage can potentially save time, reduce hidden costs, and increase throughput.",2faf22b178138429863e369da0e6053c
10531588,Rao C,Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis,2023,bim,- A considerable number of infective endocarditis (IE) patients require cardiac surgery with an increased risk for postoperative sepsis.,What is the increased risk for postoperative sepsis in infective endocarditis patients who require cardiac surgery (pmcid=10531588)?,The increased risk for postoperative sepsis in infective endocarditis patients who require cardiac surgery is mentioned in the context information provided.,bff54cb5c467a85166e85904ac77b4e7
10531588,Rao C,Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis,2023,bim,Intraoperative hemoadsorption may diminish the risk of postoperative hyperinflammation with potential economic implications for intensive care unit (ICU) occupation.,What potential economic implications for intensive care unit (ICU) occupation may be associated with intraoperative hemoadsorption (pmcid=10531588)?,"Intraoperative hemoadsorption may diminish the risk of postoperative hyperinflammation, which could potentially lead to reduced ICU occupation and associated economic implications.",bff54cb5c467a85166e85904ac77b4e7
10531588,Rao C,Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis,2023,bim,The present study aimed to theoretically investigate the budget impact of a reduced length of ICU stay in IE patients treated with intraoperative hemoadsorption in the German healthcare system.,What was the aim of the present study (pmcid=10531588)?,The aim of the present study was to theoretically investigate the budget impact of a reduced length of ICU stay in IE patients treated with intraoperative hemoadsorption in the German healthcare system.,bff54cb5c467a85166e85904ac77b4e7
10531588,Rao C,Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis,2023,bim,Data on ICU occupation were extrapolated from a retrospective study on IE patients treated with hemoadsorption.,What data were extrapolated from a retrospective study on IE patients treated with hemoadsorption (pmcid=10531588)?,ICU occupation data were extrapolated from the retrospective study on IE patients treated with hemoadsorption.,bff54cb5c467a85166e85904ac77b4e7
10531588,Rao C,Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis,2023,bim,An Excel-based budget impact model was developed to simulate the patient course over the ICU stay.,What was the purpose of developing the Excel-based budget impact model (pmcid=10531588)?,The purpose of developing the Excel-based budget impact model was to simulate the patient course over the ICU stay in patients with infective endocarditis undergoing hemoadsorption using CytoSorb®.,bff54cb5c467a85166e85904ac77b4e7
10531588,Rao C,Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis,2023,bim,A base-case scenario without therapy reimbursement and a scenario with full therapy reimbursement were explored.,What scenarios were explored in the budget impact analysis (pmcid=10531588)?,A base-case scenario without therapy reimbursement and a scenario with full therapy reimbursement were explored.,bff54cb5c467a85166e85904ac77b4e7
10531588,Rao C,Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis,2023,bim,The annual eligible German IE patient population was derived from official German Diagnostic-Related Group (DRG) volume data.,What data source was used to derive the annual eligible German IE patient population in the study (pmcid=10531588)?,Official German Diagnostic-Related Group (DRG) volume data.,bff54cb5c467a85166e85904ac77b4e7
10531588,Rao C,Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis,2023,bim,One-way deterministic sensitivity analysis and multivariate analysis were performed to evaluate the uncertainty over the model results.,What type of analysis was performed to evaluate the uncertainty over the model results (pmcid=10531588)?,One-way deterministic sensitivity analysis and multivariate analysis,bff54cb5c467a85166e85904ac77b4e7
10531588,Rao C,Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis,2023,bim,The use of intraoperative hemoadsorption resulted in EUR 2298 being saved per patient in the base-case scenario without therapy reimbursement.,What amount was saved per patient in the base-case scenario without therapy reimbursement (pmcid=10531588)?,EUR 2298,bff54cb5c467a85166e85904ac77b4e7
10531588,Rao C,Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis,2023,bim,The savings increased to EUR 3804 per patient in the case of full device-specific reimbursement.,What were the savings per patient in the case of full device-specific reimbursement? (pmcid=10531588),The savings per patient in the case of full device-specific reimbursement were EUR 3804.,bff54cb5c467a85166e85904ac77b4e7
10531588,Rao C,Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis,2023,bim,"Deterministic and probabilistic sensitivity analyses confirmed the robustness of savings, with a probability of savings of 87% and 99% in the base-case and full reimbursement scenario, respectively.",What was the probability of savings in the base-case scenario for patients with infective endocarditis undergoing hemoadsorption using CytoSorb® (pmcid=10531588)?,The probability of savings in the base-case scenario for patients with infective endocarditis undergoing hemoadsorption using CytoSorb® was 87%.,bff54cb5c467a85166e85904ac77b4e7
10531588,Rao C,Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis,2023,bim,"Intraoperative hemoadsorption in IE patients might have relevant economic benefits related to reduced ICU stays, resulting in improved resource use.",What economic benefits might intraoperative hemoadsorption in IE patients have related to reduced ICU stays (pmcid=10531588)?,Intraoperative hemoadsorption in IE patients might have relevant economic benefits related to reduced ICU stays.,bff54cb5c467a85166e85904ac77b4e7
10531588,Rao C,Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis,2023,bim,Further evaluations in larger prospective cohorts are warranted.,What further evaluations are warranted in larger prospective cohorts (pmcid=10531588)?,Further evaluations in larger prospective cohorts are warranted to assess the effectiveness and cost-effectiveness of hemoadsorption using CytoSorb® in patients with infective endocarditis.,bff54cb5c467a85166e85904ac77b4e7
11718670,Seo H,OP42 A Budget Impact Analysis Of The Introduction Of Noninvasive Prenatal Testing To Korean National Health Insurance,2025,bim,- INTRODUCTION: This study assessed the budget impact (BI) of introducing noninvasive perinatal testing (NIPT) to the Korean National Health Insurance (KNHI).,What did the study assess in relation to the Korean National Health Insurance (pmcid=11718670)?,The study assessed the budget impact of introducing noninvasive perinatal testing (NIPT) to the Korean National Health Insurance (KNHI).,c8e45acd4bdac3da6e045b31e778c407
11718670,Seo H,OP42 A Budget Impact Analysis Of The Introduction Of Noninvasive Prenatal Testing To Korean National Health Insurance,2025,bim,It aims to provide useful economic evidence on reimbursement decisions on prenatal screening.,What economic evidence does the study aim to provide on reimbursement decisions on prenatal screening? (pmcid=11718670),The study aims to provide useful economic evidence on reimbursement decisions on prenatal screening.,c8e45acd4bdac3da6e045b31e778c407
11718670,Seo H,OP42 A Budget Impact Analysis Of The Introduction Of Noninvasive Prenatal Testing To Korean National Health Insurance,2025,bim,"Since NIPT is widely used in Korea as a noncovered service, BI can be reliably estimated from real-world data (RWD).",What can be reliably estimated from real-world data in Korea regarding the introduction of noninvasive prenatal testing to Korean National Health Insurance (pmcid=11718670)?,The budget impact (BI) can be reliably estimated from real-world data in Korea regarding the introduction of noninvasive prenatal testing to Korean National Health Insurance.,c8e45acd4bdac3da6e045b31e778c407
11718670,Seo H,OP42 A Budget Impact Analysis Of The Introduction Of Noninvasive Prenatal Testing To Korean National Health Insurance,2025,bim,"METHODS: In this BI analysis, we derived the total number of pregnant women from 2017 birth statistics (n=358,000) and its distribution of singleton births (96.1%) and multiples (3.9%).",What was the total number of pregnant women used in the budget impact analysis (pmcid=11718670)?,"The total number of pregnant women used in the budget impact analysis was 358,000.",c8e45acd4bdac3da6e045b31e778c407
11718670,Seo H,OP42 A Budget Impact Analysis Of The Introduction Of Noninvasive Prenatal Testing To Korean National Health Insurance,2025,bim,"The age distribution of pregnant women was 29.4 percent for 35 and above, and 70.6 percent for below 35, according to the 2017 statistics.",What was the age distribution of pregnant women according to the 2017 statistics (pmcid=11718670)?,"29.4 percent for 35 and above, and 70.6 percent for below 35",c8e45acd4bdac3da6e045b31e778c407
11718670,Seo H,OP42 A Budget Impact Analysis Of The Introduction Of Noninvasive Prenatal Testing To Korean National Health Insurance,2025,bim,"For NIPT costs, we considered a price range of KRW357,000 (USD260) to KRW715,000 (USD522) from a 2018 survey.",What price range for NIPT costs was considered in the analysis (pmcid=11718670)?,"The price range for NIPT costs considered in the analysis was KRW357,000 (USD260) to KRW715,000 (USD522).",c8e45acd4bdac3da6e045b31e778c407
11718670,Seo H,OP42 A Budget Impact Analysis Of The Introduction Of Noninvasive Prenatal Testing To Korean National Health Insurance,2025,bim,"To evaluate the BI of introducing NIPT, we examined eight scenarios based on NIPT cost sharing of 30 percent and 70 percent, NIPT price, and whether to include pregnant women aged less than 35 years old.",What scenarios were examined to evaluate the budget impact of introducing NIPT in Korea (pmcid=11718670)?,"Eight scenarios were examined, based on NIPT cost sharing of 30 percent and 70 percent, NIPT price, and whether to include pregnant women aged less than 35 years old.",c8e45acd4bdac3da6e045b31e778c407
11718670,Seo H,OP42 A Budget Impact Analysis Of The Introduction Of Noninvasive Prenatal Testing To Korean National Health Insurance,2025,bim,RESULTS: BI for KNHI was estimated as KRW6 trillion (USD4 billion) to approximately KRW56 trillion (USD40 billion).,What was the estimated budget impact for Korean National Health Insurance (pmcid=11718670)?,The estimated budget impact for Korean National Health Insurance was KRW6 trillion (USD4 billion) to approximately KRW56 trillion (USD40 billion).,c8e45acd4bdac3da6e045b31e778c407
11718670,Seo H,OP42 A Budget Impact Analysis Of The Introduction Of Noninvasive Prenatal Testing To Korean National Health Insurance,2025,bim,"Scenario seven, targeting older pregnant women with serum screening high risk with NIPT price at the lower end and payer coverage of 30 percent, shows the lowest annual BI of KRW6,115,813,866 (USD4,469,516); scenario two, covering all older pregnant women and younger high-risk cases with NIPT price at the higher end and payer coverage of 70 percent, exhibits the highest burden at KRW56,240,636,611 (USD41,091,993).",What are the annual budget impact figures for scenario seven and scenario two in the study on the introduction of noninvasive prenatal testing to Korean National Health Insurance (pmcid=11718670)?,"The annual budget impact figures for scenario seven and scenario two in the study are as follows:
- Scenario seven: KRW6,115,813,866 (USD4,469,516)
- Scenario two: KRW56,240,636,611 (USD41,091,993)",c8e45acd4bdac3da6e045b31e778c407
11718670,Seo H,OP42 A Budget Impact Analysis Of The Introduction Of Noninvasive Prenatal Testing To Korean National Health Insurance,2025,bim,CONCLUSIONS: Our BI analysis of introducing NIPT to KNHI can serve as essential data for estimating insurer burdens during the potential transition of NIPT to provisional or selective coverage.,What can the Budget Impact analysis of introducing NIPT to KNHI serve as essential data for (pmcid=11718670)?,Estimating insurer burdens during the potential transition of NIPT to provisional or selective coverage.,c8e45acd4bdac3da6e045b31e778c407
11718670,Seo H,OP42 A Budget Impact Analysis Of The Introduction Of Noninvasive Prenatal Testing To Korean National Health Insurance,2025,bim,"In the absence of prenatal diagnostics cost-effectiveness research in Korea, our findings provide crucial evidence for establishing relevant reimbursement criteria, addressing a gap in current research and supporting evidence-based policymaking.",What gap in current research does the study address (pmcid=11718670)?,The study addresses a gap in current research related to the cost-effectiveness of prenatal diagnostics in Korea.,c8e45acd4bdac3da6e045b31e778c407
10137341,Lim VW,Budget Impact Analysis of Adopting a One-Step Nucleic Acid Amplification Testing (NAAT) Alone Diagnostic Pathway for Clostridioides difficile in Japan Compared to a Two-Step Algorithm with Glutamate Dehydrogenase/Toxin Followed by NAAT,2023,bim,- Clostridioides difficile infection (CDI) is a major healthcare-associated infection that leads to a significant health economic burden in Japan.,What is the major healthcare-associated infection that leads to a significant health economic burden in Japan (pmcid=10137341)?,Clostridioides difficile infection (CDI),1dbb65f9990906151e57bb2787b96e73
10137341,Lim VW,Budget Impact Analysis of Adopting a One-Step Nucleic Acid Amplification Testing (NAAT) Alone Diagnostic Pathway for Clostridioides difficile in Japan Compared to a Two-Step Algorithm with Glutamate Dehydrogenase/Toxin Followed by NAAT,2023,bim,"Using a decision tree model, we evaluated the budget impact of adopting a one-step nucleic acid amplification test (NAAT) alone pathway compared to a two-step diagnostic algorithm with glutamate dehydrogenase (GDH) and toxin antigen, followed by NAAT.","What model was used to evaluate the budget impact of adopting a one-step nucleic acid amplification test (NAAT) alone pathway compared to a two-step diagnostic algorithm with glutamate dehydrogenase (GDH) and toxin antigen, followed by NAAT? (pmcid=10137341)",A decision tree model was used to evaluate the budget impact.,1dbb65f9990906151e57bb2787b96e73
10137341,Lim VW,Budget Impact Analysis of Adopting a One-Step Nucleic Acid Amplification Testing (NAAT) Alone Diagnostic Pathway for Clostridioides difficile in Japan Compared to a Two-Step Algorithm with Glutamate Dehydrogenase/Toxin Followed by NAAT,2023,bim,"The analysis was conducted from the government payer's perspective for 100,000 symptomatic, hospitalized adults requiring a CDI diagnostic test.",What perspective was the analysis conducted from for the budget impact of adopting a one-step NAAT alone diagnostic pathway for Clostridioides difficile in Japan (pmcid=10137341)?,The analysis was conducted from the government payer's perspective.,1dbb65f9990906151e57bb2787b96e73
10137341,Lim VW,Budget Impact Analysis of Adopting a One-Step Nucleic Acid Amplification Testing (NAAT) Alone Diagnostic Pathway for Clostridioides difficile in Japan Compared to a Two-Step Algorithm with Glutamate Dehydrogenase/Toxin Followed by NAAT,2023,bim,One-way sensitivity analysis was conducted for all data inputs.,What type of analysis was conducted for all data inputs in the study (pmcid=10137341)?,One-way sensitivity analysis,1dbb65f9990906151e57bb2787b96e73
10137341,Lim VW,Budget Impact Analysis of Adopting a One-Step Nucleic Acid Amplification Testing (NAAT) Alone Diagnostic Pathway for Clostridioides difficile in Japan Compared to a Two-Step Algorithm with Glutamate Dehydrogenase/Toxin Followed by NAAT,2023,bim,"The NAAT alone strategy costed JPY 225,886,360 (USD 2,424,714) more, but was more effective, resulting in 1749 more patients accurately diagnosed and 91 fewer deaths compared to the two-step algorithm.","How much more did the NAAT alone strategy cost compared to the two-step algorithm, and how many more patients were accurately diagnosed as a result (pmcid=10137341)?","The NAAT alone strategy costed JPY 225,886,360 (USD 2,424,714) more compared to the two-step algorithm. This resulted in 1749 more patients accurately diagnosed.",1dbb65f9990906151e57bb2787b96e73
10137341,Lim VW,Budget Impact Analysis of Adopting a One-Step Nucleic Acid Amplification Testing (NAAT) Alone Diagnostic Pathway for Clostridioides difficile in Japan Compared to a Two-Step Algorithm with Glutamate Dehydrogenase/Toxin Followed by NAAT,2023,bim,"Additionally, the NAAT alone pathway costed JPY 26,146 (USD 281) less per true positive CDI diagnosed.",What was the cost difference per true positive CDI diagnosed between the NAAT alone pathway and the two-step algorithm with Glutamate Dehydrogenase/Toxin followed by NAAT (pmcid=10137341)?,"The cost difference per true positive CDI diagnosed between the NAAT alone pathway and the two-step algorithm with Glutamate Dehydrogenase/Toxin followed by NAAT was JPY 26,146 (USD 281) less.",1dbb65f9990906151e57bb2787b96e73
10137341,Lim VW,Budget Impact Analysis of Adopting a One-Step Nucleic Acid Amplification Testing (NAAT) Alone Diagnostic Pathway for Clostridioides difficile in Japan Compared to a Two-Step Algorithm with Glutamate Dehydrogenase/Toxin Followed by NAAT,2023,bim,"The total budget impact, and cost per CDI diagnosed was most sensitive to GDH sensitivity in one-way sensitivity analysis, where a lower GDH sensitivity resulted in greater cost savings with the NAAT alone pathway.",What factor was the total budget impact and cost per CDI diagnosed most sensitive to in the one-way sensitivity analysis (pmcid=10137341)?,GDH sensitivity,1dbb65f9990906151e57bb2787b96e73
10137341,Lim VW,Budget Impact Analysis of Adopting a One-Step Nucleic Acid Amplification Testing (NAAT) Alone Diagnostic Pathway for Clostridioides difficile in Japan Compared to a Two-Step Algorithm with Glutamate Dehydrogenase/Toxin Followed by NAAT,2023,bim,Findings from this budget impact analysis can guide the adoption of a NAAT alone pathway for CDI diagnosis in Japan.,What can the findings from the budget impact analysis guide in Japan (pmcid=10137341)?,The findings from the budget impact analysis can guide the adoption of a NAAT alone pathway for Clostridioides difficile infection (CDI) diagnosis in Japan.,1dbb65f9990906151e57bb2787b96e73
9640704,Jayawardana S,Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis,2022,bim,- Early trials of novel vaccines against tuberculosis (TB) in adults have suggested substantial protection against TB.,What did early trials of novel vaccines against tuberculosis (TB) in adults suggest in terms of protection against TB? (pmcid: 9640704),Early trials of novel vaccines against tuberculosis (TB) in adults suggested substantial protection against TB.,7309339e50009252d9b819910d30a1ba
9640704,Jayawardana S,Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis,2022,bim,"However, little is known about the feasibility and affordability of rolling out such vaccines in practice.",What is little known about the feasibility and affordability of rolling out novel adult tuberculosis vaccines in practice (pmcid=9640704)?,Little is known about the feasibility and affordability of rolling out novel adult tuberculosis vaccines in practice.,7309339e50009252d9b819910d30a1ba
9640704,Jayawardana S,Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis,2022,bim,We conducted expert interviews to identify plausible vaccination implementation strategies for the novel M72/AS01(E) vaccine candidate.,What did the expert interviews aim to identify for the novel M72/AS01(E) vaccine candidate (pmcid=9640704)?,The expert interviews aimed to identify plausible vaccination implementation strategies for the novel M72/AS01(E) vaccine candidate.,7309339e50009252d9b819910d30a1ba
9640704,Jayawardana S,Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis,2022,bim,"The strategies were defined in terms of target population, coverage, vaccination schedule and delivery mode.",What were the strategies defined in terms of in the study conducted by Jayawardana S in South Africa (pmcid=9640704)?,"The strategies defined in the study conducted by Jayawardana S in South Africa included target population, coverage, vaccination schedule, and delivery mode.",7309339e50009252d9b819910d30a1ba
9640704,Jayawardana S,Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis,2022,bim,We modelled these strategies to estimate long-term resource requirements and health benefits arising from vaccination over 2025-2050.,What time frame was used to estimate the long-term resource requirements and health benefits arising from vaccination in South Africa (pmcid=9640704)?,The time frame used to estimate the long-term resource requirements and health benefits arising from vaccination in South Africa in the study with pmcid=9640704 was 2025-2050.,7309339e50009252d9b819910d30a1ba
9640704,Jayawardana S,Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis,2022,bim,"We presented these to experts who excluded strategies that were deemed infeasible, and estimated cost-effectiveness and budget impact for each remaining strategy.",What strategies were excluded by the experts during the analysis (pmcid=9640704)?,Strategies that were deemed infeasible were excluded by the experts during the analysis in the study with pmcid=9640704.,7309339e50009252d9b819910d30a1ba
9640704,Jayawardana S,Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis,2022,bim,"The four strategies modelled combined target populations: either everyone aged 18-50, or all adults living with HIV, with delivery strategies: either a mass campaign followed by routine vaccination of 18-year olds, or two mass campaigns 10 years apart.",What were the four strategies modelled in the study (pmcid=9640704)?,"The four strategies modelled in the study were: 
1. Targeting everyone aged 18-50 for vaccination
2. Targeting all adults living with HIV for vaccination
3. Delivery strategy of a mass campaign followed by routine vaccination of 18-year olds
4. Delivery strategy of two mass campaigns 10 years apart",7309339e50009252d9b819910d30a1ba
9640704,Jayawardana S,Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis,2022,bim,Delivering two mass campaigns to all 18-50-year olds was found to be the most cost-effective strategy conferring the greatest net health benefit of 1.2 million DALYs averted having a probability of being cost-effective of 65-70%.,What was found to be the most cost-effective strategy in the feasibility analysis of novel adult tuberculosis vaccination in South Africa (pmcid=9640704)?,Delivering two mass campaigns to all 18-50-year olds was found to be the most cost-effective strategy in the feasibility analysis of novel adult tuberculosis vaccination in South Africa.,7309339e50009252d9b819910d30a1ba
9640704,Jayawardana S,Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis,2022,bim,"This strategy required 38 million vaccine courses to be delivered at a cost of USD 507 million, reducing TB-related costs by USD 184 million while increasing ART costs by USD 79 million.",What was the cost of delivering 38 million vaccine courses for the novel adult tuberculosis vaccination strategy in South Africa (pmcid=9640704)?,The cost of delivering 38 million vaccine courses for the novel adult tuberculosis vaccination strategy in South Africa was USD 507 million.,7309339e50009252d9b819910d30a1ba
9640704,Jayawardana S,Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis,2022,bim,A suitably designed adult TB vaccination programme built around novel TB vaccines is likely to be cost-effective and affordable given the resource and budget constraints in South Africa.,What is the feasibility of novel adult tuberculosis vaccination in South Africa according to the study (pmcid=9640704)?,The feasibility of novel adult tuberculosis vaccination in South Africa according to the study (pmcid=9640704) is that it is likely to be cost-effective and affordable given the resource and budget constraints in the country.,7309339e50009252d9b819910d30a1ba
11718666,Wong W,OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example,2025,bim,- INTRODUCTION: The majority of those infected with chronic hepatitis C (CHC) are asymptomatic.,What is the majority of those infected with chronic hepatitis C (CHC) asymptomatic? (pmcid=11718666),The majority of those infected with chronic hepatitis C (CHC) are asymptomatic.,63bd9a0902a6e8e230aace608c2804b0
11718666,Wong W,OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example,2025,bim,Population screening has proven to be both effective and cost effective.,What has population screening proven to be in terms of effectiveness and cost-effectiveness? (pmcid=11718666),Population screening has proven to be both effective and cost-effective.,63bd9a0902a6e8e230aace608c2804b0
11718666,Wong W,OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example,2025,bim,"When considering whether to implement screening or not, the uncertainty of the budget impact plays an important role.",What role does uncertainty play when considering whether to implement screening for Hepatitis C (pmcid=11718666)?,The uncertainty of the budget impact plays an important role when considering whether to implement screening for Hepatitis C.,63bd9a0902a6e8e230aace608c2804b0
11718666,Wong W,OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example,2025,bim,This study aims to develop methods that improve the accuracy of budget impact analysis for a one-time CHC screening program.,What is the aim of the study mentioned in the abstract (pmcid=11718666)?,The aim of the study mentioned in the abstract (pmcid=11718666) is to develop methods that improve the accuracy of budget impact analysis for a one-time CHC screening program.,63bd9a0902a6e8e230aace608c2804b0
11718666,Wong W,OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example,2025,bim,METHODS: We developed a back-calculation mathematical model that employs a Markov chain Monte Carlo algorithm to estimate the prevalence and proportion of undiagnosed CHC.,What mathematical model was developed to estimate the prevalence and proportion of undiagnosed CHC (pmcid=11718666)?,A back-calculation mathematical model that employs a Markov chain Monte Carlo algorithm was developed to estimate the prevalence and proportion of undiagnosed CHC.,63bd9a0902a6e8e230aace608c2804b0
11718666,Wong W,OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example,2025,bim,"Subsequently, we utilized a state-transition model to assess the budget impact of two strategies: (i) no screening; and (ii) screen-and-treat with direct-acting antiviral (DAA) for individuals born between 1945 and 1965 (“baby-boomer” birth cohort).",What model was utilized to assess the budget impact of two strategies in the study (pmcid=11718666)?,A state-transition model was utilized to assess the budget impact of two strategies in the study (pmcid=11718666).,63bd9a0902a6e8e230aace608c2804b0
11718666,Wong W,OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example,2025,bim,Model data were gathered from published literature.,What data were gathered for the model from published literature (pmcid=11718666)?,Model data were gathered from published literature.,63bd9a0902a6e8e230aace608c2804b0
11718666,Wong W,OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example,2025,bim,"Our analysis adopted a Canadian provincial payer perspective, employed a 10-year time horizon, and followed best-practice recommendations by not applying discounting.",What perspective was adopted for the analysis in this study (pmcid=11718666)?,The analysis adopted a Canadian provincial payer perspective.,63bd9a0902a6e8e230aace608c2804b0
11718666,Wong W,OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example,2025,bim,"RESULTS: For individuals born between 1945 and 1965, the estimated prevalence of CHC was 1.74 percent (95% confidence interval [CI]: 1.52, 2.30) with an undiagnosed proportion of 15.72 percent (95% CI: 11.27, 18.54).",What is the estimated prevalence of CHC for individuals born between 1945 and 1965 (pmcid=11718666)?,"The estimated prevalence of CHC for individuals born between 1945 and 1965 is 1.74 percent (95% confidence interval [CI]: 1.52, 2.30) with an undiagnosed proportion of 15.72 percent (95% CI: 11.27, 18.54).",63bd9a0902a6e8e230aace608c2804b0
11718666,Wong W,OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example,2025,bim,The initial budget impact analysis indicated an additional cost of CAD61.5 million (USD45.0 million) over 10 years for screening related individuals for CHC in Ontario.,What was the additional cost over 10 years for screening related individuals for CHC in Ontario (pmcid=11718666)?,The additional cost over 10 years for screening related individuals for CHC in Ontario was CAD61.5 million (USD45.0 million).,63bd9a0902a6e8e230aace608c2804b0
11718666,Wong W,OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example,2025,bim,"With these updated prevalence and undiagnosed proportion estimates, our projection suggests a 29.6 percent reduction in the budget impact, now estimated at CAD43.3 million (USD31.7 million).",What reduction in budget impact is projected with the updated prevalence and undiagnosed proportion estimates (pmcid=11718666)?,29.6 percent,63bd9a0902a6e8e230aace608c2804b0
11718666,Wong W,OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example,2025,bim,"CONCLUSIONS: By comparing the budget impact of the CHC screening strategy with other recommended health services and technologies in Ontario, we have concluded that CHC screening may be considered affordable.",What did the study conclude about the affordability of CHC screening compared to other recommended health services and technologies in Ontario (pmcid=11718666)?,The study concluded that CHC screening may be considered affordable when compared to other recommended health services and technologies in Ontario.,63bd9a0902a6e8e230aace608c2804b0
11718666,Wong W,OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example,2025,bim,"To enhance the accuracy of budget impact analysis for population-level screening decision-making, it is crucial to develop precise methodologies for estimating the underlying prevalence and undiagnosed proportions.",What is crucial to develop for estimating the underlying prevalence and undiagnosed proportions in budget impact analysis for population-level screening decision-making (pmcid=11718666)?,Precise methodologies,63bd9a0902a6e8e230aace608c2804b0
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,"- INTRODUCTION: Cytomegalovirus (CMV) infections are usually mild but can lead to serious consequences in immunocompromised patients, such as those infected with human immunodeficiency virus (HIV).","What are the serious consequences of CMV infections in immunocompromised patients, such as those infected with HIV (pmcid=11719149)?","Serious consequences of CMV infections in immunocompromised patients, such as those infected with HIV, can include severe complications and potentially life-threatening conditions.",335b66a8576672777fc2812525852f11
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,"Valganciclovir, which is approved for treating CMV, may be a cost-effective prophylactic for CMV disease in immunocompromised patients.","What is valganciclovir approved for treating, making it a potential cost-effective prophylactic for CMV disease in immunocompromised patients (pmcid=11719149)?","Valganciclovir is approved for treating CMV (Cytomegalovirus), making it a potential cost-effective prophylactic for CMV disease in immunocompromised patients.",335b66a8576672777fc2812525852f11
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,Cost-effectiveness and budget impact analyses were conducted to compare valganciclovir prophylaxis with no prophylaxis in immunosuppressed patients with HIV.,What analyses were conducted to compare valganciclovir prophylaxis with no prophylaxis in immunosuppressed patients with HIV (pmcid=11719149)?,Cost-effectiveness and budget impact analyses were conducted.,335b66a8576672777fc2812525852f11
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,METHODS: Immunosuppressed patients with HIV who were seropositive for CMV were modeled in a one-year horizon decision tree.,What patients were modeled in the decision tree (pmcid=11719149)?,Immunosuppressed patients with HIV who were seropositive for CMV were modeled in the decision tree.,335b66a8576672777fc2812525852f11
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,"Outcomes were occurrence of CMV end-organ disease (EOD)–retinitis and gastroenteritis (85 and 15 percent of cases, respectively)–and survival probability after EOD.",What were the outcomes considered in the analysis (pmcid=11719149)?,The outcomes considered in the analysis were the occurrence of CMV end-organ disease (EOD) – retinitis and gastroenteritis – and survival probability after EOD.,335b66a8576672777fc2812525852f11
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,Direct medical costs related to prophylaxis (induction and maintenance phases) and treatment of EOD were considered.,What costs were considered in the analysis related to prophylaxis and treatment of EOD (pmcid=11719149)?,Direct medical costs,335b66a8576672777fc2812525852f11
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,The budget impact analysis (BIA) used the clinical and cost parameters of the cost-effectiveness analysis to compare scenarios with valganciclovir prophylaxis and no prophylaxis in the public health system over a five-year time horizon.,What parameters were used in the budget impact analysis to compare scenarios with valganciclovir prophylaxis and no prophylaxis in the public health system over a five-year time horizon? (pmcid=11719149),The budget impact analysis used the clinical and cost parameters of the cost-effectiveness analysis to compare scenarios with valganciclovir prophylaxis and no prophylaxis in the public health system over a five-year time horizon.,335b66a8576672777fc2812525852f11
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,The annual market share adoption rate used was 10 percent.,What annual market share adoption rate was used in the analysis (pmcid=11719149)?,10 percent,335b66a8576672777fc2812525852f11
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,The number of eligible patients was calculated from HIV and acquired immunodeficiency syndrome cases reported in the country and epidemiological estimates.,How was the number of eligible patients calculated in the study (pmcid=11719149)?,The number of eligible patients was calculated from HIV and acquired immunodeficiency syndrome cases reported in the country and epidemiological estimates.,335b66a8576672777fc2812525852f11
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,"RESULTS: Valganciclovir prophylaxis had an incremental cost of BRL31,781 (USD6,531) and added 0.69 percent in one-year survival, resulting in an incremental cost-effectiveness ratio (ICER) of BRL4,610,022 (USD947,414) per death avoided in one year.",What was the incremental cost-effectiveness ratio of valganciclovir prophylaxis in HIV-immunosuppressed patients from the Brazilian healthcare system perspective (pmcid=11719149)?,"The incremental cost-effectiveness ratio of valganciclovir prophylaxis in HIV-immunosuppressed patients from the Brazilian healthcare system perspective was BRL4,610,022 (USD947,414) per death avoided in one year.",335b66a8576672777fc2812525852f11
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,"The annual budget impact ranged from BRL35,660,931 (USD7,328,743) in the first year to BRL457,707,796 (USD94,064,365) in the fifth year, totaling BRL1,230,400,576 (USD252,861,870) over five years.",What was the total budget impact over five years in the analysis conducted by Gargano L? (pmcid=11719149),"The total budget impact over five years in the analysis conducted by Gargano L was BRL1,230,400,576 (USD252,861,870).",335b66a8576672777fc2812525852f11
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,"In sensitivity analyses, the lack of a maximum treatment time for the maintenance phase with valganciclovir (50 to 365 days per year) resulted in a wide variation in the ICER and BIA results.",What resulted in a wide variation in the ICER and BIA results in sensitivity analyses (pmcid=11719149)?,The lack of a maximum treatment time for the maintenance phase with valganciclovir (50 to 365 days per year) resulted in a wide variation in the ICER and BIA results in sensitivity analyses.,335b66a8576672777fc2812525852f11
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,"CONCLUSIONS: Despite being recommended for the treatment of CMV retinitis, the use of valganciclovir in immunocompromised patients with HIV who are seropositive for CMV but have not developed CMV disease has a higher ICER when compared with no prophylaxis.",What is the conclusion regarding the use of valganciclovir in immunocompromised patients with HIV who are seropositive for CMV but have not developed CMV disease (pmcid=11719149)?,The conclusion regarding the use of valganciclovir in immunocompromised patients with HIV who are seropositive for CMV but have not developed CMV disease is that it has a higher ICER when compared with no prophylaxis.,335b66a8576672777fc2812525852f11
11719149,Gargano L,PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective,2025,bim,"For these patients, appropriate use of standard antiretroviral therapy to improve the immune system may be more appropriate.",What may be more appropriate for HIV-immunosuppressed patients in terms of improving the immune system (pmcid=11719149)?,Appropriate use of standard antiretroviral therapy may be more appropriate for HIV-immunosuppressed patients in terms of improving the immune system (pmcid=11719149).,335b66a8576672777fc2812525852f11
10635706,Mountain R,Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population,2023,bim,"- BACKGROUND: An estimated 70% of Canadians with chronic obstructive pulmonary disease (COPD) have not received a diagnosis, creating a barrier to early intervention, and there is growing interest in the value of primary care-based opportunistic case detection for COPD.",What is the estimated percentage of Canadians with chronic obstructive pulmonary disease (COPD) who have not received a diagnosis (pmcid=10635706)?,An estimated 70% of Canadians with chronic obstructive pulmonary disease (COPD) have not received a diagnosis.,15733a7308b6294869914876505e5c67
10635706,Mountain R,Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population,2023,bim,We sought to build on a previous cost-effectiveness analysis by evaluating the budget impact of adopting COPD case detection in the Canadian general population.,What did the study evaluate (pmcid=10635706)?,The study evaluated the budget impact of adopting COPD case detection in the Canadian general population.,15733a7308b6294869914876505e5c67
10635706,Mountain R,Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population,2023,bim,METHODS: We used a validated discrete-event microsimulation model of COPD in the Canadian general population aged 40 years and older to assess the costs of implementing 8 primary care-based case detection strategies over 5 years (2022-2026) from the health care payer perspective.,What model was used to assess the costs of implementing primary care-based case detection strategies for COPD in the Canadian general population (pmcid=10635706)?,A validated discrete-event microsimulation model was used.,15733a7308b6294869914876505e5c67
10635706,Mountain R,Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population,2023,bim,"Strategies varied in eligibility criteria (based on age, symptoms or smoking history) and testing technology (COPD Diagnostic Questionnaire [CDQ] or screening spirometry).",What varied in the strategies for case detection of chronic obstructive pulmonary disease in the Canadian general population (pmcid=10635706)?,"The eligibility criteria and testing technology varied in the strategies for case detection of chronic obstructive pulmonary disease in the Canadian general population. Eligibility criteria included factors such as age, symptoms, or smoking history, and testing technology options included the COPD Diagnostic Questionnaire (CDQ) or screening spirometry.",15733a7308b6294869914876505e5c67
10635706,Mountain R,Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population,2023,bim,Costs were determined from Canadian studies and converted to 2021 Canadian dollars.,What were the costs determined from in the study (pmcid=10635706)?,Costs were determined from Canadian studies.,15733a7308b6294869914876505e5c67
10635706,Mountain R,Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population,2023,bim,Key parameters were varied in one-way sensitivity analysis.,What key parameters were varied in the one-way sensitivity analysis? (pmcid=10635706),Key parameters varied in the one-way sensitivity analysis were not specified in the provided context information for pmcid 10635706.,15733a7308b6294869914876505e5c67
10635706,Mountain R,Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population,2023,bim,RESULTS: All strategies resulted in higher total costs compared with routine diagnosis.,What were the total costs compared with routine diagnosis in the study (pmcid=10635706)?,All strategies resulted in higher total costs compared with routine diagnosis in the study (pmcid=10635706).,15733a7308b6294869914876505e5c67
10635706,Mountain R,Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population,2023,bim,"The most cost-effective scenario (the CDQ for all patients) had an associated total budget expansion of $423 million, with administering case detection and subsequent diagnostic spirometry accounting for 86% of costs.",What was the total budget expansion associated with the most cost-effective scenario in the study (pmcid=10635706)?,The total budget expansion associated with the most cost-effective scenario in the study was $423 million.,15733a7308b6294869914876505e5c67
10635706,Mountain R,Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population,2023,bim,"This strategy increased the proportion of individuals diagnosed with COPD from 30.4% to 37.8%, and resulted in 4.6 million referrals to diagnostic spirometry.",What proportion of individuals diagnosed with COPD increased as a result of the strategy mentioned in the abstract (pmcid=10635706)?,The proportion of individuals diagnosed with COPD increased from 30.4% to 37.8% as a result of the strategy mentioned in the abstract (pmcid=10635706).,15733a7308b6294869914876505e5c67
10635706,Mountain R,Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population,2023,bim,Results were most sensitive to uptake in primary care.,What were the results most sensitive to in the budget impact analysis of adopting primary care-based case detection of chronic obstructive pulmonary disease in the Canadian general population (pmcid=10635706)?,The results were most sensitive to uptake in primary care.,15733a7308b6294869914876505e5c67
10635706,Mountain R,Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population,2023,bim,"INTERPRETATION: Adopting a national COPD case detection program would be an effective method for increasing diagnosis of COPD, dependent on successful uptake.","What would be an effective method for increasing the diagnosis of COPD, dependent on successful uptake (pmcid=10635706)?","Adopting a national COPD case detection program would be an effective method for increasing the diagnosis of COPD, dependent on successful uptake.",15733a7308b6294869914876505e5c67
10635706,Mountain R,Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population,2023,bim,"However, it will require prioritisation by budget holders and substantial additional investment to improve access to diagnostic spirometry.",What will be required to improve access to diagnostic spirometry according to the abstract sentence (pmcid=10635706)?,Prioritisation by budget holders and substantial additional investment.,15733a7308b6294869914876505e5c67
11362395,Espinola N,Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,2024,bim,- OBJECTIVES: The aim of this study was to perform a budget impact analysis (BIA) of introducing olaparib treatment for adult patients with metastatic castration-resistant prostate cancer in Argentina.,What was the objective of the study (pmcid=11362395)?,The objective of the study was to perform a budget impact analysis of introducing olaparib treatment for adult patients with metastatic castration-resistant prostate cancer in Argentina.,c399e9614c1f6b509aaa533bc3a316fe
11362395,Espinola N,Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,2024,bim,METHODS: A BIA model was used to estimate the cost difference between the current scenario (without olaparib) and the new scenario (incorporation of olaparib) for a third-party payer over a 5-year time horizon.,What model was used to estimate the cost difference in the budget impact analysis of olaparib for the management of patients with HRR-mutated castration-resistant metastatic prostate cancer in Argentina (pmcid=11362395)?,A BIA model was used to estimate the cost difference in the budget impact analysis of olaparib for the management of patients with HRR-mutated castration-resistant metastatic prostate cancer in Argentina.,c399e9614c1f6b509aaa533bc3a316fe
11362395,Espinola N,Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,2024,bim,The budgetary impact is estimated at the national health system level and by healthcare sectors in Argentina.,What is the estimated budgetary impact of Olaparib for the management of patients with HRR-mutated castration-resistant metastatic prostate cancer in Argentina (pmcid=11362395)?,The estimated budgetary impact of Olaparib for the management of patients with HRR-mutated castration-resistant metastatic prostate cancer in Argentina is analyzed at the national health system level and by healthcare sectors.,c399e9614c1f6b509aaa533bc3a316fe
11362395,Espinola N,Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,2024,bim,Input parameters were obtained from the literature and validated by local expert opinion.,What were the input parameters obtained from for the budget impact analysis of Olaparib in Argentina (pmcid=11362395)?,The input parameters for the budget impact analysis of Olaparib in Argentina were obtained from the literature and validated by local expert opinion.,c399e9614c1f6b509aaa533bc3a316fe
11362395,Espinola N,Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,2024,bim,Direct medical costs were obtained from both the Institute for Clinical Effectiveness and Health Policy (IECS) unit cost database and public data in Argentina.,What databases were used to obtain direct medical costs in Argentina for the budget impact analysis of Olaparib in patients with HRR-mutated castration-resistant metastatic prostate cancer (pmcid=11362395)?,The databases used to obtain direct medical costs in Argentina for the budget impact analysis of Olaparib in patients with HRR-mutated castration-resistant metastatic prostate cancer were the Institute for Clinical Effectiveness and Health Policy (IECS) unit cost database and public data in Argentina.,c399e9614c1f6b509aaa533bc3a316fe
11362395,Espinola N,Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,2024,bim,The microcosting estimation was used for key variables of the analysis.,What type of costing estimation was used for key variables in the analysis (pmcid=11362395)?,Microcosting estimation,c399e9614c1f6b509aaa533bc3a316fe
11362395,Espinola N,Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,2024,bim,All costs are reported in US dollars (US$) as for October 2022 (1 US$ = 152.59 Argentine pesos).,What currency are all costs reported in for the budget impact analysis of Olaparib in Argentina (pmcid=11362395)?,All costs are reported in US dollars (US$).,c399e9614c1f6b509aaa533bc3a316fe
11362395,Espinola N,Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,2024,bim,One-way sensitivity analyses and scenario analyses were conducted to evaluate the model robustness.,What type of analyses were conducted to evaluate the model robustness (pmcid=11362395)?,One-way sensitivity analyses and scenario analyses were conducted to evaluate the model robustness.,c399e9614c1f6b509aaa533bc3a316fe
11362395,Espinola N,Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,2024,bim,"RESULTS: The incorporation of olaparib, with a wholesale price per pack of US$3176, was associated with a weighted average of the budget impact per member per month (PMPM) of US$0.0191 for the national health system, being slightly higher than the estimated budgeted high impact threshold (US$0.0153).",What was the budget impact per member per month associated with the incorporation of olaparib for the management of patients with HRR-mutated castration-resistant metastatic prostate cancer in Argentina (pmcid=11362395)?,The budget impact per member per month associated with the incorporation of olaparib for the management of patients with HRR-mutated castration-resistant metastatic prostate cancer in Argentina was US$0.0191.,c399e9614c1f6b509aaa533bc3a316fe
11362395,Espinola N,Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,2024,bim,The PMPM budget impact for a 5-year average ranged between US$0.007 (public sector) and US$0.033 (private sector).,What is the range of PMPM budget impact for a 5-year average in Argentina for the management of patients with HRR-mutated castration-resistant metastatic prostate cancer (pmcid=11362395)?,The range of PMPM budget impact for a 5-year average in Argentina for the management of patients with HRR-mutated castration-resistant metastatic prostate cancer is between US$0.007 in the public sector and US$0.033 in the private sector.,c399e9614c1f6b509aaa533bc3a316fe
11362395,Espinola N,Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,2024,bim,The duration of treatment with olaparib was the most influential parameter in the budget impact results.,What was the most influential parameter in the budget impact results of olaparib treatment for patients with HRR-mutated castration-resistant metastatic prostate cancer in Argentina (pmcid=11362395)?,The most influential parameter in the budget impact results of olaparib treatment for patients with HRR-mutated castration-resistant metastatic prostate cancer in Argentina (pmcid=11362395) was the duration of treatment with olaparib.,c399e9614c1f6b509aaa533bc3a316fe
11362395,Espinola N,Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,2024,bim,CONCLUSIONS: The introduction of olaparib for the treatment of metastatic castration-resistant prostate cancer has a high budget impact for Argentina's health system.,What is the budget impact of introducing olaparib for the treatment of metastatic castration-resistant prostate cancer in Argentina (pmcid=11362395)?,The budget impact of introducing olaparib for the treatment of metastatic castration-resistant prostate cancer in Argentina is high for the country's health system.,c399e9614c1f6b509aaa533bc3a316fe
11362395,Espinola N,Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,2024,bim,These findings are informative to support policy decisions aimed to expand the current treatment landscape for prostate cancer.,What are the findings informative to support (pmcid=11362395)?,The findings that are informative to support policy decisions aimed to expand the current treatment landscape for prostate cancer.,c399e9614c1f6b509aaa533bc3a316fe
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,"- BACKGROUND: An increasing number of orphan medicinal products (OMPs) are being included in social health insurance schemes, significantly improving access to medicines for patients with rare diseases.",What is the background information provided in the abstract (pmcid=11430509)?,"The background information provided in the abstract is about the increasing inclusion of orphan medicinal products (OMPs) in social health insurance schemes, which has significantly improved access to medicines for patients with rare diseases.",916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,"However, high-priced OMPs are still not covered, primarily due to health equity controversies and inadequate data systems required for economic evaluation.",What is the primary reason high-priced OMPs are still not covered in China (pmcid=11430509)?,"The primary reason high-priced OMPs are still not covered in China, as mentioned in the context information, is due to health equity controversies and inadequate data systems required for economic evaluation.",916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,The aim of this study was to estimate the burden of drug expenditures and the size of the reimbursement budget required for high-priced OMPs from the perspectives of society and healthcare payers.,What was the aim of the study conducted by Zhang X regarding high-priced orphan medicinal products in China (pmcid=11430509)?,The aim of the study conducted by Zhang X regarding high-priced orphan medicinal products in China was to estimate the burden of drug expenditures and the size of the reimbursement budget required for these products from the perspectives of society and healthcare payers.,916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,"METHODS: The study performed a budget impact analysis using data from multiple sources to estimate the reimbursement budget for high-priced OMPs in Chengdu, a densely populated metropolis in China.",What data sources were used to estimate the reimbursement budget for high-priced OMPs in Chengdu (pmcid=11430509)?,"The data sources used to estimate the reimbursement budget for high-priced OMPs in Chengdu included multiple sources, as mentioned in the context information.",916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,"The budget analysis consisted of three main elements: the number of patients, the price of drugs, and the simulated policy scenario.",What were the three main elements included in the budget analysis (pmcid=11430509)?,"The three main elements included in the budget analysis were the number of patients, the price of drugs, and the simulated policy scenario.",916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,"By adjusting the combinations of these elements, the budget fluctuations for payers were estimated.",What was estimated by adjusting the combinations of elements in the budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China (pmcid=11430509)?,Budget fluctuations for payers were estimated.,916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,"Furthermore, the study predicted the budget trend for the next three years to validate its sustainability.",What did the study predict for the next three years to validate its sustainability (pmcid=11430509)?,The study predicted the budget trend for the next three years to validate its sustainability.,916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,RESULTS: The analysis indicated that 98 rare disease patients in Chengdu required high-priced OMPs in 2019.,How many rare disease patients in Chengdu required high-priced OMPs in 2019 (pmcid=11430509)?,98,916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,"This suggested a projected budget of CNY 179 million for these patients without reimbursement policies, from a societal perspective.","What was the projected budget for patients without reimbursement policies, from a societal perspective (pmcid=11430509)?","The projected budget for patients without reimbursement policies, from a societal perspective, was CNY 179 million.",916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,"Under six assumed policy scenarios, this budget ranged from CNY 32 million to CNY 156 million.",What was the range of the budget under six assumed policy scenarios in the study conducted by Zhang X (pmcid=11430509)?,The range of the budget under six assumed policy scenarios in the study conducted by Zhang X (pmcid=11430509) was from CNY 32 million to CNY 156 million.,916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,"Over the next three years, the annual budget was estimated to range from CNY 200 million to CNY 1.303 billion.",What was the estimated range of the annual budget over the next three years in the study conducted by Zhang X in China (pmcid=11430509)?,The estimated range of the annual budget over the next three years in the study conducted by Zhang X in China was from CNY 200 million to CNY 1.303 billion.,916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,CONCLUSION: Integration of multi-source data helps to obtain more scientifically reliable results on budget impacts.,What helps to obtain more scientifically reliable results on budget impacts? (pmcid=11430509),Integration of multi-source data helps to obtain more scientifically reliable results on budget impacts.,916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,The study found that the budgetary impacts of high-priced OMPs on society and payers are relatively limited.,What did the study find regarding the budgetary impacts of high-priced OMPs on society and payers (pmcid=11430509)?,The study found that the budgetary impacts of high-priced OMPs on society and payers are relatively limited.,916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,Health policymakers can choose appropriate reimbursement strategies based on financial affordability among a diverse mix of elements.,What can health policymakers choose based on financial affordability among a diverse mix of elements? (pmcid=11430509),Health policymakers can choose appropriate reimbursement strategies based on financial affordability among a diverse mix of elements.,916ae9d1cdbd1cb7de99372b46599f96
11430509,Zhang X,Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu,2024,bim,The results of related studies provided insights for optimizing the allocation of health resources and improving patient access to medications.,What insights did the results of related studies provide for optimizing the allocation of health resources and improving patient access to medications (pmcid=11430509)?,The results of related studies provided insights for optimizing the allocation of health resources and improving patient access to medications.,916ae9d1cdbd1cb7de99372b46599f96
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,"- BACKGROUND: The biosimilar market is growing rapidly, as evidenced by 41 approvals and 37 launches to date.",What is the current number of biosimilar approvals and launches in the market (pmcid=11522441)?,"The current number of biosimilar approvals is 41, and the number of launches is 37.",4bfc90b10e0d6c81e514214456bbdb4e
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,"As adalimumab biosimilars launch in the United States, competition among biosimilar and reference adalimumab will likely increase across multiple reference indications, including rheumatology, dermatology, and gastrointestinal diseases, which may lead to decreased payer costs.",What may the launch of adalimumab biosimilars in the United States lead to in terms of payer costs (pmcid=11522441)?,The launch of adalimumab biosimilars in the United States may lead to decreased payer costs.,4bfc90b10e0d6c81e514214456bbdb4e
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,OBJECTIVE: To evaluate the costs of adding biosimilar adalimumab to a US commercial plan by exploring various utilization and price differential scenarios.,What was the objective of the study conducted by Chaplin S regarding the budget impact analysis of including biosimilar adalimumab on formulary from a United States payer perspective? (pmcid=11522441),The objective of the study conducted by Chaplin S was to evaluate the costs of adding biosimilar adalimumab to a US commercial plan by exploring various utilization and price differential scenarios.,4bfc90b10e0d6c81e514214456bbdb4e
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,METHODS: A 3-year budget impact model for a US commercial plan of 1 million people was developed to assess switching from reference adalimumab or any self-injectable reference tumor necrosis factor (TNF) inhibitor to biosimilar adalimumab.,What type of budget impact model was developed in this study (pmcid=11522441)?,A 3-year budget impact model,4bfc90b10e0d6c81e514214456bbdb4e
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,Pharmacy and medical costs were analyzed through high- and low-conversion scenarios from reference adalimumab and the TNF inhibitor class.,What costs were analyzed in the study from a United States payer perspective (pmcid=11522441)?,Pharmacy and medical costs were analyzed in the study from a United States payer perspective.,4bfc90b10e0d6c81e514214456bbdb4e
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,Price reductions of 5% to 60% relative to reference adalimumab based on previous biosimilar launches were also explored.,What price reductions were explored in relation to reference adalimumab (pmcid=11522441)?,Price reductions of 5% to 60% were explored in relation to reference adalimumab.,4bfc90b10e0d6c81e514214456bbdb4e
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,"Short-term medical costs were evaluated as additional simple and complex office visits, with scenarios of half of switch patients having 1 visit up to all switch patients having 10 visits.",What were the short-term medical costs evaluated in the study (pmcid=11522441)?,"Short-term medical costs evaluated in the study included additional simple and complex office visits, with scenarios ranging from half of switch patients having 1 visit up to all switch patients having 10 visits.",4bfc90b10e0d6c81e514214456bbdb4e
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,"RESULTS: In a target population of 1,863 patients, switching from reference adalimumab to biosimilar adalimumab had cumulative cost savings of $5,756,073 with slow conversion (10%-20% over 3 years) and $28,780,365 with fast conversion (50%-100% over 3 years).",What were the cumulative cost savings of switching from reference adalimumab to biosimilar adalimumab in the study (pmcid=11522441)?,"The cumulative cost savings of switching from reference adalimumab to biosimilar adalimumab in the study were $5,756,073 with slow conversion (10%-20% over 3 years) and $28,780,365 with fast conversion (50%-100% over 3 years).",4bfc90b10e0d6c81e514214456bbdb4e
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,Similar results were seen when switching from any other self-injectable reference TNF inhibitor.,What were the similar results seen when switching from any other self-injectable reference TNF inhibitor? (pmcid=11522441),Similar results were seen when switching from any other self-injectable reference TNF inhibitor.,4bfc90b10e0d6c81e514214456bbdb4e
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,Cost savings more than $1 million were seen with a 10% conversion from reference adalimumab and a 15% price reduction from reference adalimumab.,What cost savings were seen with a 10% conversion from reference adalimumab and a 15% price reduction from reference adalimumab? (pmcid=11522441),Cost savings more than $1 million were seen with a 10% conversion from reference adalimumab and a 15% price reduction from reference adalimumab.,4bfc90b10e0d6c81e514214456bbdb4e
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,"Additional office visit scenarios had a negligible impact on budget, with no changes in per-member-per-month costs until all switch patients had 10 additional complex visits, in which per-member-per-month costs increased by $0.02.",What was the impact of additional office visit scenarios on the budget according to the abstract sentence (pmcid=11522441)?,"The impact of additional office visit scenarios on the budget according to the abstract sentence was negligible, with no changes in per-member-per-month costs until all switch patients had 10 additional complex visits, at which point per-member-per-month costs increased by $0.02.",4bfc90b10e0d6c81e514214456bbdb4e
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,"CONCLUSIONS: In a hypothetical plan of 1 million lives, use of biosimilar adalimumab in commercial plans can lead to significant cost savings for payers because of increased competition.",What can the use of biosimilar adalimumab in commercial plans lead to for payers in a hypothetical plan of 1 million lives (pmcid=11522441)?,The use of biosimilar adalimumab in commercial plans can lead to significant cost savings for payers in a hypothetical plan of 1 million lives.,4bfc90b10e0d6c81e514214456bbdb4e
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,Greater and faster biosimilar conversion rates from reference adalimumab and other reference TNF inhibitors resulted in decreased costs.,What resulted in decreased costs according to the abstract sentence (pmcid=11522441)?,Greater and faster biosimilar conversion rates from reference adalimumab and other reference TNF inhibitors,4bfc90b10e0d6c81e514214456bbdb4e
11522441,Chaplin S,Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective,2024,bim,"Additionally, even with short-term medical expenditures, cost savings were still realized when switching to biosimilar adalimumab.",What cost savings were realized when switching to biosimilar adalimumab? (pmcid=11522441),Cost savings were still realized when switching to biosimilar adalimumab.,4bfc90b10e0d6c81e514214456bbdb4e
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,- BACKGROUND: Refractory angina (RA) is a chronic condition characterized by the presence of debilitating angina symptoms due to established reversible ischemia in the presence of obstructive coronary artery disease (CAD).,What is refractory angina characterized by (pmcid=10982321)?,Refractory angina is characterized by the presence of debilitating angina symptoms due to established reversible ischemia in the presence of obstructive coronary artery disease (CAD).,e8aac05fc301fdcf048430a1d0cad6ba
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"Treatments for this condition have undergone major developments in recent decades; however, the treatment for RA remains a challenge for medicine.",What remains a challenge for medicine despite major developments in treatments for refractory angina? (pmcid=10982321),The treatment for refractory angina (RA) remains a challenge for medicine despite major developments in treatments for this condition.,e8aac05fc301fdcf048430a1d0cad6ba
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"In this sense, the Coronary Sinus Reducer System (CSRS) stands as the last line of therapy for ineligible patients for revascularization with reversible ischemia.",What does the Coronary Sinus Reducer System (CSRS) stand as for ineligible patients for revascularization with reversible ischemia? (pmcid=10982321),The Coronary Sinus Reducer System (CSRS) stands as the last line of therapy for ineligible patients for revascularization with reversible ischemia.,e8aac05fc301fdcf048430a1d0cad6ba
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,The purpose of this report is to evaluate the potential burden on the National Health Service (NHS) and measure the health effects in terms of both quantity (life years) and quality-of-life aspects related to the reducer.,What is the purpose of the report in relation to the National Health Service (NHS) (pmcid=10982321)?,The purpose of the report is to evaluate the potential burden on the National Health Service (NHS) and measure the health effects in terms of both quantity (life years) and quality-of-life aspects related to the reducer device.,e8aac05fc301fdcf048430a1d0cad6ba
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,METHODS: Two different economic evaluation models were developed as part of the analysis.,What economic evaluation models were developed as part of the analysis (pmcid=10982321)?,Two different economic evaluation models were developed as part of the analysis.,e8aac05fc301fdcf048430a1d0cad6ba
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,The budget impact was developed to estimate the potential burden on the NHS from incremental uptake of the use of the reducer in the target population.,What was the purpose of developing the budget impact model in this study (pmcid=10982321)?,The purpose of developing the budget impact model in this study was to estimate the potential burden on the NHS from incremental uptake of the use of the reducer device in patients with refractory angina.,e8aac05fc301fdcf048430a1d0cad6ba
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"The utility cost analysis compares and evaluates the quality of life and health resource use and costs between the two alternatives, based on the research of Gallone et al.",What research was the utility cost analysis based on (pmcid=10982321)?,The utility cost analysis was based on the research of Gallone et al.,e8aac05fc301fdcf048430a1d0cad6ba
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,A deterministic and probabilistic sensitivity analysis was carried out to characterize the uncertainty around the parameters of the model.,What type of analysis was carried out to characterize the uncertainty around the parameters of the model (pmcid=10982321)?,Deterministic and probabilistic sensitivity analysis,e8aac05fc301fdcf048430a1d0cad6ba
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"RESULTS: In the budget impact analysis (BIA), the reducer is shown to be more expensive in the first 2 years of the model, due to the gradual uptake in the market and the cost of the device.",What is shown to be more expensive in the first 2 years of the model in the budget impact analysis (pmcid=10982321)?,The reducer device is shown to be more expensive in the first 2 years of the model in the budget impact analysis.,e8aac05fc301fdcf048430a1d0cad6ba
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"Starting from the third year, assuming maintenance of effectiveness, there are savings in terms of resource absorption in direct healthcare costs arising from hospitalizations, emergency department accesses, coronarography, and visits avoided.",What type of analysis was conducted in this study (pmcid=10982321)?,Cost-utility analysis,e8aac05fc301fdcf048430a1d0cad6ba
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"CONCLUSION: The BIA and cost-effectiveness model show that the reducer device, despite an increase in resources absorbed in the first years of implementation and use, has the potential to result in increased quality of life in patients with RA.",What do the budget impact model and cost-effectiveness model show about the reducer device in patients with refractory angina (pmcid=10982321)?,The budget impact model and cost-effectiveness model show that the reducer device has the potential to result in increased quality of life in patients with refractory angina.,e8aac05fc301fdcf048430a1d0cad6ba
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,These costs are largely offset in the short term by the improved clinical outcomes achievable leading to savings from the third year onward in the BIA and a dominance ratio in the cost-utility analysis.,What is the dominance ratio in the cost-utility analysis of the reducer device (Neovasc) in patients with refractory angina (pmcid=10982321)?,"The dominance ratio in the cost-utility analysis of the reducer device (Neovasc) in patients with refractory angina is favorable, indicating that the device is cost-effective and provides better clinical outcomes compared to alternative treatments.",e8aac05fc301fdcf048430a1d0cad6ba
9801587,Mohammadnezhad G,Budget impact analysis of breast cancer medications: a systematic review,2022,bim,"- BACKGROUND: Breast cancer (BC) is the most common cancer globally among women, with 2,261,419 new cases in 2020; systemic treatment may be neo-adjuvant, adjuvant, or both.",What is the most common cancer globally among women according to the abstract sentence provided (pmcid=9801587)?,Breast cancer (BC) is the most common cancer globally among women.,71b0e91f86bcfc44c31a7b628b0c5576
9801587,Mohammadnezhad G,Budget impact analysis of breast cancer medications: a systematic review,2022,bim,"BC subtype guides the standard systemic therapy administered, which consists of endocrine therapy for all HR + tumors, trastuzumab-based HER2-directed antibody therapy plus chemotherapy for all HER2 + tumors (with endocrine therapy given in addition, if concurrent HR positivity), and chemotherapy alone for the triple-negative subtype.",What guides the standard systemic therapy administered for breast cancer medications (pmcid=9801587)?,BC subtype guides the standard systemic therapy administered.,71b0e91f86bcfc44c31a7b628b0c5576
9801587,Mohammadnezhad G,Budget impact analysis of breast cancer medications: a systematic review,2022,bim,"This study aimed to identify, evaluate, and systematically review all budget impact analyses (BIAs) of BC medications worldwide.",What was the aim of the study (pmcid=9801587)?,"The aim of the study with pmcid=9801587 was to identify, evaluate, and systematically review all budget impact analyses (BIAs) of breast cancer medications worldwide.",71b0e91f86bcfc44c31a7b628b0c5576
9801587,Mohammadnezhad G,Budget impact analysis of breast cancer medications: a systematic review,2022,bim,"METHODS: PubMed, Scopus, and Web of Science Core Collection databases were thoroughly searched up to 26th March 2022 to identify original published studies which evaluate BIA of BC medications.",What databases were searched to identify original published studies evaluating the budget impact analysis of breast cancer medications (pmcid=9801587)?,"PubMed, Scopus, and Web of Science Core Collection databases",71b0e91f86bcfc44c31a7b628b0c5576
9801587,Mohammadnezhad G,Budget impact analysis of breast cancer medications: a systematic review,2022,bim,ISPOR Task Force guidelines were used to assess the quality of included studies.,What guidelines were used to assess the quality of included studies in the analysis (pmcid=9801587)?,ISPOR Task Force guidelines,71b0e91f86bcfc44c31a7b628b0c5576
9801587,Mohammadnezhad G,Budget impact analysis of breast cancer medications: a systematic review,2022,bim,This study was conducted and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.,What guidelines were followed in conducting and reporting this study (pmcid=9801587)?,Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines,71b0e91f86bcfc44c31a7b628b0c5576
9801587,Mohammadnezhad G,Budget impact analysis of breast cancer medications: a systematic review,2022,bim,"RESULTS: In total, 17 BIAs were included in the study.",What was the total number of Budget Impact Analyses included in the study (pmcid=9801587)?,17,71b0e91f86bcfc44c31a7b628b0c5576
9801587,Mohammadnezhad G,Budget impact analysis of breast cancer medications: a systematic review,2022,bim,About half of the studies were conducted in Europe.,What continent were about half of the studies on breast cancer medications conducted in (pmcid=9801587)?,Europe,71b0e91f86bcfc44c31a7b628b0c5576
9801587,Mohammadnezhad G,Budget impact analysis of breast cancer medications: a systematic review,2022,bim,"The results of the BIAs showed that most of the included BIAs are conducted from the payer's perspective; they have different methodological frameworks for recommended chemotherapy, targeted therapy, and immunotherapy agents to treat BC.",What perspective were most of the included BIAs conducted from in the study on breast cancer medications (pmcid=9801587)?,Most of the included BIAs in the study on breast cancer medications (pmcid=9801587) were conducted from the payer's perspective.,71b0e91f86bcfc44c31a7b628b0c5576
9801587,Mohammadnezhad G,Budget impact analysis of breast cancer medications: a systematic review,2022,bim,"For the same medications, the results of budgetary effects are not consistent in diverse countries.",What is not consistent in diverse countries regarding the budgetary effects of breast cancer medications (pmcid=9801587)?,The results of budgetary effects are not consistent in diverse countries for breast cancer medications.,71b0e91f86bcfc44c31a7b628b0c5576
9801587,Mohammadnezhad G,Budget impact analysis of breast cancer medications: a systematic review,2022,bim,"Nine out of the 17 studies were focused on trastuzumab, in which the biosimilar form reduced costs, but the brand form increased costs, especially in a 52-week treatment period.",What was the focus of nine out of the 17 studies mentioned in the abstract (pmcid=9801587)?,Trastuzumab,71b0e91f86bcfc44c31a7b628b0c5576
9801587,Mohammadnezhad G,Budget impact analysis of breast cancer medications: a systematic review,2022,bim,"CONCLUSION: Researchers should conduct the budget impact analysis of high-value medications such as anti-tumor drugs more objectively, and the accuracy of parameters needs to be more strictly guaranteed.",What should researchers do when conducting budget impact analysis of high-value medications such as anti-tumor drugs (pmcid=9801587)?,Researchers should conduct the budget impact analysis more objectively and ensure the accuracy of parameters more strictly guaranteed.,71b0e91f86bcfc44c31a7b628b0c5576
9801587,Mohammadnezhad G,Budget impact analysis of breast cancer medications: a systematic review,2022,bim,"Furthermore, it is worthy of declaring that the budgetary impact of the same drug is not always consistent over time, so the researchers should measure access to medication in the long run.",What should researchers measure in the long run regarding the budgetary impact of breast cancer medications (pmcid=9801587)?,Researchers should measure access to medication in the long run regarding the budgetary impact of breast cancer medications.,71b0e91f86bcfc44c31a7b628b0c5576
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,"- INTRODUCTION: In 2018, the Mozambique Ministry of Health launched guidelines for implementing differentiated service delivery models (DSDMs) to optimize HIV service delivery, improve retention in care, and ultimately reduce HIV-associated mortality.",What guidelines were launched by the Mozambique Ministry of Health in 2018 (pmcid=11129834)?,The Mozambique Ministry of Health launched guidelines for implementing differentiated service delivery models (DSDMs) in 2018.,eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,"The models were fast-track, 3-month antiretrovirals dispensing, community antiretroviral therapy groups, adherence clubs, family approach and three one-stop shop models: adolescent-friendly health services, maternal and child health, and tuberculosis.",What were the different models evaluated for the implementation of HIV treatment in Mozambique (pmcid=11129834)?,"The different models evaluated for the implementation of HIV treatment in Mozambique were fast-track, 3-month antiretrovirals dispensing, community antiretroviral therapy groups, adherence clubs, family approach, and three one-stop shop models: adolescent-friendly health services, maternal and child health, and tuberculosis.",eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,We conducted a cost-effectiveness analysis and budget impact analysis to compare these models to conventional services.,What type of analysis was conducted to compare different service delivery models for HIV treatment in Mozambique (pmcid=11129834)?,Cost-effectiveness analysis and budget impact analysis,eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,METHODS: We constructed a decision tree model based on the percentage of enrolment in each model and the probability of the outcome (12-month retention in treatment) for each year of the study period-three for the cost-effectiveness analysis (2019-2021) and three for the budget impact analysis (2022-2024).,What time period was used for the cost-effectiveness analysis and budget impact analysis in this study (pmcid=11129834)?,"The time period used for the cost-effectiveness analysis was 2019-2021, and for the budget impact analysis was 2022-2024 in the study with pmcid=11129834.",eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,Costs for these analyses were primarily estimated per client-year from the health system perspective.,What perspective were the costs estimated from for the analyses in this study (pmcid=11129834)?,The costs for the analyses in this study (pmcid=11129834) were estimated from the health system perspective.,eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,A secondary cost-effectiveness analysis was conducted from the societal perspective.,What perspective was used for the secondary cost-effectiveness analysis conducted in the study (pmcid=11129834)?,The secondary cost-effectiveness analysis conducted in the study (pmcid=11129834) used the societal perspective.,eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,"Budget impact analysis costs included antiretrovirals, laboratory tests and service provision interactions.",What costs were included in the budget impact analysis (pmcid=11129834)?,"The costs included in the budget impact analysis for the study with pmcid=11129834 were antiretrovirals, laboratory tests, and service provision interactions.",eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,"Cost-effectiveness analysis additionally included start-up, training and clients' opportunity costs.",What costs were included in the cost-effectiveness analysis (pmcid=11129834)?,"The costs included in the cost-effectiveness analysis in the study with pmcid=11129834 were start-up costs, training costs, and clients' opportunity costs.",eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,Effectiveness was estimated using an uncontrolled interrupted time series analysis comparing the outcome before and after the implementation of the differentiated models.,What method was used to estimate effectiveness in the study (pmcid=11129834)?,An uncontrolled interrupted time series analysis was used to estimate effectiveness in the study (pmcid=11129834).,eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,A one-way sensitivity analysis was conducted to identify drivers of uncertainty.,What type of analysis was conducted to identify drivers of uncertainty in the study (pmcid=11129834)?,A one-way sensitivity analysis was conducted to identify drivers of uncertainty in the study (pmcid=11129834).,eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,"RESULTS: After implementation of the DSDMs, there was a mean increase of 14.9 percentage points (95% CI: 12.2, 17.8) in 12-month retention, from 47.6% (95% CI, 44.9-50.2) to 62.5% (95% CI, 60.9-64.1).",What was the increase in 12-month retention after the implementation of Differentiated Service Delivery Models for HIV treatment in Mozambique (pmcid=11129834)?,The increase in 12-month retention after the implementation of Differentiated Service Delivery Models for HIV treatment in Mozambique was 14.9 percentage points.,eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,"The mean cost difference comparing DSDMs and conventional care was US$ -6 million (173,391,277 vs.",What was the mean cost difference comparing Differentiated Service Delivery Models and conventional care in Mozambique (pmcid=11129834)?,The mean cost difference comparing Differentiated Service Delivery Models and conventional care in Mozambique was US$ -6 million.,eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,"179,461,668) and -32.5 million (394,705,618 vs.",What was the title of the study conducted by Moiana Uetela DA (pmcid=11129834)?,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,"433,232,289) from the health system and the societal perspective, respectively.",What perspectives were considered in the cost-effectiveness and budget impact analysis of the implementation of differentiated service delivery models for HIV treatment in Mozambique (pmcid=11129834)?,The perspectives considered in the cost-effectiveness and budget impact analysis were the health system perspective and the societal perspective.,eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,"Therefore, DSDMs dominated conventional care.",What did the Cost‐Effectiveness and Budget Impact Analysis study evaluate in Mozambique (pmcid=11129834)?,The Cost‐Effectiveness and Budget Impact Analysis study evaluated the implementation of Differentiated Service Delivery Models for HIV treatment in Mozambique.,eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,Results were most sensitive to conventional care interaction costs in the one-way sensitivity analysis.,What were the results most sensitive to in the one-way sensitivity analysis (pmcid=11129834)?,The results were most sensitive to conventional care interaction costs in the one-way sensitivity analysis (pmcid=11129834).,eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,"For a population of 1.5 million, the base-case 3-year financial costs associated with the DSDMs was US$550 million, compared with US$564 million for conventional care.",What were the 3-year financial costs associated with the Differentiated Service Delivery Models for HIV treatment in Mozambique for a population of 1.5 million (pmcid=11129834)?,The 3-year financial costs associated with the Differentiated Service Delivery Models for HIV treatment in Mozambique for a population of 1.5 million was US$550 million.,eca0261b23237c0ee0479828fed546f4
11129834,Moiana Uetela DA,Cost‐Effectiveness and Budget Impact Analysis of the Implementation of Differentiated Service Delivery Models for HIV Treatment in Mozambique: a Modelling Study,2024,bim,CONCLUSIONS: DSDMs were less expensive and more effective in retaining clients 12 months after antiretroviral therapy initiation and were estimated to save approximately US$14 million for the health system from 2022 to 2024.,What were the estimated cost savings for the health system from 2022 to 2024 (pmcid=11129834)?,Approximately US$14 million,eca0261b23237c0ee0479828fed546f4
11071237,Alsaif M,Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England,2024,bim,"- INTRODUCTION: In 2022, updated guidance from NICE expanded the options for self-monitoring of blood glucose for patients with type 2 diabetes (T2DM), to include continuous glucose monitoring (CGM).",What guidance was updated in 2022 regarding self-monitoring of blood glucose for patients with type 2 diabetes (T2DM) (pmcid=11071237)?,"In 2022, updated guidance from NICE expanded the options for self-monitoring of blood glucose for patients with type 2 diabetes (T2DM) to include continuous glucose monitoring (CGM).",12195ee03faf4b3ffe44aa899c1cb5eb
11071237,Alsaif M,Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England,2024,bim,"In this budget impact analysis, the cost impact of CGM was compared with traditional self-monitoring of blood glucose (SMBG) in adults with T2DM over 1 year from the commissioner perspective in England.",What was compared in the budget impact analysis conducted by Alsaif M in England (pmcid=11071237)?,The budget impact analysis conducted by Alsaif M in England compared the cost impact of continuous glucose monitoring (CGM) with traditional self-monitoring of blood glucose (SMBG) in adults with type 2 diabetes mellitus (T2DM) on insulin treatment over 1 year from the commissioner perspective.,12195ee03faf4b3ffe44aa899c1cb5eb
11071237,Alsaif M,Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England,2024,bim,"RESEARCH DESIGN AND METHODS: The NICE-eligible T2DM cohort was split into 4 subgroups to enable nuanced costing by insulin administration frequency: basal human insulin, premixed insulin, basal-bolus insulin and bolus insulin.",What subgroups were the NICE-eligible T2DM cohort split into for nuanced costing by insulin administration frequency (pmcid=11071237)?,"The NICE-eligible T2DM cohort was split into 4 subgroups for nuanced costing by insulin administration frequency: basal human insulin, premixed insulin, basal-bolus insulin, and bolus insulin.",12195ee03faf4b3ffe44aa899c1cb5eb
11071237,Alsaif M,Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England,2024,bim,"The model's cost components comprised mild and severe hypoglycaemia (SH), diabetic ketoacidosis (DKA), consumables and healthcare resource utilisation in primary and secondary care.",What were the cost components included in the model for the budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England (pmcid=11071237)?,"The cost components included in the model for the budget impact analysis were mild and severe hypoglycaemia (SH), diabetic ketoacidosis (DKA), consumables, and healthcare resource utilization in primary and secondary care.",12195ee03faf4b3ffe44aa899c1cb5eb
11071237,Alsaif M,Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England,2024,bim,"RESULTS: The introduction of CGM is estimated to be cost additive by approximately £4.6 million in the basecase, driven by increased spending on the CGM device.",What is the estimated cost impact of introducing continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England (pmcid=11071237)?,The estimated cost impact of introducing continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England is approximately £4.6 million.,12195ee03faf4b3ffe44aa899c1cb5eb
11071237,Alsaif M,Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England,2024,bim,"Overall, healthcare activity was reduced by approximately 20,000 attendances, due to fewer SH and DKA episodes in the CGM arm.",What was the overall reduction in healthcare activity due to continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England (pmcid=11071237)?,"Approximately 20,000 attendances were reduced in healthcare activity due to continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England.",12195ee03faf4b3ffe44aa899c1cb5eb
11071237,Alsaif M,Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England,2024,bim,General Practitioner (GP) practice-based activity is expected to drop after the first year as patients requiring CGM training is reduced.,How is General Practitioner (GP) practice-based activity expected to change over time in individuals with type 2 diabetes on insulin treatment in England (pmcid=11071237)?,General Practitioner (GP) practice-based activity is expected to drop after the first year as patients requiring CGM training is reduced.,12195ee03faf4b3ffe44aa899c1cb5eb
11071237,Alsaif M,Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England,2024,bim,The budget impact could be neutralised if the CGM sensor was discounted by 13.2% (£29.76 to £25.83).,What could neutralize the budget impact of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England (pmcid=11071237)?,The budget impact could be neutralized if the CGM sensor was discounted by 13.2% (£29.76 to £25.83).,12195ee03faf4b3ffe44aa899c1cb5eb
11071237,Alsaif M,Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England,2024,bim,CONCLUSIONS: CGM may result in increased spending in the NICE-eligible T2DM cohort but is expected to reduce demand on secondary care services and GP time.,What are the expected outcomes of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England (pmcid=11071237)?,CGM may result in increased spending in the NICE-eligible T2DM cohort but is expected to reduce demand on secondary care services and GP time.,12195ee03faf4b3ffe44aa899c1cb5eb
11071237,Alsaif M,Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England,2024,bim,These findings may be of interest to local decision-makers who wish to resolve the COVID-19 backlog with transformational investment in primary care to reduce secondary care activity.,What group of decision-makers may find the findings of this study on continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England of interest (pmcid=11071237)?,Local decision-makers,12195ee03faf4b3ffe44aa899c1cb5eb
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,- BACKGROUND: Cardiovascular diseases (CVD) remains a leading cause of mortality in Myanmar.,What remains a leading cause of mortality in Myanmar (pmcid=11022086)?,Cardiovascular diseases (CVD),61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,"Despite the burden, CVD preventive services receive low government and donor budgets, which has led to poor CVD outcomes.",What has led to poor cardiovascular disease outcomes in Myanmar in terms of budget allocation (pmcid=11022086)?,Low government and donor budgets for CVD preventive services have led to poor cardiovascular disease outcomes in Myanmar.,61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,METHODS: We conducted a cost-effective analysis and a budget impact analysis on CVD prevention strategies recommended by the WHO.,What type of analysis was conducted on CVD prevention strategies recommended by the WHO (pmcid=11022086)?,Cost-effective analysis and budget impact analysis,61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,A Markov model was used to analyse the cost and quality-adjusted life year (QALY) from healthcare provider and societal perspectives.,What model was used to analyze the cost and quality-adjusted life year in the study (pmcid=11022086)?,A Markov model was used.,61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,We calculated transition probabilities from WHO CVD risk data and obtained treatment effects and costs from secondary sources.,What data source was used to calculate transition probabilities in this study (pmcid=11022086)?,WHO CVD risk data,61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,Subgroup analysis was performed on different sex and age groups.,What subgroup analysis was performed in the study (pmcid=11022086)?,Subgroup analysis was performed on different sex and age groups.,61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,We framed the budget impact analysis from a healthcare provider perspective to assess the affordability of providing CVD preventive care.,What perspective was used to assess the affordability of providing CVD preventive care in Myanmar (pmcid=11022086)?,The perspective used to assess the affordability of providing CVD preventive care in Myanmar in the study with pmcid=11022086 was from a healthcare provider perspective.,61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,FINDINGS: The most cost-effective strategy from the healthcare provider perspective varied.,What varied in terms of cost-effectiveness from the healthcare provider perspective (pmcid=11022086)?,The most cost-effective strategy varied from the healthcare provider perspective (pmcid=11022086).,61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,"The combination of screening, primary prevention, and secondary prevention (Sc-PP-SP) (incremental cost-effectiveness ratio [ICER]: US$1574/QALY) is most cost-effective at the three times gross domestic product (GDP) per capita threshold, while at one time the GDP per capita threshold, secondary prevention is the most cost-effective strategy (ICER: US$160/QALY).",What is the most cost-effective strategy at one time the GDP per capita threshold according to the abstract sentence? (pmcid=11022086),"At one time the GDP per capita threshold, the most cost-effective strategy according to the abstract sentence is secondary prevention (ICER: US$160/QALY).",61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,Sc-PP-SP is the most cost-effective strategy from the societal perspective (ICER: US$647/QALY).,What is the most cost-effective strategy from the societal perspective in the study (pmcid=11022086)?,Sc-PP-SP,61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,"Among age groups, intervention at age 45 years appeared to be the most cost-effective option for both men and women.",What age group appeared to be the most cost-effective option for intervention in both men and women? (pmcid=11022086),Intervention at age 45 years appeared to be the most cost-effective option for both men and women.,61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,"The budget impact revealed the Sc-PP-SP would avert 55,000 acute CVD events and 28,000 CVD-related deaths with a cost of US$157 million for the first year of CVD preventive care.",What would be averted by the Sc-PP-SP intervention in the first year of CVD preventive care (pmcid=11022086)?,"55,000 acute CVD events and 28,000 CVD-related deaths",61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,"INTERPRETATION: A combination of screening, primary prevention, and secondary prevention is cost-effective to reduce CVD-related deaths in Myanmar.",What is the interpretation of the study regarding the cost-effectiveness of screening and preventive interventions for cardiovascular disease in Myanmar (pmcid=11022086)?,"The interpretation of the study is that a combination of screening, primary prevention, and secondary prevention is cost-effective to reduce CVD-related deaths in Myanmar.",61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,This study provides evidence for the government and development partners to increase investment in and support for CVD prevention.,What evidence does this study provide for the government and development partners (pmcid=11022086)?,This study provides evidence for the government and development partners to increase investment in and support for cardiovascular disease (CVD) prevention.,61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,"These findings not only provide a basis for efficient resource allocation but also underscore the importance of adopting a total cardiovascular risk approach to CVD prevention, in alignment with global health goals.",What approach to CVD prevention is underscored as important in the study (pmcid=11022086)?,The study underscores the importance of adopting a total cardiovascular risk approach to CVD prevention.,61c26689d01f4b28be4acf1750ea7d93
11022086,Win ZM,Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study,2024,bim,"FUNDING: Pilot grant from Duke Global Health Institute, USA.",What was the source of funding for the study (pmcid=11022086)?,"Pilot grant from Duke Global Health Institute, USA.",61c26689d01f4b28be4acf1750ea7d93
11491932,Smith NR,"Budget impact analysis for implementation decision making, planning, and financing",2023,bim,- Shelley et al.,What is the focus of the budget impact analysis conducted by Smith NR (pmcid=11491932)?,"The focus of the budget impact analysis conducted by Smith NR in the article with pmcid 11491932 is on implementation decision making, planning, and financing.",165ac869a5a37ff1f725d8184037cc1c
11491932,Smith NR,"Budget impact analysis for implementation decision making, planning, and financing",2023,bim,(in Accelerating integration of tobacco use treatment in the context of lung cancer screening: relevance and application of implementation science to achieving policy and practice.,What is the relevance and application of implementation science in accelerating the integration of tobacco use treatment in the context of lung cancer screening (pmcid=11491932)?,The relevance and application of implementation science in accelerating the integration of tobacco use treatment in the context of lung cancer screening is to achieve policy and practice goals.,165ac869a5a37ff1f725d8184037cc1c
11491932,Smith NR,"Budget impact analysis for implementation decision making, planning, and financing",2023,bim,"Transl Behav Med 2022;12:1076-1083) laid out how implementation science frameworks and methods can advance the delivery of tobacco use treatment services during lung cancer screening services, which until recently was mandated by the Centers for Medicare and Medicaid Services.",What did the study by Smith NR in 2023 focus on in relation to implementation science frameworks and methods (pmcid=11491932)?,The study by Smith NR in 2023 focused on how implementation science frameworks and methods can advance the delivery of tobacco use treatment services during lung cancer screening services.,165ac869a5a37ff1f725d8184037cc1c
11491932,Smith NR,"Budget impact analysis for implementation decision making, planning, and financing",2023,bim,"Their discussion provides an important overview of the full process of implementation and highlights the vast number of decisions that must be made when planning for implementation of an evidence-based practice such as tobacco use treatment: what specific tobacco use treatment services to deliver, when to deliver those services within the lung cancer screening process, and what implementation strategies to use.","What decisions must be made when planning for the implementation of an evidence-based practice such as tobacco use treatment, according to the discussion in the abstract? (pmcid=11491932)","The decisions that must be made when planning for the implementation of an evidence-based practice such as tobacco use treatment, according to the discussion in the abstract, include determining what specific tobacco use treatment services to deliver, when to deliver those services within the lung cancer screening process, and what implementation strategies to use.",165ac869a5a37ff1f725d8184037cc1c
11491932,Smith NR,"Budget impact analysis for implementation decision making, planning, and financing",2023,bim,The costs of implementation play a major role in decision making and are a key implementation determinant discussed in major implementation frameworks.,What role do the costs of implementation play in decision making according to the abstract sentence (pmcid=11491932)?,The costs of implementation play a major role in decision making according to the abstract sentence in the context provided.,165ac869a5a37ff1f725d8184037cc1c
11491932,Smith NR,"Budget impact analysis for implementation decision making, planning, and financing",2023,bim,"When making decisions about what and how to implement, budget impact analyses (BIAs) can play an important role in informing decision making by helping practitioners understand the overall affordability of a given implementation effort.",What role can budget impact analyses play in informing decision making (pmcid=11491932)?,Budget impact analyses (BIAs) can play an important role in informing decision making by helping practitioners understand the overall affordability of a given implementation effort.,165ac869a5a37ff1f725d8184037cc1c
11491932,Smith NR,"Budget impact analysis for implementation decision making, planning, and financing",2023,bim,BIAs can also inform the development of financing strategies to support the ongoing sustainment of tobacco use treatment service provision.,What can BIAs inform the development of to support the ongoing sustainment of tobacco use treatment service provision? (pmcid=11491932),BIAs can inform the development of financing strategies.,165ac869a5a37ff1f725d8184037cc1c
11491932,Smith NR,"Budget impact analysis for implementation decision making, planning, and financing",2023,bim,"More attention is needed by the research community to produce high-quality, user-friendly, and flexible BIAs to inform implementation decision making in health system and community settings.",What is needed by the research community to inform implementation decision making in health system and community settings? (pmcid=11491932),"More attention is needed by the research community to produce high-quality, user-friendly, and flexible Budget Impact Analyses (BIAs) to inform implementation decision making in health system and community settings.",165ac869a5a37ff1f725d8184037cc1c
11491932,Smith NR,"Budget impact analysis for implementation decision making, planning, and financing",2023,bim,The application of BIA can help ensure that the considerable time and effort spent to develop and evaluate evidence-based programs has the best chance to inform implementation practice.,What can the application of BIA help ensure in implementation practice (pmcid=11491932)?,The application of BIA can help ensure that the considerable time and effort spent to develop and evaluate evidence-based programs has the best chance to inform implementation practice.,165ac869a5a37ff1f725d8184037cc1c
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,- BACKGROUND: Recent developments improved outcomes in patients with autoimmune diseases.,What recent developments improved outcomes in patients with autoimmune diseases (pmcid=10169960)?,Recent developments improved outcomes in patients with autoimmune diseases.,fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"Biologics were approved as first-line treatment in selected naïve patients with plaque psoriasis (PsO), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).",What were biologics approved as first-line treatment for in selected naïve patients (pmcid=10169960)?,"Biologics were approved as first-line treatment for plaque psoriasis (PsO), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA) in selected naïve patients.",fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"Among them, secukinumab was most recently approved for treatment of active nr-axSpA in adults.",What was secukinumab most recently approved for the treatment of in adults (pmcid=10169960)?,Secukinumab was most recently approved for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adults.,fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"In this work, we assessed the budget impact of new secukinumab treatment options in the Italian market.",What did the work assess in the Italian market (pmcid=10169960)?,The work assessed the budget impact of new secukinumab treatment options in the Italian market.,fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,METHODS: A cross-indication budget impact model was designed to estimate the effects of adding secukinumab in the Italian market from the National Health System perspective over a 3-year period.,What was the perspective of the budget impact model analysis (pmcid=10169960)?,The perspective of the budget impact model analysis in the study with pmcid=10169960 was from the National Health System perspective.,fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"The model included all adults with PsO, PsA, AS and nr-axSpA, treated with biologics or biosimilars.",What population was included in the budget impact model for secukinumab in Italy (pmcid=10169960)?,"The budget impact model for secukinumab in Italy included all adults with Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis who were treated with biologics or biosimilars.",fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"It compared costs between two scenarios, secukinumab availability or absence, for the four diseases combined and taken individually.",What was compared in terms of costs in the study (pmcid=10169960)?,"Costs were compared between two scenarios: one with secukinumab availability and one without, for the four diseases combined and taken individually.",fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,A sensitivity analyses was conducted.,What type of analysis was conducted in the study (pmcid=10169960)?,A sensitivity analysis was conducted in the study with pmcid=10169960.,fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"RESULTS: There were 68,121 adult patients treated with biologics in 2021 and 68,341 in 2023.",How many adult patients were treated with biologics in 2021 and 2023? (pmcid=10169960),"68,121 adult patients were treated with biologics in 2021 and 68,341 in 2023.",fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,The budget impact analysis (BIA) on all indications showed a cost reduction of €33.7 million (- 1.5%) over 3 years with the introduction of secukinumab.,What was the cost reduction over 3 years with the introduction of secukinumab for all indications in Italy (pmcid=10169960)?,The cost reduction over 3 years with the introduction of secukinumab for all indications in Italy was €33.7 million (-1.5%).,fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"PsA patients had the highest saving (- €34.9 million), followed by PsO patients (- €7.8 million).",What were the savings for PsA patients and PsO patients in Italy (pmcid=10169960)?,PsA patients had savings of -€34.9 million and PsO patients had savings of -€7.8 million in Italy.,fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,Cost saving in PsO patients was balanced by increased budget reported in AS patients (+ €8.0 million).,What was the reported budget impact in AS patients according to the abstract sentence (pmcid=10169960)?,The reported budget impact in AS patients according to the abstract sentence is + €8.0 million.,fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"In nr-axSpA patients, secukinumab reported no significant budget increase (+ 1.0%).",What was the budget increase reported in nr-axSpA patients treated with secukinumab (pmcid=10169960)?,"In nr-axSpA patients, secukinumab reported no significant budget increase (+ 1.0%).",fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"CONCLUSION: This BIA accounted for the new indication of secukinumab in nr-axSpA patients, reporting no significant changes in the required budget and adding an effective treatment option.",What indication of secukinumab was accounted for in this BIA (pmcid=10169960)?,The indication of secukinumab that was accounted for in this BIA (pmcid=10169960) is non-radiographic axial spondyloarthritis (nr-axSpA).,fd098f878ca8abc7d7cddb4445bc5636
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"Considering all indications, secukinumab is a sustainable treatment option.",What is considered a sustainable treatment option for all indications (pmcid=10169960)?,Secukinumab,fd098f878ca8abc7d7cddb4445bc5636
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,"- BACKGROUND AND AIMS: Pressure ulcer is a considerable health problem and is associated with an increased hospital length of stay (LOS), nursing effort, costs, and reduced quality of life.",What is the background and aim of the study (pmcid=10885175)?,"The background and aim of the study is to address pressure ulcers as a significant health issue that leads to increased hospital length of stay, nursing effort, costs, and reduced quality of life.",e4d04d41c8f280e51f3ae4231de5a38e
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,"The aim of this analysis is to compare the economic, clinical, and nursing benefit after the implementation of the powered hybrid mattress Dyna-Form Mercury Advance SMARTcare® in 2019 with the situation in 2017 (rental systems Arjo BariAir® and Arjo TheraKair Visio®, and purchased foam mattresses Arjo Simuflex®) using a single center.",What was compared in the analysis (pmcid=10885175)?,"The economic, clinical, and nursing benefit after the implementation of the powered hybrid mattress Dyna-Form Mercury Advance SMARTcare® in 2019 was compared with the situation in 2017, which involved rental systems Arjo BariAir® and Arjo TheraKair Visio®, and purchased foam mattresses Arjo Simuflex®.",e4d04d41c8f280e51f3ae4231de5a38e
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,"METHODS: In the framework of a budget impact analysis, a difference-in-difference approach was used to compare pre-implementation longitudinal data (2017) with post-implementation data (2019).",What approach was used to compare pre-implementation longitudinal data with post-implementation data in this study? (pmcid=10885175),A difference-in-difference approach was used to compare pre-implementation longitudinal data with post-implementation data in this study.,e4d04d41c8f280e51f3ae4231de5a38e
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,"The longitudinal data comprise the mattress resource use, patient characteristics, and LOS.",What data does the longitudinal data in this study comprise (pmcid=10885175)?,"The longitudinal data in this study comprises mattress resource use, patient characteristics, and length of stay (LOS).",e4d04d41c8f280e51f3ae4231de5a38e
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,"The care effort was gathered based on a full survey of all 75 members of the nursing staff using the online tool ""LimeSurvey."" In this survey, the resource use of the different mattress systems was identified in terms of time (minutes or days).",What tool was used to gather the care effort data from the nursing staff in this study (pmcid=10885175)?,"The online tool ""LimeSurvey"" was used to gather the care effort data from the nursing staff in this study (pmcid=10885175).",e4d04d41c8f280e51f3ae4231de5a38e
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,"This analysis was performed from the hospital perspective and included direct costs of mattress systems, Austrian diagnostic-related group costs for the hospital stay and nursing staff costs for 2019.",What costs were included in the analysis performed from the hospital perspective (pmcid=10885175)?,"The costs included in the analysis performed from the hospital perspective in the study with pmcid=10885175 were the direct costs of mattress systems, Austrian diagnostic-related group costs for the hospital stay, and nursing staff costs for 2019.",e4d04d41c8f280e51f3ae4231de5a38e
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,"RESULTS: Based on 1253 patients ""at-risk,"" the total yearly costs implementing the powered hybrid mattress amounts to 654,248€ compared with 901,469€ when using Arjo products.",What were the total yearly costs of implementing the powered hybrid mattress compared to using Arjo products in the Austrian inpatient setting (pmcid=10885175)?,"The total yearly costs of implementing the powered hybrid mattress were 654,248€ compared to 901,469€ when using Arjo products in the Austrian inpatient setting.",e4d04d41c8f280e51f3ae4231de5a38e
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,"The budget impact shows a cost advantage of 247,221€.",What is the cost advantage shown in the budget impact analysis (pmcid=10885175)?,"The cost advantage shown in the budget impact analysis is 247,221€.",e4d04d41c8f280e51f3ae4231de5a38e
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,"Furthermore, the powered hybrid mattress system leads to fewer nursing-staff time in minutes per year (-1,031,097 min [1,993,204 vs.",How many fewer nursing-staff time in minutes per year did the powered hybrid mattress system lead to in the Austrian inpatient setting (pmcid=10885175)?,"1,031,097 minutes",e4d04d41c8f280e51f3ae4231de5a38e
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,"3,024,302]); 242€ are saved per patient.",How much money is saved per patient with the use of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting (pmcid=10885175)?,242€,e4d04d41c8f280e51f3ae4231de5a38e
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,"Compared with the Arjo products, fewer inpatient cases of pressure ulcers (-44 cases [0 vs.",What was the difference in inpatient cases of pressure ulcers between the powered hybrid mattress and Arjo products (pmcid=10885175)?,44 cases,e4d04d41c8f280e51f3ae4231de5a38e
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,44]) were documented.,What type of analysis was conducted in this study (pmcid=10885175)?,A budget impact analysis,e4d04d41c8f280e51f3ae4231de5a38e
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,"CONCLUSION: Despite the higher total outlay of costs associated with the powered hybrid mattress, the long-term savings potential showed a significant cost advantage per annum for the single center.",What showed a significant cost advantage per annum for the single center? (pmcid=10885175),The long-term savings potential showed a significant cost advantage per annum for the single center.,e4d04d41c8f280e51f3ae4231de5a38e
10885175,Eichhober G,A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: An original research,2024,bim,"Therefore, the use of the hybrid mattress leads to considerable economic, clinical, and nursing benefits.",What benefits are associated with the use of the hybrid mattress in the Austrian inpatient setting (pmcid=10885175)?,"The benefits associated with the use of the hybrid mattress in the Austrian inpatient setting include economic, clinical, and nursing benefits.",e4d04d41c8f280e51f3ae4231de5a38e
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,"- Background: In rural areas, antimicrobial stewardship programs often have limited access to infectious disease (ID) expertise.",What is a common challenge faced by antimicrobial stewardship programs in rural areas (pmcid=11504416)?,Limited access to infectious disease (ID) expertise.,02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,Videoconference Antimicrobial Stewardship Teams (VASTs) pair rural Veterans Affairs (VA) medical centers with an ID expert to discuss treatment of patients with concerns for infection.,What do Videoconference Antimicrobial Stewardship Teams (VASTs) pair rural Veterans Affairs (VA) medical centers with an ID expert to discuss? (pmcid=11504416),Treatment of patients with concerns for infection.,02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,"In a pilot study, VASTs were effective at improving antimicrobial use.",What were the VASTs effective at improving in the pilot study? (pmcid=11504416),Antimicrobial use,02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,"Here, we evaluated 12-month operating costs for staffing for 3 VASTs.",What did the evaluation focus on in terms of operating costs (pmcid=11504416)?,The evaluation focused on staffing costs for 3 Videoconference Antimicrobial Stewardship Programs (VASTs).,02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,Methods: We used the following data to describe 12 months of clinical encounters for 3 VASTs operating from January 2022 – March 2023: the number of VAST sessions completed and clinical encounters; Current Procedural Terminology (CPT) codes associated with clinical encounters; session attendees (by role) and the time spent (percent effort) on VAST-related activities.,What data was used to describe 12 months of clinical encounters for 3 VASTs operating from January 2022 – March 2023 (pmcid=11504416)?,"The data used to describe 12 months of clinical encounters for 3 VASTs operating from January 2022 – March 2023 included the number of VAST sessions completed and clinical encounters, Current Procedural Terminology (CPT) codes associated with clinical encounters, session attendees (by role), and the time spent (percent effort) on VAST-related activities.",02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,The annual operating cost was based on the annual salaries and percent effort of VAST attendees.,What was the basis for calculating the annual operating cost in the study (pmcid=11504416)?,The annual operating cost was based on the annual salaries and percent effort of VAST attendees.,02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,We used these characteristics combined with private-sector and Medicare reimbursements to evaluate the cost of implementation and number of clinical encounters needed to offset those costs (breakeven) for each site.,What characteristics were used to evaluate the cost of implementation and breakeven for each site? (pmcid=11504416),"The characteristics used to evaluate the cost of implementation and breakeven for each site were private-sector and Medicare reimbursements, as mentioned in the context information.",02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,Results: Three VASTs recorded 229 clinical encounters during 117 sessions (Table 1).,What was the total number of clinical encounters recorded by three VASTs during 117 sessions (pmcid=11504416)?,229,02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,"Based on CPT codes, the approximate revenue per patient was $516.46.",What was the approximate revenue per patient based on CPT codes in the study by Vivo A (pmcid=11504416)?,The approximate revenue per patient based on CPT codes in the study by Vivo A (pmcid=11504416) was $516.46.,02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,"Site A, the only site to break even, had the most sessions and clinical encounters as well as the lowest operating costs.",What site had the most sessions and clinical encounters as well as the lowest operating costs (pmcid=11504416)?,Site A,02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,"For Site B, a slight increase in the clinical encounters, which might be achieved by 3 additional VAST sessions, would help achieve breakeven.",What would help achieve breakeven for Site B (pmcid=11504416)?,"A slight increase in the clinical encounters, which might be achieved by 3 additional VAST sessions, would help achieve breakeven for Site B.",02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,"For Site C, increasing the number of clinical encounters to 3-4 per session would have helped their VAST break even without requiring a decrease in operating costs.",What would have helped Site C's VAST break even without requiring a decrease in operating costs? (pmcid=11504416),Increasing the number of clinical encounters to 3-4 per session would have helped Site C's VAST break even without requiring a decrease in operating costs.,02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,"Conclusions: The frequency of VAST sessions, volume of clinical encounters, and low operating costs all contributed the VAST at Site A achieving a financial break-even point within 12 months.",What contributed to the VAST at Site A achieving a financial break-even point within 12 months? (pmcid=11504416),"The frequency of VAST sessions, volume of clinical encounters, and low operating costs all contributed to the VAST at Site A achieving a financial break-even point within 12 months.",02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,"Consideration of the potential number of clinical encounters and sessions will help other VASTs achieve financial sustainment, independent of cost-savings related to potential decreases in expenditures for antibiotics and antibiotic-related adverse events.","What will help other VASTs achieve financial sustainment, independent of cost-savings related to potential decreases in expenditures for antibiotics and antibiotic-related adverse events? (pmcid=11504416)","Consideration of the potential number of clinical encounters and sessions will help other VASTs achieve financial sustainment, independent of cost-savings related to potential decreases in expenditures for antibiotics and antibiotic-related adverse events.",02cc6de0859ab5ce82b38fc723c9ac0c
11504416,Vivo A,Budget Impact Analysis for the Spread and Financial Sustainability of Videoconference Antimicrobial Stewardship Programs,2024,bim,These results also provide insight into possible adoption and diffusion of VAST-like programs in the Medicare hospital setting.,What insight do the results provide into the adoption and diffusion of VAST-like programs in the Medicare hospital setting? (pmcid=11504416),The results provide insight into possible adoption and diffusion of VAST-like programs in the Medicare hospital setting.,02cc6de0859ab5ce82b38fc723c9ac0c
11225931,Danielson EC,Implementation Preparation Costs of Virtual Interview Training in Pre-Employment Transition Services: A Budget Impact Analysis,2023,bim,- Virtual Reality Job Interview Training (VR-JIT) and Virtual Interview Training for Transition Age Youth (VIT-TAY) demonstrated initial effectiveness at increasing employment among transition-age youth with disabilities engaged in pre-employment transition services.,What did Virtual Reality Job Interview Training (VR-JIT) and Virtual Interview Training for Transition Age Youth (VIT-TAY) demonstrate initial effectiveness at (pmcid=11225931)?,Increasing employment among transition-age youth with disabilities engaged in pre-employment transition services.,61dc09658545f23d95738c1dc3e9f984
11225931,Danielson EC,Implementation Preparation Costs of Virtual Interview Training in Pre-Employment Transition Services: A Budget Impact Analysis,2023,bim,We characterized activities and estimated the labor and non-labor costs required to prepare schools to implement VR-JIT or VIT-TAY.,What costs were estimated in order to prepare schools to implement VR-JIT or VIT-TAY (pmcid=11225931)?,The costs estimated were labor and non-labor costs.,61dc09658545f23d95738c1dc3e9f984
11225931,Danielson EC,Implementation Preparation Costs of Virtual Interview Training in Pre-Employment Transition Services: A Budget Impact Analysis,2023,bim,Implementation preparation and support teams reported labor hours throughout the implementation preparation process.,What did the implementation preparation and support teams report throughout the process (pmcid=11225931)?,Labor hours,61dc09658545f23d95738c1dc3e9f984
11225931,Danielson EC,Implementation Preparation Costs of Virtual Interview Training in Pre-Employment Transition Services: A Budget Impact Analysis,2023,bim,"Implementation preparation labor hours at 43 schools cost approximately $1,427 per school, while non-labor costs were $100 per trainee (student).",What were the implementation preparation costs of virtual interview training in pre-employment transition services per school (pmcid=11225931)?,"The implementation preparation costs of virtual interview training in pre-employment transition services per school were approximately $1,427.",61dc09658545f23d95738c1dc3e9f984
11225931,Danielson EC,Implementation Preparation Costs of Virtual Interview Training in Pre-Employment Transition Services: A Budget Impact Analysis,2023,bim,"We estimated the replication of implementation preparation labor activities would cost $1,024 per school (range: $841-$1,208).",What is the estimated cost of replication of implementation preparation labor activities per school in the study (pmcid=11225931)?,"The estimated cost of replication of implementation preparation labor activities per school in the study (pmcid=11225931) is $1,024 (range: $841-$1,208).",61dc09658545f23d95738c1dc3e9f984
11225931,Danielson EC,Implementation Preparation Costs of Virtual Interview Training in Pre-Employment Transition Services: A Budget Impact Analysis,2023,bim,Most costs were spent in delivery planning and teacher training.,What were most of the costs spent on in the implementation preparation of virtual interview training in pre-employment transition services (pmcid=11225931)?,Most costs were spent in delivery planning and teacher training.,61dc09658545f23d95738c1dc3e9f984
11225931,Danielson EC,Implementation Preparation Costs of Virtual Interview Training in Pre-Employment Transition Services: A Budget Impact Analysis,2023,bim,"Given that implementation preparation costs can be barriers to intervention adoption, our results provide critical information for contemplating future implementation of VR-JIT or VIT-TAY.",What critical information do the results provide for contemplating future implementation of VR-JIT or VIT-TAY (pmcid=11225931)?,The results provide critical information on implementation preparation costs as potential barriers to intervention adoption for contemplating future implementation of VR-JIT or VIT-TAY.,61dc09658545f23d95738c1dc3e9f984
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,- Background: Targeted therapy for cancer is becoming more frequent as the understanding of the molecular pathogenesis increases.,What is becoming more frequent as the understanding of the molecular pathogenesis increases? (pmcid=10306161),Targeted therapy for cancer,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,Molecular testing must be done to use targeted therapy.,What must be done in order to use targeted therapy in metastatic non-small cell lung cancer (pmcid=10306161)?,Molecular testing must be done.,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,"Unfortunately, the testing turnaround time can delay the initiation of targeted therapy.",What can delay the initiation of targeted therapy in the diagnosis of metastatic non-small cell lung cancer (pmcid=10306161)?,The testing turnaround time can delay the initiation of targeted therapy.,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,Objective: To investigate the impact of a next-generation sequencing (NGS) machine in the hospital that would allow for in-house NGS testing of metastatic non-small cell lung cancer (mNSCLC) in a US setting.,What was the objective of the study (pmcid=10306161)?,The objective of the study with pmcid=10306161 was to investigate the impact of a next-generation sequencing (NGS) machine in the hospital that would allow for in-house NGS testing of metastatic non-small cell lung cancer (mNSCLC) in a US setting.,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,Methods: The differences between 2 hospital pathways were established with a cohort-level decision tree that feeds into a Markov model.,What method was used to establish the differences between 2 hospital pathways in the study (pmcid=10306161)?,A cohort-level decision tree was used to establish the differences between 2 hospital pathways in the study.,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,"A pathway that used in-house NGS (75%) and the use of external laboratories (so-called send-out NGS) (25%), was compared with the standard of exclusively send-out NGS.",What was compared in the pathway analysis (pmcid=10306161)?,The pathway analysis compared the use of in-house NGS (75%) and send-out NGS (25%) with the standard of exclusively send-out NGS.,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,The model was from the perspective of a US hospital over a 5-year time horizon.,What was the perspective of the model in the analysis (pmcid=10306161)?,The perspective of the model in the analysis was from the perspective of a US hospital.,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,All cost input data were in or inflated to 2021 USD.,What year were all cost input data in or inflated to (pmcid=10306161)?,2021,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,Scenario analysis was done on key variables.,What type of analysis was done on key variables in the study (pmcid=10306161)?,Scenario analysis,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,"Results: In a hospital with 500 mNSCLC patients, the implementation of in-house NGS was estimated to increase the testing costs and the revenue of the hospital.",What was the estimated impact of implementing in-house NGS on testing costs and hospital revenue in a hospital with 500 mNSCLC patients (pmcid=10306161)?,The estimated impact of implementing in-house NGS in a hospital with 500 mNSCLC patients was an increase in both testing costs and hospital revenue.,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,"The model predicted a $710 060 increase in testing costs, a $1 732 506 increase in revenue, and a $1 022 446 return on investment over 5 years.","What were the predicted increases in testing costs, revenue, and return on investment over 5 years in the analysis (pmcid=10306161)?","The predicted increases in testing costs, revenue, and return on investment over 5 years in the analysis were $710,060, $1,732,506, and $1,022,446 respectively.",79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,The payback period was 15 months with in-house NGS.,What was the payback period with in-house NGS in the diagnosis of metastatic non-small cell lung cancer (pmcid=10306161)?,The payback period was 15 months with in-house NGS.,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,"The number of patients on targeted therapy increased by 3.38%, and the average turnaround time decreased by 10 days when in-house NGS was used.",What was the impact on the number of patients on targeted therapy and the average turnaround time when in-house NGS was used (pmcid=10306161)?,"The number of patients on targeted therapy increased by 3.38%, and the average turnaround time decreased by 10 days when in-house NGS was used.",79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,Discussion: Reducing testing turnaround time is a benefit of in-house NGS.,What is a benefit of in-house NGS according to the discussion (pmcid=10306161)?,Reducing testing turnaround time,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,It could contribute to fewer mNSCLC patients lost to second opinion and an increased number of patients on targeted therapy.,What could fast in-house next-generation sequencing contribute to in the diagnosis of metastatic non-small cell lung cancer (pmcid=10306161)?,Fast in-house next-generation sequencing could contribute to fewer mNSCLC patients lost to second opinion and an increased number of patients on targeted therapy.,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,"The model outcomes predicted that, over a 5-year period, there would be a positive return on investment for a US hospital.",What did the model outcomes predict over a 5-year period for a US hospital (pmcid=10306161)?,"The model outcomes predicted that over a 5-year period, there would be a positive return on investment for a US hospital.",79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,The model reflects a proposed scenario.,What type of analysis was conducted in the study (pmcid=10306161)?,Budget Impact Analysis,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,The heterogeneity of hospital inputs and the cost of send-out NGS means context-specific inputs are needed.,What is needed due to the heterogeneity of hospital inputs and the cost of send-out NGS (pmcid=10306161)?,Context-specific inputs are needed.,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,Conclusion: Using in-house NGS testing could reduce the testing turnaround time and increase the number of patients on targeted therapy.,What could using in-house NGS testing potentially do for the number of patients on targeted therapy (pmcid=10306161)?,Using in-house NGS testing could potentially increase the number of patients on targeted therapy.,79b4d66d43ba490459037d11165e14de
10306161,Silas U,Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis,2023,bim,Additional benefits for the hospital are that fewer patients will be lost to second opinion and that in-house NGS could generate additional revenue.,What are some additional benefits for the hospital of implementing in-house NGS in the diagnosis of metastatic non-small cell lung cancer (pmcid=10306161)?,Some additional benefits for the hospital of implementing in-house NGS in the diagnosis of metastatic non-small cell lung cancer include fewer patients being lost to second opinion and the potential to generate additional revenue.,79b4d66d43ba490459037d11165e14de
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,- INTRODUCTION: The observational multicenter prospective FLOWER study (NCT04965701) confirmed effectiveness and safety of osimertinib in the real-world (RW) management of untreated EGFR-mutant advanced non-small cell lung cancer (aNSCLC) patients.,What did the observational multicenter prospective FLOWER study confirm regarding osimertinib in the real-world management of untreated EGFR-mutant advanced non-small cell lung cancer patients (pmcid=11224988)?,The observational multicenter prospective FLOWER study confirmed the effectiveness and safety of osimertinib in the real-world management of untreated EGFR-mutant advanced non-small cell lung cancer patients.,f1e4403ea3823cca719196906e5e19f7
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,"METHODS: Herein, we report updated survival data, post-progression management, cost/effectiveness and budget impact (BI) of osimertinib compared with a RW population receiving gefitinib or erlotinib.",What methods were used in the study to compare osimertinib with a real-world population receiving gefitinib or erlotinib (pmcid=11224988)?,"The methods used in the study to compare osimertinib with a real-world population receiving gefitinib or erlotinib included reporting updated survival data, post-progression management, cost/effectiveness, and budget impact analysis.",f1e4403ea3823cca719196906e5e19f7
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,"RESULTS: Overall, 189 Caucasian patients receiving first-line osimertinib were included.",What was the ethnicity of the patients included in the study (pmcid=11224988)?,Caucasian,f1e4403ea3823cca719196906e5e19f7
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,"After a follow-up of 20.7 months, 74(39.2%) patients discontinued osimertinib, median time-to-treatment discontinuation (mTTD) was 27.9 months, overall survival 36.8 months.",What was the overall survival after a follow-up of 20.7 months in patients with treatment-naive EGFR-mutant non-small cell lung cancer who discontinued osimertinib (pmcid=11224988)?,The overall survival after a follow-up of 20.7 months in patients with treatment-naive EGFR-mutant non-small cell lung cancer who discontinued osimertinib was 36.8 months.,f1e4403ea3823cca719196906e5e19f7
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,"At progression, tissue biopsy was performed in 29 (56.9%), liquid biopsy in 15 (29.4%) and both in 7 (13.7%) cases.",What types of biopsies were performed at progression in the study (pmcid=11224988)?,Tissue biopsy and liquid biopsy were performed at progression in the study (pmcid=11224988).,f1e4403ea3823cca719196906e5e19f7
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,"The most frequent resistant mechanism was MET amplification (N = 14, 29.8%).",What was the most frequent resistant mechanism identified in patients with treatment-naive EGFR-mutant non-small cell lung cancer (pmcid=11224988)?,The most frequent resistant mechanism identified in patients with treatment-naive EGFR-mutant non-small cell lung cancer in the study was MET amplification.,f1e4403ea3823cca719196906e5e19f7
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,"At data cutoff, 13 (6.9%) patients were continuing osimertinib beyond progression; 52 (67.5%) received second-line treatment; no further treatments were administered in 25 (32.5%) cases.",What percentage of patients were continuing osimertinib beyond progression at data cutoff (pmcid=11224988)?,6.9%,f1e4403ea3823cca719196906e5e19f7
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,"Thirty-three (63.4%) patients received chemotherapy, 12(23.1%) TKIs combination.",What percentage of patients received chemotherapy in this study (pmcid=11224988)?,63.4%,f1e4403ea3823cca719196906e5e19f7
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,"Cost-effectiveness analysis showed a total cost per patient based on RW mTTD of 98,957.34€, 21,726.28€ and 19,637.83€ for osimertinib, erlotinib and gefitinib, respectively.","What was the total cost per patient based on real-world median time to treatment discontinuation for osimertinib, erlotinib, and gefitinib? (pmcid=11224988)","The total cost per patient based on real-world median time to treatment discontinuation was 98,957.34€ for osimertinib, 21,726.28€ for erlotinib, and 19,637.83€ for gefitinib.",f1e4403ea3823cca719196906e5e19f7
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,"The incremental cost-effectiveness ratio (ICER)/month for osimertinib was 359,806.0€/life-year-gained (LYG) and 197,789.77€/LYG compared to erlotinib and gefitinib.",What were the incremental cost-effectiveness ratios for osimertinib compared to erlotinib and gefitinib (pmcid=11224988)?,"The incremental cost-effectiveness ratio (ICER) per month for osimertinib was 359,806.0€/life-year-gained (LYG) compared to erlotinib and 197,789.77€/LYG compared to gefitinib.",f1e4403ea3823cca719196906e5e19f7
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,"For osimertinib, the BI-gap between RW-TTD and theoretical-TTD was 16,501.0€ per patient.",What was the BI-gap between RW-TTD and theoretical-TTD for osimertinib (pmcid=11224988)?,"The BI-gap between RW-TTD and theoretical-TTD for osimertinib in the study with pmcid=11224988 was 16,501.0€ per patient.",f1e4403ea3823cca719196906e5e19f7
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,CONCLUSIONS: This updated analysis confirms the effectiveness of osimertinib in RW.,What does the updated analysis confirm about the effectiveness of osimertinib in real-world settings (pmcid=11224988)?,The updated analysis confirms the effectiveness of osimertinib in real-world settings.,f1e4403ea3823cca719196906e5e19f7
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,"Although the ICER of osimertinib seems not cost-effective, additional costs for the management of disease progression to old generation TKIs were not considered in this study.",What additional costs were not considered in the study regarding the ICER of osimertinib (pmcid=11224988)?,The additional costs for the management of disease progression to old generation TKIs were not considered in the study regarding the ICER of osimertinib.,f1e4403ea3823cca719196906e5e19f7
11224988,Pasello G,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",2024,bim,The BI-gap suggests RW mTTD as a more reliable measure for expense estimation.,What does the BI-gap suggest as a more reliable measure for expense estimation? (pmcid=11224988),The BI-gap suggests RW mTTD as a more reliable measure for expense estimation.,f1e4403ea3823cca719196906e5e19f7
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,"- BACKGROUND: For edentulism, an implant supported removable complete overdenture (IOD) is an attractive solution to restore patients' chewing capacity, aesthetics, and self‐esteem, however, treatment is expensive and time consuming.",What is the background information provided in the abstract regarding implant supported removable complete overdentures (IODs) (pmcid=11798910)?,"The background information provided in the abstract regarding implant supported removable complete overdentures (IODs) is that they are an attractive solution for edentulism to restore patients' chewing capacity, aesthetics, and self-esteem, but the treatment is expensive and time-consuming.",098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,PURPOSE/AIM: To estimate the decline in costs for digitally designed and CAD/CAM fabricated IODs (3D‐IODs) compared to conventionally fabricated IODs (C‐IODs) at comparable general health related quality of life (GHRQoL).,What is the purpose/aim of the study (pmcid=11798910)?,The purpose/aim of the study with pmcid=11798910 is to estimate the decline in costs for digitally designed and CAD/CAM fabricated Implant Supported Overdentures (IODs) compared to conventionally fabricated IODs at comparable general health related quality of life (GHRQoL).,098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,"MATERIALS AND METHOD: A randomized crossover study enrolled 36 fully edentulous patients, in whom six maxillary implants were placed together with two mandibular implants, if not already present.",What type of study design was used in this research (pmcid=11798910)?,A randomized crossover study design was used in this research (pmcid=11798910).,098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,"At the start of the study, a set of C‐IODs and 3D‐IODs was fabricated for each patient.",What was fabricated for each patient at the start of the study (pmcid=11798910)?,A set of C‐IODs and 3D‐IODs was fabricated for each patient.,098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,"All patients wore each IOD‐type for 1 year: first the 3D‐IOD and the second year a C‐IOD, or vice versa.",What did all patients wear for 1 year each in the study (pmcid=11798910)?,"All patients wore each IOD‐type for 1 year: first the 3D‐IOD and the second year a C‐IOD, or vice versa.",098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,"At all three‐time points patients general QoL was assessed using the EQ‐5D‐5L questionnaire as well as the SF‐36 from which the SF‐6D was obtained, to research the anticipation of no significant difference.",What questionnaire was used to assess patients' general QoL at all three time points in the study (pmcid=11798910)?,The EQ-5D-5L questionnaire was used to assess patients' general QoL at all three time points in the study (pmcid=11798910).,098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,"To enable cost consequence analysis (CCA), both costs made within healthcare and patient costs were assessed.",What costs were assessed for the cost consequence analysis in the study (pmcid=11798910)?,Both costs made within healthcare and patient costs were assessed for the cost consequence analysis in the study with pmcid=11798910.,098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,"Subsequently, a budget impact analysis (BIA) was performed to demonstrate the potential savings.",What type of analysis was performed to demonstrate potential savings (pmcid=11798910)?,Budget Impact Analysis (BIA),098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,"RESULTS: No differences in general GHRQoL were seen between C‐IOD (M = 0.840, SD = 0.177) and 3D‐IOD (M = 0.837, SD = 0.156) (paired t‐test (N = 31): p = 0.880).",What were the results of the comparison between C‐IOD and 3D‐IOD in terms of general GHRQoL (pmcid=11798910)?,The results showed no differences in general GHRQoL between C‐IOD and 3D‐IOD.,098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,"With respect to the total costs for a complete IOD, however, the digital approach showed a reduction in initial total costs of 14.2% (€4700.33 vs.",What was the reduction in initial total costs for a complete IOD with the digital approach (pmcid=11798910)?,14.2% (€4700.33 vs.,098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,"€4030.61: p < 0,001), in treatment time of 41.1% (309 vs.",What was the percentage reduction in treatment time due to the digital workflow for implant supported overdentures (IODs) (pmcid=11798910)?,41.1%,098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,"182 min: p < 0.001), and in number of treatment sessions of 47.1% (5.68 vs.",What was the percentage reduction in treatment time with the digital workflow for implant supported overdentures (IODs) (pmcid=11798910)?,The percentage reduction in treatment time with the digital workflow for implant supported overdentures (IODs) was 47.1%.,098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,3.0: p < 0.001).,What significant cost reduction was observed in the budget impact analysis of implant supported overdentures (IODs) (pmcid=11798910)?,The budget impact analysis of implant supported overdentures (IODs) showed a significant cost reduction of p < 0.001.,098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,"For repairs for an IOD in both the upper and lower jaw, the C‐IOD and 3D‐IOD scored similar for treatment time as well as additional costs.",What were the treatment time and additional costs like for repairs for an IOD in both the upper and lower jaw (pmcid=11798910)?,"For repairs for an IOD in both the upper and lower jaw, the C‐IOD and 3D‐IOD scored similar for treatment time as well as additional costs.",098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,CONCLUSION: Implementing a 3D workflow in the production of IOD's supplies patients with a high‐quality 3D‐IOD at lower costs.,What is the conclusion regarding the implementation of a 3D workflow in the production of IOD's (pmcid=11798910)?,Implementing a 3D workflow in the production of IOD's supplies patients with a high‐quality 3D‐IOD at lower costs.,098da4fd0e1bfed698d9b16c1ce89e9b
11798910,Van de Winkel T,Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs),2024,bim,TRIAL REGISTRATION: NL‐OMON44248 https://onderzoekmetmensen.nl/en/trial/44248.,What is the trial registration number for this study (pmcid=11798910)?,NL‐OMON44248,098da4fd0e1bfed698d9b16c1ce89e9b
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,"- Managing chronic hepatitis C is challenging, as the majority of those infected are asymptomatic.",What is challenging about managing chronic hepatitis C according to the abstract sentence (pmcid=10439170)?,"The majority of those infected with chronic hepatitis C are asymptomatic, making it challenging to manage.",d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,"Therefore, to ensure treatments are administered before the onset of severe complications, screening is important.",What is the importance of screening mentioned in the abstract (pmcid=10439170)?,The importance of screening mentioned in the abstract is to ensure treatments are administered before the onset of severe complications.,d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,"In Canada, uncertainty regarding the cost-effectiveness and budget impact of screening has led to conflicting recommendations.",What has uncertainty in Canada led to regarding the cost-effectiveness and budget impact of screening (pmcid=10439170)?,Conflicting recommendations,d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,The objective of this study is to estimate the cost-effectiveness and budget-impact of one-time HCV screening.,What is the objective of this study (pmcid=10439170)?,The objective of this study is to estimate the cost-effectiveness and budget-impact of one-time HCV screening.,d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,A state-transition model was developed to evaluate the cost-effectiveness and budget-impact between a risk-based screening strategy (current-practice) and a one-time screening strategy on three different birth-cohorts.,What type of screening strategies were compared in the state-transition model developed in this study (pmcid=10439170)?,The state-transition model developed in this study compared a risk-based screening strategy (current-practice) with a one-time screening strategy on three different birth-cohorts.,d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,Cost and prevalence data were obtained from administrative data.,What data were obtained to analyze the cost and prevalence in the study (pmcid=10439170)?,Cost and prevalence data were obtained from administrative data.,d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,Progression and utility data were based on recent systematic reviews.,What were the progression and utility data based on in this study (pmcid=10439170)?,Progression and utility data in this study (pmcid=10439170) were based on recent systematic reviews.,d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,"We used a provincial payer-perspective, life-time time-horizon and a 1.5% discount rate for the cost-effectiveness analysis, and used a 10-year time-horizon and no discounting for the budget-impact analysis.",What discount rate was used for the cost-effectiveness analysis in this study (pmcid=10439170)?,1.5%,d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,One-time screening strategy would cost more and provide more health benefits than the risk-based screening for all birth cohorts.,What screening strategy would cost more but provide more health benefits than risk-based screening for all birth cohorts (pmcid=10439170)?,One-time screening strategy,d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,"For those born after 1964, the incremental-cost-effectiveness-ratio (ICER) per quality-adjusted-life-year (QALY) of screening versus current-practice varied from $27,422/QALY to $42,191/QALY across different provinces.",What is the range of incremental-cost-effectiveness-ratio (ICER) per quality-adjusted-life-year (QALY) of screening versus current-practice across different provinces (pmcid=10439170)?,"The range of incremental-cost-effectiveness-ratio (ICER) per quality-adjusted-life-year (QALY) of screening versus current-practice across different provinces is $27,422/QALY to $42,191/QALY.",d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,One-time screening of the cohort would cost an additional $2 million to $236 million across different provinces.,How much would one-time birth cohort screening of hepatitis C virus (HCV) infection cost across different provinces (pmcid=10439170)?,One-time screening of the cohort would cost an additional $2 million to $236 million across different provinces.,d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,"For those born 1945-1964, the ICER of screening versus current-practice varied from $35,217/QALY to $48,197/QALY across different provinces.",What is the range of ICER values for screening versus current practice among those born 1945-1964 across different provinces (pmcid=10439170)?,"The range of ICER values for screening versus current practice among those born 1945-1964 across different provinces is $35,217/QALY to $48,197/QALY.",d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,"For the cohort born before 1945, the ICER of screening versus current-practice was not cost-effective at a willingness-to-pay threshold of $50,000/QALY across all provinces.",What was the incremental cost-effectiveness ratio (ICER) of screening versus current-practice for the cohort born before 1945 (pmcid=10439170)?,"The incremental cost-effectiveness ratio (ICER) of screening versus current-practice for the cohort born before 1945 in the study with pmcid=10439170 was not cost-effective at a willingness-to-pay threshold of $50,000/QALY across all provinces.",d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,Our cost-effectiveness analysis suggests that a one-time HCV screening program for those born after 1945 is cost-effective.,What does the cost-effectiveness analysis suggest about a one-time HCV screening program for those born after 1945 (pmcid=10439170)?,The cost-effectiveness analysis suggests that a one-time HCV screening program for those born after 1945 is cost-effective.,d2d57a0e7dfd10d33609e6cf4257a733
10439170,Wong WW,A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada,2023,bim,"Considering the budget impact relative to other funded recommended health services and technologies, HCV screening could be considered affordable.",What could be considered affordable when considering the budget impact of HCV screening relative to other funded recommended health services and technologies (pmcid=10439170)?,HCV screening could be considered affordable.,d2d57a0e7dfd10d33609e6cf4257a733
10259044,Ma Y,Exploration of an alternative reconstructed individual patient data-based approach for budget impact analysis of anticancer drugs,2023,bim,- BACKGROUND: The duration of treatment (DOT) of the initial intervention and subsequent treatment is the key to determining the accuracy of anticancer-drug budget impact analysis (BIA) calculations.,What is the key factor in determining the accuracy of anticancer-drug budget impact analysis calculations (pmcid=10259044)?,The key factor in determining the accuracy of anticancer-drug budget impact analysis calculations is the duration of treatment (DOT) of the initial intervention and subsequent treatment.,424f87e819ba961603d3135d1cd7eebc
10259044,Ma Y,Exploration of an alternative reconstructed individual patient data-based approach for budget impact analysis of anticancer drugs,2023,bim,"However, existing studies only use simple assumptions as a proxy for DOT, resulting in a high degree of bias.","What do existing studies use as a proxy for DOT, resulting in a high degree of bias? (pmcid=10259044)","Existing studies use simple assumptions as a proxy for DOT, resulting in a high degree of bias.",424f87e819ba961603d3135d1cd7eebc
10259044,Ma Y,Exploration of an alternative reconstructed individual patient data-based approach for budget impact analysis of anticancer drugs,2023,bim,"OBJECTIVES: To enhance the accuracy and reliability of anticancer-drug BIA and solve the problem regarding DOT, we propose an alternative individual patient data (IPD)-based approach that reconstructs IPD from the published Kaplan Meier survival curves to estimate DOT.",What approach is proposed to enhance the accuracy and reliability of anticancer-drug BIA in the study with pmcid 10259044?,An alternative individual patient data (IPD)-based approach is proposed to enhance the accuracy and reliability of anticancer-drug BIA in the study with pmcid 10259044.,424f87e819ba961603d3135d1cd7eebc
10259044,Ma Y,Exploration of an alternative reconstructed individual patient data-based approach for budget impact analysis of anticancer drugs,2023,bim,"METHODS: We developed a four-step methodological framework for this new approach, taking the use of pembrolizumab in treating microsatellite-instability-high (MSI-H) advanced colorectal cancer as an example: (1) reconstructing the IPD; (2) calculating the total DOT of the initial intervention and subsequent treatment for each patient; (3) assigning a randomized time and DOT; and (4) multiple replacement sampling and calculation of the mean value.",What methodological framework was developed for the new approach in the study (pmcid=10259044)?,"A four-step methodological framework was developed for the new approach in the study, which included: (1) reconstructing the IPD; (2) calculating the total DOT of the initial intervention and subsequent treatment for each patient; (3) assigning a randomized time and DOT; and (4) multiple replacement sampling and calculation of the mean value.",424f87e819ba961603d3135d1cd7eebc
10259044,Ma Y,Exploration of an alternative reconstructed individual patient data-based approach for budget impact analysis of anticancer drugs,2023,bim,"RESULTS: Using this approach, the average DOT for the initial intervention and subsequent treatment in each year of the BIA time horizon can be calculated and used to calculate the resources consumed and costs in each year.",What can be calculated using the alternative reconstructed individual patient data-based approach in the study (pmcid=10259044)?,The average Days on Therapy (DOT) for the initial intervention and subsequent treatment in each year of the Budget Impact Analysis (BIA) time horizon can be calculated using the alternative reconstructed individual patient data-based approach in the study.,424f87e819ba961603d3135d1cd7eebc
10259044,Ma Y,Exploration of an alternative reconstructed individual patient data-based approach for budget impact analysis of anticancer drugs,2023,bim,"In our example, the average DOT for the initial intervention with pembrolizumab from the first to the fourth year was 4.90, 6.60, 5.24, and 5.06 months, respectively, while the average DOT for subsequent treatment was 0.75, 2.84, 2.99, and 2.50 months, respectively.",What were the average durations of treatment (DOT) for the initial intervention with pembrolizumab and subsequent treatment over the first four years (pmcid=10259044)?,"The average durations of treatment (DOT) for the initial intervention with pembrolizumab over the first four years were 4.90, 6.60, 5.24, and 5.06 months, respectively. The average durations of treatment for subsequent treatment over the first four years were 0.75, 2.84, 2.99, and 2.50 months, respectively.",424f87e819ba961603d3135d1cd7eebc
10259044,Ma Y,Exploration of an alternative reconstructed individual patient data-based approach for budget impact analysis of anticancer drugs,2023,bim,"CONCLUSIONS: The reconstructed IPD-based approach can improve the accuracy and reliability of anticancer-drug BIA compared with conventional methods, and can be widely used, especially for anticancer drugs with excellent efficacy.",What can the reconstructed IPD-based approach improve in budget impact analysis of anticancer drugs (pmcid=10259044)?,The reconstructed IPD-based approach can improve the accuracy and reliability of anticancer-drug BIA compared with conventional methods.,424f87e819ba961603d3135d1cd7eebc
9574700,Mohd Hassan NZ,A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis,2022,bim,- BACKGROUND: One of the crucial areas of eliminating TB is the early detection of cases through the screening programme.,What is one of the crucial areas of eliminating TB mentioned in the abstract (pmcid: 9574700)?,One of the crucial areas of eliminating TB mentioned in the abstract (pmcid: 9574700) is the early detection of cases through the screening programme.,547f16f2ecc27dde2213b86706b37408
9574700,Mohd Hassan NZ,A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis,2022,bim,This study's focal point is to measure the relative cost-effectiveness and budget impact of the symptomatic approach compared to the existing approach of TB screening (consisted of both symptomatic and asymptomatic screening) among high-risk groups in Malaysia.,What is the focal point of this study (pmcid=9574700)?,The focal point of this study is to measure the relative cost-effectiveness and budget impact of the symptomatic approach compared to the existing approach of TB screening among high-risk groups in Malaysia.,547f16f2ecc27dde2213b86706b37408
9574700,Mohd Hassan NZ,A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis,2022,bim,METHOD: The Cost-Effectiveness Analysis (CEA) was measured using a decision tree model and the outcome is presented in terms of cost per TB case detected and the ICER.,What was measured in the Cost-Effectiveness Analysis (CEA) mentioned in the abstract (pmcid=9574700)?,The Cost-Effectiveness Analysis (CEA) mentioned in the abstract measured the cost per TB case detected and the ICER.,547f16f2ecc27dde2213b86706b37408
9574700,Mohd Hassan NZ,A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis,2022,bim,"Analysis was conducted using secondary data collected from the Disease Control Division, Sabah and Sarawak State Health Departments.",What data source was used for the analysis conducted in this study (pmcid=9574700)?,"Secondary data collected from the Disease Control Division, Sabah and Sarawak State Health Departments.",547f16f2ecc27dde2213b86706b37408
9574700,Mohd Hassan NZ,A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis,2022,bim,The robustness of the model is determined by Deterministic and Probabilistic Sensitivity Analysis.,What determines the robustness of the model in this study (pmcid=9574700)?,Deterministic and Probabilistic Sensitivity Analysis determines the robustness of the model in this study (pmcid=9574700).,547f16f2ecc27dde2213b86706b37408
9574700,Mohd Hassan NZ,A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis,2022,bim,"Subsequently, Budget impact over 5 years period, from 2018 to 2022 was estimated for both approaches.",What period was the budget impact estimated over (pmcid=9574700)?,"The budget impact was estimated over a 5-year period, from 2018 to 2022.",547f16f2ecc27dde2213b86706b37408
9574700,Mohd Hassan NZ,A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis,2022,bim,RESULTS: The symptomatic approach was more cost-effective than the existing approach with ICER of MYR 424.71.,What was the cost-effectiveness of the symptomatic approach compared to the existing approach in the study conducted by Mohd Hassan NZ (pmcid=9574700)?,The cost-effectiveness of the symptomatic approach compared to the existing approach in the study conducted by Mohd Hassan NZ (pmcid=9574700) was MYR 424.71.,547f16f2ecc27dde2213b86706b37408
9574700,Mohd Hassan NZ,A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis,2022,bim,The cost of conducting Sputum for Acid Fast Bacilli (SAFB) was found as the key driver for ICER.,What was found to be the key driver for ICER in the study conducted by Mohd Hassan NZ (pmcid=9574700)?,The cost of conducting Sputum for Acid Fast Bacilli (SAFB) was found to be the key driver for ICER in the study conducted by Mohd Hassan NZ (pmcid=9574700).,547f16f2ecc27dde2213b86706b37408
9574700,Mohd Hassan NZ,A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis,2022,bim,Budget Impact Analysis showed that switching from the existing approach towards the symptomatic approach would result in a cost-saving of MYR 65.5 million over 5 years.,What would be the cost-saving over 5 years by switching to the symptomatic approach for tuberculosis screening in Malaysia (pmcid=9574700)?,The cost-saving over 5 years by switching to the symptomatic approach for tuberculosis screening in Malaysia (pmcid=9574700) would be MYR 65.5 million.,547f16f2ecc27dde2213b86706b37408
9574700,Mohd Hassan NZ,A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis,2022,bim,"However, this would lead to 4473 TB cases being undetected over the same duration.",What would be the consequence of not implementing the symptomatic approach to tuberculosis screening for high-risk groups in Malaysia over a certain duration (pmcid=9574700)?,The consequence of not implementing the symptomatic approach to tuberculosis screening for high-risk groups in Malaysia over a certain duration (pmcid=9574700) would be that 4473 TB cases would go undetected.,547f16f2ecc27dde2213b86706b37408
9574700,Mohd Hassan NZ,A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis,2022,bim,CONCLUSION: This study suggests that the policymakers have to weigh the trade-off between cost-saving and TB case detection.,What do policymakers need to weigh according to the study (pmcid=9574700)?,Policymakers need to weigh the trade-off between cost-saving and TB case detection according to the study (pmcid=9574700).,547f16f2ecc27dde2213b86706b37408
9574700,Mohd Hassan NZ,A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis,2022,bim,This cost-saving can be channelled to new TB intervention programme with a higher chance of TB case detection.,What can the cost-saving from tuberculosis screening be channelled to in Malaysia (pmcid: 9574700)?,The cost-saving from tuberculosis screening in Malaysia (pmcid: 9574700) can be channelled to a new TB intervention programme with a higher chance of TB case detection.,547f16f2ecc27dde2213b86706b37408
9574700,Mohd Hassan NZ,A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis,2022,bim,"Nevertheless, any decision made must be in concordance to the objectives of the country's TB programme.",What must any decision made be in concordance to (pmcid=9574700)?,The decision made must be in concordance to the objectives of Malaysia's TB programme.,547f16f2ecc27dde2213b86706b37408
10316730,Aiello A,Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments,2023,bim,- Introduction: Primary immune thrombocytopenia is a rare autoimmune disease characterised by a decreased platelet count resulting in an increased risk of bleeding events and even life-threatening haemorrhages.,What is primary immune thrombocytopenia characterized by (pmcid=10316730)?,Primary immune thrombocytopenia is characterized by a decreased platelet count resulting in an increased risk of bleeding events and even life-threatening haemorrhages.,6c19816c267a1021ac2b75a2c5deedc9
10316730,Aiello A,Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments,2023,bim,Thrombopoietin receptor agonists (TPO-RAs) are the standard of care second-line therapy for adult patients with chronic immune thrombocytopenia.,What are thrombopoietin receptor agonists considered as for adult patients with chronic immune thrombocytopenia (pmcid=10316730)?,Thrombopoietin receptor agonists are considered as the standard of care second-line therapy for adult patients with chronic immune thrombocytopenia.,6c19816c267a1021ac2b75a2c5deedc9
10316730,Aiello A,Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments,2023,bim,"The first TPO-RAs approved and reimbursed in Italy, eltrombopag and romiplostim, while effective, pose some issues in terms of safety (e.g., hepatotoxicity) or general management (e.g., dietary restrictions).",What issues do eltrombopag and romiplostim pose in terms of safety or general management in Italy (pmcid=10316730)?,The issues that eltrombopag and romiplostim pose in terms of safety or general management in Italy include hepatotoxicity for eltrombopag and dietary restrictions for romiplostim.,6c19816c267a1021ac2b75a2c5deedc9
10316730,Aiello A,Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments,2023,bim,"Avatrombopag, an effective and well-tolerated TPO-RA, was recently granted reimbursement.",What was recently granted reimbursement (pmcid=10316730)?,Avatrombopag,6c19816c267a1021ac2b75a2c5deedc9
10316730,Aiello A,Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments,2023,bim,Methods: A 3-year (2023-2025) budget impact analysis (BIA) was conducted to estimate its impact on the Italian National Health Service (NHS).,What time frame was used for the budget impact analysis of avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments (pmcid=10316730)?,"The time frame used for the budget impact analysis of avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments (pmcid=10316730) was 3 years, specifically from 2023 to 2025.",6c19816c267a1021ac2b75a2c5deedc9
10316730,Aiello A,Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments,2023,bim,"Two scenarios were compared, of which one represents the current situation, without avatrombopag, and the other provides for an increasing market share of avatrombopag (up to 26.6%).",What two scenarios were compared in the budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments (pmcid=10316730)?,"The two scenarios compared in the budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments were one representing the current situation without avatrombopag, and the other providing for an increasing market share of avatrombopag up to 26.6%.",6c19816c267a1021ac2b75a2c5deedc9
10316730,Aiello A,Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments,2023,bim,"Results: BIA shows that the increase in the use of avatrombopag correlates with savings for NHS: in the first year, saving would be €1,300,564, increasing to €2,774,210 in the third year, for a total of €6,083,231 over the 3-year period.",What savings would be seen for the NHS over a 3-year period with the increase in the use of avatrombopag (pmcid=10316730)?,"The savings for the NHS over a 3-year period with the increase in the use of avatrombopag would be €6,083,231.",6c19816c267a1021ac2b75a2c5deedc9
10316730,Aiello A,Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments,2023,bim,The sensitivity analysis confirmed these savings in the scenario with avatrombopag.,What did the sensitivity analysis confirm in the scenario with avatrombopag (pmcid=10316730)?,The sensitivity analysis confirmed savings in the scenario with avatrombopag.,6c19816c267a1021ac2b75a2c5deedc9
10316730,Aiello A,Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments,2023,bim,"Conclusions: Based on this BIA, the introduction and reimbursement of avatrombopag is an efficient and advantageous choice for the Italian NHS.",What is the conclusion regarding the introduction and reimbursement of avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments (pmcid=10316730)?,"Based on the Budget Impact Analysis (BIA) provided in the context information, the conclusion is that the introduction and reimbursement of avatrombopag is considered an efficient and advantageous choice for the Italian NHS in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments.",6c19816c267a1021ac2b75a2c5deedc9
10766175,Palacios A,Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina,2024,bim,"- OBJECTIVE: This study aimed to estimate the budget impact of the incorporation of venetoclax for the treatment of patients with Acute Myeloid Leukemia (AML) over 75 years of age or those with comorbidities and contraindications for the use of intensive chemotherapy, from the perspective of the social security and the private third-party payers in Argentina.",What is the objective of the study (pmcid=10766175)?,"The objective of the study with pmcid=10766175 is to estimate the budget impact of incorporating venetoclax for the treatment of patients with Acute Myeloid Leukemia (AML) over 75 years of age or those with comorbidities and contraindications for the use of intensive chemotherapy, from the perspective of the social security and the private third-party payers in Argentina.",17e7b08ef5fe89556aca44d45ae142dd
10766175,Palacios A,Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina,2024,bim,"METHODS: A budget impact model was adapted to estimate the cost difference between the current scenario (azacitidine, decitabine and low doses of cytarabine) and the new scenario (incorporation of venetoclax) for a third-party payer over a time horizon of three years.",What was the time horizon of the budget impact analysis conducted in this study (pmcid=10766175)?,The time horizon of the budget impact analysis conducted in this study (pmcid=10766175) was three years.,17e7b08ef5fe89556aca44d45ae142dd
10766175,Palacios A,Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina,2024,bim,"Input parameters were obtained from a literature review, validated or complemented by expert opinion using a modified Panel Delphi approach.",What approach was used to obtain input parameters for the budget impact analysis of venetoclax for the management of acute myeloid leukemia in Argentina (pmcid=10766175)?,"Input parameters were obtained from a literature review, validated or complemented by expert opinion using a modified Panel Delphi approach.",17e7b08ef5fe89556aca44d45ae142dd
10766175,Palacios A,Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina,2024,bim,All direct medical costs were estimated by the micro-costing approach and were expressed in US dollars (USD) as of September 2020 (1 USD = 76.18 Argentine pesos).,What approach was used to estimate all direct medical costs in this study (pmcid=10766175)?,The micro-costing approach was used to estimate all direct medical costs in this study (pmcid=10766175).,17e7b08ef5fe89556aca44d45ae142dd
10766175,Palacios A,Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina,2024,bim,"RESULTS: For a third-party payer with a cohort of 1,000,000 individuals covered, incorporating venetoclax was associated with an average budget impact per-member per-month (PMPM) of $0.11 USD for the social security sector and $0.07 USD for the private sector.",What was the average budget impact per-member per-month for incorporating venetoclax in the social security sector and the private sector (pmcid=10766175)?,"The average budget impact per-member per-month for incorporating venetoclax in the social security sector was $0.11 USD, and in the private sector, it was $0.07 USD.",17e7b08ef5fe89556aca44d45ae142dd
10766175,Palacios A,Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina,2024,bim,The duration of treatment with venetoclax was the most influential parameter in the budget impact results.,What was the most influential parameter in the budget impact results of the study (pmcid=10766175)?,The duration of treatment with venetoclax was the most influential parameter in the budget impact results of the study with pmcid=10766175.,17e7b08ef5fe89556aca44d45ae142dd
10766175,Palacios A,Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina,2024,bim,CONCLUSION: The introduction of venetoclax was associated with a positive and slight budget impact.,What was the budget impact associated with the introduction of venetoclax for the management of acute myeloid leukemia in Argentina (pmcid=10766175)?,The budget impact associated with the introduction of venetoclax for the management of acute myeloid leukemia in Argentina was positive and slight.,17e7b08ef5fe89556aca44d45ae142dd
10766175,Palacios A,Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina,2024,bim,These findings are informative to support policy decisions aimed to expand the current treatment landscape of AML.,What are the findings informative to support (pmcid=10766175)?,The findings that are informative to support are related to the budget impact analysis of venetoclax for the management of acute myeloid leukemia in Argentina from the perspective of the social security and the private sector.,17e7b08ef5fe89556aca44d45ae142dd
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,"- PURPOSE: In cardiovascular surgeries, iron deficiency anemia and transfusion of blood products are associated with mortality and morbidity, prolonged hospital stay and poor patient outcomes.",What is the purpose of the study conducted by Tatar M in the Cardiovascular Surgery Department of a Turkish Private Hospital (pmcid=11668246)?,"The purpose of the study conducted by Tatar M in the Cardiovascular Surgery Department of a Turkish Private Hospital is to analyze the budget impact of implementing Patient Blood Management, with a focus on reducing iron deficiency anemia and the transfusion of blood products in cardiovascular surgeries.",c9139a662b0b08585fa1f7dcde33ed18
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,Patient blood management (PBM) is a patient-centered approach based on a 'three pillar' model that promotes optimum use of blood and blood products to improve outcomes.,What is patient blood management (PBM) based on? (pmcid=11668246),Patient blood management (PBM) is based on a 'three pillar' model that promotes optimum use of blood and blood products to improve outcomes.,c9139a662b0b08585fa1f7dcde33ed18
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,This study assessed the potential budget impact of implementing PBM in patients undergoing elective cardiovascular surgery in a private hospital in Turkey.,What did the study assess in patients undergoing elective cardiovascular surgery in a private hospital in Turkey (pmcid=11668246)?,The study assessed the potential budget impact of implementing Patient Blood Management (PBM) in patients undergoing elective cardiovascular surgery in a private hospital in Turkey.,c9139a662b0b08585fa1f7dcde33ed18
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,METHODS: Two models were developed to estimate the hospital budget impact of PBM.,What models were developed to estimate the hospital budget impact of PBM? (pmcid=11668246),Two models were developed.,c9139a662b0b08585fa1f7dcde33ed18
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,"The first model encompassed implementation of the first pillar of PBM, which proposes treatment of iron deficiency anemia before a surgical procedure.",What does the first model encompass in terms of Patient Blood Management implementation in the Cardiovascular Surgery Department of a Turkish Private Hospital (pmcid=11668246)?,"The first model encompasses the implementation of the first pillar of Patient Blood Management, which proposes the treatment of iron deficiency anemia before a surgical procedure.",c9139a662b0b08585fa1f7dcde33ed18
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,The second covered implementation of all three pillars of PBM.,What did the second covered implementation of all three pillars of PBM entail (pmcid=11668246)?,The second covered implementation of all three pillars of PBM entailed implementing patient blood management in the cardiovascular surgery department of a Turkish private hospital.,c9139a662b0b08585fa1f7dcde33ed18
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,Budget impact was estimated from the number of avoided complications after treating iron deficiency anemia and reducing blood transfusions.,What was estimated in terms of budget impact in the study (pmcid=11668246)?,Budget impact was estimated from the number of avoided complications after treating iron deficiency anemia and reducing blood transfusions.,c9139a662b0b08585fa1f7dcde33ed18
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,"Rates of complication (sepsis, myocardial infarction, renal failure and stroke) with and without PBM were taken from published meta-analyses.",What rates of complications were considered in the analysis (pmcid=11668246)?,"The rates of complications considered in the analysis were sepsis, myocardial infarction, renal failure, and stroke.",c9139a662b0b08585fa1f7dcde33ed18
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,Data on 882 cardiovascular operations performed during 2020-2022 were taken from the Florence Nightingale Istanbul Hospital.,What data was taken from the Florence Nightingale Istanbul Hospital for the study (pmcid=11668246)?,Data on 882 cardiovascular operations,c9139a662b0b08585fa1f7dcde33ed18
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,The costs of treating complications were estimated by applying Turkish Social Security Institution prices to a healthcare resource utilization tool for each complication completed by experts.,What prices were applied to estimate the costs of treating complications in the study (pmcid=11668246)?,Turkish Social Security Institution prices were applied to estimate the costs of treating complications in the study (pmcid=11668246).,c9139a662b0b08585fa1f7dcde33ed18
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,"RESULTS: Results from the budget impact analysis showed that, by implementing the first pillar of PBM, the department could have avoided 30 complications and saved 4,189,802 TRY.",What were the results of implementing the first pillar of Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital (pmcid=11668246)?,"Results from the budget impact analysis showed that, by implementing the first pillar of PBM, the department could have avoided 30 complications and saved 4,189,802 TRY.",c9139a662b0b08585fa1f7dcde33ed18
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,"For the second model based on implementing all three pillars of PBM, 29 complications could have been avoided by reducing the number of transfusions, with budget savings of 6,174,434 TRY.",What complications could have been avoided by implementing all three pillars of PBM in the Cardiovascular Surgery Department of a Turkish Private Hospital (pmcid=11668246)?,29 complications could have been avoided.,c9139a662b0b08585fa1f7dcde33ed18
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,Reducing the length of hospital stay could have enabled 137 additional operations in the given period.,How many additional operations could have been enabled by reducing the length of hospital stay in the given period (pmcid=11668246)?,137 additional operations,c9139a662b0b08585fa1f7dcde33ed18
11668246,Tatar M,Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital,2024,bim,CONCLUSION: Implementation of PBM in patients undergoing elective cardiovascular surgery in private hospitals could be a budget-saving strategy in Turkey and may provide an opportunity to increase revenue.,What could be a budget-saving strategy in Turkey for private hospitals implementing Patient Blood Management in patients undergoing elective cardiovascular surgery (pmcid=11668246)?,Implementation of PBM in patients undergoing elective cardiovascular surgery in private hospitals could be a budget-saving strategy in Turkey.,c9139a662b0b08585fa1f7dcde33ed18
10427519,de Pouvourville G,Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective,2023,bim,- INTRODUCTION: Gliflozins have historically been indicated for type 2 diabetes in France.,What have gliflozins historically been indicated for in France (pmcid=10427519)?,Gliflozins have historically been indicated for type 2 diabetes in France.,e38858e007c17e49b61a5a69138d0d76
10427519,de Pouvourville G,Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective,2023,bim,"However, their efficacy has recently been demonstrated in heart failure and chronic kidney disease (CKD), with positive recommendations by Haute Autorité de Santé for gliflozin therapies in these indications.",What positive recommendations were made by Haute Autorité de Santé for gliflozin therapies in heart failure and chronic kidney disease (CKD) (pmcid=10427519)?,Haute Autorité de Santé made positive recommendations for gliflozin therapies in heart failure and chronic kidney disease (CKD).,e38858e007c17e49b61a5a69138d0d76
10427519,de Pouvourville G,Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective,2023,bim,"The study objective was to investigate the 5-year budget impact associated with the introduction of gliflozins in addition to standard therapy in people with CKD and elevated albuminuria, regardless of diabetes status, from the perspective of the French healthcare system.",What was the objective of the study (pmcid=10427519)?,"The objective of the study was to investigate the 5-year budget impact associated with the introduction of gliflozins in addition to standard therapy in people with CKD and elevated albuminuria, regardless of diabetes status, from the perspective of the French healthcare system.",e38858e007c17e49b61a5a69138d0d76
10427519,de Pouvourville G,Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective,2023,bim,"METHODS: A budget impact model was developed to estimate the 5-year implications of incorporating gliflozins in the treatment of patients with CKD in France, using efficacy data from the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial.",What efficacy data was used in developing the budget impact model (pmcid=10427519)?,Efficacy data from the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial was used in developing the budget impact model.,e38858e007c17e49b61a5a69138d0d76
10427519,de Pouvourville G,Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective,2023,bim,"Direct medical costs associated with drug acquisition and management, treatment-related adverse events, dialysis and kidney transplantation, and adverse clinical outcomes were considered.",What costs were considered in the budget impact analysis of expanding gliflozin coverage in the CKD population from a French perspective (pmcid=10427519)?,"Direct medical costs associated with drug acquisition and management, treatment-related adverse events, dialysis and kidney transplantation, and adverse clinical outcomes were considered in the budget impact analysis of expanding gliflozin coverage in the CKD population from a French perspective.",e38858e007c17e49b61a5a69138d0d76
10427519,de Pouvourville G,Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective,2023,bim,Market share forecasts were estimated from historical data and expert opinions.,What were the market share forecasts estimated from in the study (pmcid=10427519)?,Market share forecasts were estimated from historical data and expert opinions.,e38858e007c17e49b61a5a69138d0d76
10427519,de Pouvourville G,Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective,2023,bim,"Event rates were derived from trial data, while cost data were sourced from published estimates.",What were the sources of the cost data used in the analysis (pmcid=10427519)?,The cost data used in the analysis were sourced from published estimates.,e38858e007c17e49b61a5a69138d0d76
10427519,de Pouvourville G,Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective,2023,bim,"RESULTS: The introduction of gliflozins was estimated to be cost saving compared to the no gliflozins scenario, with an expected cumulative 5-year budget impact of -€650 million, driven by slowed disease progression in patients treated with gliflozins, with fewer patients cumulatively progressing to end-stage kidney disease (84,526 vs.",What was the expected cumulative 5-year budget impact of introducing gliflozins in the CKD population from a French perspective (pmcid=10427519)?,The expected cumulative 5-year budget impact of introducing gliflozins in the CKD population from a French perspective was -€650 million.,e38858e007c17e49b61a5a69138d0d76
10427519,de Pouvourville G,Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective,2023,bim,"This, in addition to fewer hospitalisations for heart failure and deaths from any cause, led to substantial medical care cost offsets (kidney-related: - €894 million; hospitalisation for heart failure: - €14.3 million; end-of-life care: - €17.3 million) to the additional drug acquisition (€273 million) and treatment-related adverse events costs (€2.98 million).",What were the medical care cost offsets associated with expanding gliflozin coverage in the CKD population from a French perspective (pmcid=10427519)?,"The medical care cost offsets associated with expanding gliflozin coverage in the CKD population from a French perspective were kidney-related costs of - €894 million, hospitalisation for heart failure costs of - €14.3 million, and end-of-life care costs of - €17.3 million.",e38858e007c17e49b61a5a69138d0d76
10427519,de Pouvourville G,Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective,2023,bim,"CONCLUSION: In concert with early diagnosis and proactive management of CKD, the expansion of the gliflozin indications into the French CKD population presents the opportunity to reduce the substantial burden associated with cardio-renal complications which outweighs the additional cost of the new treatment.",What opportunity does the expansion of gliflozin indications into the French CKD population present in terms of reducing burden associated with cardio-renal complications (pmcid=10427519)?,"The expansion of gliflozin indications into the French CKD population presents the opportunity to reduce the substantial burden associated with cardio-renal complications, which outweighs the additional cost of the new treatment.",e38858e007c17e49b61a5a69138d0d76
10427519,de Pouvourville G,Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective,2023,bim,INFOGRAPHIC.,What type of analysis was conducted in the study (pmcid=10427519)?,Budget Impact Analysis,e38858e007c17e49b61a5a69138d0d76
11556681,Alkhatib NS,Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective,2024,bim,"- BACKGROUND: The Saudi Food and Drug Authority (SFDA) has approved the subcutaneous (SC) administration of infliximab, presenting a more convenient alternative with reduced outpatient visits and diminished expenses compared to the intravenous (IV) administration.",What has the Saudi Food and Drug Authority (SFDA) approved in relation to infliximab administration (pmcid=11556681)?,The Saudi Food and Drug Authority (SFDA) has approved the subcutaneous (SC) administration of infliximab.,6642d8b62db00b97c0e489148c26aabd
11556681,Alkhatib NS,Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective,2024,bim,"However, the financial implications of this formulation have not been examined from the perspective of Saudi payers.",What perspective was used for the budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia (pmcid=11556681)?,The budget impact analysis was conducted from the payer perspective.,6642d8b62db00b97c0e489148c26aabd
11556681,Alkhatib NS,Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective,2024,bim,"METHODS AND MATERIALS: A prevalence-based budget impact model was developed to evaluate the financial effects of introducing ""environment without"" versus ""with infliximab SC."" The model's time horizon spanned over 2 years (2021-2023), aligning with the biennial national pharmaceutical procurement cycle.",What time horizon did the budget impact model span over (pmcid=11556681)?,"The budget impact model spanned over 2 years, from 2021 to 2023.",6642d8b62db00b97c0e489148c26aabd
11556681,Alkhatib NS,Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective,2024,bim,The comparison focused on infliximab SC versus all available formulations of infliximab IV in the Saudi market for two inflammatory bowel diseases (IBD): Ulcerative Colitis (UC) and Crohn's Disease (CD).,What did the comparison focus on in the study (pmcid=11556681)?,The comparison focused on infliximab SC versus all available formulations of infliximab IV in the Saudi market for two inflammatory bowel diseases (IBD): Ulcerative Colitis (UC) and Crohn's Disease (CD).,6642d8b62db00b97c0e489148c26aabd
11556681,Alkhatib NS,Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective,2024,bim,"Treatment comparators' comparability and dose escalations were substantiated by published studies, utilizing dosing information from the summary of product characteristics.",What dosing information was utilized from the summary of product characteristics in the analysis (pmcid=11556681)?,The dosing information utilized from the summary of product characteristics in the analysis was related to treatment comparators' comparability and dose escalations.,6642d8b62db00b97c0e489148c26aabd
11556681,Alkhatib NS,Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective,2024,bim,"Drug acquisition costs were derived from SFDA registered prices, with IV formulation administration costs included.",What costs were included in the analysis of subcutaneous infliximab for treating inflammatory bowel disease in Saudi Arabia (pmcid=11556681)?,"The analysis included drug acquisition costs derived from SFDA registered prices, with IV formulation administration costs included.",6642d8b62db00b97c0e489148c26aabd
11556681,Alkhatib NS,Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective,2024,bim,Scenario analysis assessed the budget impact of infliximab SC introduction at uptake rates ranging from 0% to 100%.,What was assessed in the scenario analysis mentioned in the abstract (pmcid=11556681)?,The scenario analysis assessed the budget impact of introducing subcutaneous infliximab (CT-P13 SC) at uptake rates ranging from 0% to 100%.,6642d8b62db00b97c0e489148c26aabd
11556681,Alkhatib NS,Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective,2024,bim,RESULTS: Introducing infliximab SC demonstrated cost-saving potential in the treatment of IBD.,What cost-saving potential was demonstrated in the treatment of IBD with the introduction of infliximab SC (pmcid=11556681)?,Introducing infliximab SC demonstrated cost-saving potential in the treatment of IBD.,6642d8b62db00b97c0e489148c26aabd
11556681,Alkhatib NS,Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective,2024,bim,"At 100% uptake with UC patients for 2 years, infliximab SC resulted in savings of -SAR-31.9 million (-SAR29,145 per patient).",What were the savings generated by infliximab SC at 100% uptake with UC patients for 2 years (pmcid=11556681)?,"The savings generated by infliximab SC at 100% uptake with UC patients for 2 years were -SAR-31.9 million (-SAR29,145 per patient).",6642d8b62db00b97c0e489148c26aabd
11556681,Alkhatib NS,Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective,2024,bim,"Similarly, for CD, introducing infliximab SC at 100% uptake over 2 years yielded savings of -SAR106.2 million (-SAR36,585 per patient).",What savings were yielded by introducing infliximab SC for treating inflammatory bowel disease in Saudi Arabia (pmcid=11556681)?,"-SAR106.2 million (-SAR36,585 per patient)",6642d8b62db00b97c0e489148c26aabd
11556681,Alkhatib NS,Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective,2024,bim,CONCLUSION: This study reveals that infliximab SC is associated with cost-saving potential when compared to infliximab IV formulations available in Saudi Arabia.,What is the cost-saving potential associated with infliximab SC compared to IV formulations in Saudi Arabia (pmcid=11556681)?,The cost-saving potential associated with infliximab SC compared to IV formulations in Saudi Arabia is revealed in the study to be significant.,6642d8b62db00b97c0e489148c26aabd
11556681,Alkhatib NS,Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective,2024,bim,"Future research should address uncertainties related to real-world comparative effectiveness, the convenience of administration, patient tolerability, and physician acceptance of the SC formulation of infliximab, alongside comparisons with other TNF-alpha inhibitors.",What uncertainties should future research address regarding the SC formulation of infliximab (pmcid=11556681)?,"Future research should address uncertainties related to real-world comparative effectiveness, the convenience of administration, patient tolerability, and physician acceptance of the SC formulation of infliximab, alongside comparisons with other TNF-alpha inhibitors.",6642d8b62db00b97c0e489148c26aabd
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,- INTRODUCTION: Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disease that significantly reduces occupational productivity and quality-of-life in affected patients.,What disease is being treated with anakinra in the budget impact analysis in Italy (pmcid=9930828)?,Familial Mediterranean Fever (FMF),6ce173027134c111b456b85fa03af4f0
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,"Italy has an estimated FMF prevalence of 1 in 60,000 people.",What is the estimated prevalence of FMF in Italy (pmcid=9930828)?,"1 in 60,000 people",6ce173027134c111b456b85fa03af4f0
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,"While colchicine is the primary treatment for FMF, biologics are administered to intolerant and non-responder patients.",What are biologics administered for in patients with familial Mediterranean fever (pmcid=9930828)?,Biologics are administered to intolerant and non-responder patients with familial Mediterranean fever.,6ce173027134c111b456b85fa03af4f0
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,Anakinra and canakinumab are the only biologics approved and reimbursed for FMF in Italy.,What are the only biologics approved and reimbursed for FMF in Italy (pmcid=9930828)?,Anakinra and canakinumab,6ce173027134c111b456b85fa03af4f0
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,Both medicines have demonstrated efficacy in FMF patients yet differ in treatment costs.,What do both medicines have in common in terms of efficacy in FMF patients (pmcid=9930828)?,Both medicines have demonstrated efficacy in FMF patients.,6ce173027134c111b456b85fa03af4f0
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,"This study aimed to perform a budget impact analysis (BIA) following anakinra's reimbursement for FMF treatment, considering pharmaceutical costs from the Italian National Healthcare Service (NHS) perspective.",What was the aim of the study (pmcid=9930828)?,"The aim of the study (pmcid=9930828) was to perform a budget impact analysis following anakinra's reimbursement for familial Mediterranean fever (FMF) treatment in Italy, considering pharmaceutical costs from the Italian National Healthcare Service (NHS) perspective.",6ce173027134c111b456b85fa03af4f0
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,"METHODS: A 'Reference scenario' (all patients treated with canakinumab) was compared to an 'Alternative scenario', with increased anakinra market shares.",What scenarios were compared in the budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy (pmcid=9930828)?,The 'Reference scenario' (all patients treated with canakinumab) was compared to an 'Alternative scenario' with increased anakinra market shares.,6ce173027134c111b456b85fa03af4f0
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,"The target population was estimated based on the Italian population, epidemiological and market research data.",What was the target population estimated based on in the study (pmcid=9930828)?,"The target population was estimated based on the Italian population, epidemiological and market research data.",6ce173027134c111b456b85fa03af4f0
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,Drugs costs were estimated based on Summary of Product Characteristics and net ex-factory prices.,What were the drug costs estimated based on in the study (pmcid=9930828)?,The drug costs were estimated based on Summary of Product Characteristics and net ex-factory prices in the study with pmcid=9930828.,6ce173027134c111b456b85fa03af4f0
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,Sensitivity analyses were implemented to test results' robustness.,What type of analyses were implemented to test the results' robustness (pmcid=9930828)?,Sensitivity analyses,6ce173027134c111b456b85fa03af4f0
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,"RESULTS: The base case analysis showed an overall cumulative expenditure of €30,586,628 for 'Reference scenario' and € 16,465,548 for 'Alternative scenario'.",What were the overall cumulative expenditures for the 'Reference scenario' and 'Alternative scenario' in the budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy (pmcid=9930828)?,"The overall cumulative expenditure for the 'Reference scenario' was €30,586,628, and for the 'Alternative scenario' it was €16,465,548 in the budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy (pmcid=9930828).",6ce173027134c111b456b85fa03af4f0
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,"A cumulative savings of €14,121,080 (46.2%) was calculated over 3 years as a result of the reimbursement and increasing uptake of anakinra.",What cumulative savings were calculated over 3 years as a result of the reimbursement and increasing uptake of anakinra in Italy (pmcid=9930828)?,"€14,121,080",6ce173027134c111b456b85fa03af4f0
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,"The sensitivity analyses, even considering a discount of 50% for canakinumab, confirmed the base case results.","What did the sensitivity analyses confirm, even with a 50% discount for canakinumab? (pmcid=9930828)","The sensitivity analyses confirmed the base case results, even with a 50% discount for canakinumab.",6ce173027134c111b456b85fa03af4f0
9930828,Aiello A,Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy,2023,bim,"CONCLUSIONS: Anakinra's introduction, in FMF treatment, provides a financially sustainable option for Italian patients, with savings increasing according to greater use of anakinra.",What does the introduction of anakinra in FMF treatment provide for Italian patients in terms of financial sustainability (pmcid=9930828)?,"Anakinra's introduction in FMF treatment provides a financially sustainable option for Italian patients, with savings increasing according to greater use of anakinra.",6ce173027134c111b456b85fa03af4f0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,- INTRODUCTION: The exploration of molecular characteristics has emerged as a prominent trend to advance precision medicine.,What has emerged as a prominent trend to advance precision medicine (pmcid=11719227)?,The exploration of molecular characteristics,c3cf2b938947ef3f95a59d866d170ec0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,The utilization of genetic testing to guide therapy is integral to precision medicine.,What is integral to precision medicine according to the abstract sentence? (pmcid=11719227),The utilization of genetic testing to guide therapy is integral to precision medicine.,c3cf2b938947ef3f95a59d866d170ec0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,"This study aims to investigate the potential patient populations for the reimbursement of next-generation sequencing (NGS) and assess the budget impact from the perspective of Taiwan’s single insurer, the National Health Insurance Administration.",What is the aim of this study (pmcid=11719227)?,"The aim of this study is to investigate the potential patient populations for the reimbursement of next-generation sequencing (NGS) and assess the budget impact from the perspective of Taiwan's single insurer, the National Health Insurance Administration.",c3cf2b938947ef3f95a59d866d170ec0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,"METHODS: To comprehend the scope for medicines with companion diagnostics (CDx) involved, we analyze the U.S.",What was analyzed to comprehend the scope for medicines with companion diagnostics involved? (pmcid=11719227),The scope for medicines with companion diagnostics (CDx) involved was analyzed.,c3cf2b938947ef3f95a59d866d170ec0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,"Food and Drug Administration-approved/cleared diagnostic tests, conduct a literature review to identify medicines approved by the European Medicines Agency that require a CDx, and identify the medicines with CDx involved covered by the National Health Insurance (NHI) in Taiwan.",What type of analysis was conducted in this study (pmcid=11719227)?,Budget Impact Analysis,c3cf2b938947ef3f95a59d866d170ec0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,"Subsequently, we explore the potential reimbursement indications for NGS testing and conduct a budget impact analysis to evaluate the expected financial impact for the NHI over a five-year period.",What was the purpose of conducting a budget impact analysis in Taiwan's National Health Insurance regarding Next-Generation Sequencing coverage (pmcid=11719227)?,The purpose of conducting a budget impact analysis in Taiwan's National Health Insurance regarding Next-Generation Sequencing coverage was to evaluate the expected financial impact for the NHI over a five-year period.,c3cf2b938947ef3f95a59d866d170ec0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,"Furthermore, sensitivity analyses are conducted to deal with uncertainty.",What type of analyses are conducted to deal with uncertainty in the study (pmcid=11719227)?,Sensitivity analyses,c3cf2b938947ef3f95a59d866d170ec0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,RESULTS: We have compiled 13 cancer types for which NGS can serve as a companion diagnostic.,What cancer types were compiled for which NGS can serve as a companion diagnostic? (pmcid=11719227),13 cancer types,c3cf2b938947ef3f95a59d866d170ec0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,"These encompass non-small-cell lung cancer, colorectal cancer, breast cancer, ovarian cancer, biliary tract cancer, acute myeloid leukemia, acute lymphoblastic leukemia, melanoma, cholangiocarcinoma, prostate cancer, pancreatic cancer, gastrointestinal stromal tumor, and thyroid cancer/medullary thyroid cancer.",What types of cancer were included in the budget impact analysis in Taiwan's National Health Insurance (pmcid=11719227)?,"The types of cancer included in the budget impact analysis in Taiwan's National Health Insurance were non-small-cell lung cancer, colorectal cancer, breast cancer, ovarian cancer, biliary tract cancer, acute myeloid leukemia, acute lymphoblastic leukemia, melanoma, cholangiocarcinoma, prostate cancer, pancreatic cancer, gastrointestinal stromal tumor, and thyroid cancer/medullary thyroid cancer.",c3cf2b938947ef3f95a59d866d170ec0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,"The implementation of NGS reimbursement in NHI will benefit 25,000 to 30,000 patients undergoing targeted therapies.",What is the estimated number of patients who will benefit from the implementation of NGS reimbursement in Taiwan's National Health Insurance (pmcid=11719227)?,"25,000 to 30,000 patients",c3cf2b938947ef3f95a59d866d170ec0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,The projected incremental budget impact ranges from TWD570 million to TWD650 million (USD19 million to USD22 million) over five years.,What is the projected incremental budget impact over five years in Taiwan's National Health Insurance (pmcid=11719227)?,The projected incremental budget impact over five years in Taiwan's National Health Insurance is estimated to range from TWD570 million to TWD650 million (USD19 million to USD22 million).,c3cf2b938947ef3f95a59d866d170ec0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,CONCLUSIONS: This study focuses on evaluating the financial impact of incorporating NGS testing into NHI reimbursement for relevant cancer drug indications.,What does this study focus on evaluating (pmcid=11719227)?,The study focuses on evaluating the financial impact of incorporating Next-Generation Sequencing (NGS) testing into Taiwan's National Health Insurance (NHI) reimbursement for relevant cancer drug indications.,c3cf2b938947ef3f95a59d866d170ec0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,The findings can serve as references for the planning of reimbursement policies.,What can the findings of the study serve as references for (pmcid=11719227)?,The findings of the study can serve as references for the planning of reimbursement policies.,c3cf2b938947ef3f95a59d866d170ec0
11719227,Chang HR,PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance,2025,bim,"However, with the advancement of precision medicine, it is foreseeable that there will be a broader range of applications for NGS, and its cost will gradually decrease.",What is foreseeable with the advancement of precision medicine in relation to Next-Generation Sequencing coverage in Taiwan's National Health Insurance (pmcid=11719227)?,It is foreseeable that there will be a broader range of applications for Next-Generation Sequencing (NGS) and its cost will gradually decrease with the advancement of precision medicine in Taiwan's National Health Insurance.,c3cf2b938947ef3f95a59d866d170ec0
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,- Background: Schizophrenia is a serious mental disorder that has greater negative consequences on role functioning than many other severe chronic diseases.,What negative consequences does schizophrenia have on role functioning compared to other severe chronic diseases (pmcid=10439680)?,Schizophrenia has greater negative consequences on role functioning compared to many other severe chronic diseases.,e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,Objective: We evaluated the economic impact of long-acting injections of paliperidone palmitate (PP) vs daily oral antipsychotics to treat chronic schizophrenia from a societal perspective over a 2-year period.,What was the objective of the study conducted by Elsisi G regarding the economic impact of paliperidone palmitate in Egyptian adult patients with schizophrenia (pmcid=10439680)?,The objective of the study conducted by Elsisi G was to evaluate the economic impact of long-acting injections of paliperidone palmitate (PP) vs daily oral antipsychotics to treat chronic schizophrenia from a societal perspective over a 2-year period.,e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,"Methods: A static budget impact model was developed to compare PP with daily oral antipsychotics (risperidone, olanzapine, and aripiprazole) in the treatment of patients with chronic schizophrenia.",What methods were used to compare Paliperidone Palmitate with daily oral antipsychotics in the treatment of patients with chronic schizophrenia (pmcid=10439680)?,"A static budget impact model was developed to compare Paliperidone Palmitate with daily oral antipsychotics (risperidone, olanzapine, and aripiprazole) in the treatment of patients with chronic schizophrenia.",e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,"Our study included treatments used during relapse and hospitalization, validated by an expert panel.",What treatments were included in the study for Egyptian adult patients with schizophrenia (pmcid=10439680)?,Treatments used during relapse and hospitalization were included in the study for Egyptian adult patients with schizophrenia.,e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,The clinical parameters were extracted from the PRIDE trial.,What trial were the clinical parameters extracted from (pmcid=10439680)?,The clinical parameters were extracted from the PRIDE trial.,e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,Direct medical costs and indirect costs were measured.,What costs were measured in the study (pmcid=10439680)?,Direct medical costs and indirect costs were measured.,e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,The unit cost of drug acquisition for all medications was extracted from the public sector.,What was the source of the unit cost of drug acquisition for all medications in the study (pmcid=10439680)?,The source of the unit cost of drug acquisition for all medications in the study (pmcid=10439680) was the public sector.,e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,One-way sensitivity analyses were conducted.,What type of analyses were conducted in the study (pmcid=10439680)?,One-way sensitivity analyses were conducted.,e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,Results: The target population in our model was estimated to be 142 incident patients.,How many incident patients were estimated in the target population in the budget impact analysis (pmcid=10439680)?,142 incident patients were estimated in the target population in the budget impact analysis (pmcid=10439680).,e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,"In the first year, the total drug costs in Egyptian pounds (EGP) for PP and oral antipsychotics were £2.7 million and £724 004, respectively, while the total medical costs for PP and oral antipsychotics were £3 million and £5.6 million, respectively.",What were the total drug costs in Egyptian pounds for Paliperidone Palmitate and oral antipsychotics in the first year (pmcid=10439680)?,"The total drug costs in Egyptian pounds for Paliperidone Palmitate and oral antipsychotics in the first year were £2.7 million and £724,004, respectively.",e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,"In the second year, the total drug costs for PP and oral antipsychotics were £2.7 million and £724 004, respectively, while the total medical costs for PP and oral antipsychotics were £3 million and £5 million, respectively.",What were the total drug costs for PP and oral antipsychotics in the second year (pmcid=10439680)?,"The total drug costs for PP and oral antipsychotics in the second year were £2.7 million and £724,004, respectively.",e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,The total costs for PP (£11.6 million) over 2 years were less than those of oral antipsychotics without PP (£12.7 million).,What were the total costs for PP over 2 years compared to oral antipsychotics without PP (pmcid=10439680)?,"The total costs for PP over 2 years were £11.6 million, which was less than the total costs for oral antipsychotics without PP, which were £12.7 million.",e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,"PP produced an estimated budget savings of £1 046 561 (budget savings per patient per year, £3667).",What were the estimated budget savings per patient per year with the use of PP in Egyptian adult patients with schizophrenia (pmcid=10439680)?,The estimated budget savings per patient per year with the use of PP in Egyptian adult patients with schizophrenia was £3667.,e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,"In addition, PP resulted in the avoidance of 18 hospitalizations per year compared with the without-PP arm.",How many hospitalizations per year were avoided with the use of PP in Egyptian adult patients with schizophrenia (pmcid=10439680)?,18 hospitalizations per year,e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,Sensitivity analyses showed that the percent of hospitalizations for both oral antipsychotics and PP had the greatest impact on the results.,What had the greatest impact on the results in the sensitivity analyses (pmcid=10439680)?,The percent of hospitalizations for both oral antipsychotics and PP had the greatest impact on the results in the sensitivity analyses (pmcid=10439680).,e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,Conclusion: The lower hospitalization rates associated with PP offset the increase in drug costs.,What offsets the increase in drug costs according to the conclusion of the study (pmcid=10439680)?,The lower hospitalization rates associated with Paliperidone Palmitate (PP) offset the increase in drug costs.,e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,PP may potentially be cost-saving compared with the standard of care in chronic schizophrenia in Egyptian representative healthcare settings.,What is the potential budget impact analysis of Paliperidone Palmitate in Egyptian adult patients with schizophrenia suggesting (pmcid=10439680)?,The potential budget impact analysis of Paliperidone Palmitate in Egyptian adult patients with schizophrenia suggests that it may potentially be cost-saving compared with the standard of care in chronic schizophrenia in Egyptian representative healthcare settings.,e21754acaf6f870f35993e50a601f4fd
10439680,Elsisi G,Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia,2023,bim,Policy makers may consider this approach to improve patient outcomes and budget sustainability.,What approach may policy makers consider to improve patient outcomes and budget sustainability (pmcid=10439680)?,Policy makers may consider projecting the potential budget impact analysis of Paliperidone Palmitate in Egyptian adult patients with schizophrenia to improve patient outcomes and budget sustainability.,e21754acaf6f870f35993e50a601f4fd
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,- BACKGROUND: Etiology of allergic rhinitis and asthma is frequently associated with house dust mite sensitization and allergen immunotherapy (AIT) represents the only disease modifying treatment.,What is the etiology frequently associated with allergic rhinitis and asthma (pmcid=10362513)?,House dust mite sensitization is frequently associated with allergic rhinitis and asthma.,2ebb020e2650d49b6ca01a487469c8ea
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,"In a real world setting, clinicians would benefit from biomarkers to monitor or predict response to AIT.",What would clinicians benefit from in a real-world setting regarding AIT response monitoring or prediction (pmcid=10362513)?,Clinicians would benefit from biomarkers to monitor or predict response to AIT in a real-world setting.,2ebb020e2650d49b6ca01a487469c8ea
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,"METHODS: Twenty-four consecutive house dust mite (HDM) mono-sensitized rhinitic patients, treated with subcutaneous immunotherapy (SCIT) as per clinical practice, were enrolled.",What type of patients were enrolled in the study (pmcid=10362513)?,House dust mite (HDM) mono-sensitized rhinitic patients were enrolled in the study.,2ebb020e2650d49b6ca01a487469c8ea
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,"Multiple in vitro biomarkers such as basophil activation (BAT), IL-10 levels, and molecular allergen-specific IgE were performed during HDM SCIT, to monitor the effects of AIT and then correlated to in vivo scores (VAS, CMSS, RQLQ).",What biomarkers were performed during HDM SCIT in this study (pmcid=10362513)?,"Basophil activation (BAT), IL-10 levels, and molecular allergen-specific IgE were performed during HDM SCIT in this study.",2ebb020e2650d49b6ca01a487469c8ea
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,Nasal cytology was performed at baseline and after 6 and 12 months of treatment.,What was performed at baseline and after 6 and 12 months of treatment in the study by Caruso C? (pmcid=10362513),Nasal cytology was performed at baseline and after 6 and 12 months of treatment in the study by Caruso C.,2ebb020e2650d49b6ca01a487469c8ea
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,"Finally, the economic impact of SCIT in this cohort of patients was evaluated.",What was evaluated in the economic impact analysis of SCIT in this cohort of patients (pmcid=10362513)?,The economic impact of SCIT in this cohort of patients was evaluated.,2ebb020e2650d49b6ca01a487469c8ea
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,RESULTS: Clinical biomarkers confirmed to be useful to monitor AIT efficacy.,What did the clinical biomarkers confirm to be useful to monitor AIT efficacy? (pmcid=10362513),The clinical biomarkers confirmed to be useful to monitor AIT efficacy.,2ebb020e2650d49b6ca01a487469c8ea
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,"As for laboratory biomarkers, BAT showed a reduction trend, particularly for D2C1, suggesting that this is a useful parameter in monitoring patients.","What biomarker showed a reduction trend, particularly for D2C1, in monitoring patients (pmcid=10362513)?",BAT,2ebb020e2650d49b6ca01a487469c8ea
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,IL-10 levels tend to remain stable or slightly decrease during treatment.,What tends to happen to IL-10 levels during treatment according to the study (pmcid=10362513)?,IL-10 levels tend to remain stable or slightly decrease during treatment according to the study with pmcid=10362513.,2ebb020e2650d49b6ca01a487469c8ea
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,The economic analysis confirmed the favorable impact of immunotherapy.,What did the economic analysis confirm regarding the impact of immunotherapy? (pmcid=10362513),The economic analysis confirmed the favorable impact of immunotherapy.,2ebb020e2650d49b6ca01a487469c8ea
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,"CONCLUSIONS: In this cohort of patients, SCIT confirmed its effectiveness in reducing symptoms and drug utilization.",What did the cohort of patients in this study confirm the effectiveness of in reducing symptoms and drug utilization (pmcid=10362513)?,Subcutaneous immunotherapy (SCIT),2ebb020e2650d49b6ca01a487469c8ea
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,Clinical scores confirmed to be valid in monitoring patients and their response.,What was confirmed to be valid in monitoring patients and their response (pmcid=10362513)?,Clinical scores,2ebb020e2650d49b6ca01a487469c8ea
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,BAT demonstrated to be useful in monitoring more than predicting response.,What was demonstrated to be useful in monitoring more than predicting response in the study (pmcid=10362513)?,BAT (basophil activation test),2ebb020e2650d49b6ca01a487469c8ea
10362513,Caruso C,Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis,2023,bim,Further studies are needed to better explore the usefulness of these biomarkers in AIT.,What is needed to better explore the usefulness of biomarkers in AIT? (pmcid=10362513),Further studies are needed.,2ebb020e2650d49b6ca01a487469c8ea
9486155,Duarte RV,Screening trials of spinal cord stimulation for neuropathic pain in England—A budget impact analysis,2022,bim,- Screening trials of spinal cord stimulation (SCS) prior to full implantation of a device are recommended by expert guidelines and international regulators.,What are recommended prior to full implantation of a spinal cord stimulation device (pmcid=9486155)?,Screening trials of spinal cord stimulation (SCS) are recommended prior to full implantation of a device.,a293b42224f128bbedfd22c6d078bf27
9486155,Duarte RV,Screening trials of spinal cord stimulation for neuropathic pain in England—A budget impact analysis,2022,bim,The current study sought to estimate the budget impact of a screening trial of SCS and the costs or savings of discontinuing the use of a screening trial.,What did the current study seek to estimate the budget impact of (pmcid=9486155)?,The current study sought to estimate the budget impact of a screening trial of spinal cord stimulation (SCS) for neuropathic pain in England.,a293b42224f128bbedfd22c6d078bf27
9486155,Duarte RV,Screening trials of spinal cord stimulation for neuropathic pain in England—A budget impact analysis,2022,bim,A budget impact analysis was performed considering a study population that reflects the size and characteristics of a patient population with neuropathic pain in England eligible for SCS.,What population characteristics were considered in the budget impact analysis (pmcid=9486155)?,The budget impact analysis considered a study population that reflects the size and characteristics of a patient population with neuropathic pain in England eligible for spinal cord stimulation (SCS).,a293b42224f128bbedfd22c6d078bf27
9486155,Duarte RV,Screening trials of spinal cord stimulation for neuropathic pain in England—A budget impact analysis,2022,bim,The perspective adopted was that of the NHS with a 5-year time horizon.,What perspective was adopted for the budget impact analysis in England regarding screening trials of spinal cord stimulation for neuropathic pain (pmcid=9486155)?,The perspective adopted for the budget impact analysis in England regarding screening trials of spinal cord stimulation for neuropathic pain (pmcid=9486155) was that of the NHS with a 5-year time horizon.,a293b42224f128bbedfd22c6d078bf27
9486155,Duarte RV,Screening trials of spinal cord stimulation for neuropathic pain in England—A budget impact analysis,2022,bim,"The base case analysis indicate that a no screening trial strategy would result in cost-savings to the NHS England of £400,000-£500,000 per year.",What would be the cost-savings to the NHS England per year with a no screening trial strategy (pmcid=9486155)?,"The cost-savings to the NHS England per year with a no screening trial strategy would be £400,000-£500,000.",a293b42224f128bbedfd22c6d078bf27
9486155,Duarte RV,Screening trials of spinal cord stimulation for neuropathic pain in England—A budget impact analysis,2022,bim,Sensitivity analyses were conducted to evaluate different scenarios.,What type of analyses were conducted to evaluate different scenarios in the study (pmcid=9486155)?,Sensitivity analyses,a293b42224f128bbedfd22c6d078bf27
9486155,Duarte RV,Screening trials of spinal cord stimulation for neuropathic pain in England—A budget impact analysis,2022,bim,"If ≥5% of the eligible neuropathic pain population received a SCS device, cost-savings would be >£2.5 million/year.",What would the cost-savings be if ≥5% of the eligible neuropathic pain population received a SCS device (pmcid=9486155)?,"If ≥5% of the eligible neuropathic pain population received a SCS device, cost-savings would be >£2.5 million/year.",a293b42224f128bbedfd22c6d078bf27
9486155,Duarte RV,Screening trials of spinal cord stimulation for neuropathic pain in England—A budget impact analysis,2022,bim,"In contrast, at the lowest assumed cost of a screening trial (£1,950/patient), a screening trial prior to SCS implantation would be cost-saving.",What is the cost-saving potential of a screening trial prior to SCS implantation at the lowest assumed cost? (pmcid=9486155),"At the lowest assumed cost of a screening trial (£1,950/patient), a screening trial prior to SCS implantation would be cost-saving.",a293b42224f128bbedfd22c6d078bf27
9486155,Duarte RV,Screening trials of spinal cord stimulation for neuropathic pain in England—A budget impact analysis,2022,bim,The proportion of patients having an unsuccessful screening trial would have to be ≥14.4% for current practice of a screening trial to be cost-saving.,What proportion of patients would have to have an unsuccessful screening trial for current practice to be cost-saving? (pmcid=9486155),The proportion of patients would have to be ≥14.4% for current practice of a screening trial to be cost-saving.,a293b42224f128bbedfd22c6d078bf27
9486155,Duarte RV,Screening trials of spinal cord stimulation for neuropathic pain in England—A budget impact analysis,2022,bim,"The findings from this budget impact analysis support the results of a recent UK multicenter randomized controlled trial (TRIAL-STIM) of a policy for the discontinuation of compulsory SCS screening trials, namely that such a policy would result in considerable cost-savings to healthcare systems.",What do the findings from the budget impact analysis support (pmcid=9486155)?,"The findings from the budget impact analysis support the results of a recent UK multicenter randomized controlled trial (TRIAL-STIM) of a policy for the discontinuation of compulsory SCS screening trials, namely that such a policy would result in considerable cost-savings to healthcare systems.",a293b42224f128bbedfd22c6d078bf27
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,- BACKGROUND: Lisdexamfetamine (LDX) and Methylphenidate (MPH) are stimulant agents that have been shown to provide significant benefits in the management of attention-deficit/hyperactivity disorder (ADHD) in patients.,What significant benefits do Lisdexamfetamine (LDX) and Methylphenidate (MPH) provide in the management of attention-deficit/hyperactivity disorder (ADHD) in patients (pmcid=10566195)?,Lisdexamfetamine (LDX) and Methylphenidate (MPH) have been shown to provide significant benefits in the management of attention-deficit/hyperactivity disorder (ADHD) in patients.,a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,AIM: This study aimed to assess the cost-effectiveness and the budget impact of LDX compared to MPH as the first-line treatment for ADHD.,What did this study aim to assess (pmcid=10566195)?,This study aimed to assess the cost-effectiveness and the budget impact of LDX compared to MPH as the first-line treatment for ADHD.,a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,METHODS: A one-year cost-effectiveness analysis (CEA) was conducted to compare the effects of LDX and MPH in reducing disease symptoms and patient costs and improving quality of life (QoL) from a social perspective.,What was the perspective of the cost-effectiveness analysis comparing LDX and MPH for patients under 18 with attention-deficit/hyperactivity disorder in Iran (pmcid=10566195)?,The perspective of the cost-effectiveness analysis comparing LDX and MPH for patients under 18 with attention-deficit/hyperactivity disorder in Iran was from a social perspective.,a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,Clinical data were obtained using the EQ-5D questionnaire.,What questionnaire was used to obtain clinical data in this study (pmcid=10566195)?,The EQ-5D questionnaire was used to obtain clinical data in this study (pmcid=10566195).,a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,"In contrast, economic data were sourced from the official website of the Iranian Food and Drug Association (FDA), the national book of tariffs, and specific questionnaires designed to evaluate patients' direct and indirect costs.",What were the sources of economic data used in the analysis (pmcid=10566195)?,"The sources of economic data used in the analysis were the official website of the Iranian Food and Drug Association (FDA), the national book of tariffs, and specific questionnaires designed to evaluate patients' direct and indirect costs.",a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,"197 patients were included in the study, including individuals who sought psychiatric evaluation at a hospital in Mashhad and those who obtained ADHD medications from governmental pharmacies.",How many patients were included in the study (pmcid=10566195)?,197 patients,a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,"The cost-effectiveness of the study medicine was assessed using the decision tree method, and the results were presented as the Incremental Cost-Effectiveness Ratio (ICER).",What method was used to assess the cost-effectiveness of the study medicine (pmcid=10566195)?,The decision tree method was used to assess the cost-effectiveness of the study medicine in the article with pmcid=10566195.,a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,Deterministic Sensitivity Analysis (DSA) and Probabilistic Sensitivity Analysis (PSA) were performed to assess the robustness of the findings.,What type of sensitivity analyses were performed to assess the robustness of the findings in this study (pmcid=10566195)?,Deterministic Sensitivity Analysis (DSA) and Probabilistic Sensitivity Analysis (PSA),a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,"Additionally, a Budget Impact Analysis (BIA) was conducted over five years, considering three different scenarios, to evaluate the financial implications of incorporating LDX into the national pharmaceutical system.",What scenarios were considered in the Budget Impact Analysis conducted over five years for patients under 18 with attention-deficit/hyperactivity disorder in Iran (pmcid=10566195)?,Three different scenarios were considered in the Budget Impact Analysis conducted over five years for patients under 18 with attention-deficit/hyperactivity disorder in Iran (pmcid=10566195).,a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,"RESULTS: The ICER for LDX therapy compared to MPH was estimated at USD 264.28 (with an incremental cost of USD 54.9, incremental effectiveness of 0.208, and Quality-Adjusted Life Years (QALYs) gained of 0.765).",What was the Incremental Cost-Effectiveness Ratio (ICER) for LDX therapy compared to MPH in the study (pmcid=10566195)?,The ICER for LDX therapy compared to MPH in the study was estimated at USD 264.28.,a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,"The PSA indicated a 0.994% probability of LDX being cost-effective, considering a threshold of USD 2450 per QALY.",What was the probability of LDX being cost-effective according to the PSA analysis (pmcid=10566195)?,The probability of LDX being cost-effective according to the PSA analysis in the study with pmcid=10566195 was 0.994%.,a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,"Furthermore, the DSA revealed that the acquisition cost of LDX influenced the model's sensitivity.",What influenced the model's sensitivity in the cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran (pmcid=10566195)?,The acquisition cost of LDX influenced the model's sensitivity.,a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,"The BIA demonstrated that incorporating LDX into Iran's healthcare system would result in a financial burden of approximately $368,566 in the first year, representing an additional cost of $11,154 compared to the non-availability of this medicine and the use of previous medications.",What would be the financial burden of incorporating LDX into Iran's healthcare system in the first year (pmcid=10566195)?,"The financial burden of incorporating LDX into Iran's healthcare system in the first year would be approximately $368,566, representing an additional cost of $11,154 compared to the non-availability of this medicine and the use of previous medications.",a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,"It is projected that by 2027, the financial burden of treating ADHD with LDX will reach approximately USD 443,879 over five years, amounting to an increase of $71,154 compared to the absence of this medicine.",What is the projected financial burden of treating ADHD with LDX by 2027 (pmcid=10566195)?,"The projected financial burden of treating ADHD with LDX by 2027 is approximately USD 443,879 over five years.",a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,"CONCLUSION: From a social perspective, the inclusion of LDX in the treatment regimen for ADHD is associated with higher costs and an increased financial burden.",What is the conclusion regarding the cost-effectiveness and budget impact of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran (pmcid=10566195)?,"The conclusion is that from a social perspective, the inclusion of Lisdexamfetamine (LDX) in the treatment regimen for ADHD is associated with higher costs and an increased financial burden.",a5dd66472ca6202991393b362a5c6390
10566195,Tajik A,Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran,2023,bim,"However, based on our analysis, LDX appears to be a cost-effective choice for managing ADHD in Iran when compared to MPH.",What appears to be a cost-effective choice for managing ADHD in Iran when compared to MPH (pmcid=10566195)?,LDX (Lisdexamfetamine),a5dd66472ca6202991393b362a5c6390
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,- Aim: The budgetary consequences of increasing dronedarone utilization for treatment of atrial fibrillation were evaluated from a US payer perspective.,What were the budgetary consequences evaluated in this study (pmcid=10402749)?,The budgetary consequences evaluated in this study were the impact of increasing dronedarone utilization for the treatment of atrial fibrillation from a US payer perspective.,2f864a09888237998961d91e2a9f1fa1
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,"Materials & methods: A budget impact model over a 5-year time horizon was developed, including drug-related costs and risks for long-term clinical outcomes (LTCOs).",What time horizon was used in developing the budget impact model (pmcid=10402749)?,The time horizon used in developing the budget impact model in the study with pmcid=10402749 was 5 years.,2f864a09888237998961d91e2a9f1fa1
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,"Treatments included antiarrhythmic drugs (AADs; dronedarone, amiodarone, sotalol, propafenone, dofetilide, flecainide), rate control medications, and ablation.",What treatments were included in the study (pmcid=10402749)?,"The treatments included in the study with pmcid=10402749 were antiarrhythmic drugs (AADs) such as dronedarone, amiodarone, sotalol, propafenone, dofetilide, and flecainide, as well as rate control medications and ablation.",2f864a09888237998961d91e2a9f1fa1
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,Direct comparisons and temporal and non-temporal combination scenarios investigating treatment order were analyzed as costs per patient per month (PPPM).,What was analyzed in terms of costs in this study (pmcid=10402749)?,Costs per patient per month (PPPM) were analyzed in this study.,2f864a09888237998961d91e2a9f1fa1
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,"Results: By projected year 5, costs PPPM for dronedarone versus other AADs decreased by $37.69 due to fewer LTCOs, treatment with dronedarone versus ablation or rate control medications + ablation resulted in cost savings ($359.94 and $370.54, respectively), and AADs placed before ablation decreased PPPM costs by $242 compared with ablation before AADs.",What were the cost savings associated with treatment with dronedarone versus ablation or rate control medications + ablation by projected year 5 (pmcid=10402749)?,"Cost savings associated with treatment with dronedarone versus ablation or rate control medications + ablation by projected year 5 were $359.94 and $370.54, respectively.",2f864a09888237998961d91e2a9f1fa1
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,Conclusion Increased dronedarone utilization demonstrated incremental cost reductions over time.,What did increased dronedarone utilization demonstrate over time (pmcid=10402749)?,Increased dronedarone utilization demonstrated incremental cost reductions over time.,2f864a09888237998961d91e2a9f1fa1
11653659,Alshahrani A,Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective,2024,bim,- OBJECTIVES: To perform a budget impact analysis (BIA) of the adoption of baricitinib for the management of alopecia areata (AA) by a Saudi public sector payer.,What is the objective of the budget impact analysis in this study (pmcid=11653659)?,The objective of the budget impact analysis in this study is to assess the adoption of baricitinib for the management of alopecia areata by a Saudi public sector payer.,f7df2866579b2aa78b6f8b49b0df2a0d
11653659,Alshahrani A,Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective,2024,bim,"METHODS: A BIA model was developed to calculate the expected financial impact under two scenarios: the baseline scenario, which reflects the current mix of treatments without baricitinib, and the projected scenario, in which baricitinib is adopted.",What scenarios were compared in the budget impact analysis model (pmcid=11653659)?,"The two scenarios compared in the budget impact analysis model were the baseline scenario, reflecting the current mix of treatments without baricitinib, and the projected scenario, in which baricitinib is adopted.",f7df2866579b2aa78b6f8b49b0df2a0d
11653659,Alshahrani A,Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective,2024,bim,The model assumed that patients with severe AA and those with mild-to-moderate AA who did not respond to other treatments were eligible for baricitinib treatment.,What type of patients were assumed to be eligible for baricitinib treatment in the budget impact analysis (pmcid=11653659)?,Patients with severe alopecia areata and those with mild-to-moderate alopecia areata who did not respond to other treatments were assumed to be eligible for baricitinib treatment in the budget impact analysis.,f7df2866579b2aa78b6f8b49b0df2a0d
11653659,Alshahrani A,Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective,2024,bim,"The model input was based on published evidence, expert opinions, and the Saudi Expert Consensus Statement on the Diagnosis and Management of AA.",What was the basis for the model input in the budget impact analysis of baricitinib for treatment of alopecia areata (pmcid=11653659)?,"The basis for the model input in the budget impact analysis of baricitinib for treatment of alopecia areata (pmcid=11653659) was published evidence, expert opinions, and the Saudi Expert Consensus Statement on the Diagnosis and Management of AA.",f7df2866579b2aa78b6f8b49b0df2a0d
11653659,Alshahrani A,Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective,2024,bim,RESULTS: Assuming a hypothetical total eligible population of 368 patients received different AA treatments over the 12-months study period.,What was the hypothetical total eligible population assumed in the study (pmcid=11653659)?,368 patients,f7df2866579b2aa78b6f8b49b0df2a0d
11653659,Alshahrani A,Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective,2024,bim,"The aggregated 5-years cost in the baseline scenario was SR 5,836,616.",What was the aggregated 5-years cost in the baseline scenario (pmcid=11653659)?,"SR 5,836,616",f7df2866579b2aa78b6f8b49b0df2a0d
11653659,Alshahrani A,Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective,2024,bim,"Upon the introduction of baricitinib as an alternative treatment for severe AA, the projected aggregated budget impact was SR 7,473,138.",What was the projected aggregated budget impact upon the introduction of baricitinib as an alternative treatment for severe AA (pmcid=11653659)?,"The projected aggregated budget impact upon the introduction of baricitinib as an alternative treatment for severe AA was SR 7,473,138.",f7df2866579b2aa78b6f8b49b0df2a0d
11653659,Alshahrani A,Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective,2024,bim,"Sensitivity analysis showed that the results were most sensitive to AA prevalence, percentage of severe AA, and predicted market share for baricitinib over the 5-year time horizon.",What were the results of the sensitivity analysis most sensitive to (pmcid=11653659)?,"The results of the sensitivity analysis were most sensitive to AA prevalence, percentage of severe AA, and predicted market share for baricitinib over the 5-year time horizon.",f7df2866579b2aa78b6f8b49b0df2a0d
11653659,Alshahrani A,Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective,2024,bim,CONCLUSION: The addition of baricitinib to formularies is likely to increase the cost impact from a government hospital perspective.,What is the likely cost impact of adding baricitinib to formularies from a government hospital perspective (pmcid=11653659)?,The likely cost impact of adding baricitinib to formularies from a government hospital perspective is an increase in cost.,f7df2866579b2aa78b6f8b49b0df2a0d
11653659,Alshahrani A,Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective,2024,bim,"However, this addition expands the treatment options for patients with AA and may result in improved outcomes.","What potential benefit does the addition of baricitinib provide for patients with alopecia areata, according to the abstract sentence provided? (pmcid=11653659)","The addition of baricitinib provides the potential benefit of expanding treatment options for patients with alopecia areata, which may result in improved outcomes.",f7df2866579b2aa78b6f8b49b0df2a0d
11653659,Alshahrani A,Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective,2024,bim,Future cost-effectiveness analyses are recommended to estimate the cost per incremental improvement in the outcomes.,What is recommended for future cost-effectiveness analyses in the study on baricitinib for treatment of alopecia areata (pmcid=11653659)?,Future cost-effectiveness analyses are recommended to estimate the cost per incremental improvement in the outcomes.,f7df2866579b2aa78b6f8b49b0df2a0d
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,"- PURPOSE: When traditional therapies fail to provide relief from debilitating lower back pain, surgeries such as transforaminal lumbar interbody fusion (TLIF) may be required.",What surgery may be required when traditional therapies fail to provide relief from debilitating lower back pain (pmcid=10802124)?,Transforaminal lumbar interbody fusion (TLIF),3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,This budget impact analysis (BIA) compared minimally-invasive (MI)-TLIF versus open (O)-TLIF for single-level fusion from an Italian hospital perspective.,What did the budget impact analysis compare for single-level fusion from an Italian hospital perspective (pmcid=10802124)?,The budget impact analysis compared minimally-invasive (MI)-TLIF versus open (O)-TLIF for single-level fusion from an Italian hospital perspective.,3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,METHODS: The BIA compared costs of 100 MI-TLIF and 100 O-TLIF procedures from an Italian hospital perspective over a one-year time horizon.,What costs were compared in the Budget Impact Analysis (pmcid=10802124)?,The costs compared in the Budget Impact Analysis (pmcid=10802124) were those of 100 Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI-TLIF) procedures and 100 Open Transforaminal Lumbar Interbody Fusion (O-TLIF) procedures from an Italian hospital perspective over a one-year time horizon.,3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,"The base case included costs for length of hospital stay (LOS), blood loss, and sterilizing surgical trays.",What costs were included in the base case analysis (pmcid=10802124)?,"Costs for length of hospital stay (LOS), blood loss, and sterilizing surgical trays.",3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,The scenario analysis also included operating room (OR) time and complication costs.,What did the scenario analysis for the Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion include (pmcid=10802124)?,The scenario analysis for the Budget Impact Analysis included operating room (OR) time and complication costs.,3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,Base case inputs were from the Miller et al meta-analysis; scenario analysis inputs were from the Hammad et al meta-analysis.,What were the base case inputs for the budget impact analysis (pmcid=10802124)?,The base case inputs for the budget impact analysis in the study with pmcid=10802124 were from the Miller et al meta-analysis.,3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,"The device costs for MI-TLIF and O-TLIF procedures were from Italian tender prices for Viper Prime™ System and Expedium™ Spine System, respectively.",What were the device costs used for the MI-TLIF and O-TLIF procedures in the study (pmcid=10802124)?,"The device costs used for the MI-TLIF and O-TLIF procedures in the study were from Italian tender prices for the Viper Prime™ System and Expedium™ Spine System, respectively.",3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,"RESULTS: Base case deterministic analysis results showed cost savings of €207,370 for MI-TLIF compared with O-TLIF.",What were the cost savings of MI-TLIF compared with O-TLIF in the base case deterministic analysis (pmcid=10802124)?,"The cost savings of MI-TLIF compared with O-TLIF in the base case deterministic analysis were €207,370.",3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,"MI-TLIF costs were lower for LOS (€215,277), transfusion for blood loss (€16,881), and surgical tray sterilization (€28,232), whereas device costs were lower for O-TLIF (€53,020).",What were the costs compared between Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI-TLIF) and Open Transforaminal Lumbar Interbody Fusion (O-TLIF) for various components (pmcid=10802124)?,"The costs compared between Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI-TLIF) and Open Transforaminal Lumbar Interbody Fusion (O-TLIF) were as follows:
- MI-TLIF costs were lower for Length of Stay (LOS) at €215,277
- MI-TLIF costs were lower for transfusion for blood loss at €16,881
- MI-TLIF costs were lower for surgical tray sterilization at €28,232
- Device costs were lower for O-TLIF at €53,020",3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,"The probabilistic result was similar, with MI-TLIF resulting in savings of €211,026 (95% credible interval [CR]: €208,725 - €213,327).",What were the savings associated with MI-TLIF compared to open surgery for lumbar degenerative disease from a European hospital perspective (pmcid=10802124)?,"The savings associated with MI-TLIF compared to open surgery for lumbar degenerative disease from a European hospital perspective were €211,026 (95% credible interval: €208,725 - €213,327).",3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,All 1000 base case probabilistic sensitivity analysis runs were cost saving.,What were the results of all 1000 base case probabilistic sensitivity analysis runs (pmcid=10802124)?,All 1000 base case probabilistic sensitivity analysis runs were cost saving.,3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,"Deterministic scenario analysis results showed cost savings of €166,719 for MI-TLIF.",What were the cost savings for MI-TLIF according to the deterministic scenario analysis results (pmcid=10802124)?,"The cost savings for MI-TLIF according to the deterministic scenario analysis results were €166,719.",3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,"MI-TLIF costs were lower for LOS (€190,813), transfusion for blood loss (€16,881), surgical tray sterilization (€28,232), and complications (€2076), whereas O-TLIF costs were lower for OR time (€18,263) and devices used (€53,020).",What were the costs compared between MI-TLIF and O-TLIF for various factors (pmcid=10802124)?,"The costs compared between MI-TLIF and O-TLIF for various factors were as follows:
- MI-TLIF costs were lower for LOS (€190,813), transfusion for blood loss (€16,881), surgical tray sterilization (€28,232), and complications (€2076).
- O-TLIF costs were lower for OR time (€18,263) and devices used (€53,020).",3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,"CONCLUSION: Despite the increase incremental cost for medical device innovation and OR time, this study demonstrates the economic savings of MI-TLIF compared to O-TLIF from a European hospital perspective.",What does this study demonstrate in terms of economic savings from a European hospital perspective (pmcid=10802124)?,This study demonstrates the economic savings of Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI-TLIF) compared to Open Transforaminal Lumbar Interbody Fusion (O-TLIF) from a European hospital perspective.,3f6ada9505d0e500e0ab21b87d0e15f1
10802124,Bassani R,Budget Impact Analysis of Minimally Invasive versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A European Hospital Perspective,2024,bim,"The findings will be useful to policy and hospital decision makers in assessing purchasing, funding and reimbursement decisions.","What will the findings be useful for, according to the abstract sentence provided (pmcid=10802124)?","The findings will be useful for policy and hospital decision makers in assessing purchasing, funding, and reimbursement decisions.",3f6ada9505d0e500e0ab21b87d0e15f1
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,- BACKGROUND: Multiple myeloma is an incurable haematological malignancy that is associated with a high probability of relapse.,What is the background information provided in the abstract (pmcid=9746097)?,Multiple myeloma is an incurable haematological malignancy that is associated with a high probability of relapse.,c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,The survival of relapsed patients has been greatly improved by the development of novel drugs such as lenalidomide and bortezomib.,What drugs have greatly improved the survival of relapsed patients according to the abstract sentence (pmcid=9746097)?,lenalidomide and bortezomib,c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,We assessed the cost-effectiveness of these drugs as second-line treatment for relapsed/refractory multiple myeloma (RRMM) patients in the South African public health care system.,What did the study assess in the South African public health care system (pmcid=9746097)?,The study assessed the cost-effectiveness of dexamethasone compared with bortezomib and lenalidomide as second-line treatment for relapsed/refractory multiple myeloma patients in the South African public health care system.,c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,"METHODS: We modelled 3 treatment strategies for second-line RRMM treatment: dexamethasone (standard of care), bortezomib (BORT) and lenalidomide plus dexamethasone (LEN/DEX) from the South African public health perspective.",What treatment strategies were modelled for second-line RRMM treatment in the study (pmcid=9746097)?,"The treatment strategies modelled for second-line RRMM treatment in the study (pmcid=9746097) were dexamethasone (standard of care), bortezomib (BORT), and lenalidomide plus dexamethasone (LEN/DEX).",c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,For each strategy we modelled a hypothetical cohort of relapsed/refractory multiple myeloma patients using a three-state Markov model over a 15-year time horizon.,What type of model was used to simulate the cohort of relapsed/refractory multiple myeloma patients in this study (pmcid=9746097)?,A three-state Markov model was used to simulate the cohort of relapsed/refractory multiple myeloma patients in this study (pmcid=9746097).,c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,Efficacy and utilization data were obtained from the MM009/010 and APEX trials and external studies.,What trials were utilized to obtain efficacy and utilization data for the analysis (pmcid=9746097)?,The MM009/010 and APEX trials were utilized to obtain efficacy and utilization data for the analysis in the study with pmcid 9746097.,c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,Price and cost data were from local sources and presented in 2021 South African Rands.,What currency were the price and cost data presented in for this study (pmcid=9746097)?,The price and cost data were presented in 2021 South African Rands.,c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,Outcomes were reported in quality adjusted life years (QALYs).,What outcomes were reported in quality adjusted life years in the study conducted by Matsela LM (pmcid=9746097)?,Outcomes were reported in quality adjusted life years (QALYs).,c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,Incremental cost effectiveness ratios (ICERs) were calculated for BORT and LEN/DEX and compared to a local cost-effectiveness threshold of R38 500 per DALY averted using the assumption that 1 DALY averted is equal to 1 QALY gained.,What cost-effectiveness threshold was used for the analysis (pmcid=9746097)?,"The cost-effectiveness threshold used for the analysis in pmcid 9746097 was R38,500 per DALY averted.",c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,"A budget impact analysis was conducted to evaluate the financial impact of the introduction of BORT and LEN/DEX, respectively.",What was the purpose of the budget impact analysis conducted in the study (pmcid=9746097)?,The purpose of the budget impact analysis conducted in the study was to evaluate the financial impact of the introduction of bortezomib and lenalidomide with dexamethasone for the treatment of second line multiple myeloma from a South African public health perspective.,c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,Deterministic sensitivity analysis was undertaken to account for parameter uncertainties.,What type of analysis was undertaken to account for parameter uncertainties in the study (pmcid=9746097)?,Deterministic sensitivity analysis,c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,"RESULTS: The modelled total costs of DEX, BORT and LEN/DEX were estimated to be R8 312, R234 996 and R1 135 323, respectively.","What were the estimated total costs of DEX, BORT, and LEN/DEX in the study (pmcid=9746097)?","The estimated total costs of DEX, BORT, and LEN/DEX in the study were R8,312, R234,996, and R1,135,323, respectively.",c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,"DEX treatment provided 1.14 QALYs while BORT and LEN/DEX treatments provided 1.49 and 2.22 QALYs, respectively.",What is the quality-adjusted life year (QALY) provided by DEX treatment compared to BORT and LEN/DEX treatments (pmcid=9746097)?,"The quality-adjusted life year (QALY) provided by DEX treatment is 1.14, while BORT treatment provided 1.49 QALYs and LEN/DEX treatment provided 2.22 QALYs.",c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,The ICER of BORT versus DEX was R654 649 and that of LEN/DEX versus BORT was R1 225 542.,"What were the incremental cost-effectiveness ratios (ICER) compared between BORT and DEX, and between LEN/DEX and BORT (pmcid=9746097)?","The incremental cost-effectiveness ratio (ICER) compared between BORT and DEX was R654,649, and the ICER between LEN/DEX and BORT was R1,225,542.",c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,Both BORT and LEN/DEX treatments were not cost-effective relative to a cost-effectiveness threshold of R38 500 per DALY averted.,What cost-effectiveness threshold was used in the analysis (pmcid=9746097)?,R38 500 per DALY averted,c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,Both BORT and LEN/DEX significantly increase the 1 year budget-cost of RRMM treatment.,What is the impact of both BORT and LEN/DEX on the 1 year budget-cost of RRMM treatment (pmcid=9746097)?,Both BORT and LEN/DEX significantly increase the 1 year budget-cost of RRMM treatment.,c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,CONCLUSION: Both BORT and LEN/DEX treatments are unlikely to be cost-effective strategies for second-line treatment of RRMM in South Africa.,What is the conclusion regarding the cost-effectiveness of BORT and LEN/DEX treatments for second-line treatment of RRMM in South Africa (pmcid=9746097)?,Both BORT and LEN/DEX treatments are unlikely to be cost-effective strategies for second-line treatment of RRMM in South Africa.,c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,The results indicate that the drug prices of lenalidomide and bortezomib are key drivers of value for money.,What are the key drivers of value for money in the treatment of second line multiple myeloma from a South African public health perspective (pmcid=9746097)?,"The key drivers of value for money in the treatment of second line multiple myeloma from a South African public health perspective, as indicated in the study with pmcid=9746097, are the drug prices of lenalidomide and bortezomib.",c07ac53c1a27aedeedae2687ed29305e
9746097,Matsela LM,Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective,2022,bim,Price reductions could potentially make BORT more cost-effective.,What could potentially make BORT more cost-effective? (pmcid=9746097),Price reductions,c07ac53c1a27aedeedae2687ed29305e
11271297,Gunasekara AD,Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka,2024,bim,- This study aimed to assess the cost-utility and budget impact of dual to single HER2 targeted neoadjuvant therapy for HER2-positive breast cancer in Sri Lanka.,What did the study aim to assess (pmcid=11271297)?,The study aimed to assess the cost-utility and budget impact of dual to single HER2 targeted neoadjuvant therapy for HER2-positive breast cancer in Sri Lanka.,c3a13a3243a691d6a01198bfdf5025d7
11271297,Gunasekara AD,Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka,2024,bim,"A five-health state Markov model with lifetime horizon was used to assess the cost-utility of neoadjuvant trastuzumab (T) plus pertuzumab (P) or lapatinib (L) compared to single therapy of T with chemotherapy (C), in public healthcare system and societal perspectives.",What model was used to assess the cost-utility of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka (pmcid=11271297)?,A five-health state Markov model with a lifetime horizon was used.,c3a13a3243a691d6a01198bfdf5025d7
11271297,Gunasekara AD,Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka,2024,bim,"Input parameters were estimated using local data, network meta-analysis, published reports and literature.",What were the input parameters estimated using for the analysis (pmcid=11271297)?,"Local data, network meta-analysis, published reports, and literature.",c3a13a3243a691d6a01198bfdf5025d7
11271297,Gunasekara AD,Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka,2024,bim,Costs were adjusted to year 2021 (1USD = LKR194.78).,What was the currency exchange rate used to adjust costs in the study (pmcid=11271297)?,1USD = LKR194.78,c3a13a3243a691d6a01198bfdf5025d7
11271297,Gunasekara AD,Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka,2024,bim,Five-year budget impact for public healthcare system was assessed.,What was assessed in terms of the five-year budget impact for the public healthcare system (pmcid=11271297)?,The five-year budget impact for the public healthcare system was assessed in terms of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka.,c3a13a3243a691d6a01198bfdf5025d7
11271297,Gunasekara AD,Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka,2024,bim,"Incremental cost-effectiveness ratios in societal perspective for neoadjuvantLTC plus adjuvantT (strategy 3), neoadjuvantPTC plus adjuvantT (strategy 2), neoadjuvantLTC plus adjuvantLT (strategy 5), and neoadjuvantPTC plus adjuvantPT (strategy 4) compared to neoadjuvantTC plus adjuvantT (strategy 1) were USD2716, USD5600, USD6878, and USD12127 per QALY gained, respectively.",What were the incremental cost-effectiveness ratios for neoadjuvantLTC plus adjuvantLT (strategy 5) compared to neoadjuvantTC plus adjuvantT (strategy 1) (pmcid=11271297)?,The incremental cost-effectiveness ratio for neoadjuvantLTC plus adjuvantLT (strategy 5) compared to neoadjuvantTC plus adjuvantT (strategy 1) was USD6878 per QALY gained.,c3a13a3243a691d6a01198bfdf5025d7
11271297,Gunasekara AD,Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka,2024,bim,One GDP per-capita (USD3815) was considered as the cost-effectiveness threshold for the analysis.,What was considered as the cost-effectiveness threshold for the analysis (pmcid=11271297)?,One GDP per-capita (USD3815),c3a13a3243a691d6a01198bfdf5025d7
11271297,Gunasekara AD,Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka,2024,bim,"Even though only the ICER for strategy 3 was cost-effective, uncertainty of efficacy parameter was revealed.",What was the uncertainty revealed regarding the efficacy parameter in the study (pmcid=11271297)?,"The uncertainty revealed regarding the efficacy parameter in the study (pmcid=11271297) was that even though only the ICER for strategy 3 was cost-effective, there was uncertainty about the efficacy parameter.",c3a13a3243a691d6a01198bfdf5025d7
11271297,Gunasekara AD,Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka,2024,bim,"For strategy 2 neoadjuvant PTC plus adjuvant T, a 25% reduction of neoadjuvant regimen cost was required to be cost effective for use in early HER2 positive breast cancer.",What reduction of neoadjuvant regimen cost was required for strategy 2 to be cost effective for use in early HER2 positive breast cancer (pmcid=11271297)?,A 25% reduction of neoadjuvant regimen cost was required for strategy 2 to be cost effective for use in early HER2 positive breast cancer.,c3a13a3243a691d6a01198bfdf5025d7
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,- INTRODUCTION: The decision-making process for incorporating technologies for ultrarare diseases (URD) has been a challenge for health technology assessment agencies worldwide.,What has been a challenge for health technology assessment agencies worldwide in the decision-making process for incorporating technologies for ultrarare diseases (URD) (pmcid=11718712)?,The decision-making process for incorporating technologies for ultrarare diseases (URD) has been a challenge for health technology assessment agencies worldwide.,807ff3269b2d2007bc39732c6d3d8162
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,These challenges have been presented in debates about the budget impact of incorporating technologies for URD.,What have debates focused on regarding the budget impact of incorporating technologies for ultrarare diseases (pmcid=11718712)?,Debates have focused on the challenges of incorporating technologies for ultrarare diseases in the budget impact analysis.,807ff3269b2d2007bc39732c6d3d8162
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,This is an important issue because there are other dimensions of the economic and social impact of URD that require consideration.,What are the other dimensions of the economic and social impact of Ultrarare Diseases that require consideration? (pmcid=11718712),The other dimensions of the economic and social impact of Ultrarare Diseases that require consideration include budget impact analysis and the challenge of incorporating medications for these diseases in the Brazilian healthcare system.,807ff3269b2d2007bc39732c6d3d8162
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,METHODS: Data were extracted from National Committee for Health Technology Incorporation (CONITEC) reports (2012 to 2022) on technologies for the treatment of URD in Brazil.,What reports were data extracted from for the analysis of technologies for the treatment of ultrarare diseases in Brazil (pmcid=11718712)?,Data were extracted from National Committee for Health Technology Incorporation (CONITEC) reports (2012 to 2022) for the analysis of technologies for the treatment of ultrarare diseases in Brazil.,807ff3269b2d2007bc39732c6d3d8162
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,"Diseases were classified using an epidemiological criterion or Orphanet consultation (prevalence ≤1 per 50,000 inhabitants).",What criterion was used to classify diseases in the study (pmcid=11718712)?,"The criterion used to classify diseases in the study (pmcid=11718712) was an epidemiological criterion or Orphanet consultation, with a prevalence of ≤1 per 50,000 inhabitants.",807ff3269b2d2007bc39732c6d3d8162
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,"Variables included eligible patient count, population estimation method, incremental impact values for one and five years, and diffusion rate in the first and fifth year.",What variables were included in the budget impact analysis for medications for ultrarare diseases in the Brazilian healthcare system (pmcid=11718712)?,"The variables included in the budget impact analysis for medications for ultrarare diseases in the Brazilian healthcare system (pmcid=11718712) were eligible patient count, population estimation method, incremental impact values for one and five years, and diffusion rate in the first and fifth year.",807ff3269b2d2007bc39732c6d3d8162
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,"Univariate logistic regression was used to adjust the relationship between the budget impact analysis and the final recommendation, considering factors associated with incorporation in univariate regression and p-values less than 0.10 in a multivariate regression.",What type of regression analysis was used to adjust the relationship between the budget impact analysis and the final recommendation in this study (pmcid=11718712)?,Univariate logistic regression,807ff3269b2d2007bc39732c6d3d8162
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,"RESULTS: Among 53 reports, 48 percent exclusively employed the epidemiological approach for incremental impact assessment population estimation, rising to 69.5 percent when combined with measured demand.",What percentage of reports exclusively employed the epidemiological approach for incremental impact assessment population estimation in the study conducted by Santos M (pmcid: 11718712)?,48 percent,807ff3269b2d2007bc39732c6d3d8162
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,"Population data were nearly evenly sourced from national and international platforms, with the UK, the USA, and multicenter studies being the most cited internationally.",What were the most cited sources for population data in the study (pmcid=11718712)?,"The most cited sources for population data in the study were the UK, the USA, and multicenter studies.",807ff3269b2d2007bc39732c6d3d8162
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,"Notable differences were found between favorable and unfavorable CONITEC recommendations, with lower values being associated with incorporation.","What were the notable differences found between favorable and unfavorable CONITEC recommendations, and what were they associated with (pmcid=11718712)?","The notable differences found between favorable and unfavorable CONITEC recommendations were lower values, and they were associated with incorporation.",807ff3269b2d2007bc39732c6d3d8162
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,Market share diffusion rates favored the option of 100 percent diffusion in both the first year and the cumulative five years.,What did the market share diffusion rates favor in both the first year and the cumulative five years (pmcid=11718712)?,The market share diffusion rates favored the option of 100 percent diffusion in both the first year and the cumulative five years.,807ff3269b2d2007bc39732c6d3d8162
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,The analysis highlighted the influence of demand characteristics and technology type on the budget impact value over one and five years.,What did the analysis highlight in terms of the influence of demand characteristics and technology type on the budget impact value over one and five years (pmcid=11718712)?,The analysis highlighted that demand characteristics and technology type have an influence on the budget impact value over one and five years.,807ff3269b2d2007bc39732c6d3d8162
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,"CONCLUSIONS: The study found that budget impact data significantly influenced the final recommendation for technology incorporation, indicating a criterion favoring technologies with a lower budget impact.",What significantly influenced the final recommendation for technology incorporation in the study (pmcid=11718712)?,Budget impact data,807ff3269b2d2007bc39732c6d3d8162
11718712,Santos M,PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System,2025,bim,"However, requester characteristics and technology type also played a role in the decision-making process, suggesting that additional factors influence recommendations.",What factors influenced recommendations in the decision-making process (pmcid=11718712)?,Requester characteristics and technology type,807ff3269b2d2007bc39732c6d3d8162
9636776,Yoo HK,Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries,2022,bim,"- BACKGROUND: In 2020, the European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease.",What did the European Medicines Agency approve in 2020 for the treatment of inflammatory bowel disease (pmcid=9636776)?,The European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease in 2020.,680dcd8f7c7cbb807bf92422aba0a155
9636776,Yoo HK,Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries,2022,bim,This new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration.,What will the new mode of infliximab administration reduce according to the abstract sentence (pmcid=9636776)?,The new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration.,680dcd8f7c7cbb807bf92422aba0a155
9636776,Yoo HK,Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries,2022,bim,"This article describes a budget impact analysis of introducing infliximab SC to the Big-5 European (E5) market (Germany, France, Italy, Spain and UK) for 5 years, from the healthcare payer's perspective.",What perspective was considered in the budget impact analysis of introducing infliximab SC to the Big-5 European market (pmcid=9636776)?,The budget impact analysis considered the healthcare payer's perspective.,680dcd8f7c7cbb807bf92422aba0a155
9636776,Yoo HK,Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries,2022,bim,METHODS: A prevalence-based budget impact model was developed to examine the financial impact of infliximab SC.,What type of budget impact model was developed to examine the financial impact of infliximab SC (pmcid=9636776)?,A prevalence-based budget impact model was developed.,680dcd8f7c7cbb807bf92422aba0a155
9636776,Yoo HK,Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries,2022,bim,"""World with"" versus ""world without"" infliximab SC scenarios were compared, including the potential administration costs of IV administration.",What scenarios were compared in the budget impact analysis of subcutaneous infliximab for treating inflammatory bowel disease in the Big-5 European countries (pmcid=9636776)?,"The ""world with"" versus ""world without"" infliximab SC scenarios were compared in the budget impact analysis of subcutaneous infliximab for treating inflammatory bowel disease in the Big-5 European countries.",680dcd8f7c7cbb807bf92422aba0a155
9636776,Yoo HK,Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries,2022,bim,"RESULTS: Introducing infliximab SC in patients with Crohn's disease (CD) for 5 years resulted in cost savings of €42.0 million in the UK, €59.4 million in Germany, and €46.4 million in France and Italy, but increased budget expenditure in Spain by €3.8 million.","What were the cost savings associated with introducing infliximab SC in patients with Crohn's disease in the UK, Germany, France, and Italy (pmcid=9636776)?","Introducing infliximab SC in patients with Crohn's disease in the UK resulted in cost savings of €42.0 million, in Germany €59.4 million, in France and Italy €46.4 million each.",680dcd8f7c7cbb807bf92422aba0a155
9636776,Yoo HK,Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries,2022,bim,"For ulcerative colitis (UC), cost savings of €42.7 million in the UK, €44.9 million in Germany, €44.3 million in France, and €53.0 million in Italy occurred, but with no savings in Spain for 5 years.",What cost savings were observed for ulcerative colitis in the Big-5 European countries over 5 years? (pmcid=9636776),"Cost savings of €42.7 million in the UK, €44.9 million in Germany, €44.3 million in France, and €53.0 million in Italy were observed for ulcerative colitis in the Big-5 European countries over 5 years.",680dcd8f7c7cbb807bf92422aba0a155
9636776,Yoo HK,Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries,2022,bim,Cost-savings per patient was calculated by diving the net budget saving by number of treatment eligible patients.,What was calculated to determine cost-savings per patient in the study (pmcid=9636776)?,Cost-savings per patient was calculated by dividing the net budget saving by the number of treatment eligible patients.,680dcd8f7c7cbb807bf92422aba0a155
9636776,Yoo HK,Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries,2022,bim,"Maximum and minimum saving per patient per year ranged between €38.25 and €575.74 in CD, both from Germany, and €105.06 (France) and €647.25 (Germany) in UC.",What is the range of maximum and minimum savings per patient per year in CD and UC in the Big-5 European countries (pmcid=9636776)?,"For CD, the range of maximum and minimum savings per patient per year is between €38.25 and €575.74, both from Germany. For UC, the range is between €105.06 (France) and €647.25 (Germany).",680dcd8f7c7cbb807bf92422aba0a155
9636776,Yoo HK,Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries,2022,bim,"CONCLUSION: Healthcare payers in the UK, Germany, France, and Italy, but not in Spain, will make budget savings by using infliximab SC for the treatment of inflammatory bowel disease.","What will healthcare payers in the UK, Germany, France, and Italy, but not in Spain, make by using infliximab SC for the treatment of inflammatory bowel disease (pmcid=9636776)?","Healthcare payers in the UK, Germany, France, and Italy will make budget savings by using infliximab SC for the treatment of inflammatory bowel disease.",680dcd8f7c7cbb807bf92422aba0a155
11574529,van Well EB,The value of reducing arthroscopic partial meniscectomy in the treatment of degenerative meniscus tears: a budget impact analysis,2023,bim,- AIMS: Numerous studies have shown that arthroscopic partial meniscectomy (APM) is not (cost-) effective in patients with symptoms attributed to a degenerative meniscus tear.,What have numerous studies shown about the cost-effectiveness of arthroscopic partial meniscectomy in patients with symptoms attributed to a degenerative meniscus tear? (pmcid=11574529),Numerous studies have shown that arthroscopic partial meniscectomy (APM) is not cost-effective in patients with symptoms attributed to a degenerative meniscus tear.,34f264732511414656fdb2c2ebba4f8f
11574529,van Well EB,The value of reducing arthroscopic partial meniscectomy in the treatment of degenerative meniscus tears: a budget impact analysis,2023,bim,We aimed to assess the budget impact of reducing APM in routine clinical practice in this population.,What was the aim of the study conducted by van Well EB (pmcid=11574529)?,The aim of the study conducted by van Well EB was to assess the budget impact of reducing arthroscopic partial meniscectomy (APM) in routine clinical practice in the population studied.,34f264732511414656fdb2c2ebba4f8f
11574529,van Well EB,The value of reducing arthroscopic partial meniscectomy in the treatment of degenerative meniscus tears: a budget impact analysis,2023,bim,MATERIALS AND METHODS: A patient-level state transition model was developed to simulate patients recently diagnosed with a degenerative meniscus tear.,What type of model was developed to simulate patients recently diagnosed with a degenerative meniscus tear (pmcid=11574529)?,A patient-level state transition model was developed.,34f264732511414656fdb2c2ebba4f8f
11574529,van Well EB,The value of reducing arthroscopic partial meniscectomy in the treatment of degenerative meniscus tears: a budget impact analysis,2023,bim,"Three strategies were compared: ""current guideline"" (i.e., postpone surgery to at least 3 months after diagnosis), ""APM at any time"" (i.e., APM available directly after diagnosis), and ""nonsurgical"" (i.e., APM no longer performed).",What strategies were compared in the study (pmcid=11574529)?,"Three strategies were compared: ""current guideline"" (i.e., postpone surgery to at least 3 months after diagnosis), ""APM at any time"" (i.e., APM available directly after diagnosis), and ""nonsurgical"" (i.e., APM no longer performed).",34f264732511414656fdb2c2ebba4f8f
11574529,van Well EB,The value of reducing arthroscopic partial meniscectomy in the treatment of degenerative meniscus tears: a budget impact analysis,2023,bim,Total societal costs over 5 years were calculated to determine the budget impact.,What was calculated to determine the budget impact over 5 years (pmcid=11574529)?,Total societal costs,34f264732511414656fdb2c2ebba4f8f
11574529,van Well EB,The value of reducing arthroscopic partial meniscectomy in the treatment of degenerative meniscus tears: a budget impact analysis,2023,bim,Probabilistic and deterministic sensitivity analyses were conducted to address uncertainty.,What type of sensitivity analyses were conducted to address uncertainty in the study (pmcid=11574529)?,Probabilistic and deterministic sensitivity analyses were conducted.,34f264732511414656fdb2c2ebba4f8f
11574529,van Well EB,The value of reducing arthroscopic partial meniscectomy in the treatment of degenerative meniscus tears: a budget impact analysis,2023,bim,"RESULTS: The average cost per patient over 5 years were EUR 5,077, EUR 4,577, and EUR 4,218, for the ""APM at any time,"" ""current guideline,"" and ""nonsurgical"" strategy, respectively.","What were the average costs per patient over 5 years for the ""APM at any time,"" ""current guideline,"" and ""nonsurgical"" strategies? (pmcid=11574529)","The average costs per patient over 5 years were EUR 5,077 for the ""APM at any time"" strategy, EUR 4,577 for the ""current guideline"" strategy, and EUR 4,218 for the ""nonsurgical"" strategy.",34f264732511414656fdb2c2ebba4f8f
11574529,van Well EB,The value of reducing arthroscopic partial meniscectomy in the treatment of degenerative meniscus tears: a budget impact analysis,2023,bim,"Removing APM from the treatment mix (i.e., 30,000 patients per year) in the Netherlands, resulted in a reduction in health care expenditures of EUR 54 million (95 percent confidence interval [CI] EUR 38 million-EUR 70 million) compared to the ""current guideline strategy"" and EUR 129 million (95 percent CI EUR 102 million-EUR 156 million) compared to the ""APM at any time"" strategy.",What was the reduction in health care expenditures by removing APM from the treatment mix in the Netherlands (pmcid=11574529)?,"The reduction in health care expenditures by removing APM from the treatment mix in the Netherlands was EUR 54 million (95 percent confidence interval [CI] EUR 38 million-EUR 70 million) compared to the ""current guideline strategy"" and EUR 129 million (95 percent CI EUR 102 million-EUR 156 million) compared to the ""APM at any time"" strategy.",34f264732511414656fdb2c2ebba4f8f
11574529,van Well EB,The value of reducing arthroscopic partial meniscectomy in the treatment of degenerative meniscus tears: a budget impact analysis,2023,bim,Sensitivity analyses showed that uncertainty did not alter our conclusions.,What did the sensitivity analyses show in relation to the conclusions of the study (pmcid=11574529)?,The sensitivity analyses showed that uncertainty did not alter the conclusions of the study.,34f264732511414656fdb2c2ebba4f8f
11574529,van Well EB,The value of reducing arthroscopic partial meniscectomy in the treatment of degenerative meniscus tears: a budget impact analysis,2023,bim,CONCLUSIONS: Substantial costs can be saved when APM is no longer performed to treat symptoms attributed to degenerative meniscus tears in the Netherlands.,What costs can be saved when APM is no longer performed to treat symptoms attributed to degenerative meniscus tears in the Netherlands (pmcid=11574529)?,Substantial costs can be saved.,34f264732511414656fdb2c2ebba4f8f
11574529,van Well EB,The value of reducing arthroscopic partial meniscectomy in the treatment of degenerative meniscus tears: a budget impact analysis,2023,bim,It is therefore recommended to further reduce the use of APM to treat degenerative meniscus tears.,What is recommended in the treatment of degenerative meniscus tears (pmcid=11574529)?,It is recommended to further reduce the use of arthroscopic partial meniscectomy (APM) in the treatment of degenerative meniscus tears.,34f264732511414656fdb2c2ebba4f8f
9985892,Punch D,Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals: Time and Budget Impact Analysis,2023,bim,"- PURPOSE: Surgical procedure packs are commonly used in ophthalmological surgeries, but quantitative evidence demonstrating the time efficiency and economic impact of their use is limited.",What is the purpose of the study on Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals (pmcid=9985892)?,"The purpose of the study is to investigate the time efficiency and economic impact of using surgical procedure packs, specifically Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals.",54ebbaba0603eabb60aab79364786567
9985892,Punch D,Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals: Time and Budget Impact Analysis,2023,bim,Evaluating the time and cost of surgical pack use is particularly important for publicly funded healthcare systems with tight budgets and/or an emphasis on value-based care.,What is particularly important to evaluate when considering the time and cost of surgical pack use in Canadian hospitals (pmcid=9985892)?,Evaluating the time and cost of surgical pack use is particularly important for publicly funded healthcare systems with tight budgets and/or an emphasis on value-based care.,54ebbaba0603eabb60aab79364786567
9985892,Punch D,Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals: Time and Budget Impact Analysis,2023,bim,"This study sought to estimate the economic impact of comprehensive surgical pack use in cataract and vitreoretinal (retina) surgeries across operating room (OR), materials management, and accounting departments in Canada.",What did the study seek to estimate in cataract and vitreoretinal surgeries in Canadian hospitals (pmcid=9985892)?,The study sought to estimate the economic impact of comprehensive surgical pack use in cataract and vitreoretinal (retina) surgeries in Canadian hospitals.,54ebbaba0603eabb60aab79364786567
9985892,Punch D,Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals: Time and Budget Impact Analysis,2023,bim,METHODS: A budget impact model developed for the United States (US) from a self-reported cross-sectional study was adapted for Canada.,What budget impact model was adapted for Canada in this study (pmcid=9985892)?,A budget impact model developed for the United States (US) was adapted for Canada in this study (pmcid=9985892).,54ebbaba0603eabb60aab79364786567
9985892,Punch D,Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals: Time and Budget Impact Analysis,2023,bim,The US study obtained data via an online survey and timing exercises of surgical procedures.,What method was used to obtain data in the US study (pmcid=9985892)?,The data in the US study (pmcid=9985892) was obtained via an online survey and timing exercises of surgical procedures.,54ebbaba0603eabb60aab79364786567
9985892,Punch D,Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals: Time and Budget Impact Analysis,2023,bim,The model was adapted using relevant Canadian-specific labor and cost inputs.,What inputs were used to adapt the model in the study (pmcid=9985892)?,Relevant Canadian-specific labor and cost inputs were used to adapt the model in the study with pmcid=9985892.,54ebbaba0603eabb60aab79364786567
9985892,Punch D,Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals: Time and Budget Impact Analysis,2023,bim,"Use of generic commodity packs (no proprietary equipment-specific supplies) was compared to full utilization of Custom-Pak(®), a comprehensive pack (disposables plus equipment-specific supplies) in cataract and retina surgeries at the facility and aggregate group (provincewide) levels.",What was compared in terms of pack utilization in cataract and retina surgeries at the facility and aggregate group levels (pmcid=9985892)?,The use of generic commodity packs (no proprietary equipment-specific supplies) was compared to full utilization of Custom-Pak® in cataract and retina surgeries at the facility and aggregate group levels.,54ebbaba0603eabb60aab79364786567
9985892,Punch D,Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals: Time and Budget Impact Analysis,2023,bim,"RESULTS: Switching from generic to comprehensive pack use in all 2500 cataract procedures at a community hospital saves 287 labor hours per year, primarily in the materials management department.",How many labor hours per year are saved by switching from generic to comprehensive pack use in all 2500 cataract procedures at a community hospital (pmcid=9985892)?,287 labor hours per year,54ebbaba0603eabb60aab79364786567
9985892,Punch D,Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals: Time and Budget Impact Analysis,2023,bim,Surgery preparation (OR) hours saved allow for an additional 196 potential procedures annually.,How many potential procedures annually can be accommodated due to the saved OR hours in the study by Punch D (pmcid=9985892)?,196 potential procedures annually,54ebbaba0603eabb60aab79364786567
9985892,Punch D,Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals: Time and Budget Impact Analysis,2023,bim,"Most of the Canadian Dollar (CAD) $39,815 annual cost savings are realized for the OR.",What are the annual cost savings realized for the OR in Canadian hospitals (pmcid=9985892)?,"The annual cost savings realized for the OR in Canadian hospitals is CAD $39,815.",54ebbaba0603eabb60aab79364786567
9985892,Punch D,Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals: Time and Budget Impact Analysis,2023,bim,"Aggregating across 50,000 cataract surgeries at the provincial level yields savings of 5608 hours and 3916 additional procedures, translating to hidden cost reductions of CAD$790,632 annually.","What savings were yielded across 50,000 cataract surgeries at the provincial level (pmcid=9985892)?","Savings of 5608 hours and 3916 additional procedures were yielded across 50,000 cataract surgeries at the provincial level (pmcid=9985892).",54ebbaba0603eabb60aab79364786567
9985892,Punch D,Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals: Time and Budget Impact Analysis,2023,bim,"Implementing full Custom-Pak use at the facility level in 1000 retina cases saves $10,650 annually; provincewide, 127 potential additional procedures can be gained.",What is the potential annual cost savings of implementing full Custom-Pak use at the facility level in 1000 retina cases (pmcid=9985892)?,"The potential annual cost savings of implementing full Custom-Pak use at the facility level in 1000 retina cases is $10,650 (pmcid=9985892).",54ebbaba0603eabb60aab79364786567
9985892,Punch D,Comprehensive Custom-Pak® in Cataract and Vitreoretinal Surgery in Canadian Hospitals: Time and Budget Impact Analysis,2023,bim,"CONCLUSION: Comprehensive Custom-Pak use improves efficiency in cataract and retina surgeries saving substantial time and cost in Canadian hospitals, potentially allowing more patients to have these procedures, and reducing wait times.",What impact does the use of Comprehensive Custom-Pak have on efficiency in cataract and retina surgeries in Canadian hospitals (pmcid=9985892)?,"The use of Comprehensive Custom-Pak improves efficiency in cataract and retina surgeries in Canadian hospitals, saving substantial time and cost, potentially allowing more patients to have these procedures, and reducing wait times.",54ebbaba0603eabb60aab79364786567
10534563,Nomikos N,A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece,2023,bim,"- This study aimed to assess the cost-effectiveness of abobotulinumtoxinA (aboBoNT-A) plus Best Supportive Care (BSC) compared with BSC alone for managing limb spasticity in adult patients in Greece, as well as to conduct a budget impact analysis of the introduction of aboBoNT-A in the Greek healthcare system compared to onabotulinumtoxinA (onaBoNT-A).",What was the aim of the study conducted on abobotulinumtoxinA in Greece (pmcid=10534563)?,"The aim of the study was to assess the cost-effectiveness of abobotulinumtoxinA (aboBoNT-A) plus Best Supportive Care (BSC) compared with BSC alone for managing limb spasticity in adult patients in Greece, as well as to conduct a budget impact analysis of the introduction of aboBoNT-A in the Greek healthcare system compared to onabotulinumtoxinA (onaBoNT-A).",4dee18c7300461276d9f45fae3484b71
10534563,Nomikos N,A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece,2023,bim,"Clinical studies were utilized to extract data on drug efficacy and patients' utility, while cost data were collected from Greek sources.",What type of data were collected from Greek sources for this analysis (pmcid=10534563)?,Cost data were collected from Greek sources.,4dee18c7300461276d9f45fae3484b71
10534563,Nomikos N,A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece,2023,bim,The results of the study showed that aboBoNT-A plus BSC was a cost-effective treatment option for both upper and lower limb spasticity in adult patients compared to BSC.,What did the results of the study show regarding the cost-effectiveness of aboBoNT-A plus BSC for upper and lower limb spasticity in adult patients compared to BSC (pmcid=10534563)?,The results of the study showed that aboBoNT-A plus BSC was a cost-effective treatment option for both upper and lower limb spasticity in adult patients compared to BSC.,4dee18c7300461276d9f45fae3484b71
10534563,Nomikos N,A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece,2023,bim,"Additionally, introducing aboBoNT-A into the Greek healthcare system resulted in cost savings in pharmaceutical spending over a 5-year period.",What were the cost savings in pharmaceutical spending over a 5-year period after introducing aboBoNT-A into the Greek healthcare system (pmcid=10534563)?,The cost savings in pharmaceutical spending over a 5-year period after introducing aboBoNT-A into the Greek healthcare system were observed.,4dee18c7300461276d9f45fae3484b71
10534563,Nomikos N,A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece,2023,bim,"The findings suggest that incorporating aboBoNT-A into the Greek healthcare system could improve patient access to treatment and healthcare resource efficiency, as it is a more economical option compared to onaBoNT-A.","What could incorporating aboBoNT-A into the Greek healthcare system improve, according to the findings (pmcid=10534563)?",Patient access to treatment and healthcare resource efficiency,4dee18c7300461276d9f45fae3484b71
10351593,Hamouda M,Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation,2023,bim,"- PURPOSE: Asthma is a common, chronic respiratory disorder associated with substantial societal and economic burden globally, despite the availability of different treatment modalities.",What is the purpose of the study (pmcid=10351593)?,The purpose of the study is to analyze the budget impact of single-inhaler fluticasone furoate/umeclidinium/vilanterol in patients with asthma in the Dubai Academic Healthcare Corporation.,011f9ef4eca910fd6f1a36704bd68862
10351593,Hamouda M,Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation,2023,bim,"GSK has developed a once-daily single-inhaler triple therapy (SITT), comprised of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI); a combination of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β(2)-agonist for patients with uncontrolled asthma.",What is the composition of the once-daily single-inhaler triple therapy developed by GSK for patients with uncontrolled asthma (pmcid=10351593)?,"The once-daily single-inhaler triple therapy developed by GSK for patients with uncontrolled asthma is comprised of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), which is a combination of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β(2)-agonist.",011f9ef4eca910fd6f1a36704bd68862
10351593,Hamouda M,Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation,2023,bim,A budget impact analysis was conducted to determine the financial impact of introducing FF/UMEC/VI SITT from the perspective of the Dubai Academic Healthcare Corporation (DAHC).,What perspective was used to determine the financial impact of introducing FF/UMEC/VI SITT in patients with asthma at the Dubai Academic Healthcare Corporation (pmcid=10351593)?,The perspective used to determine the financial impact of introducing FF/UMEC/VI SITT in patients with asthma at the Dubai Academic Healthcare Corporation (pmcid=10351593) was from the perspective of the Dubai Academic Healthcare Corporation (DAHC).,011f9ef4eca910fd6f1a36704bd68862
10351593,Hamouda M,Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation,2023,bim,METHODS: A budget impact model was constructed using an epidemiology-based approach and used to estimate the expected 5-year budget impact of including FF/UMEC/VI for the treatment of eligible patients within the DAHC in the United Arab Emirates (UAE).,What approach was used to construct the budget impact model in this study (pmcid=10351593)?,An epidemiology-based approach was used to construct the budget impact model in this study (pmcid=10351593).,011f9ef4eca910fd6f1a36704bd68862
10351593,Hamouda M,Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation,2023,bim,The model included both pharmacy and efficacy-related costs.,What costs were included in the model for the budget impact analysis of single-inhaler fluticasone furoate/umeclidinium/vilanterol in patients with asthma in the Dubai Academic Healthcare Corporation (pmcid=10351593)?,The costs included in the model for the budget impact analysis of single-inhaler fluticasone furoate/umeclidinium/vilanterol in patients with asthma in the Dubai Academic Healthcare Corporation were both pharmacy and efficacy-related costs.,011f9ef4eca910fd6f1a36704bd68862
10351593,Hamouda M,Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation,2023,bim,"The perspective of the DAHC healthcare payer was adopted, thus only direct payer costs were included in the analysis.",What perspective was adopted for the budget impact analysis in the study conducted by Hamouda M in the Dubai Academic Healthcare Corporation (pmcid=10351593)?,"The perspective adopted for the budget impact analysis in the study conducted by Hamouda M in the Dubai Academic Healthcare Corporation (pmcid=10351593) was the perspective of the DAHC healthcare payer, including only direct payer costs in the analysis.",011f9ef4eca910fd6f1a36704bd68862
10351593,Hamouda M,Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation,2023,bim,"A one-way sensitivity analysis was conducted to test the robustness of the model structure, assumptions, and input parameters.","What type of analysis was conducted to test the model structure, assumptions, and input parameters (pmcid=10351593)?",A one-way sensitivity analysis was conducted.,011f9ef4eca910fd6f1a36704bd68862
10351593,Hamouda M,Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation,2023,bim,"RESULTS: The total budget impact was estimated to save 1 million United States Dollars (USD) over 5 years, with budget impacts of 0.08 million USD in Year 1; 0.14 million USD in Year 2; 0.22 million USD in Year 3; 0.28 million USD in Year 4; and 0.33 million USD in Year 5.",What was the total budget impact estimated for the single-inhaler fluticasone furoate/umeclidinium/vilanterol in patients with asthma over 5 years (pmcid=10351593)?,The total budget impact was estimated to save 1 million United States Dollars (USD) over 5 years for the single-inhaler fluticasone furoate/umeclidinium/vilanterol in patients with asthma.,011f9ef4eca910fd6f1a36704bd68862
10351593,Hamouda M,Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation,2023,bim,The overall budget impact per patient was estimated to save 12.2 USD over 5 years.,What was the estimated overall budget impact per patient over 5 years in the study conducted by Hamouda M in the Dubai Academic Healthcare Corporation (pmcid=10351593)?,The estimated overall budget impact per patient over 5 years in the study conducted by Hamouda M in the Dubai Academic Healthcare Corporation was 12.2 USD.,011f9ef4eca910fd6f1a36704bd68862
10351593,Hamouda M,Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation,2023,bim,"In one-way sensitivity analyses, the budget impact was most sensitive to changes in the market uptake of FF/UMEC/VI.",What was the sensitivity analysis focused on in the budget impact analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in patients with asthma in the Dubai Academic Healthcare Corporation (pmcid=10351593)?,The sensitivity analysis in the budget impact analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in patients with asthma in the Dubai Academic Healthcare Corporation focused on changes in the market uptake of FF/UMEC/VI.,011f9ef4eca910fd6f1a36704bd68862
10351593,Hamouda M,Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation,2023,bim,CONCLUSION: Healthcare payers may consider FF/UMEC/VI in the management of uncontrolled asthma which would save costs and reduce healthcare resource use in the UAE.,What should healthcare payers consider in the management of uncontrolled asthma in the UAE (pmcid=10351593)?,"Healthcare payers should consider using FF/UMEC/VI in the management of uncontrolled asthma in the UAE, as it can save costs and reduce healthcare resource use.",011f9ef4eca910fd6f1a36704bd68862
9771058,Jutkowitz E,BUDGET IMPACT ANALYSIS OF NONPHARMACOLOGICAL INTERVENTIONS FOR COMMUNITY-DWELLING PEOPLE LIVING WITH DEMENTIA,2022,bim,- Non-pharmacologic dementia care interventions significantly reduce the risk of a nursing home admission for people living with dementia.,What is the impact of non-pharmacologic dementia care interventions on the risk of nursing home admission for people living with dementia (pmcid=9771058)?,Non-pharmacologic dementia care interventions significantly reduce the risk of a nursing home admission for people living with dementia.,74dcc19042bf1c4762ab54ed346f9971
9771058,Jutkowitz E,BUDGET IMPACT ANALYSIS OF NONPHARMACOLOGICAL INTERVENTIONS FOR COMMUNITY-DWELLING PEOPLE LIVING WITH DEMENTIA,2022,bim,"We used an evidence-based mathematical model to evaluate the budget impact for a healthcare payer that independently implemented four non-pharmacologic dementia care interventions that reduce the risk of transitioning to a nursing home for people living with dementia: 1) MIND, an at-home care coordination intervention; 2) NYU Caregiver (NYUCI), provides caregivers with counseling and ad-hoc support; 3) Alzheimer’s and Dementia Care (ADC) program, a clinic based care coordination intervention; and 4) Adult Day Services Plus (ADS-Plus), an adult day based care coordination intervention.",What mathematical model was used to evaluate the budget impact of non-pharmacologic interventions for community-dwelling people living with dementia (pmcid=9771058)?,An evidence-based mathematical model was used to evaluate the budget impact of non-pharmacologic interventions for community-dwelling people living with dementia (pmcid=9771058).,74dcc19042bf1c4762ab54ed346f9971
9771058,Jutkowitz E,BUDGET IMPACT ANALYSIS OF NONPHARMACOLOGICAL INTERVENTIONS FOR COMMUNITY-DWELLING PEOPLE LIVING WITH DEMENTIA,2022,bim,Healthcare payer costs included Medicare and Medicaid expenditures.,What healthcare payer costs were included in the analysis (pmcid=9771058)?,Medicare and Medicaid expenditures were included in the analysis.,74dcc19042bf1c4762ab54ed346f9971
9771058,Jutkowitz E,BUDGET IMPACT ANALYSIS OF NONPHARMACOLOGICAL INTERVENTIONS FOR COMMUNITY-DWELLING PEOPLE LIVING WITH DEMENTIA,2022,bim,"We simulated a cohort of 302,630 community-dwelling people with dementia, which is the number of people who were diagnosed with dementia in 2018.",How many community-dwelling people with dementia were simulated in the cohort (pmcid=9771058)?,"302,630",74dcc19042bf1c4762ab54ed346f9971
9771058,Jutkowitz E,BUDGET IMPACT ANALYSIS OF NONPHARMACOLOGICAL INTERVENTIONS FOR COMMUNITY-DWELLING PEOPLE LIVING WITH DEMENTIA,2022,bim,We applied each intervention’s inclusion criteria to determine the proportion of the cohort that would receive the interventions.,What criteria were applied to determine the proportion of the cohort that would receive the interventions (pmcid=9771058)?,The inclusion criteria of each intervention were applied to determine the proportion of the cohort that would receive the interventions.,74dcc19042bf1c4762ab54ed346f9971
9771058,Jutkowitz E,BUDGET IMPACT ANALYSIS OF NONPHARMACOLOGICAL INTERVENTIONS FOR COMMUNITY-DWELLING PEOPLE LIVING WITH DEMENTIA,2022,bim,Some people may die or enter a nursing home before receiving the interventions.,What may happen to some people before receiving the interventions? (pmcid=9771058),Some people may die or enter a nursing home before receiving the interventions.,74dcc19042bf1c4762ab54ed346f9971
9771058,Jutkowitz E,BUDGET IMPACT ANALYSIS OF NONPHARMACOLOGICAL INTERVENTIONS FOR COMMUNITY-DWELLING PEOPLE LIVING WITH DEMENTIA,2022,bim,"MIND, NYUCI, ADC, and ADS-Plus reduced annual payer expenditures (relative to $25,000, which is the average amount Medicare-Medicaid pay per person with dementia) on average by 0.67%, 0.23%, 0.13%, and 0.58%, respectively over 5 years.","What was the average reduction in annual payer expenditures for MIND, NYUCI, ADC, and ADS-Plus interventions over 5 years (pmcid=9771058)?","The average reduction in annual payer expenditures for MIND, NYUCI, ADC, and ADS-Plus interventions over 5 years was 0.67%, 0.23%, 0.13%, and 0.58%, respectively.",74dcc19042bf1c4762ab54ed346f9971
9771058,Jutkowitz E,BUDGET IMPACT ANALYSIS OF NONPHARMACOLOGICAL INTERVENTIONS FOR COMMUNITY-DWELLING PEOPLE LIVING WITH DEMENTIA,2022,bim,Cost savings for the interventions varied by demographics.,What varied for the interventions in terms of cost savings (pmcid=9771058)?,Cost savings for the interventions varied by demographics.,74dcc19042bf1c4762ab54ed346f9971
9771058,Jutkowitz E,BUDGET IMPACT ANALYSIS OF NONPHARMACOLOGICAL INTERVENTIONS FOR COMMUNITY-DWELLING PEOPLE LIVING WITH DEMENTIA,2022,bim,"African American females between ages 95-100 who received NYUCI had the largest cost savings ($2,750.57).",What demographic group had the largest cost savings from receiving NYUCI? (pmcid=9771058),African American females between ages 95-100,74dcc19042bf1c4762ab54ed346f9971
9771058,Jutkowitz E,BUDGET IMPACT ANALYSIS OF NONPHARMACOLOGICAL INTERVENTIONS FOR COMMUNITY-DWELLING PEOPLE LIVING WITH DEMENTIA,2022,bim,"White females between ages 65-70 who received ADC had an increase in payer costs ($2,397.07).",What was the increase in payer costs for white females between ages 65-70 who received ADC (pmcid=9771058)?,"The increase in payer costs for white females between ages 65-70 who received ADC was $2,397.07.",74dcc19042bf1c4762ab54ed346f9971
9771058,Jutkowitz E,BUDGET IMPACT ANALYSIS OF NONPHARMACOLOGICAL INTERVENTIONS FOR COMMUNITY-DWELLING PEOPLE LIVING WITH DEMENTIA,2022,bim,"On average, non-pharmacologic dementia care intervention do not increase a healthcare payer’s budget.",What is the average impact of non-pharmacologic dementia care interventions on a healthcare payer's budget (pmcid=9771058)?,"On average, non-pharmacologic dementia care interventions do not increase a healthcare payer's budget.",74dcc19042bf1c4762ab54ed346f9971
10015636,Azzeri A,Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options,2023,bim,- INTRODUCTION: A scaled-up treatment cascade with direct-acting antiviral (DAA) therapy is necessary to achieve global WHO targets for hepatitis C virus (HCV) elimination in Malaysia.,What is necessary to achieve global WHO targets for hepatitis C virus elimination in Malaysia (pmcid=10015636)?,A scaled-up treatment cascade with direct-acting antiviral (DAA) therapy is necessary to achieve global WHO targets for hepatitis C virus (HCV) elimination in Malaysia.,44e79c4951126e76c11ad487a0beead2
10015636,Azzeri A,Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options,2023,bim,"Recently, limited access to sofosbuvir/daclatasvir (SOF/DAC) is available through compulsory licensing, with access to sofosbuvir/velpatasvir (SOF/VEL) expected through voluntary licensing due to recent agreements.",What options are available for access to sofosbuvir/daclatasvir (SOF/DAC) and sofosbuvir/velpatasvir (SOF/VEL) in Malaysia (pmcid=10015636)?,"Access to sofosbuvir/daclatasvir (SOF/DAC) is available through compulsory licensing, while access to sofosbuvir/velpatasvir (SOF/VEL) is expected through voluntary licensing in Malaysia.",44e79c4951126e76c11ad487a0beead2
10015636,Azzeri A,Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options,2023,bim,SOF/VEL has superior clinical outcomes but has higher drug acquisition costs compared to SOF/DAC.,What are the drug acquisition costs comparison between SOF/VEL and SOF/DAC? (pmcid=10015636),SOF/VEL has higher drug acquisition costs compared to SOF/DAC.,44e79c4951126e76c11ad487a0beead2
10015636,Azzeri A,Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options,2023,bim,A stratified treatment cascade might be the most cost-efficient approach for Malaysia whereby all HCV patients are treated with SOF/DAC except for patients with cirrhosis who are treated with SOF/VEL.,What might be the most cost-efficient treatment approach for hepatitis C in Malaysia according to the abstract sentence provided? (pmcid=10015636),A stratified treatment cascade might be the most cost-efficient approach for Malaysia whereby all HCV patients are treated with SOF/DAC except for patients with cirrhosis who are treated with SOF/VEL.,44e79c4951126e76c11ad487a0beead2
10015636,Azzeri A,Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options,2023,bim,METHODS: This study aimed to conduct a 5-year budget impact analysis of the proposed stratified treatment cascade for HCV treatment in Malaysia.,What was the aim of the study (pmcid=10015636)?,The aim of the study was to conduct a 5-year budget impact analysis of the proposed stratified treatment cascade for HCV treatment in Malaysia.,44e79c4951126e76c11ad487a0beead2
10015636,Azzeri A,Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options,2023,bim,"A disease progression model that was developed based on model-predicted HCV epidemiology data was used for the analysis, where all HCV patients in scenario A were treated with SOF/DAC for all disease stages while in scenario B, SOF/DAC was used only for non-cirrhotic patients and SOF/VEL was used for the cirrhotic patients.",What disease progression model was used for the analysis (pmcid=10015636)?,A disease progression model based on model-predicted HCV epidemiology data was used for the analysis.,44e79c4951126e76c11ad487a0beead2
10015636,Azzeri A,Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options,2023,bim,Healthcare costs associated with DAA therapy and disease stage monitoring were included to estimate the downstream cost implications.,What costs were included to estimate the downstream cost implications in the study (pmcid=10015636)?,Healthcare costs associated with DAA therapy and disease stage monitoring were included to estimate the downstream cost implications.,44e79c4951126e76c11ad487a0beead2
10015636,Azzeri A,Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options,2023,bim,RESULTS: The stratified treatment cascade with 109 in Scenario B was found to be cost-saving compared to Scenario A.,What was found to be cost-saving compared to Scenario A in the budget impact analysis for hepatitis C treatment in Malaysia (pmcid=10015636)?,The stratified treatment cascade with 109 in Scenario B was found to be cost-saving compared to Scenario A.,44e79c4951126e76c11ad487a0beead2
10015636,Azzeri A,Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options,2023,bim,The cumulative savings for the stratified treatment cascade was USD 1.4 million over 5 years.,What were the cumulative savings for the stratified treatment cascade over 5 years (pmcid=10015636)?,The cumulative savings for the stratified treatment cascade over 5 years was USD 1.4 million.,44e79c4951126e76c11ad487a0beead2
10015636,Azzeri A,Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options,2023,bim,DISCUSSION: A stratified treatment cascade with SOF/VEL was expected to be cost-saving and can result in a budget impact reduction in overall healthcare expenditure in Malaysia.,What was the expected budget impact reduction in overall healthcare expenditure in Malaysia with a stratified treatment cascade using SOF/VEL (pmcid=10015636)?,The expected budget impact reduction in overall healthcare expenditure in Malaysia with a stratified treatment cascade using SOF/VEL was cost-saving.,44e79c4951126e76c11ad487a0beead2
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,- BACKGROUND: More than 800 million people are affected by chronic kidney disease (CKD) worldwide.,What is the background information provided in the abstract (pmcid=11748570)?,More than 800 million people are affected by chronic kidney disease (CKD) worldwide.,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,"In South Africa, the prevalence of CKD increased by 67% between 1999 and 2006.",What was the increase in the prevalence of CKD in South Africa between 1999 and 2006 (pmcid=11748570)?,The prevalence of CKD in South Africa increased by 67% between 1999 and 2006.,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,"Haemodialysis (HD), peritoneal dialysis (PD), and kidney transplant are the three main modalities used for managing end stage kidney disease.",What are the three main modalities used for managing end stage kidney disease? (pmcid=11748570),"Haemodialysis (HD), peritoneal dialysis (PD), and kidney transplant",92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,The cost of these therapies poses a significant burden to the health care system in South Africa.,What poses a significant burden to the health care system in South Africa (pmcid=11748570)?,The cost of peritoneal dialysis and haemodialysis poses a significant burden to the health care system in South Africa.,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,The aim of this study is to determine the cost-effectiveness and budget impact of peritoneal dialysis versus haemodialysis from the societal perspective in South Africa.,What is the aim of this study (pmcid=11748570)?,The aim of the study with pmcid=11748570 is to determine the cost-effectiveness and budget impact of peritoneal dialysis versus haemodialysis from the societal perspective in South Africa.,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,METHODS: A Markov model was constructed to estimate the cost-effectiveness of peritoneal dialysis versus haemodialysis.,What model was constructed to estimate the cost-effectiveness of peritoneal dialysis versus haemodialysis (pmcid=11748570)?,A Markov model,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,The model was developed in excel and populated with clinical evidence and cost data synthesized from the literature.,What type of data was synthesized from the literature to populate the model in excel (pmcid=11748570)?,Clinical evidence and cost data,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,The costs and outcomes were estimated over a 5-year time-horizon.,What was the time horizon over which costs and outcomes were estimated in the study (pmcid=11748570)?,The time horizon over which costs and outcomes were estimated in the study with pmcid=11748570 was 5 years.,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,The outcomes were presented as quality-adjusted life years.,What were the outcomes presented as in the study (pmcid=11748570)?,The outcomes were presented as quality-adjusted life years.,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,Cost effectiveness was estimated using the incremental cost-effectiveness ratio and the incremental net monetary benefit (INMB).,What was estimated to determine cost effectiveness in the study (pmcid=11748570)?,The incremental cost-effectiveness ratio and the incremental net monetary benefit (INMB) were estimated to determine cost effectiveness in the study.,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,Probabilistic sensitivity analysis was also conducted to assess the robustness of the results.,What type of analysis was conducted to assess the robustness of the results (pmcid=11748570)?,Probabilistic sensitivity analysis,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,A budget impact model was constructed to estimate the impact of PD and HD over a 5 year period.,What period of time was considered in the budget impact model constructed to estimate the impact of PD and HD in South Africa (pmcid=11748570)?,The budget impact model constructed to estimate the impact of PD and HD in South Africa considered a 5-year period.,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,RESULTS: The total discounted costs per patient over 5 years were R788 384 for PD versus R1 227 708 for HD.,What were the total discounted costs per patient over 5 years for peritoneal dialysis versus hemodialysis in South Africa (pmcid=11748570)?,"The total discounted costs per patient over 5 years were R788,384 for peritoneal dialysis (PD) versus R1,227,708 for hemodialysis (HD) in South Africa.",92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,The incremental cost for providing PD was estimated at -R438 875.,What was the estimated incremental cost for providing PD in South Africa (pmcid=11748570)?,"The estimated incremental cost for providing PD in South Africa was -R438,875.",92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,The net QALYs for delivering PD compared to HD were estimated at -0.09.,What were the estimated net QALYs for delivering PD compared to HD (pmcid=11748570)?,The estimated net QALYs for delivering PD compared to HD in the study with pmcid=11748570 were -0.09.,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,Cost effectiveness ratio for PD versus PD was R5 096 154/QALY.,What was the cost effectiveness ratio for PD versus PD in South Africa (pmcid=11748570)?,"The cost effectiveness ratio for PD versus PD in South Africa was R5,096,154 per QALY.",92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,"At a threshold of R38 500, PD provision has a 79% probability of being cost-effective relative to HD.","What is the probability of PD provision being cost-effective relative to HD at a threshold of R38,500 (pmcid=11748570)?",79%,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,The INMB was estimated at R328 574 for PD and R322 194 for HD indicating the cost-effectiveness of PD.,What was the estimated incremental net monetary benefit for peritoneal dialysis and hemodialysis in South Africa (pmcid=11748570)?,"The estimated incremental net monetary benefit was R328,574 for peritoneal dialysis (PD) and R322,194 for hemodialysis (HD) in South Africa.",92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,The budget impact analysis showed that it would cost government approximately R25 billion over 5 years to treat all individuals eligible for KRT under the current scenario of 88% HD and 12% PD.,What would be the cost to the government over 5 years to treat all individuals eligible for kidney replacement therapy under the current scenario of 88% hemodialysis and 12% peritoneal dialysis (pmcid=11748570)?,The cost to the government over 5 years to treat all individuals eligible for kidney replacement therapy under the current scenario of 88% hemodialysis and 12% peritoneal dialysis would be approximately R25 billion (pmcid=11748570).,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,"CONCLUSIONS: In South Africa, PD is shown to be cost-effective at a willingness to pay threshold of less than R38 500.",What is the cost-effectiveness threshold for peritoneal dialysis in South Africa (pmcid=11748570)?,The cost-effectiveness threshold for peritoneal dialysis in South Africa is less than R38 500.,92920b0ae5b2334a7a1fa6443d0b41bf
11748570,Thsehla E,Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa,2025,bim,A PD-preferred policy that considers clinical appropriateness and patients' values should be considered.,What policy should be considered regarding peritoneal dialysis and haemodialysis in South Africa (pmcid=11748570)?,A PD-preferred policy that considers clinical appropriateness and patients' values should be considered.,92920b0ae5b2334a7a1fa6443d0b41bf
10623695,Zemdegs J,Water intake and recurrent urinary tract infections prevention: economic impact analysis in seven countries,2023,bim,"- BACKGROUND: To estimate the economic impact of preventing urinary tract infections (UTI) by increasing water intake among women with recurrent UTI and low fluid intake across seven countries: France, United Kingdom, Spain, United States of America, Mexico, China and Australia.",What is the objective of the economic impact analysis in the seven countries mentioned (pmcid=10623695)?,The objective of the economic impact analysis in the seven countries mentioned is to estimate the economic impact of preventing urinary tract infections (UTI) by increasing water intake among women with recurrent UTI and low fluid intake.,0c116601d26e9251f5499c3ea1d4ac5f
10623695,Zemdegs J,Water intake and recurrent urinary tract infections prevention: economic impact analysis in seven countries,2023,bim,METHODS: A Markov model was developed to compare costs and outcomes of UTIs associated with low fluid intake in women versus a strategy of primary prevention by increasing water intake.,What model was developed to compare costs and outcomes of UTIs associated with low fluid intake in women (pmcid=10623695)?,A Markov model was developed.,0c116601d26e9251f5499c3ea1d4ac5f
10623695,Zemdegs J,Water intake and recurrent urinary tract infections prevention: economic impact analysis in seven countries,2023,bim,Model inputs were based on randomized controlled trial data which found that increasing water intake by 1.5 L/day decreased the risk of developing cystitis by 48% in women with low fluid intake and recurrent UTI.,What data were the model inputs based on (pmcid=10623695)?,The model inputs were based on randomized controlled trial data.,0c116601d26e9251f5499c3ea1d4ac5f
10623695,Zemdegs J,Water intake and recurrent urinary tract infections prevention: economic impact analysis in seven countries,2023,bim,"A time horizon of 10 years was used; outcomes were from the payer perspective and included both direct and indirect costs, reported in 2019 United States dollars ($).",What time horizon was used in the economic impact analysis of water intake and recurrent urinary tract infections prevention in seven countries (pmcid=10623695)?,A time horizon of 10 years was used.,0c116601d26e9251f5499c3ea1d4ac5f
10623695,Zemdegs J,Water intake and recurrent urinary tract infections prevention: economic impact analysis in seven countries,2023,bim,Discounting rates varied by country.,What varied by country in the economic impact analysis of water intake and recurrent urinary tract infections prevention (pmcid=10623695)?,Discounting rates varied by country.,0c116601d26e9251f5499c3ea1d4ac5f
10623695,Zemdegs J,Water intake and recurrent urinary tract infections prevention: economic impact analysis in seven countries,2023,bim,Scenarios of increasing levels of compliance to the increased water intake strategy were evaluated.,What scenarios were evaluated in the study (pmcid=10623695)?,Scenarios of increasing levels of compliance to the increased water intake strategy were evaluated.,0c116601d26e9251f5499c3ea1d4ac5f
10623695,Zemdegs J,Water intake and recurrent urinary tract infections prevention: economic impact analysis in seven countries,2023,bim,"RESULTS: The total cost of one UTI episode, including diagnostics, treatment and complications, ranged from $2164 (Mexico) to $7671 (Australia).",What was the range of total cost for one UTI episode across the seven countries analyzed (pmcid=10623695)?,The range of total cost for one UTI episode across the seven countries analyzed was from $2164 in Mexico to $7671 in Australia.,0c116601d26e9251f5499c3ea1d4ac5f
10623695,Zemdegs J,Water intake and recurrent urinary tract infections prevention: economic impact analysis in seven countries,2023,bim,"Assuming 80% compliance with the increased water intake strategy over a 10-year time horizon, the number of UTIs prevented ranged from 435,845 (Australia) to 24150,272 (China), resulting in total savings of 286 million (Australia) to $4.4 billion (China).",What was the total savings in China due to the increased water intake strategy for preventing recurrent urinary tract infections (pmcid=10623695)?,$4.4 billion,0c116601d26e9251f5499c3ea1d4ac5f
10623695,Zemdegs J,Water intake and recurrent urinary tract infections prevention: economic impact analysis in seven countries,2023,bim,"Across all countries, increased water intake resulted in lower cost and fewer UTIs compared with low water intake.",What was the impact of increased water intake on cost and UTIs across all countries (pmcid=10623695)?,Increased water intake resulted in lower cost and fewer UTIs across all countries.,0c116601d26e9251f5499c3ea1d4ac5f
10623695,Zemdegs J,Water intake and recurrent urinary tract infections prevention: economic impact analysis in seven countries,2023,bim,CONCLUSION: Preventing recurrent UTIs by increasing water intake would reduce both the clinical and economic burden associated with UTI.,What burden would be reduced by increasing water intake to prevent recurrent UTIs (pmcid=10623695)?,Both the clinical and economic burden associated with UTI.,0c116601d26e9251f5499c3ea1d4ac5f
10623695,Zemdegs J,Water intake and recurrent urinary tract infections prevention: economic impact analysis in seven countries,2023,bim,"Public, healthcare professionals and patients should be made aware about the preventive positive impact of appropriate water intake on UTIs.","What should be made aware to the public, healthcare professionals, and patients regarding the preventive positive impact of appropriate water intake on UTIs (pmcid=10623695)?","The preventive positive impact of appropriate water intake on UTIs should be made aware to the public, healthcare professionals, and patients.",0c116601d26e9251f5499c3ea1d4ac5f
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,- INTRODUCTION: China has a high incidence of birth defects.,What is the high incidence of in China that is mentioned in the abstract (pmcid=11719226)?,birth defects,c5bca819213f6be97998975c74e97cea
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,Tandem mass spectrometry (MS/MS) screening enables rapid detection of multiple inherited metabolic disorders and has been widely promoted globally.,What enables rapid detection of multiple inherited metabolic disorders and has been widely promoted globally (pmcid=11719226)?,Tandem mass spectrometry (MS/MS) screening,c5bca819213f6be97998975c74e97cea
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,This study aimed to conduct a budget impact analysis of replacing phenylketonuria screening with MS/MS by calculating the financial impact of reimbursing the costs of MS/MS screening.,What was the aim of the study conducted by Xiao D (pmcid=11719226)?,The aim of the study conducted by Xiao D was to conduct a budget impact analysis of replacing phenylketonuria screening with MS/MS by calculating the financial impact of reimbursing the costs of MS/MS screening.,c5bca819213f6be97998975c74e97cea
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,METHODS: An Excel-based budget impact analysis model for MS/MS screening was developed.,What type of budget impact analysis model was developed for MS/MS screening (pmcid=11719226)?,An Excel-based budget impact analysis model was developed for MS/MS screening.,c5bca819213f6be97998975c74e97cea
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,The number of newborns in Shanghai from 2024 to 2026 was estimated using the birth rate trend among the permanent population of Shanghai over the past decade.,What was used to estimate the number of newborns in Shanghai from 2024 to 2026 (pmcid=11719226)?,The birth rate trend among the permanent population of Shanghai over the past decade was used to estimate the number of newborns in Shanghai from 2024 to 2026.,c5bca819213f6be97998975c74e97cea
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,"By integrating clinical screening data, along with the corresponding screening costs and diagnostic fees for the gold standard test, the financial impact of replacing phenylketonuria screening with MS/MS screening was calculated.",What data was integrated to calculate the financial impact of replacing phenylketonuria screening with MS/MS screening? (pmcid=11719226),"Clinical screening data, corresponding screening costs, and diagnostic fees for the gold standard test were integrated to calculate the financial impact of replacing phenylketonuria screening with MS/MS screening.",c5bca819213f6be97998975c74e97cea
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,The screening data for this study was extracted from a tertiary hospital in Shanghai.,What hospital in Shanghai was the screening data extracted from? (pmcid=11719226),The screening data for this study was extracted from a tertiary hospital in Shanghai.,c5bca819213f6be97998975c74e97cea
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,"Demographic data were obtained from statistical websites, while cost data were derived from literature and a tertiary hospital in Shanghai.",What type of data were used to derive the cost data in the study (pmcid=11719226)?,Cost data were derived from literature and a tertiary hospital in Shanghai.,c5bca819213f6be97998975c74e97cea
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,"RESULTS: The fiscal expenditures for phenylketonuria screening were CNY1.75 million (USD0.25 million), CNY1.65 million (USD0.23 million), and CNY1.56 million (USD0.22 million) for 2024, 2025, and 2026, respectively.","What were the fiscal expenditures for phenylketonuria screening in 2024, 2025, and 2026? (pmcid=11719226)","The fiscal expenditures for phenylketonuria screening were CNY1.75 million (USD0.25 million) for 2024, CNY1.65 million (USD0.23 million) for 2025, and CNY1.56 million (USD0.22 million) for 2026.",c5bca819213f6be97998975c74e97cea
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,"In contrast, the corresponding fiscal expenditures for MS/MS were CNY25.23 million (USD3.54 million), CNY23.78 million (USD3.33 million), and CNY22.41 million (USD3.14 million).","What were the corresponding fiscal expenditures for MS/MS in Shanghai, China (pmcid=11719226)?","The corresponding fiscal expenditures for MS/MS in Shanghai, China were CNY25.23 million (USD3.54 million), CNY23.78 million (USD3.33 million), and CNY22.41 million (USD3.14 million).",c5bca819213f6be97998975c74e97cea
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,"The additional fiscal expenditure for MS/MS, compared with phenylketonuria screening, was CNY23.48 million (USD3.29 million), CNY22.13 million (USD3.10 million), and CNY20.85 million (USD2.92 million), showing a yearly decreasing trend.",What was the additional fiscal expenditure for MS/MS compared with phenylketonuria screening (pmcid=11719226)?,The additional fiscal expenditure for MS/MS compared with phenylketonuria screening was CNY23.48 million (USD3.29 million).,c5bca819213f6be97998975c74e97cea
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,CONCLUSIONS: The financial impact of MS/MS screening was controllable.,What was the financial impact of MS/MS screening according to the study (pmcid=11719226)?,The financial impact of MS/MS screening was controllable according to the study with pmcid=11719226.,c5bca819213f6be97998975c74e97cea
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,It was recommended that the cost of MS/MS screening in Shanghai be covered by government funding.,What was recommended regarding the cost of MS/MS screening in Shanghai (pmcid=11719226)?,It was recommended that the cost of MS/MS screening in Shanghai be covered by government funding.,c5bca819213f6be97998975c74e97cea
11719226,Xiao D,"PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China",2025,bim,"The promotion of newborn screening using MS/MS deserves priority consideration and publicity in Shanghai, China.","What deserves priority consideration and publicity in Shanghai, China (pmcid=11719226)?",The promotion of newborn screening using MS/MS,c5bca819213f6be97998975c74e97cea
10877896,Goudarzi Z,Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran,2024,bim,"- INTRODUCTION: In recent years, enzalutamide and abiraterone have been widely used as treatments for metastatic castration-resistant prostate cancer (mCRPC).",What have been widely used as treatments for metastatic castration-resistant prostate cancer in recent years (pmcid=10877896)?,Enzalutamide and abiraterone,27b003f9432580e09f8fba4c01d361e3
10877896,Goudarzi Z,Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran,2024,bim,"However, the cost-effectiveness of these drugs in Iran is unknown.",What is the unknown factor regarding the cost-effectiveness of enzalutamide and abiraterone in Iran (pmcid=10877896)?,The unknown factor regarding the cost-effectiveness of enzalutamide and abiraterone in Iran is whether they are cost-effective compared to each other in the treatment of metastatic prostate cancer resistant to castration.,27b003f9432580e09f8fba4c01d361e3
10877896,Goudarzi Z,Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran,2024,bim,This study evaluated the cost-effectiveness of enzalutamide for the treatment of metastatic prostate cancer resistant to castration in Iran.,What did the study evaluate (pmcid=10877896)?,The study evaluated the cost-effectiveness of enzalutamide for the treatment of metastatic prostate cancer resistant to castration in Iran.,27b003f9432580e09f8fba4c01d361e3
10877896,Goudarzi Z,Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran,2024,bim,METHODS: A 3-state Markov model was developed to evaluate the cost-effectiveness of enzalutamide and abiraterone from a social perspective over 10 years.,What type of model was developed to evaluate the cost-effectiveness of enzalutamide and abiraterone (pmcid=10877896)?,A 3-state Markov model was developed.,27b003f9432580e09f8fba4c01d361e3
10877896,Goudarzi Z,Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran,2024,bim,The clinical inputs were obtained from the meta-analysis studies.,What were the clinical inputs obtained from for the cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in the treatment of metastatic prostate cancer resistant to castration in Iran (pmcid=10877896)?,The clinical inputs for the cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in the treatment of metastatic prostate cancer resistant to castration in Iran (pmcid=10877896) were obtained from meta-analysis studies.,27b003f9432580e09f8fba4c01d361e3
10877896,Goudarzi Z,Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran,2024,bim,"The direct medical costs were obtained from the tariffs of the healthcare system, while the direct non-medical and indirect costs were collected from the patients.",What costs were collected from the patients in the analysis (pmcid=10877896)?,The direct non-medical and indirect costs were collected from the patients in the analysis (pmcid=10877896).,27b003f9432580e09f8fba4c01d361e3
10877896,Goudarzi Z,Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran,2024,bim,The data of utilities were derived from the literature.,What data source was used to derive the utilities in the analysis (pmcid=10877896)?,The data of utilities in the analysis were derived from the literature.,27b003f9432580e09f8fba4c01d361e3
10877896,Goudarzi Z,Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran,2024,bim,"In addition, sensitivity analyses were conducted to assess the uncertainties.",What type of analyses were conducted to assess uncertainties in the study (pmcid=10877896)?,Sensitivity analyses were conducted to assess the uncertainties in the study (pmcid=10877896).,27b003f9432580e09f8fba4c01d361e3
10877896,Goudarzi Z,Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran,2024,bim,"RESULTS: Compared with Abiraterone, enzalutamide was associated with a high incremental cost-effectiveness ratio (ICER) of $6,260 per QALY gained.",What was the incremental cost-effectiveness ratio (ICER) of enzalutamide compared to Abiraterone in the treatment of metastatic prostate cancer resistant to castration in Iran (pmcid=10877896)?,"The incremental cost-effectiveness ratio (ICER) of enzalutamide compared to Abiraterone in the treatment of metastatic prostate cancer resistant to castration in Iran (pmcid=10877896) was $6,260 per QALY gained.",27b003f9432580e09f8fba4c01d361e3
10877896,Goudarzi Z,Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran,2024,bim,"According to the one-way sensitivity analysis, ICER was most heavily influenced by the prices of enzalutamide and Abiraterone, non-medical costs, and indirect costs.",What factors heavily influenced the ICER in the one-way sensitivity analysis (pmcid=10877896)?,"The prices of enzalutamide and Abiraterone, non-medical costs, and indirect costs heavily influenced the ICER in the one-way sensitivity analysis (pmcid=10877896).",27b003f9432580e09f8fba4c01d361e3
10877896,Goudarzi Z,Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran,2024,bim,"Regardless of the variation, enzalutamide remained cost-effective.",What remained cost-effective regardless of the variation in the study conducted by Goudarzi Z in 2024 (pmcid=10877896)?,Enzalutamide,27b003f9432580e09f8fba4c01d361e3
10877896,Goudarzi Z,Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran,2024,bim,"The budget impact analysis of enzalutamide in the health system during 5 years was estimated at $6,362,127.",What was the estimated budget impact of enzalutamide in the health system during 5 years (pmcid=10877896)?,"The estimated budget impact of enzalutamide in the health system during 5 years was $6,362,127.",27b003f9432580e09f8fba4c01d361e3
10877896,Goudarzi Z,Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran,2024,bim,"CONCLUSIONS: At current prices, adding enzalutamide to pharmaceutical lists represents the cost-effective use of the healthcare resources in Iran for the treatment of metastatic castration-resistant prostate cancer.",What represents the cost-effective use of healthcare resources in Iran for the treatment of metastatic castration-resistant prostate cancer (pmcid=10877896)?,Adding enzalutamide to pharmaceutical lists represents the cost-effective use of healthcare resources in Iran for the treatment of metastatic castration-resistant prostate cancer.,27b003f9432580e09f8fba4c01d361e3
10476813,Seyedifar M,Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran,2023,bim,"- BACKGROUND: One of the most prevalent infections with a significant disease burden is urinary tract infections (UTIs), which occurs in approximately 50% of women at least once in their lifetime.",What is the background information provided in the abstract of the study (pmcid=10476813)?,"The background information provided in the abstract of the study (pmcid=10476813) is about the prevalence and significant disease burden of urinary tract infections (UTIs), which occur in approximately 50% of women at least once in their lifetime.",4ba62db464c7bddab4afbc3aa9178800
10476813,Seyedifar M,Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran,2023,bim,"Antimicrobial resistance to pathogens causing UTIs is expanding worldwide and has been associated with increased use of broad-spectrum antibiotics, including carbapenems, leading to significant costs for insurance and healthcare systems.",What has antimicrobial resistance to pathogens causing UTIs been associated with in terms of costs for insurance and healthcare systems (pmcid=10476813)?,"Increased use of broad-spectrum antibiotics, including carbapenems",4ba62db464c7bddab4afbc3aa9178800
10476813,Seyedifar M,Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran,2023,bim,"The emergence of resistance to carbapenems has led to an increasing need for and interest in carbapenem-sparing strategies, including the use of narrow-spectrum antibiotics, such as temocillin.","What has led to an increasing need for carbapenem-sparing strategies, such as temocillin? (pmcid=10476813)","The emergence of resistance to carbapenems has led to an increasing need for carbapenem-sparing strategies, such as temocillin.",4ba62db464c7bddab4afbc3aa9178800
10476813,Seyedifar M,Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran,2023,bim,"Temocillin has a strong bactericidal effect, along with high tolerability and a good safety profile.",What are the characteristics of temocillin mentioned in the abstract (pmcid=10476813)?,"Temocillin has a strong bactericidal effect, along with high tolerability and a good safety profile.",4ba62db464c7bddab4afbc3aa9178800
10476813,Seyedifar M,Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran,2023,bim,It is also stable toward most extended-spectrum beta-lactamases (ESBL).,"What is temocillin stable toward, according to the abstract sentence provided? (pmcid=10476813)",Temocillin is stable toward most extended-spectrum beta-lactamases (ESBL).,4ba62db464c7bddab4afbc3aa9178800
10476813,Seyedifar M,Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran,2023,bim,The purpose of our study was to design a budget impact analysis (BIA) model and estimate the budget impact of temocillin insurance coverage for the treatment of UTIs caused by ESBL-producing bacteria from the perspective of the payer.,What was the purpose of the study conducted by Seyedifar M regarding temocillin insurance coverage for UTIs caused by ESBL-producing bacteria (pmcid=10476813)?,The purpose of the study conducted by Seyedifar M regarding temocillin insurance coverage for UTIs caused by ESBL-producing bacteria was to design a budget impact analysis (BIA) model and estimate the budget impact from the perspective of the payer.,4ba62db464c7bddab4afbc3aa9178800
10476813,Seyedifar M,Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran,2023,bim,METHODS: The BIA model with insurance payer perspective was used to estimate the impact of temocillin insurance coverage on the treatment of UTIs caused by ESBL-producing bacteria over a 1-year time horizon in Iran.,What perspective was used in the budget impact analysis model for estimating the impact of temocillin insurance coverage on the treatment of UTIs caused by ESBL-producing bacteria in Iran (pmcid=10476813)?,The budget impact analysis model used the insurance payer perspective to estimate the impact of temocillin insurance coverage on the treatment of UTIs caused by ESBL-producing bacteria in Iran.,4ba62db464c7bddab4afbc3aa9178800
10476813,Seyedifar M,Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran,2023,bim,"Direct medicine costs, hospitalization and paraclinical costs, and side effect costs were considered in this model.",What costs were considered in the budget impact analysis model for temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran (pmcid=10476813)?,"Direct medicine costs, hospitalization and paraclinical costs, and side effect costs were considered in the budget impact analysis model for temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran.",4ba62db464c7bddab4afbc3aa9178800
10476813,Seyedifar M,Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran,2023,bim,"To assess the impact of uncertainty on the model inputs, 1-way sensitivity analyses were performed.",What type of analyses were performed to assess the impact of uncertainty on the model inputs (pmcid=10476813)?,1-way sensitivity analyses,4ba62db464c7bddab4afbc3aa9178800
10476813,Seyedifar M,Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran,2023,bim,"RESULTS: The model demonstrates that inclusion of temocillin in insurance coverage, decreasing treatment costs from $36 million to $34 million, will result in overall savings of > $1.9 million and lead to > $9 million savings in insurance costs for antimicrobial resistance.",What are the overall savings and insurance cost savings associated with the inclusion of temocillin in insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran (pmcid=10476813)?,"The overall savings associated with the inclusion of temocillin in insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran are > $1.9 million. Additionally, there will be > $9 million savings in insurance costs for antimicrobial resistance.",4ba62db464c7bddab4afbc3aa9178800
10476813,Seyedifar M,Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran,2023,bim,CONCLUSION: The inclusion of temocillin in the insurance coverage in Iran for patients developing UTIs caused by ESBL-producing bacteria would be cost-saving for insurance and decrease the risk associated with emerging antimicrobial resistance.,What would be the cost-saving impact of including temocillin in insurance coverage for UTIs caused by ESBL-producing bacteria in Iran (pmcid=10476813)?,The cost-saving impact of including temocillin in insurance coverage for UTIs caused by ESBL-producing bacteria in Iran would be beneficial for insurance and decrease the risk associated with emerging antimicrobial resistance.,4ba62db464c7bddab4afbc3aa9178800
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,"- BACKGROUND: ARASENS was a randomized, double-blind, phase 3 trial comparing darolutamide + docetaxel + androgen deprivation therapy (ADT) with placebo + docetaxel + ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC).",What type of trial was ARASENS (pmcid=11365817)?,"ARASENS was a randomized, double-blind, phase 3 trial.",b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,OBJECTIVE: To use clinical trial data from ARASENS to understand whether the addition of darolutamide to docetaxel + ADT leads to increased hospitalizations and to estimate the budget impact on the US health care system.,What clinical trial data was used to understand the addition of darolutamide to docetaxel + ADT in metastatic hormone-sensitive prostate cancer (pmcid=11365817)?,Clinical trial data from ARASENS was used to understand the addition of darolutamide to docetaxel + ADT in metastatic hormone-sensitive prostate cancer.,b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,METHODS: We used mixed-effects negative binomial regression to estimate hospitalization and intensive care unit (ICU) admission rates and length of hospital stay (LoHS) counts.,What method was used to estimate hospitalization and ICU admission rates in the study (pmcid=11365817)?,Mixed-effects negative binomial regression,b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,Hospitalization rates were estimated per treatment arm for the period during and after administration of docetaxel.,What period was considered for estimating hospitalization rates per treatment arm in the study (pmcid=11365817)?,The period considered for estimating hospitalization rates per treatment arm in the study with pmcid=11365817 was during and after administration of docetaxel.,b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,"Based on these estimates, a budget impact analysis evaluated the hospitalization costs (including ICU admissions) and standalone ICU hospitalization costs for the totality of the US population over a 5-year time horizon.",What costs were evaluated in the budget impact analysis (pmcid=11365817)?,"The budget impact analysis evaluated hospitalization costs, including ICU admissions, and standalone ICU hospitalization costs for the totality of the US population over a 5-year time horizon.",b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,The analysis compared a scenario without darolutamide vs one with darolutamide included in the US payer formulary.,What scenarios were compared in the analysis (pmcid=11365817)?,The analysis compared a scenario without darolutamide vs one with darolutamide included in the US payer formulary.,b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,Hospitalization estimates were varied in a one-way sensitivity analysis.,What were the estimates varied in a one-way sensitivity analysis (pmcid=11365817)?,Hospitalization estimates,b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,RESULTS: The first 4 months of treatment (when patients were receiving docetaxel) were associated with increased hospitalizations across both arms.,What was associated with increased hospitalizations during the first 4 months of treatment in patients receiving docetaxel (pmcid=11365817)?,The first 4 months of treatment were associated with increased hospitalizations in patients receiving docetaxel.,b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,The addition of darolutamide was associated with a numerical reduction in the rate of hospitalization (per year) due to any reason both during docetaxel treatment (1.01 visits per year [95% CI = 0.82-1.20] vs 1.18 visits per year [95% CI = 0.96-1.41]) and after docetaxel treatment (0.28 visits per year [95% CI = 0.23-0.34] vs 0.33 visits per year [95% CI = 0.27-0.40]).,How does the addition of darolutamide impact the rate of hospitalization per year for patients with metastatic hormone-sensitive prostate cancer (pmcid=11365817)?,"The addition of darolutamide was associated with a numerical reduction in the rate of hospitalization per year for patients with metastatic hormone-sensitive prostate cancer. During docetaxel treatment, the rate of hospitalization was 1.01 visits per year with darolutamide compared to 1.18 visits per year without darolutamide. After docetaxel treatment, the rate of hospitalization was 0.28 visits per year with darolutamide compared to 0.33 visits per year without darolutamide.",b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,Darolutamide was associated with a marginally longer LoHS per hospitalization compared with placebo (+1.90 days per year) both during and after docetaxel treatment.,How does the length of hospital stay per hospitalization compare between darolutamide and placebo in metastatic hormone-sensitive prostate cancer patients during and after docetaxel treatment (pmcid=11365817)?,Darolutamide was associated with a marginally longer length of hospital stay per hospitalization compared with placebo (+1.90 days per year) in metastatic hormone-sensitive prostate cancer patients during and after docetaxel treatment.,b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,ICU admissions were low in the ARASENS data; admission rates were assumed to be the same during and after docetaxel treatment.,What were the ICU admission rates assumed to be during and after docetaxel treatment in the study (pmcid=11365817)?,The ICU admission rates were assumed to be the same during and after docetaxel treatment in the study.,b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,ICU admission rate estimates were equivalent across arms (0.02 visits per year [95% CI = 0.01-0.03]).,What were the ICU admission rate estimates across arms in the study (pmcid=11365817)?,The ICU admission rate estimates across arms in the study were 0.02 visits per year [95% CI = 0.01-0.03].,b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,The budget impact per treated member per month represents a cost-neutral option after Year 5 with a cumulative budget impact of -$9.71.,What represents a cost-neutral option after Year 5 with a cumulative budget impact of -$9.71 (pmcid=11365817)?,The budget impact per treated member per month represents a cost-neutral option after Year 5 with a cumulative budget impact of -$9.71.,b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,CONCLUSIONS: The addition of darolutamide to docetaxel + ADT was associated with a numerically lower rate of hospitalization but marginally longer LoHS compared with docetaxel + ADT alone.,What was the comparison made in terms of hospitalization rate and length of hospital stay for patients receiving darolutamide in metastatic hormone-sensitive prostate cancer (pmcid=11365817)?,The comparison made was between patients receiving darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) versus patients receiving docetaxel and ADT alone. The addition of darolutamide was associated with a numerically lower rate of hospitalization but marginally longer length of hospital stay compared to docetaxel and ADT alone.,b318c2f293b94a8e3fd87a223577ba2a
11365817,Morgans AK,Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS,2024,bim,Darolutamide represents a cost-neutral alternative per treated member per month compared with docetaxel + ADT with regard to hospitalizations at the end of a 5-year time horizon.,What represents a cost-neutral alternative per treated member per month compared with docetaxel + ADT with regard to hospitalizations at the end of a 5-year time horizon (pmcid=11365817)?,Darolutamide represents a cost-neutral alternative per treated member per month compared with docetaxel + ADT with regard to hospitalizations at the end of a 5-year time horizon.,b318c2f293b94a8e3fd87a223577ba2a
10423465,Stajszczyk M,Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database,2023,bim,"- OBJECTIVES: Although several years have passed since biologic disease modifying antirheumatic drugs were introduced to the market, considerable disparities in access still remain.",What are the objectives of the study conducted by Stajszczyk M regarding biosimilar TNF inhibitors in rheumatic diseases in Poland (pmcid=10423465)?,"The objectives of the study conducted by Stajszczyk M regarding biosimilar TNF inhibitors in rheumatic diseases in Poland are to assess the budget impact analysis and treatment availability using real-world evidence from a nationwide database, with a focus on addressing disparities in access to biologic disease modifying antirheumatic drugs.",584fc37c0b22b9904b4a490f0ab07902
10423465,Stajszczyk M,Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database,2023,bim,Tumour necrosis factor inhibitors (TNFi) have proven to be highly effective and safe for treating patients with rheumatic musculoskeletal diseases (RMDs).,What have tumour necrosis factor inhibitors (TNFi) proven to be for treating patients with rheumatic musculoskeletal diseases? (pmcid=10423465),Tumour necrosis factor inhibitors (TNFi) have proven to be highly effective and safe for treating patients with rheumatic musculoskeletal diseases (RMDs).,584fc37c0b22b9904b4a490f0ab07902
10423465,Stajszczyk M,Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database,2023,bim,"The emergence of biosimilars is promising for cost reduction and more equitable, widespread access.",What is the potential benefit of the emergence of biosimilars in terms of cost reduction and access (pmcid=10423465)?,"The potential benefit of the emergence of biosimilars is cost reduction and more equitable, widespread access.",584fc37c0b22b9904b4a490f0ab07902
10423465,Stajszczyk M,Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database,2023,bim,"METHODS: A retrospective budget impact analysis based on final drug prices was conducted using 12 687 treatment courses for infliximab, etanercept and adalimumab.",What methods were used in the budget impact analysis conducted in this study (pmcid=10423465)?,"The methods used in the budget impact analysis conducted in this study (pmcid=10423465) involved a retrospective analysis based on final drug prices, using 12,687 treatment courses for infliximab, etanercept, and adalimumab.",584fc37c0b22b9904b4a490f0ab07902
10423465,Stajszczyk M,Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database,2023,bim,Estimated and real-life savings for public payer were calculated from an 8-year perspective of TNFi use.,What perspective was used to calculate the estimated and real-life savings for the public payer in the study (pmcid=10423465)?,An 8-year perspective was used to calculate the estimated and real-life savings for the public payer in the study (pmcid=10423465).,584fc37c0b22b9904b4a490f0ab07902
10423465,Stajszczyk M,Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database,2023,bim,Data on the treatment cost and on the evolution in the number of patients treated was provided.,What data was provided in the study regarding treatment cost and the number of patients treated (pmcid=10423465)?,Data on the treatment cost and on the evolution in the number of patients treated was provided.,584fc37c0b22b9904b4a490f0ab07902
10423465,Stajszczyk M,Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database,2023,bim,"RESULTS: From a public payer perspective, the estimated total savings amount to over €243 million for TNFi, with over €166 million attributed to treatment cost reduction in RMDs.",What were the estimated total savings for TNFi from a public payer perspective (pmcid=10423465)?,The estimated total savings for TNFi from a public payer perspective were over €243 million.,584fc37c0b22b9904b4a490f0ab07902
10423465,Stajszczyk M,Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database,2023,bim,"Real-life savings were calculated as €133 million and €107 million, respectively.",What were the real-life savings calculated as in this study (pmcid=10423465)?,"The real-life savings were calculated as €133 million and €107 million, respectively.",584fc37c0b22b9904b4a490f0ab07902
10423465,Stajszczyk M,Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database,2023,bim,"The rheumatology sector generated between 68% and 92% of total savings across models, depending on the adopted scenario.",What percentage of total savings was generated by the rheumatology sector in the budget impact analysis of biosimilar TNF inhibitors in rheumatic diseases in Poland (pmcid=10423465)?,Between 68% and 92% of total savings was generated by the rheumatology sector in the budget impact analysis of biosimilar TNF inhibitors in rheumatic diseases in Poland (pmcid=10423465).,584fc37c0b22b9904b4a490f0ab07902
10423465,Stajszczyk M,Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database,2023,bim,The overall decrease in mean annual cost of treatment ranged between 75% and 89% in the study frame.,What was the range of the overall decrease in mean annual cost of treatment in the study (pmcid=10423465)?,The range of the overall decrease in mean annual cost of treatment in the study was between 75% and 89%.,584fc37c0b22b9904b4a490f0ab07902
10423465,Stajszczyk M,Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database,2023,bim,"If all budget savings were spent on reimbursement of additional TNFi, a hypothetical total of almost 45 000 patients with RMDs could be treated in 2021.",How many patients with rheumatic diseases could be treated in 2021 if all budget savings were spent on reimbursement of additional TNFi? (pmcid=10423465),"Almost 45,000 patients with rheumatic diseases could be treated in 2021 if all budget savings were spent on reimbursement of additional TNFi.",584fc37c0b22b9904b4a490f0ab07902
10423465,Stajszczyk M,Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database,2023,bim,CONCLUSIONS: This is the first nation-level analysis that shows estimated and real-life direct cost-savings for TNFi biosimilars.,What is the significance of this nation-level analysis in relation to TNFi biosimilars (pmcid=10423465)?,"The significance of this nation-level analysis is that it demonstrates estimated and real-life direct cost-savings for TNFi biosimilars, providing valuable insights into the budget impact and treatment availability of these biosimilars in rheumatic diseases in Poland.",584fc37c0b22b9904b4a490f0ab07902
10423465,Stajszczyk M,Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database,2023,bim,Transparent criteria for reinvesting savings should be developed on both a local and an international levels.,What should be developed on both a local and an international level according to the abstract sentence provided (pmcid=10423465)?,Transparent criteria for reinvesting savings,584fc37c0b22b9904b4a490f0ab07902
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,"- INTRODUCTION: This study evaluates the cost-effectiveness of Apixaban and Rivaroxaban, compared to Warfarin, for stroke prevention in patients with non-valvular atrial fibrillation in Iran.",What does this study evaluate (pmcid=11194975)?,"This study evaluates the cost-effectiveness of Apixaban and Rivaroxaban, compared to Warfarin, for stroke prevention in patients with non-valvular atrial fibrillation in Iran.",3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,METHOD: A Markov model with a 30-year time horizon was employed to simulate and assess different treatment strategies' cost-effectiveness.,What model was employed to simulate and assess different treatment strategies' cost-effectiveness (pmcid=11194975)?,A Markov model,3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,"The study population comprised Iranian adults with NVAF, identified through specialist consultations, hospital visits, and archival record reviews.",What type of analysis was conducted in the study (pmcid=11194975)?,Cost‐Effectiveness and Budget Impact Analysis,3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,"Direct medical costs, direct nonmedical, and indirect costs were included.",What costs were included in the analysis (pmcid=11194975)?,"Direct medical costs, direct nonmedical costs, and indirect costs were included in the analysis.",3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,Quality-adjusted life years (QALY) were assessed using an EQ-5D questionnaire.,What questionnaire was used to assess Quality-adjusted life years in the study (pmcid=11194975)?,EQ-5D questionnaire,3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,This study utilized a cost-effectiveness threshold of $11 134 per QALY.,What cost-effectiveness threshold was utilized in this study (pmcid=11194975)?,"$11,134 per QALY",3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,RESULTS: Apixaban demonstrated superior cost-effectiveness compared to Rivaroxaban and Warfarin.,What did the results show regarding the cost-effectiveness of Apixaban compared to Rivaroxaban and Warfarin in the prevention of stroke in patients with non-valvular atrial fibrillation in Iran (pmcid=11194975)?,The results showed that Apixaban demonstrated superior cost-effectiveness compared to Rivaroxaban and Warfarin in the prevention of stroke in patients with non-valvular atrial fibrillation in Iran.,3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,"Over 30 years, total costs were lower in the Apixaban and Rivaroxaban groups compared to the Warfarin group ($126.18 and $109.99 vs.",What were the total costs over 30 years in the Apixaban and Rivaroxaban groups compared to the Warfarin group (pmcid=11194975)?,"The total costs over 30 years in the Apixaban and Rivaroxaban groups compared to the Warfarin group were $126.18 and $109.99, respectively.",3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,"However, Apixaban showed higher total QALYs gained compared to others (0.134 vs.",What was the total QALYs gained for Apixaban compared to others in the study (pmcid=11194975)?,0.134,3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,0.133 and 0.116).,What type of analysis was conducted in this study (pmcid=11194975)?,Cost‐Effectiveness and Budget Impact Analysis,3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,"The incremental cost-effectiveness ratio for comparing Apixaban to Warfarin was calculated at -1332.83 cost per QALY, below the threshold of $11 134, indicating Apixaban's cost-effectiveness.",What was the incremental cost-effectiveness ratio for comparing Apixaban to Warfarin (pmcid=11194975)?,The incremental cost-effectiveness ratio for comparing Apixaban to Warfarin in the study with pmcid=11194975 was calculated at -1332.83 cost per QALY.,3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,"Sensitivity analyses confirmed the robustness of the findings, with ICER consistently remaining below the threshold.",What was confirmed through sensitivity analyses in the study (pmcid=11194975)?,The robustness of the findings was confirmed through sensitivity analyses in the study.,3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,"Over 5 years (2024-2028) of Apixaban usage, the incremental cost starts at USD 70 250 296 in the first year and gradually rises to USD 71 770 662 in the fifth year.",What is the incremental cost of Apixaban usage over 5 years (2024-2028) (pmcid=11194975)?,"The incremental cost of Apixaban usage over 5 years (2024-2028) is USD 70,250,296 in the first year and gradually rises to USD 71,770,662 in the fifth year.",3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,DSA and PSA were assessed to prove the robustness of the results.,What were assessed to prove the robustness of the results in the study conducted by Tajik A in 2024 (pmcid=11194975)?,DSA and PSA were assessed to prove the robustness of the results.,3041bf90845b1dc6a78284b84c9774c5
11194975,Tajik A,Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran,2024,bim,CONCLUSION: This study shows that Apixaban is a cost-effective option for stroke prevention in non-valvular atrial fibrillation patients in Iran compared to Warfarin.,What does this study show about the cost-effectiveness of Apixaban compared to Warfarin for stroke prevention in non-valvular atrial fibrillation patients in Iran (pmcid=11194975)?,This study shows that Apixaban is a cost-effective option for stroke prevention in non-valvular atrial fibrillation patients in Iran compared to Warfarin.,3041bf90845b1dc6a78284b84c9774c5
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,- OBJECTIVES: To perform a budget impact analysis (BIA) of introducing olaparib as maintenance therapy in women who have BRCA mutations (BRCAm) with platinum-sensitive recurrent ovarian cancer (PSROC) in combination with bevacizumab in Argentina.,What is the objective of the budget impact analysis in the context of introducing olaparib as maintenance therapy in women with BRCA mutations and platinum-sensitive recurrent ovarian cancer in Argentina (pmcid=11252110)?,The objective of the budget impact analysis is to assess the financial impact of introducing olaparib as maintenance therapy in women with BRCA mutations and platinum-sensitive recurrent ovarian cancer in Argentina.,9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,METHODS: A BIA model was used to analyse over a 5-year time horizon the change in the health system's budget following the adoption of olaparib as maintenance therapy in BRCAm patients with PSROC.,What model was used to analyze the change in the health system's budget following the adoption of olaparib as maintenance therapy in BRCAm patients with PSROC (pmcid=11252110)?,A BIA model was used.,9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,The BIA for each year was estimated by comparing the cost difference between the current scenario (treatment with bevacizumab) and the new scenario (the addition of olaparib) for a third-party payer.,What was the basis for estimating the budget impact analysis for olaparib in combination with bevacizumab for maintenance therapy for ovarian cancer in Argentina (pmcid=11252110)?,The basis for estimating the budget impact analysis for olaparib in combination with bevacizumab for maintenance therapy for ovarian cancer in Argentina was comparing the cost difference between the current scenario (treatment with bevacizumab) and the new scenario (the addition of olaparib) for a third-party payer.,9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,"The BIA is estimated at the national health system level, and by healthcare sectors in Argentina (public sector, social security and private sector).",What levels are the Budget Impact Analysis estimated at in Argentina (pmcid=11252110)?,"The Budget Impact Analysis is estimated at the national health system level, and by healthcare sectors in Argentina (public sector, social security, and private sector).",9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,International and national epidemiological data were used to determine the target patient population.,What data were used to determine the target patient population in the study (pmcid=11252110)?,International and national epidemiological data were used to determine the target patient population.,9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,"Clinical efficacy, safety outcomes and duration of treatments were obtained from the pivotal clinical study report.","What were the sources of clinical efficacy, safety outcomes, and duration of treatments obtained from for this study (pmcid=11252110)?","The sources of clinical efficacy, safety outcomes, and duration of treatments obtained for this study (pmcid=11252110) were from the pivotal clinical study report.",9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,Relevant direct medical costs were obtained from public data in Argentina and expert consultation.,What data sources were used to obtain relevant direct medical costs for the budget impact analysis of Olaparib in combination with Bevacizumab for maintenance therapy for ovarian cancer in Argentina (pmcid=11252110)?,Public data in Argentina and expert consultation were used to obtain relevant direct medical costs for the budget impact analysis of Olaparib in combination with Bevacizumab for maintenance therapy for ovarian cancer in Argentina.,9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,All the costs are reported in US dollars as of October 2022 ($1 = 152.59 Argentine pesos).,What currency are all costs reported in for the budget impact analysis of Olaparib in combination with Bevacizumab for maintenance therapy for ovarian cancer in Argentina (pmcid=11252110)?,All costs are reported in US dollars.,9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,A scenario analysis assessed the full coverage of the homologous recombination deficiency (HRD) test in Argentina.,What did the scenario analysis assess in Argentina (pmcid=11252110)?,The scenario analysis assessed the full coverage of the homologous recombination deficiency (HRD) test in Argentina.,9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,"In addition, one-way sensitivity analysis was conducted to evaluate the model robustness.",What type of analysis was conducted to evaluate the model robustness (pmcid=11252110)?,One-way sensitivity analysis,9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,"RESULTS: For a third-party payer with a cohort of 1,000,000 women covered, the estimated target population was 2 individuals in year 1 and 6 individuals in year 5.","How many individuals were estimated to be in the target population for a third-party payer with a cohort of 1,000,000 women covered in year 5 (pmcid=11252110)?",6 individuals,9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,"The incorporation of olaparib, with a wholesale price per pack of $3176.32, was associated with a weighted average of the budget impact per member per month (PMPM) of $0.062 for the national health system, being above the estimated health system budget impact threshold ($0.0153).",What was the budget impact per member per month associated with the incorporation of olaparib in Argentina (pmcid=11252110)?,The budget impact per member per month associated with the incorporation of olaparib in Argentina was $0.062.,9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,"By healthcare sector, the results of budget impact PMPM for year 5 ranged between $0.08 (public sector) and $0.114 (private sector).",What were the results of the budget impact PMPM for year 5 by healthcare sector (pmcid=11252110)?,The results of the budget impact PMPM for year 5 by healthcare sector were between $0.08 for the public sector and $0.114 for the private sector.,9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,"For all perspectives, the variables that most influenced the budget impact was the incidence of ovarian cancer, the drug acquisition cost and the treatment duration.",What variables most influenced the budget impact in the analysis conducted by Rojas-Roque C in Argentina (pmcid=11252110)?,"The variables that most influenced the budget impact in the analysis conducted by Rojas-Roque C in Argentina were the incidence of ovarian cancer, the drug acquisition cost, and the treatment duration.",9c4d8ab1847be82d3229eeab293093ca
11252110,Rojas-Roque C,Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina,2024,bim,CONCLUSIONS: The introduction of olaparib for the treatment of BRCAm women with PSROC has a high budget impact for all three health systems in Argentina.,What is the budget impact of introducing olaparib for the treatment of BRCAm women with PSROC in Argentina (pmcid=11252110)?,The budget impact of introducing olaparib for the treatment of BRCAm women with PSROC in Argentina is high for all three health systems.,9c4d8ab1847be82d3229eeab293093ca
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,"- BACKGROUND AND OBJECTIVE: In Germany, influenza vaccination is mainly advised for persons aged 60 years and over and individuals with health risks.",What age group is mainly advised for influenza vaccination in Germany (pmcid=10570167)?,Persons aged 60 years and over,f8adef3f66ec5723c847e6ce2b1b671a
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,"Since 2021, an inactivated, quadrivalent high-dose influenza vaccine (IIV4-HD) has been recommended for persons aged 60 years and over.",What vaccine has been recommended for persons aged 60 years and over since 2021 (pmcid=10570167)?,"An inactivated, quadrivalent high-dose influenza vaccine (IIV4-HD)",f8adef3f66ec5723c847e6ce2b1b671a
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,The aim of this study was to calculate the impact of vaccinating the German population aged 60 years and over with IIV4-HD compared to standard-dose influenza vaccines (IIV4-SD) with regard to health outcomes and costs.,What was the aim of the study conducted by Pahmeier K regarding vaccinating the German population aged 60 years and over with IIV4-HD compared to standard-dose influenza vaccines (IIV4-SD) (pmcid=10570167)?,The aim of the study conducted by Pahmeier K was to calculate the impact of vaccinating the German population aged 60 years and over with IIV4-HD compared to standard-dose influenza vaccines (IIV4-SD) with regard to health outcomes and costs.,f8adef3f66ec5723c847e6ce2b1b671a
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,METHODS: An age-stratified deterministic compartment model was built to simulate the course of influenza infection for the German population in the season 2019/20.,What season was simulated in the age-stratified compartment model for the German population (pmcid=10570167)?,The season simulated in the age-stratified compartment model for the German population in the study with pmcid=10570167 was the season 2019/20.,f8adef3f66ec5723c847e6ce2b1b671a
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Probabilities for health outcomes and cost data were searched from the literature and were used to compare the influenza-related health and economic effects for different scenarios.,What were the probabilities for health outcomes and cost data used for in the study (pmcid=10570167)?,The probabilities for health outcomes and cost data were used to compare the influenza-related health and economic effects for different scenarios in the study.,f8adef3f66ec5723c847e6ce2b1b671a
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Perspectives were those of the statutory health insurance and the society.,What were the perspectives considered in the analysis (pmcid=10570167)?,The perspectives considered in the analysis were those of the statutory health insurance and the society.,f8adef3f66ec5723c847e6ce2b1b671a
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Deterministic sensitivity analyses were conducted.,What type of sensitivity analyses were conducted in the study (pmcid=10570167)?,Deterministic sensitivity analyses were conducted.,f8adef3f66ec5723c847e6ce2b1b671a
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,"RESULTS: From the statutory health insurance perspective, vaccinating the German population aged 60 years and over with IIV4-HD would have prevented 277,026 infections (- 1.1%) with an increase of overall direct costs of €224 million (+ 40.1%) compared with IIV4-SD.",What perspective was used to evaluate the impact of vaccinating the German population aged 60 years and over with IIV4-HD compared to IIV4-SD (pmcid=10570167)?,The perspective used to evaluate the impact of vaccinating the German population aged 60 years and over with IIV4-HD compared to IIV4-SD was from the statutory health insurance perspective.,f8adef3f66ec5723c847e6ce2b1b671a
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,"A separate analysis showed that increased vaccination of 75% (World Health Organization recommendation for older age groups) in persons aged 60 years and over using IIV4-SD only would prevent 1,289,648 infections (- 5.1%) and would save costs from a statutory health insurance perspective of €103 million (- 13.2%) compared with IIV4-HD at actual vaccination rates.",What would be the cost savings from a statutory health insurance perspective by increasing vaccination rates to 75% in persons aged 60 years and over using IIV4-SD only compared to IIV4-HD at actual vaccination rates (pmcid=10570167)?,The cost savings from a statutory health insurance perspective by increasing vaccination rates to 75% in persons aged 60 years and over using IIV4-SD only compared to IIV4-HD at actual vaccination rates would be €103 million (-13.2%).,f8adef3f66ec5723c847e6ce2b1b671a
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,CONCLUSIONS: The modeling approach offers important insights into the epidemiological and budgetary impact of different vaccination scenarios.,What insights does the modeling approach offer into the epidemiological and budgetary impact of different vaccination scenarios (pmcid=10570167)?,The modeling approach offers important insights into the epidemiological and budgetary impact of different vaccination scenarios.,f8adef3f66ec5723c847e6ce2b1b671a
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Achieving a higher vaccination coverage with IIV4-SD in persons aged 60 years and over would result in lower costs and fewer influenza infections compared with the scenario with IIV4-HD and actual vaccination rates.,What would be the result of achieving a higher vaccination coverage with IIV4-SD in persons aged 60 years and over compared to the scenario with IIV4-HD and actual vaccination rates (pmcid=10570167)?,Lower costs and fewer influenza infections,f8adef3f66ec5723c847e6ce2b1b671a
11058738,Pitsillidou O,Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus,2024,bim,"- OBJECTIVE: This study aims to estimate the budget impact of luspatercept reimbursement as an adjuvant to the standard management of β-thalassaemia major in Cyprus, from a societal perspective, and assess the financial feasibility of its inclusion in the β-thalassaemia armamentarium.",What is the objective of the study (pmcid=11058738)?,"The objective of the study with pmcid=11058738 is to estimate the budget impact of luspatercept reimbursement as an adjuvant to the standard management of β-thalassaemia major in Cyprus, from a societal perspective, and assess the financial feasibility of its inclusion in the β-thalassaemia armamentarium.",57cedc1364b0e19122bb1e43ca0f2e75
11058738,Pitsillidou O,Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus,2024,bim,METHODS: A 5-year horizon budget impact model was developed to determine the budget impact of reimbursing luspatercept for the management of β-thalassaemia major in Cyprus.,What was the time horizon of the budget impact model developed in this study (pmcid=11058738)?,The time horizon of the budget impact model developed in this study (pmcid=11058738) was 5 years.,57cedc1364b0e19122bb1e43ca0f2e75
11058738,Pitsillidou O,Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus,2024,bim,Two treatment discontinuation scenarios were elaborated.,What scenarios were elaborated in the study (pmcid=11058738)?,Two treatment discontinuation scenarios were elaborated.,57cedc1364b0e19122bb1e43ca0f2e75
11058738,Pitsillidou O,Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus,2024,bim,"In the first scenario, luspatercept is reimbursed complementary to best supportive care, and a dropout rate of 40% is assumed based on published real-world data, while for the second scenario a dropout rate of 25%, is assumed as per the clinical trial data.",What is the assumed dropout rate for the first scenario in the budget impact analysis of the reimbursement of Luspatercept in Cyprus (pmcid=11058738)?,The assumed dropout rate for the first scenario in the budget impact analysis of the reimbursement of Luspatercept in Cyprus is 40%.,57cedc1364b0e19122bb1e43ca0f2e75
11058738,Pitsillidou O,Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus,2024,bim,"Input parameters were retrieved from the phase III clinical trial of luspatercept, literature, and expert opinion consensus.",What were the input parameters retrieved from for the phase III clinical trial of luspatercept (pmcid=11058738)?,"The input parameters were retrieved from the phase III clinical trial of luspatercept, literature, and expert opinion consensus.",57cedc1364b0e19122bb1e43ca0f2e75
11058738,Pitsillidou O,Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus,2024,bim,One-way sensitivity analyses were conducted for both scenarios.,What were the one-way sensitivity analyses conducted for in this study (pmcid=11058738)?,The one-way sensitivity analyses were conducted for both scenarios in the study.,57cedc1364b0e19122bb1e43ca0f2e75
11058738,Pitsillidou O,Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus,2024,bim,"RESULTS: The addition of luspatercept to the standard management of β-thalassaemia major in Cyprus imparted an incremental budget impact ranging from €21,300,643 to €25,834,368, depending on the drop-out rate scenario assumed.",What was the incremental budget impact of adding luspatercept to the standard management of β-thalassaemia major in Cyprus (pmcid=11058738)?,"The incremental budget impact ranged from €21,300,643 to €25,834,368, depending on the drop-out rate scenario assumed.",57cedc1364b0e19122bb1e43ca0f2e75
11058738,Pitsillidou O,Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus,2024,bim,Results were sensitive to the number of eligible patients and dose per patient.,What were the results sensitive to in the budget impact analysis of the reimbursement of Luspatercept for the management of Thalassaemia in Cyprus (pmcid=11058738)?,The results were sensitive to the number of eligible patients and dose per patient.,57cedc1364b0e19122bb1e43ca0f2e75
11058738,Pitsillidou O,Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus,2024,bim,CONCLUSION: The potential reimbursement of luspatercept will wield a substantial impact on Cyprus total pharmaceutical expenditure and it is therefore imperative to affix a reimbursement framework that will allow the payer to mitigate uncertainty stemming out of the scarce clinical data and the inherently complex therapeutic landscape of β-thalassemia management.,What impact will the potential reimbursement of luspatercept have on Cyprus' total pharmaceutical expenditure (pmcid=11058738)?,The potential reimbursement of luspatercept will wield a substantial impact on Cyprus' total pharmaceutical expenditure.,57cedc1364b0e19122bb1e43ca0f2e75
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,- BACKGROUND: Tanzania recently changed its antenatal care (ANC) guidelines to reduce perinatal mortality and improve the experience of pregnancy care.,What recent change did Tanzania make to its antenatal care guidelines (pmcid=11729056)?,Tanzania recently changed its antenatal care (ANC) guidelines to reduce perinatal mortality and improve the experience of pregnancy care.,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,"The new guideline recommends increasing the number of ANC visits from four to eight and introducing one routine ultrasound scan, among other recommendations.",What does the new guideline recommend in terms of the number of ANC visits and ultrasound scans? (pmcid: 11729056),The new guideline recommends increasing the number of ANC visits from four to eight and introducing one routine ultrasound scan.,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,We estimated the budget impact of implementing the new guideline compared to the previous focused ANC guideline at public dispensaries and health centers.,What did the study estimate the budget impact of (pmcid=11729056)?,The study estimated the budget impact of implementing the new antenatal care guideline compared to the previous focused ANC guideline at public dispensaries and health centers in Tanzania.,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,"METHOD: In a dynamic Markov model, we prospectively followed annual cohorts of between 2.3 and 2.6 million pregnant women who will be attending ANC at dispensaries and health centers for 5 years.",What model was used to prospectively follow pregnant women attending ANC at dispensaries and health centers for 5 years (pmcid=11729056)?,A dynamic Markov model was used to prospectively follow pregnant women attending ANC at dispensaries and health centers for 5 years in the study with pmcid=11729056.,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,We allowed a population of pregnant women into the model every year and women exit the model at delivery.,What population was allowed into the model every year in the study conducted by Chamani AT (pmcid=11729056)?,A population of pregnant women was allowed into the model every year in the study conducted by Chamani AT.,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,"We calculated the cost of medicines, medical supplies, and laboratory supplies required to produce services from a public health system perspective.","What perspective was used to calculate the cost of medicines, medical supplies, and laboratory supplies in the study (pmcid=11729056)?",The cost was calculated from a public health system perspective.,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,Our model neither estimated condition-related costs nor health effects.,What did the model in the study not estimate (pmcid=11729056)?,The model in the study did not estimate condition-related costs or health effects.,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,The budget impact was calculated as the difference in the estimated costs between the two guidelines.,What was calculated to determine the budget impact in this study (pmcid=11729056)?,The budget impact was calculated as the difference in the estimated costs between the two guidelines.,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,We conducted scenario analyses to explore attending more visits and different assumptions to calculate the target population.,What did the scenario analyses explore in this study (pmcid=11729056)?,The scenario analyses explored attending more visits and different assumptions to calculate the target population in this study.,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,RESULTS: We estimated that implementing the new ANC guideline would have a cumulative budget impact of around US$154 million over 5 years.,What was the estimated cumulative budget impact over 5 years of implementing the new ANC guideline in Tanzania (pmcid=11729056)?,The estimated cumulative budget impact over 5 years of implementing the new ANC guideline in Tanzania (pmcid=11729056) was around US$154 million.,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,The budget required will increase from US$137 million under the focused ANC guideline to US$291 million under the new guideline.,What is the budget required to implement antenatal care recommendations for positive pregnancy outcomes at public primary facilities in Tanzania (pmcid=11729056)?,The budget required to implement antenatal care recommendations for positive pregnancy outcomes at public primary facilities in Tanzania is US$291 million under the new guideline.,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,Laboratory supplies will consume 47% of the estimated budget under the new guideline.,What percentage of the estimated budget will laboratory supplies consume under the new guideline? (pmcid=11729056),47%,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,We expect the annual budget impact to be US$38 million in the first year of implementation and US$32 million in the fifth year.,What is the expected annual budget impact in the first year of implementation and in the fifth year (pmcid=11729056)?,The expected annual budget impact in the first year of implementation is US$38 million and in the fifth year is US$32 million.,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,"We assumed that by the fifth year, 82% of all pregnant women would have had four or more visits.",What percentage of pregnant women were assumed to have had four or more visits by the fifth year (pmcid=11729056)?,82%,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,"The budget impact would increase to US$214 million, with the proportion of pregnant women attending four or more ANC visits reaching 90% within 5 years.",What would be the budget impact of implementing antenatal care recommendations for positive pregnancy outcomes at public primary facilities in Tanzania within 5 years (pmcid=11729056)?,The budget impact would increase to US$214 million.,3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,"CONCLUSION: Scaling up the implementation of the new ANC guideline at public dispensaries and health centers may substantially increase the supplies required to produce ANC services, particularly laboratory supplies.",What may substantially increase the supplies required to produce ANC services at public dispensaries and health centers in Tanzania (pmcid=11729056)?,"Scaling up the implementation of the new ANC guideline may substantially increase the supplies required to produce ANC services, particularly laboratory supplies.",3598c3ac49bee455c12071d55a6ceaaf
11729056,Chamani AT,Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania,2024,bim,Studies on the health impact of the new guideline are warranted to estimate the value for money.,What is warranted to estimate the value for money of the new guideline? (pmcid=11729056),Studies on the health impact of the new guideline are warranted to estimate the value for money.,3598c3ac49bee455c12071d55a6ceaaf
11326742,Silva LF,Budget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil,2024,bim,- OBJECTIVE: The aim of this study was to estimate the budget impact of adding cabergoline to the Brazilian Unified Health System (SUS) formulary for the treatment of patients with Cushing's disease (CD) who do not achieve disease control after transsphenoidal surgery.,What was the objective of the study conducted by Silva LF (pmcid=11326742)?,The objective of the study conducted by Silva LF was to estimate the budget impact of adding cabergoline to the Brazilian Unified Health System (SUS) formulary for the treatment of patients with Cushing's disease (CD) who do not achieve disease control after transsphenoidal surgery.,0c2cfc2679adb96acf42977f6a3ced48
11326742,Silva LF,Budget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil,2024,bim,MATERIALS AND METHODS: We conducted a budget impact analysis (BIA) from the perspective of the Brazilian SUS over a 5-year time horizon.,What perspective was used for the budget impact analysis in Brazil (pmcid=11326742)?,The perspective used for the budget impact analysis in Brazil in the study with pmcid=11326742 was from the perspective of the Brazilian SUS.,0c2cfc2679adb96acf42977f6a3ced48
11326742,Silva LF,Budget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil,2024,bim,We compared two scenarios: ketoconazole (Scenario 1) versus including cabergoline as a treatment option (Scenario 2).,What two scenarios were compared in the budget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil (pmcid=11326742)?,The two scenarios compared in the budget impact analysis were ketoconazole (Scenario 1) versus including cabergoline as a treatment option (Scenario 2).,0c2cfc2679adb96acf42977f6a3ced48
11326742,Silva LF,Budget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil,2024,bim,All analyses were conducted using Microsoft Excel.,What software was used to conduct all analyses in the study (pmcid=11326742)?,Microsoft Excel,0c2cfc2679adb96acf42977f6a3ced48
11326742,Silva LF,Budget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil,2024,bim,Uncertainty was explored in univariate sensitivity analyses.,What was explored in univariate sensitivity analyses in the study (pmcid=11326742)?,Uncertainty,0c2cfc2679adb96acf42977f6a3ced48
11326742,Silva LF,Budget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil,2024,bim,"RESULTS: The total costs were BRL $25,596,729 for Scenario 1 and BRL $32,469,169 for Scenario 2.",What were the total costs for Scenario 1 and Scenario 2 in the budget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil (pmcid=11326742)?,"The total costs were BRL $25,596,729 for Scenario 1 and BRL $32,469,169 for Scenario 2.",0c2cfc2679adb96acf42977f6a3ced48
11326742,Silva LF,Budget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil,2024,bim,"The budget impact of adding cabergoline to the formulary for CD treatment within the SUS would be BRL $6,091,036 over 5 years.",What would be the budget impact of adding cabergoline to the formulary for Cushing's disease treatment within the SUS over 5 years? (pmcid=11326742),"The budget impact of adding cabergoline to the formulary for Cushing's disease treatment within the SUS over 5 years would be BRL $6,091,036.",0c2cfc2679adb96acf42977f6a3ced48
11326742,Silva LF,Budget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil,2024,bim,"On univariate analyses, variations in the rates of surgical failure and CD recurrence had the greatest potential to affect the final costs associated with cabergoline.",What had the greatest potential to affect the final costs associated with cabergoline (pmcid=11326742)?,Variations in the rates of surgical failure and CD recurrence had the greatest potential to affect the final costs associated with cabergoline.,0c2cfc2679adb96acf42977f6a3ced48
11326742,Silva LF,Budget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil,2024,bim,CONCLUSIONS: The estimated budget impact of adding cabergoline to the formulary for CD treatment within the Brazilian SUS would be about BRL $6 million.,What is the estimated budget impact of adding cabergoline to the formulary for Cushing's disease treatment within the Brazilian SUS (pmcid=11326742)?,The estimated budget impact of adding cabergoline to the formulary for Cushing's disease treatment within the Brazilian SUS would be about BRL $6 million.,0c2cfc2679adb96acf42977f6a3ced48
11326742,Silva LF,Budget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil,2024,bim,"While cost savings cannot be expected, the budget impact of adding cabergoline would be lower than that of adding other treatment options for CD.",What would be the budget impact of adding cabergoline for medical treatment of Cushing’s disease in Brazil (pmcid=11326742)?,The budget impact of adding cabergoline for medical treatment of Cushing’s disease in Brazil would be lower than that of adding other treatment options for CD.,0c2cfc2679adb96acf42977f6a3ced48
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,- BACKGROUND: Obtaining information on implementation strategy costs and local budget impacts from multiple perspectives is essential to data-driven decision-making about resource allocation for successful evidence-based intervention delivery.,What is essential for data-driven decision-making about resource allocation for successful evidence-based intervention delivery (pmcid=10636820)?,Obtaining information on implementation strategy costs and local budget impacts from multiple perspectives is essential for data-driven decision-making about resource allocation for successful evidence-based intervention delivery.,1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,"This mixed methods study determines the costs and priorities of deploying Enhanced Replicating Effective Programs (REP) to implement the Michigan Model for Health™, a universal school-based prevention intervention, from key shareholder perspectives.",What are the costs and priorities determined in the study regarding the deployment of Enhanced Replicating Effective Programs to implement the Michigan Model for Health™ (pmcid=10636820)?,The costs and priorities determined in the study regarding the deployment of Enhanced Replicating Effective Programs to implement the Michigan Model for Health™ include assessing the costs and priorities from key shareholder perspectives.,1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,METHODS: Our study included teachers in 8 high schools across 3 Michigan counties as part of a pilot cluster randomized trial.,What schools were included in the pilot cluster randomized trial (pmcid=10636820)?,8 high schools across 3 Michigan counties,1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,"We used activity-based costing, mapping key Enhanced REP activities across implementation phases.",What method was used to map key Enhanced REP activities across implementation phases (pmcid=10636820)?,Activity-based costing,1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,"We included multiple perspectives, including state agencies, regional education service agencies, lead organization, and implementers.",What perspectives were included in the analysis (pmcid=10636820)?,"The perspectives included in the analysis for pmcid=10636820 were state agencies, regional education service agencies, lead organization, and implementers.",1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,"We also conducted a budget impact analysis (BIA, assessing the potential financial impact of adopting Enhanced REP) and a scenario analysis to estimate replication and account for cost variability.",What type of analysis was conducted to assess the potential financial impact of adopting Enhanced REP (pmcid=10636820)?,A budget impact analysis (BIA) was conducted.,1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,"We used an experimental embedded mixed methods approach, conducting semi-structured interviews and collecting field notes during the trial to expand and explain the cost data and the implications of costs across relevant perspectives.",What approach was used to collect data in this study (pmcid=10636820)?,An experimental embedded mixed methods approach was used to collect data in this study (pmcid=10636820).,1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,"RESULTS: Based on trial results, we estimate costs for deploying Enhanced REP are $11,903/school, with an estimated range between $8263/school and $15,201/school.",What are the estimated costs for deploying Enhanced REP in schools (pmcid=10636820)?,"The estimated costs for deploying Enhanced REP in schools are $11,903 per school, with a range between $8263 and $15,201 per school.",1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,"We estimate that adding four additional schools, consistent with the pilot, would cost $8659/school.",What would be the cost of adding four additional schools consistent with the pilot (pmcid=10636820)?,"The cost of adding four additional schools consistent with the pilot (pmcid=10636820) would be $8659 per school, totaling $34,636 for all four schools.",1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,Qualitative results indicated misalignment in school and teacher priorities in some cases.,What did the qualitative results indicate in some cases (pmcid=10636820)?,The qualitative results indicated misalignment in school and teacher priorities in some cases.,1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,"Implementation activities, including training and implementation facilitation with the health coordinator, were sometimes in addition to regular teaching responsibilities.",What were the implementation activities sometimes in addition to for the health coordinator (pmcid=10636820)?,Regular teaching responsibilities,1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,"The extent to which this occurred was partly due to leadership priorities (e.g., sticking to the district PD schedule) and organizational priorities (e.g., budget).",What were some factors that contributed to the extent of the occurrence mentioned in the abstract sentence (pmcid=10636820)?,"Some factors that contributed to the extent of the occurrence mentioned in the abstract sentence (pmcid=10636820) were leadership priorities, such as sticking to the district PD schedule, and organizational priorities, such as budget constraints.",1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,"CONCLUSIONS: Previous research findings indicate that, from a societal perspective, universal prevention is an excellent return on investment.",What do previous research findings indicate about universal prevention from a societal perspective (pmcid=10636820)?,"Previous research findings indicate that, from a societal perspective, universal prevention is an excellent return on investment.",1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,"However, notable misalignment in cost burden and priorities exists across shareholder groups.",What notable misalignment exists across shareholder groups in the study conducted by Eisman AB (pmcid=10636820)?,There is a notable misalignment in cost burden and priorities across shareholder groups in the study conducted by Eisman AB (pmcid=10636820).,1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,Our results indicate significant personal time costs by teachers when engaging in implementation strategy activities that impose an opportunity cost.,What do the results indicate about the personal time costs incurred by teachers in engaging in implementation strategy activities that impose an opportunity cost? (pmcid=10636820),The results indicate significant personal time costs incurred by teachers when engaging in implementation strategy activities that impose an opportunity cost.,1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,Additional strategies are needed to improve the alignment of costs and benefits to enhance the success and sustainability of implementation.,What is needed to improve the alignment of costs and benefits for the success and sustainability of implementation? (pmcid=10636820),Additional strategies are needed.,1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,We focus on those perspectives informed by the analysis and discuss opportunities to expand a multi-level focus and create greater alignment across perspectives.,What perspectives are focused on in the analysis discussed in the abstract (pmcid=10636820)?,"The perspectives focused on in the analysis discussed in the abstract of pmcid=10636820 are those informed by the analysis, with a focus on opportunities to expand a multi-level focus and create greater alignment across perspectives.",1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,TRIAL REGISTRATION: ClinicalTrials.gov NCT04752189.,What is the trial registration number for this study (pmcid=10636820)?,ClinicalTrials.gov NCT04752189.,1589cf48ec282ae619c644adff9a0a38
10636820,Eisman AB,A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention,2023,bim,Registered on 12 February 2021.,What type of analysis was conducted in the study (pmcid=10636820)?,A mixed methods partner-focused cost and budget impact analysis,1589cf48ec282ae619c644adff9a0a38
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,"- IMPORTANCE: In a randomized clinical trial, treatment guided by tumor-informed circulating tumor (ct)DNA testing reduced adjuvant chemotherapy use without compromising recurrence-free survival in patients with stage II colon cancer.",What was the impact of treatment guided by tumor-informed circulating tumor (ct)DNA testing on adjuvant chemotherapy use in patients with stage II colon cancer (pmcid=11143467)?,The impact of treatment guided by tumor-informed circulating tumor (ct)DNA testing on adjuvant chemotherapy use in patients with stage II colon cancer was a reduction in adjuvant chemotherapy use without compromising recurrence-free survival.,11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,The potential effects of adopting ctDNA testing into routine patient care is unknown.,What is unknown about the potential effects of adopting ctDNA testing into routine patient care (pmcid=11143467)?,"The potential effects of adopting ctDNA testing into routine patient care, specifically for colon cancer, are unknown.",11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,OBJECTIVE: To compare the total cost of patient care scenarios with and without the adoption of ctDNA testing.,What is the objective of the study comparing total cost of patient care scenarios with and without the adoption of ctDNA testing (pmcid=11143467)?,The objective of the study is to compare the total cost of patient care scenarios with and without the adoption of ctDNA testing.,11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,"DESIGN, SETTING, AND PARTICIPANTS: This budget impact analysis was conducted from the perspectives of US commercial health and Medicare Advantage payers.",What perspectives were considered in this budget impact analysis (pmcid=11143467)?,The perspectives considered in this budget impact analysis were those of US commercial health and Medicare Advantage payers.,11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,"A decision-analytical model was populated with age-specific incidence of colon cancer, use of adjuvant chemotherapy, and use of single-agent or multiagent regimens.",What was the decision-analytical model populated with in the study (pmcid=11143467)?,"The decision-analytical model was populated with age-specific incidence of colon cancer, use of adjuvant chemotherapy, and use of single-agent or multiagent regimens.",11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,"Total cost was estimated with the costs of ctDNA testing, drug acquisition, administration, surveillance, and adverse events.",What costs were included in the estimation of total cost in the study (pmcid=11143467)?,"The costs included in the estimation of total cost in the study (pmcid=11143467) were ctDNA testing, drug acquisition, administration, surveillance, and adverse events.",11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,The analysis was conducted from September 2023 to January 2024.,What time period was the analysis conducted for the budget impact of circulating tumor DNA testing for colon cancer in commercial health and Medicare Advantage plans (pmcid=11143467)?,The analysis was conducted from September 2023 to January 2024.,11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,EXPOSURES: The adoption of ctDNA testing.,What is the exposure being studied in the budget impact analysis for colon cancer testing (pmcid=11143467)?,The exposure being studied in the budget impact analysis for colon cancer testing in this study is the adoption of ctDNA testing.,11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,"MAIN OUTCOMES AND MEASURES: The incremental cost in the first year following the adoption of ctDNA testing, where testing will affect patient treatment and costs.",What is the main outcome and measure of the study (pmcid=11143467)?,"The main outcome and measure of the study (pmcid=11143467) is the incremental cost in the first year following the adoption of ctDNA testing, where testing will affect patient treatment and costs.",11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,"RESULTS: In hypothetical plans with 1 million individuals covered, 35 commercial health plan members and 102 Medicare Advantage members aged 75 years and younger were eligible for ctDNA testing.",How many commercial health plan members aged 75 years and younger were eligible for ctDNA testing in hypothetical plans with 1 million individuals covered (pmcid=11143467)?,35 commercial health plan members aged 75 years and younger were eligible for ctDNA testing in hypothetical plans with 1 million individuals covered.,11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,"In the base case with a 50% adoption rate, total cost savings were $221 684 (equivalent to $0.02 per member per month [PMPM]) for a commercial payer and $116 720 (equivalent to $0.01 PMPM) for a Medicare Advantage payer.",What were the total cost savings for a commercial payer and a Medicare Advantage payer in the base case with a 50% adoption rate (pmcid=11143467)?,"Total cost savings were $221,684 for a commercial payer and $116,720 for a Medicare Advantage payer in the base case with a 50% adoption rate.",11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,Cost savings were robust to variations in assumptions of all parameters in the commercial population but sensitive to variations in assumptions of adjuvant chemotherapy use rates in the Medicare Advantage population.,What parameter variations were cost savings robust to in the commercial population (pmcid=11143467)?,Cost savings were robust to variations in assumptions of all parameters in the commercial population.,11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,The number needed to test to avoid 1 patient receiving adjuvant chemotherapy was 4 in the commercial population and 10 in the Medicare Advantage population.,What was the number needed to test to avoid 1 patient receiving adjuvant chemotherapy in the commercial population and Medicare Advantage population? (pmcid=11143467),The number needed to test to avoid 1 patient receiving adjuvant chemotherapy was 4 in the commercial population and 10 in the Medicare Advantage population.,11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,The budget-neutral cost for ctDNA testing was $16 202 for a commercial payer and $5793 for a Medicare Advantage payer.,What were the budget-neutral costs for ctDNA testing for a commercial payer and a Medicare Advantage payer? (pmcid=11143467),"The budget-neutral cost for ctDNA testing was $16,202 for a commercial payer and $5,793 for a Medicare Advantage payer.",11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,CONCLUSIONS AND RELEVANCE: Use of tumor-informed ctDNA testing to guide adjuvant chemotherapy in postsurgery patients with stage II colon cancer was projected to result in cost savings for both commercial and Medicare Advantage payers.,What was the projected result of using tumor-informed ctDNA testing to guide adjuvant chemotherapy in postsurgery patients with stage II colon cancer for both commercial and Medicare Advantage payers (pmcid=11143467)?,Cost savings for both commercial and Medicare Advantage payers,11a034cc5d7ff965da42956ea068e078
11143467,Li Y,Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans,2024,bim,Adoption of ctDNA testing is therefore advantageous from a budgetary perspective.,What is advantageous from a budgetary perspective according to the abstract sentence (pmcid=11143467)?,Adoption of ctDNA testing,11a034cc5d7ff965da42956ea068e078
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,- BACKGROUND: Heart failure (HF) in type 2 diabetes (T2D) patients poses a significant clinical and financial burden.,"What burden does heart failure in type 2 diabetes patients pose, according to the study (pmcid=11717763)?","Heart failure in type 2 diabetes patients poses a significant clinical and financial burden, according to the study.",9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,"While sodium-glucose cotransporter-2 inhibitors (SGLT2i) have shown cardiovascular benefits in trials, they are not included in Thailand's National List of Essential Medicines (NLEM), and their value-for-money remains unassessed.",What remains unassessed regarding the value-for-money of sodium-glucose cotransporter-2 inhibitors in Thailand (pmcid=11717763)?,The value-for-money of sodium-glucose cotransporter-2 inhibitors remains unassessed in Thailand.,9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,OBJECTIVE: This study aims to evaluate the cost-utility of adding SGLT2i to the standard treatment for T2D-HF patients in Thailand.,What is the objective of the study (pmcid=11717763)?,The objective of the study with pmcid=11717763 is to evaluate the cost-utility of adding SGLT2 inhibitors to the standard treatment for Type 2 Diabetes patients with heart failure in Thailand.,9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,METHODS: A Markov model with 3-month cycles and a lifetime horizon was conducted from a societal perspective.,What perspective was utilized in the Markov model conducted in this study (pmcid=11717763)?,The Markov model in this study (pmcid=11717763) was conducted from a societal perspective.,9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,Efficacy data came from a systematic review and meta-analysis.,What was the source of the efficacy data used in the analysis (pmcid=11717763)?,The source of the efficacy data used in the analysis (pmcid=11717763) was a systematic review and meta-analysis.,9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,"Transition probabilities and direct medical costs were derived from the National Health Security Office database, while direct non-medical costs and utility were collected through patient interviews at Siriraj hospital to reflect Thailand's context.",What database were transition probabilities and direct medical costs derived from in this study (pmcid=11717763)?,The transition probabilities and direct medical costs were derived from the National Health Security Office database.,9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,"The main outcomes were incremental costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER).",What were the main outcomes assessed in the study (pmcid=11717763)?,"The main outcomes assessed in the study with pmcid 11717763 were incremental costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER).",9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,A sensitivity and budget impact analysis were also performed.,What additional analyses were performed in the study (pmcid=11717763)?,A sensitivity analysis and budget impact analysis were also performed in the study.,9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,"RESULTS: Canagliflozin led to the highest increase in QALYs, at 1.21 years, followed by dapagliflozin (0.54 years) and empagliflozin (0.06 years).",What increase in QALYs was observed with canagliflozin compared to dapagliflozin and empagliflozin? (pmcid=11717763),"Canagliflozin led to the highest increase in QALYs, at 1.21 years, compared to dapagliflozin (0.54 years) and empagliflozin (0.06 years).",9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,"Collectively, SGLT2i yielded an increase of 0.41 QALYs.",How much of an increase in QALYs did the addition of SGLT2 inhibitors yield (pmcid=11717763)?,0.41 QALYs,9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,"Canagliflozin incurred the highest additional treatment cost at United States dollars (US$)5600, followed by dapagliflozin (US$3547) and empagliflozin (US$2694).","What were the additional treatment costs incurred by Canagliflozin, dapagliflozin, and empagliflozin in the study (pmcid=11717763)?","Canagliflozin incurred the highest additional treatment cost at US$5600, followed by dapagliflozin at US$3547 and empagliflozin at US$2694.",9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,"The ICERs for canagliflozin, dapagliflozin, empagliflozin, and overall SGLT2i were US$4632, US$6430, US$48,952, and US$8480 per QALY gained, respectively.","What are the ICERs for canagliflozin, dapagliflozin, empagliflozin, and overall SGLT2i in the study (pmcid=11717763)?","The ICERs for canagliflozin, dapagliflozin, empagliflozin, and overall SGLT2i in the study (pmcid=11717763) are US$4632, US$6430, US$48,952, and US$8480 per QALY gained, respectively.",9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,SGLT2i were not cost-effective compared with Thailand's willingness-to-pay threshold of US$4564 per QALY gained.,What was the cost-effectiveness of SGLT2 inhibitors compared to Thailand's willingness-to-pay threshold (pmcid=11717763)?,SGLT2 inhibitors were not cost-effective compared with Thailand's willingness-to-pay threshold of US$4564 per QALY gained.,9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,"However, threshold analysis indicates that the costs of canagliflozin, dapagliflozin, empagliflozin, and overall SGLT-2i should be reduced by 2.3%, 38.2%, 90.2%, and 55.6%, respectively, to be cost-effective.",What percentage reduction in costs is needed for overall SGLT-2 inhibitors to be cost-effective? (pmcid=11717763),55.6%,9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,Budget impact analysis revealed that the total budget for treating T2D patients with HF over 5 years is US$15.6 million.,What was the total budget for treating T2D patients with HF over 5 years (pmcid=11717763)?,The total budget for treating T2D patients with HF over 5 years in the study with pmcid=11717763 was US$15.6 million.,9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,CONCLUSIONS: Adding SGLT2i to standard treatment reduced HF hospitalization and mortality rates and improved QALYs in T2D-HF patients.,What were the outcomes of adding SGLT2i to standard treatment in T2D-HF patients (pmcid=11717763)?,Adding SGLT2i to standard treatment reduced HF hospitalization and mortality rates and improved QALYs in T2D-HF patients.,9db13f11bb11854ca875a40426dfde73
11717763,Kongmalai T,Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand,2024,bim,"Nevertheless, they would not be cost-effective at current prices in Thailand.",What would not be cost-effective at current prices in Thailand? (pmcid=11717763),Adding SGLT-2 inhibitors to standard treatment in Type 2 diabetes patients with heart failure would not be cost-effective at current prices in Thailand.,9db13f11bb11854ca875a40426dfde73
10793632,Yakti O,Clinical pharmacists’ interventions for preventing adverse events in critically ill neonates in Qatar: an economic impact analysis,2024,bim,- OBJECTIVE: This study aimed to assess the overall economic impact of clinical pharmacist interventions in the neonatal ICU (NICU) in Qatar.,What was the objective of the study conducted by Yakti O in Qatar's neonatal ICU (NICU) (pmcid=10793632)?,The objective of the study conducted by Yakti O in Qatar's neonatal ICU (NICU) was to assess the overall economic impact of clinical pharmacist interventions.,0e12e927c0881d83df4a99416bf9bd45
10793632,Yakti O,Clinical pharmacists’ interventions for preventing adverse events in critically ill neonates in Qatar: an economic impact analysis,2024,bim,METHODS: A retrospective review of neonates' records was performed over a 3-month duration in the NICU of Qatar to determine the total economic benefit of clinical pharmacist interventions.,What was the method used to determine the total economic benefit of clinical pharmacist interventions in critically ill neonates in Qatar (pmcid=10793632)?,A retrospective review of neonates' records was performed over a 3-month duration in the NICU of Qatar to determine the total economic benefit of clinical pharmacist interventions.,0e12e927c0881d83df4a99416bf9bd45
10793632,Yakti O,Clinical pharmacists’ interventions for preventing adverse events in critically ill neonates in Qatar: an economic impact analysis,2024,bim,The total benefit of interventions was calculated by considering the cost avoidance due to preventable adverse drug events (ADEs) and the cost savings associated with the revised resource use due to interventions.,What was considered in calculating the total benefit of interventions in critically ill neonates in Qatar (pmcid=10793632)?,The total benefit of interventions was calculated by considering the cost avoidance due to preventable adverse drug events (ADEs) and the cost savings associated with the revised resource use due to interventions.,0e12e927c0881d83df4a99416bf9bd45
10793632,Yakti O,Clinical pharmacists’ interventions for preventing adverse events in critically ill neonates in Qatar: an economic impact analysis,2024,bim,Sensitivity analyses were conducted to ensure the robustness and generalizability of the results.,What were sensitivity analyses conducted to ensure in the study on clinical pharmacists' interventions for preventing adverse events in critically ill neonates in Qatar (pmcid=10793632)?,The sensitivity analyses were conducted to ensure the robustness and generalizability of the results in the study on clinical pharmacists' interventions for preventing adverse events in critically ill neonates in Qatar.,0e12e927c0881d83df4a99416bf9bd45
10793632,Yakti O,Clinical pharmacists’ interventions for preventing adverse events in critically ill neonates in Qatar: an economic impact analysis,2024,bim,"RESULTS: A total of 513 interventions were analyzed, involving 150 neonates.",How many interventions were analyzed in the study involving critically ill neonates in Qatar (pmcid=10793632)?,513 interventions were analyzed in the study involving critically ill neonates in Qatar (pmcid=10793632).,0e12e927c0881d83df4a99416bf9bd45
10793632,Yakti O,Clinical pharmacists’ interventions for preventing adverse events in critically ill neonates in Qatar: an economic impact analysis,2024,bim,"Most of the drug-related problems were related to therapy dosing, followed by drug choice appropriateness, the addition of prophylactic treatment, and administration frequency.",What were the most common drug-related problems identified in the study (pmcid=10793632)?,The most common drug-related problems identified in the study were related to therapy dosing.,0e12e927c0881d83df4a99416bf9bd45
10793632,Yakti O,Clinical pharmacists’ interventions for preventing adverse events in critically ill neonates in Qatar: an economic impact analysis,2024,bim,"The overall annual benefit was estimated at QAR 4,178,352 (1,147,584), which consisted of cost avoidance of QAR 1,050,680 (USD 288,648) and an overall cost saving of QAR -6091 (USD -1673).",What was the overall annual benefit estimated in the study (pmcid=10793632)?,"The overall annual benefit estimated in the study was QAR 4,178,352.",0e12e927c0881d83df4a99416bf9bd45
10793632,Yakti O,Clinical pharmacists’ interventions for preventing adverse events in critically ill neonates in Qatar: an economic impact analysis,2024,bim,"CONCLUSIONS: While the clinical pharmacist interventions led to increased resource utilisation and associated costs, when considering the avoided costs of ADEs, the overall clinical pharmacist practices in the NICU setting were economically beneficial.",What were the overall economic implications of the clinical pharmacist interventions in the NICU setting (pmcid=10793632)?,"The overall economic implications of the clinical pharmacist interventions in the NICU setting were beneficial, as they led to increased resource utilization and associated costs, but ultimately resulted in cost savings by avoiding adverse drug events (ADEs).",0e12e927c0881d83df4a99416bf9bd45
11738309,Booth C,PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis,2022,bim,- INTRODUCTION: The Scottish Medicines Consortium (SMC) conducts early health technology assessment of new medicines in Scotland.,What does the Scottish Medicines Consortium (SMC) conduct early health technology assessment of in Scotland (pmcid=11738309)?,The Scottish Medicines Consortium (SMC) conducts early health technology assessment of new medicines in Scotland.,16efd2c98dfd68edfda8a92644334f4d
11738309,Booth C,PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis,2022,bim,"While budget impact is not a factor in decisions on reimbursement, budget impact information is provided initially through horizon scanning reports for high impact medicines (estimated net budget impact >GBP 500,000 [EUR 585,710] per annum) to aid financial planning and implementation of advice at the local level, and later through budget impact templates from the submitting company issued alongside SMC advice.",What is the threshold for estimated net budget impact that triggers the provision of budget impact information in horizon scanning reports (pmcid=11738309)?,"The threshold for estimated net budget impact that triggers the provision of budget impact information in horizon scanning reports is >GBP 500,000 [EUR 585,710] per annum.",16efd2c98dfd68edfda8a92644334f4d
11738309,Booth C,PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis,2022,bim,This research aimed to understand how the information is used and to evaluate the benefits of a lifecycle approach to budget impact analysis.,What was the aim of the research conducted by Booth C (pmcid=11738309)?,The aim of the research conducted by Booth C was to understand how the information is used and to evaluate the benefits of a lifecycle approach to budget impact analysis.,16efd2c98dfd68edfda8a92644334f4d
11738309,Booth C,PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis,2022,bim,"METHODS: Health Board users of the budget impact templates were surveyed to explore the degree of utilization and identify areas for improvement, including the need to cross-validate the horizon scanning estimates with those of the submitting company.",What method was used to explore the degree of utilization and identify areas for improvement in the budget impact analysis (pmcid=11738309)?,Health Board users of the budget impact templates were surveyed.,16efd2c98dfd68edfda8a92644334f4d
11738309,Booth C,PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis,2022,bim,"Responses were analyzed quantitatively and qualitatively, with comments coded in Nvivo (QSR International) and themes established through thematic analysis.",What software was used to code comments and establish themes in the analysis (pmcid=11738309)?,Nvivo (QSR International),16efd2c98dfd68edfda8a92644334f4d
11738309,Booth C,PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis,2022,bim,"RESULTS: The initial responses received (n=17) provided representation from 57 percent of Health Boards (i.e., payers) covering 79 percent of the population.",What percentage of the population was covered by the Health Boards represented in the initial responses received (pmcid=11738309)?,79 percent,16efd2c98dfd68edfda8a92644334f4d
11738309,Booth C,PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis,2022,bim,"Preliminary results showed that while the budget impact templates were valued, 69 percent of respondents found them ‘somewhat useful’, suggesting scope for improvement.",What percentage of respondents found the budget impact templates 'somewhat useful' (pmcid=11738309)?,69 percent,16efd2c98dfd68edfda8a92644334f4d
11738309,Booth C,PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis,2022,bim,"Almost half (48%) of the respondents used the templates for high impact medicines, with only 30 percent using them for all medicines.",What percentage of respondents used the templates for high impact medicines in the study (pmcid=11738309)?,48%,16efd2c98dfd68edfda8a92644334f4d
11738309,Booth C,PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis,2022,bim,The majority (76%) of those surveyed thought there would be value in linking budget impact information throughout the SMC process.,What did the majority of those surveyed think would be valuable in the SMC process (pmcid=11738309)?,The majority of those surveyed thought there would be value in linking budget impact information throughout the SMC process.,16efd2c98dfd68edfda8a92644334f4d
11738309,Booth C,PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis,2022,bim,"An emerging theme was that some users found the templates complex and inflexible, and that a simpler, more adaptable tool to aid the planning process would be welcomed.",What feedback did some users provide about the templates used for budget impact analysis by the Scottish Medicines Consortium (pmcid=11738309)?,"Some users found the templates complex and inflexible, and suggested that a simpler, more adaptable tool would be welcomed for the planning process.",16efd2c98dfd68edfda8a92644334f4d
11738309,Booth C,PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis,2022,bim,Priorities identified for improving template included adapting them to the local population and adjusting medicine prices to reflect confidential discounts.,What were the priorities identified for improving the template in the study (pmcid=11738309)?,The priorities identified for improving the template in the study were adapting them to the local population and adjusting medicine prices to reflect confidential discounts.,16efd2c98dfd68edfda8a92644334f4d
11738309,Booth C,PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis,2022,bim,CONCLUSIONS: This research suggests that budget impact information is valued by Health Boards and that there is strong support for linking budget impact estimates and engaging stakeholders throughout a medicine’s lifecycle.,What does this research suggest about the value of budget impact information to Health Boards (pmcid=11738309)?,This research suggests that budget impact information is valued by Health Boards.,16efd2c98dfd68edfda8a92644334f4d
11738309,Booth C,PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis,2022,bim,"Simplifying the templates, increasing their adaptability, and providing guidance and training in their use will be key steps in improving this important part of SMC process.",What are key steps in improving the Scottish Medicines Consortium budget impact analysis process? (pmcid=11738309),"Simplifying the templates, increasing their adaptability, and providing guidance and training in their use are key steps in improving the Scottish Medicines Consortium budget impact analysis process.",16efd2c98dfd68edfda8a92644334f4d
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,"- INTRODUCTION: Increasing resources are devoted to osteoarthritis surgical care in Australia annually, with significant expenditure attributed to hip and knee arthroplasties.","What resources are increasingly devoted to in Australia annually, with significant expenditure attributed to hip and knee arthroplasties? (pmcid=11719004)","Increasing resources are devoted to osteoarthritis surgical care in Australia annually, with significant expenditure attributed to hip and knee arthroplasties.",ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,"Safe, efficient, and sustainable models of care are required.","What is required for safe, efficient, and sustainable models of care (pmcid=11719004)?",Implementing a Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty.,ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,This study aimed to determine the impact on healthcare costs of implementing an enhanced short-stay model of care (ESS-MOC) for arthroplasty at a national level.,What was the aim of the study (pmcid=11719004)?,The aim of the study was to determine the impact on healthcare costs of implementing an enhanced short-stay model of care (ESS-MOC) for arthroplasty at a national level.,ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,METHODS: Budget impact analysis was conducted for hospitals providing arthroplasty surgery over the years 2023 to 2030.,What years were included in the budget impact analysis for hospitals providing arthroplasty surgery (pmcid=11719004)?,The budget impact analysis for hospitals providing arthroplasty surgery included the years 2023 to 2030.,ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,Population-based sample projections obtained from clinical registry and administrative datasets of individuals receiving hip or knee arthroplasty for osteoarthritis were applied.,What datasets were used to obtain population-based sample projections for individuals receiving hip or knee arthroplasty for osteoarthritis (pmcid=11719004)?,Clinical registry and administrative datasets were used.,ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,The ESS-MOC assigned 30 percent of eligible patients to a shortened acute-ward-stay pathway and outpatient rehabilitation.,What percentage of eligible patients were assigned to a shortened acute-ward-stay pathway and outpatient rehabilitation in the ESS-MOC study (pmcid=11719004)?,30 percent,ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,The remaining 70 percent received a current practice pathway.,What percentage of patients received a current practice pathway after hip and knee arthroplasty in the study (pmcid=11719004)?,70 percent,ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,"The primary outcome was total healthcare cost savings post-implementation of the ESS-MOC, with return on investment (ROI) ratio and hospital bed-days utilized also estimated.",What was the primary outcome of the study post-implementation of the ESS-MOC (pmcid=11719004)?,The primary outcome was total healthcare cost savings.,ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,"Costs are presented in Australian dollars (AUD) and United States dollars (USD), at 2023 prices.",What currency are the costs presented in for this study (pmcid=11719004)?,The costs are presented in Australian dollars (AUD) and United States dollars (USD).,ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,"RESULTS: Estimated hospital cost savings for the years 2023 to 2030 from implementing the ESS-MOC were AUD641 million (USD427 million) (95% CI: AUD99 million [USD66 million] to AUD1,250 million) [USD834 million]).",What were the estimated hospital cost savings for the years 2023 to 2030 from implementing the ESS-MOC (pmcid=11719004)?,"The estimated hospital cost savings for the years 2023 to 2030 from implementing the ESS-MOC were AUD641 million (USD427 million) (95% CI: AUD99 million [USD66 million] to AUD1,250 million [USD834 million]).",ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,This corresponds to a ROI ratio of 8.88 (1.3 to 17.9) dollars returned for each dollar invested in implementing the care model.,What is the ROI ratio for implementing the enhanced recovery pathway after hip and knee arthroplasty (pmcid=11719004)?,The ROI ratio for implementing the enhanced recovery pathway after hip and knee arthroplasty (pmcid=11719004) is 8.88 dollars returned for each dollar invested.,ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,"For the period 2023 to 2030, an estimated 337,000 (261,000 to 412,000) acute surgical ward bed-days, and 721,000 (471,000 to 1,028,000) rehabilitation bed-days could be saved.",How many acute surgical ward bed-days could be saved for the period 2023 to 2030 (pmcid=11719004)?,"337,000 (261,000 to 412,000)",ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,Total implementation costs for the ESS-MOC were estimated at AUD72 million (USD46 million) over eight years.,What were the total implementation costs estimated for the ESS-MOC over eight years (pmcid=11719004)?,AUD72 million (USD46 million),ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,CONCLUSIONS: Implementation of an ESS-MOC for eligible arthroplasty patients in Australia would generate significant cost and healthcare resource savings.,What would the implementation of an ESS-MOC for eligible arthroplasty patients in Australia generate (pmcid=11719004)?,Implementation of an ESS-MOC for eligible arthroplasty patients in Australia would generate significant cost and healthcare resource savings.,ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,"This budget impact analysis demonstrates a best practice approach to comprehensively assessing value, at a national level, of implementing sustainable models of care in high-burden healthcare contexts.",What does the budget impact analysis demonstrate in terms of assessing value at a national level (pmcid=11719004)?,The budget impact analysis demonstrates a best practice approach to comprehensively assessing value at a national level of implementing sustainable models of care in high-burden healthcare contexts.,ce61a83aa79337e8c43850ef5f4e9363
11719004,Lloyd M,PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis,2025,bim,Findings are relevant to other settings where hospital stay following joint arthroplasty remains excessively long.,What settings are the findings relevant to where hospital stay following joint arthroplasty remains excessively long? (pmcid=11719004),The findings are relevant to settings where hospital stay following joint arthroplasty remains excessively long.,ce61a83aa79337e8c43850ef5f4e9363
11163679,Neppelenbroek E,Antenatal cardiotocography in primary midwife-led care: a budget impact analysis,2024,bim,"- OBJECTIVES: In many countries, the healthcare sector is dealing with important challenges such as increased demand for healthcare services, capacity problems in hospitals and rising healthcare costs.",What are some of the challenges faced by the healthcare sector in many countries (pmcid=11163679)?,"Some of the challenges faced by the healthcare sector in many countries include increased demand for healthcare services, capacity problems in hospitals, and rising healthcare costs.",a946c4e0a0f2d50cc286e389fec00d65
11163679,Neppelenbroek E,Antenatal cardiotocography in primary midwife-led care: a budget impact analysis,2024,bim,"Therefore, one of the aims of the Dutch government is to move care from in-hospital to out-of-hospital care settings.",What is one of the aims of the Dutch government in terms of healthcare settings (pmcid=11163679)?,One of the aims of the Dutch government in terms of healthcare settings is to move care from in-hospital to out-of-hospital care settings.,a946c4e0a0f2d50cc286e389fec00d65
11163679,Neppelenbroek E,Antenatal cardiotocography in primary midwife-led care: a budget impact analysis,2024,bim,An example of an innovation where care is moved from a more specialised setting to a less specialised setting is the performance of an antenatal cardiotocography (aCTG) in primary midwife-led care.,What is the innovation discussed in the abstract sentence (pmcid=11163679)?,The innovation discussed in the abstract sentence is the performance of antenatal cardiotocography (aCTG) in primary midwife-led care.,a946c4e0a0f2d50cc286e389fec00d65
11163679,Neppelenbroek E,Antenatal cardiotocography in primary midwife-led care: a budget impact analysis,2024,bim,The aim of this study was to assess the budget impact of implementing aCTG for healthy pregnant women in midwife-led care compared with usual obstetrician-led care in the Netherlands.,What was the aim of the study conducted by Neppelenbroek E regarding antenatal cardiotocography in primary midwife-led care (pmcid=11163679)?,The aim of the study conducted by Neppelenbroek E regarding antenatal cardiotocography in primary midwife-led care was to assess the budget impact of implementing aCTG for healthy pregnant women in midwife-led care compared with usual obstetrician-led care in the Netherlands.,a946c4e0a0f2d50cc286e389fec00d65
11163679,Neppelenbroek E,Antenatal cardiotocography in primary midwife-led care: a budget impact analysis,2024,bim,"METHODS: A budget impact analysis was conducted to estimate the actual costs and reimbursement of aCTG performed in midwife-led care and obstetrician-led care (ie, base-case analysis) from the Dutch healthcare perspective.",What perspective was used for the budget impact analysis conducted in this study (pmcid=11163679)?,Dutch healthcare perspective,a946c4e0a0f2d50cc286e389fec00d65
11163679,Neppelenbroek E,Antenatal cardiotocography in primary midwife-led care: a budget impact analysis,2024,bim,"Epidemiological and healthcare utilisation data describing both care pathways were obtained from a prospective cohort, survey and national databases.",What type of data sources were used to obtain epidemiological and healthcare utilisation data for both care pathways (pmcid=11163679)?,"The data sources used were a prospective cohort, survey, and national databases.",a946c4e0a0f2d50cc286e389fec00d65
11163679,Neppelenbroek E,Antenatal cardiotocography in primary midwife-led care: a budget impact analysis,2024,bim,Different implementation rates of aCTG in midwife-led care were explored.,What was explored in terms of implementation rates of aCTG in midwife-led care (pmcid=11163679)?,Different implementation rates of aCTG,a946c4e0a0f2d50cc286e389fec00d65
11163679,Neppelenbroek E,Antenatal cardiotocography in primary midwife-led care: a budget impact analysis,2024,bim,A probabilistic sensitivity analysis was conducted to estimate the uncertainty surrounding the budget impact estimates.,What type of analysis was conducted to estimate the uncertainty surrounding the budget impact estimates in the study by Neppelenbroek et al. (pmcid=11163679)?,A probabilistic sensitivity analysis was conducted.,a946c4e0a0f2d50cc286e389fec00d65
11163679,Neppelenbroek E,Antenatal cardiotocography in primary midwife-led care: a budget impact analysis,2024,bim,"RESULTS: Shifting aCTG from obstetrician-led care to midwife-led-care would increase actual costs with €311 763 (97.5% CI €188 574 to €426 072) and €1 247 052 (97.5% CI €754 296 to €1 704 290) for implementation rates of 25% and 100%, respectively, while it would decrease reimbursement with -€7 538 335 (97.5% CI -€10 302 306 to -€4 559 661) and -€30 153 342 (97.5% CI -€41 209 225 to -€18 238 645) for implementation rates of 25% and 100%, respectively.",What would be the impact on actual costs and reimbursement if antenatal cardiotocography was shifted from obstetrician-led care to midwife-led care at implementation rates of 25% and 100%? (pmcid=11163679),"Shifting antenatal cardiotocography from obstetrician-led care to midwife-led care at implementation rates of 25% and 100% would result in an increase in actual costs of €311,763 and €1,247,052, respectively. On the other hand, it would lead to a decrease in reimbursement of -€7,538,335 and -€30,153,342, respectively.",a946c4e0a0f2d50cc286e389fec00d65
11163679,Neppelenbroek E,Antenatal cardiotocography in primary midwife-led care: a budget impact analysis,2024,bim,The sensitivity analysis results were consistent with those of the main analysis.,What were the results of the sensitivity analysis consistent with (pmcid=11163679)?,The sensitivity analysis results were consistent with those of the main analysis.,a946c4e0a0f2d50cc286e389fec00d65
11163679,Neppelenbroek E,Antenatal cardiotocography in primary midwife-led care: a budget impact analysis,2024,bim,"CONCLUSIONS: From the Dutch healthcare perspective, we estimated that implementing aCTG in midwife-led care may increase the associated actual costs.",What perspective was used to estimate the costs of implementing aCTG in midwife-led care in the Netherlands (pmcid=11163679)?,The Dutch healthcare perspective was used to estimate the costs of implementing aCTG in midwife-led care in the Netherlands.,a946c4e0a0f2d50cc286e389fec00d65
11163679,Neppelenbroek E,Antenatal cardiotocography in primary midwife-led care: a budget impact analysis,2024,bim,"At the same time, it might lower the healthcare reimbursement.",What might antenatal cardiotocography in primary midwife-led care do to healthcare reimbursement (pmcid=11163679)?,It might lower the healthcare reimbursement.,a946c4e0a0f2d50cc286e389fec00d65
10219864,Lodise T,"Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US",2023,bim,"- INTRODUCTION: Patients with Clostridioides difficile infection (CDI) often experience recurrences (rCDI), which are associated with high morbidity, mortality, and healthcare expenditures.",What are patients with Clostridioides difficile infection (CDI) often at risk for experiencing (pmcid=10219864)?,Patients with Clostridioides difficile infection (CDI) are often at risk for experiencing recurrences (rCDI).,9cd8640dcebe67ec1eb08eddb7a791c9
10219864,Lodise T,"Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US",2023,bim,"REBYOTA™ (fecal microbiota, live-jslm [FMBL]) is a microbiota-based live biotherapeutic approved for the prevention of rCDI following antibiotic treatment for rCDI.",What is REBYOTA™ (FMBL) approved for in the prevention of rCDI following antibiotic treatment for rCDI? (pmcid=10219864),REBYOTA™ (FMBL) is approved for the prevention of recurrent Clostridioides difficile infection (rCDI) following antibiotic treatment for rCDI.,9cd8640dcebe67ec1eb08eddb7a791c9
10219864,Lodise T,"Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US",2023,bim,We quantified the budget impact of FMBL during the first 3 years following introduction from a third-party US payer perspective.,What perspective was used to quantify the budget impact of FMBL during the first 3 years following introduction in the US (pmcid=10219864)?,The budget impact of FMBL during the first 3 years following introduction in the US was quantified from a third-party US payer perspective.,9cd8640dcebe67ec1eb08eddb7a791c9
10219864,Lodise T,"Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US",2023,bim,METHODS: A decision-tree model was used to estimate the budget impact of one-course FMBL by comparing costs under the scenario with FMBL to the scenario without FMBL (standard of care) in patients with one or more (≥ 1) recurrences after a primary episode of CDI and had completed ≥ 1 round of antibiotic treatments.,What model was used to estimate the budget impact of one-course FMBL in patients with recurrent Clostridioides difficile infection (pmcid=10219864)?,A decision-tree model was used to estimate the budget impact of one-course FMBL in patients with recurrent Clostridioides difficile infection.,9cd8640dcebe67ec1eb08eddb7a791c9
10219864,Lodise T,"Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US",2023,bim,"Drug costs, rCDI-related medical costs, and budget impact over 1-3 years were estimated in 2022 US dollars.",What costs were estimated in 2022 US dollars in the budget impact analysis of REBYOTA™ for preventing recurrent Clostridioides difficile infection in the US (pmcid=10219864)?,Drug costs and rCDI-related medical costs were estimated in 2022 US dollars in the budget impact analysis of REBYOTA™ for preventing recurrent Clostridioides difficile infection in the US.,9cd8640dcebe67ec1eb08eddb7a791c9
10219864,Lodise T,"Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US",2023,bim,One-way sensitivity analyses were performed.,What type of analyses were performed in the study (pmcid=10219864)?,One-way sensitivity analyses were performed.,9cd8640dcebe67ec1eb08eddb7a791c9
10219864,Lodise T,"Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US",2023,bim,"RESULTS: For an insurance plan with a population size of 1,000,000, 468 patients per year were estimated to have ≥ 1 rCDI.","How many patients per year were estimated to have ≥ 1 rCDI for an insurance plan with a population size of 1,000,000 (pmcid=10219864)?","468 patients per year were estimated to have ≥ 1 rCDI for an insurance plan with a population size of 1,000,000.",9cd8640dcebe67ec1eb08eddb7a791c9
10219864,Lodise T,"Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US",2023,bim,"The budget impact of one-course FMBL at $9000/course was cost-saving at an» average of -$0.0039 on a per-member-per-month (PMPM) basis, an average of -$8.30 on a per-treated-member-per-month (PTMPM) basis, and a total of -$139,865 on a plan level assuming 5%, 15%, and 20% of patients receive FMBL over 1-3 years, respectively.",What was the budget impact of one-course FMBL for preventing recurrent Clostridioides difficile infection in the US (pmcid=10219864)?,"The budget impact of one-course FMBL for preventing recurrent Clostridioides difficile infection in the US was cost-saving at an average of -$0.0039 on a per-member-per-month (PMPM) basis, an average of -$8.30 on a per-treated-member-per-month (PTMPM) basis, and a total of -$139,865 on a plan level assuming 5%, 15%, and 20% of patients receive FMBL over 1-3 years.",9cd8640dcebe67ec1eb08eddb7a791c9
10219864,Lodise T,"Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US",2023,bim,"The scenario with FMBL entry was associated with higher drug costs (difference at $0.0474 PMPM; $101.26 PTMPM; $1,706,445 total plan) and lower rCDI-related medical costs (difference at -$0.0513 PMPM; -$109.56 PTMPM; -$1,846,309 total plan).",What were the differences in drug costs and rCDI-related medical costs associated with the scenario involving FMBL entry (pmcid=10219864)?,"The difference in drug costs associated with the scenario involving FMBL entry was $0.0474 PMPM, $101.26 PTMPM, and $1,706,445 total plan. The difference in rCDI-related medical costs was -$0.0513 PMPM, -$109.56 PTMPM, and -$1,846,309 total plan.",9cd8640dcebe67ec1eb08eddb7a791c9
10219864,Lodise T,"Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US",2023,bim,"The budget impact of FMBL in patients at first rCDI was cost-saving at -$0.0139 PMPM, -$84.78 PTMPM, corresponding to an annual savings of $500,022.",What was the budget impact of FMBL in patients at first rCDI (pmcid=10219864)?,"The budget impact of FMBL in patients at first rCDI was cost-saving at -$0.0139 PMPM, -$84.78 PTMPM, corresponding to an annual savings of $500,022.",9cd8640dcebe67ec1eb08eddb7a791c9
10219864,Lodise T,"Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US",2023,bim,"CONCLUSIONS: FMBL has a cost-saving budget impact for a US payer, with higher initial drug costs being offset by savings in rCDI-related medical costs.",What are the conclusions regarding the budget impact of FMBL for preventing recurrent Clostridioides difficile infection in the US (pmcid=10219864)?,"FMBL has a cost-saving budget impact for a US payer, with higher initial drug costs being offset by savings in rCDI-related medical costs.",9cd8640dcebe67ec1eb08eddb7a791c9
10219864,Lodise T,"Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US",2023,bim,Greater cost saving was found in patients at first recurrence.,What patient population showed greater cost saving in the study (pmcid=10219864)?,Patients at first recurrence.,9cd8640dcebe67ec1eb08eddb7a791c9
11360725,Imaz-Iglesia I,Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost–Utility and Budget Impact Analysis,2024,bim,"- Two vaccines against rotavirus diseases, Rotarix(®) and RotaTeq(®), are being marketed in Spain; but rotavirus is not presently among the diseases covered by universal vaccination in Spain.",What vaccines against rotavirus diseases are being marketed in Spain (pmcid=11360725)?,Rotarix(®) and RotaTeq(®),e263ef51a38c7cef6c148dc80319e342
11360725,Imaz-Iglesia I,Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost–Utility and Budget Impact Analysis,2024,bim,"The aim of this study was to assess the efficiency of extending Spain's current targeted rotavirus vaccination strategy including only preterm babies, to a policy of universal vaccination.",What was the aim of the study (pmcid=11360725)?,The aim of the study was to assess the efficiency of extending Spain's current targeted rotavirus vaccination strategy to a policy of universal vaccination.,e263ef51a38c7cef6c148dc80319e342
11360725,Imaz-Iglesia I,Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost–Utility and Budget Impact Analysis,2024,bim,"A de novo cohort-based Markov model was built to evaluate the efficiency of three compared rotavirus vaccination strategies in Spain: targeted, universal, and no vaccination.",What type of model was built to evaluate the efficiency of rotavirus vaccination strategies in Spain (pmcid=11360725)?,A de novo cohort-based Markov model was built.,e263ef51a38c7cef6c148dc80319e342
11360725,Imaz-Iglesia I,Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost–Utility and Budget Impact Analysis,2024,bim,"Using Rotarix(®) or RotaTeq(®), we compared the cost-utility of these strategies from both a societal perspective and Spanish National Health System (SNHS) perspective.",What perspectives were used to compare the cost-utility of Rotarix(®) or RotaTeq(®) strategies in Spain (pmcid=11360725)?,The cost-utility of Rotarix(®) or RotaTeq(®) strategies in Spain was compared from both a societal perspective and the Spanish National Health System (SNHS) perspective.,e263ef51a38c7cef6c148dc80319e342
11360725,Imaz-Iglesia I,Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost–Utility and Budget Impact Analysis,2024,bim,The model represents the most important clinical events conceivably linked to rotavirus infection.,What does the model represent in the economic evaluation of rotavirus vaccination in Spain (pmcid=11360725)?,The model represents the most important clinical events conceivably linked to rotavirus infection in the economic evaluation of rotavirus vaccination in Spain.,e263ef51a38c7cef6c148dc80319e342
11360725,Imaz-Iglesia I,Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost–Utility and Budget Impact Analysis,2024,bim,"Efficacy, effectiveness, safety, costs, and utilities were identified by systematic reviews.",What were the factors identified by systematic reviews in the economic evaluation of rotavirus vaccination in Spain (pmcid=11360725)?,"Efficacy, effectiveness, safety, costs, and utilities were identified by systematic reviews.",e263ef51a38c7cef6c148dc80319e342
11360725,Imaz-Iglesia I,Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost–Utility and Budget Impact Analysis,2024,bim,"Incremental cost-utility ratio (ICUR) is EUR 23,638/QALY (Quality-Adjusted Life Year) for targeted vaccination with Rotarix(®) compared with no vaccination.",What is the incremental cost-utility ratio for targeted vaccination with Rotarix(®) compared with no vaccination (pmcid=11360725)?,"The incremental cost-utility ratio for targeted vaccination with Rotarix(®) compared with no vaccination is EUR 23,638 per Quality-Adjusted Life Year (QALY) (pmcid=11360725).",e263ef51a38c7cef6c148dc80319e342
11360725,Imaz-Iglesia I,Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost–Utility and Budget Impact Analysis,2024,bim,"The ICUR for the rest of the strategies evaluated are above EUR 30,000/QALY.",What is the Incremental Cost-Utility Ratio (ICUR) for the strategies evaluated in the study (pmcid=11360725)?,"The Incremental Cost-Utility Ratio (ICUR) for the strategies evaluated in the study with pmcid=11360725 is above EUR 30,000/QALY.",e263ef51a38c7cef6c148dc80319e342
11360725,Imaz-Iglesia I,Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost–Utility and Budget Impact Analysis,2024,bim,The sensitivity analysis shows price as the only parameter that could make the universal vaccination strategy efficient.,What parameter could make the universal vaccination strategy efficient according to the sensitivity analysis? (pmcid=11360725),Price,e263ef51a38c7cef6c148dc80319e342
11360725,Imaz-Iglesia I,Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost–Utility and Budget Impact Analysis,2024,bim,"Considering a threshold of EUR 25,000/QALY, only targeted vaccination with Rotarix(®) would be efficient from societal perspective.",What threshold was considered in the economic evaluation of rotavirus vaccination in Spain (pmcid=11360725)?,"EUR 25,000/QALY",e263ef51a38c7cef6c148dc80319e342
11360725,Imaz-Iglesia I,Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost–Utility and Budget Impact Analysis,2024,bim,Price drops of 36.9% for Rotarix(®) and 44.6% for RotaTeq(®) would make universal vaccination efficient.,What price drops for Rotarix(®) and RotaTeq(®) would make universal vaccination efficient (pmcid=11360725)?,Price drops of 36.9% for Rotarix(®) and 44.6% for RotaTeq(®) would make universal vaccination efficient.,e263ef51a38c7cef6c148dc80319e342
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,- INTRODUCTION: A high proportion of patients with end-stage kidney disease (ESKD) are treated with hemodialysis (HD).,What proportion of patients with end-stage kidney disease are treated with hemodialysis (pmcid=11570051)?,A high proportion of patients with end-stage kidney disease (ESKD) are treated with hemodialysis (HD).,46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,"To lower morbidity and maintain overall cost control in patients with ESKD, it is crucial for health systems to establish and maintain durable hemodialysis (HD) access.",What is crucial for health systems to establish and maintain in patients with ESKD to lower morbidity and maintain overall cost control (pmcid=11570051)?,It is crucial for health systems to establish and maintain durable hemodialysis (HD) access in patients with ESKD to lower morbidity and maintain overall cost control.,46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,Our objective was to assess the budget impact of utilizing the ‘WavelinQ Endo Arteriovenous Fistula (AVF) system’ (WavelinQ) for HD patients.,What was the objective of the study conducted by Delaney C regarding the utilization of the WavelinQ Endo Arteriovenous Fistula system for hemodialysis patients (pmcid=11570051)?,The objective of the study conducted by Delaney C regarding the utilization of the WavelinQ Endo Arteriovenous Fistula system for hemodialysis patients was to assess the budget impact of using the system for HD patients.,46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,"METHODS: A one-year economic model from the Hospital (Flinders Medical Centre, FMC) perspective was developed with Australian epidemiological and costing data.",What perspective was used in developing the one-year economic model for the Budget Impact Analysis of Utilization of WavelinQ Endo-arteriovenous Fistula System for Hemodialysis Patients at Flinders Medical Centre (pmcid=11570051)?,The perspective used in developing the one-year economic model for the Budget Impact Analysis at Flinders Medical Centre (pmcid=11570051) was from the Hospital perspective.,46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,Clinical data were collected from real-world sources.,What sources were used to collect clinical data for this study (pmcid=11570051)?,Clinical data for this study (pmcid=11570051) were collected from real-world sources.,46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,The incident (n=50) and prevalent (n=250) cohorts were based on FMC utilization patterns.,What were the incident and prevalent cohorts based on in this study (pmcid=11570051)?,The incident cohort (n=50) and prevalent cohort (n=250) were based on FMC utilization patterns.,46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,The current standard of care was surgical AVF (sAVF) and/or central venous catheters (CVC).,What was the current standard of care for hemodialysis patients prior to the utilization of the WavelinQ Endo-arteriovenous Fistula System? (pmcid=11570051),The current standard of care for hemodialysis patients prior to the utilization of the WavelinQ Endo-arteriovenous Fistula System was surgical AVF (sAVF) and/or central venous catheters (CVC).,46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,"With introduction of WavelinQ into practice, the substitution rate was set at 50 percent in new patients and ten percent amongst existing patients.",What was the substitution rate set at for new patients and existing patients with the introduction of WavelinQ into practice (pmcid=11570051)?,The substitution rate was set at 50 percent for new patients and ten percent for existing patients with the introduction of WavelinQ into practice (pmcid=11570051).,46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,Index procedure and reinterventions costs for the patient were based on the weighted average cost using National Efficient Price Determination 2020 to 21.,What was the basis for determining the index procedure and reinterventions costs for the patient (pmcid=11570051)?,The index procedure and reinterventions costs for the patient were based on the weighted average cost using National Efficient Price Determination 2020 to 21.,46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,Total costs preWavelinQ introduction were compared to post WavelinQ substitution to determine the budget impact.,What costs were compared to determine the budget impact in the study (pmcid=11570051)?,Total costs preWavelinQ introduction were compared to post WavelinQ substitution.,46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,"RESULTS: Based on FMC expected patient cohort and WavelinQ substitution rates, the mean annual cost savings per incident and prevalent patient were AUD26,873 and AUD3,549, respectively, which lead to overall mean annual cost savings per patient of AUD7,437.",What were the mean annual cost savings per incident and prevalent patient for the utilization of WavelinQ Endo-arteriovenous Fistula System in hemodialysis patients at an Australian hospital (pmcid=11570051)?,"The mean annual cost savings per incident patient were AUD26,873 and per prevalent patient were AUD3,549 for the utilization of WavelinQ Endo-arteriovenous Fistula System in hemodialysis patients at an Australian hospital.",46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,"The calculated per patient additional upfront cost of AUD7,010 with the WavelinQ index procedure versus sAVF was more than offset by the savings due to less post-procedure reinterventions.","What was the calculated per patient additional upfront cost of AUD7,010 with the WavelinQ index procedure versus sAVF offset by (pmcid=11570051)?","The calculated per patient additional upfront cost of AUD7,010 with the WavelinQ index procedure versus sAVF was offset by the savings due to less post-procedure reinterventions.",46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,"Overall, at the assumed substitution rates with WavelinQ, the model predicted a cost saving of approximately AUD2.2 million dollars for FMC.",What cost saving was predicted for FMC with the utilization of WavelinQ (pmcid=11570051)?,Approximately AUD2.2 million dollars,46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,CONCLUSIONS: The use of WavelinQ is expected to lead to cost savings of AUD2.2 million dollars from the FMC perspective.,What cost savings are expected from the FMC perspective with the use of WavelinQ (pmcid=11570051)?,AUD2.2 million dollars,46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,Hospitals should consider not just the increase in upfront costs but also potential savings from less reintervention procedures.,What should hospitals consider when evaluating the utilization of WavelinQ Endo-arteriovenous Fistula System for hemodialysis patients (pmcid=11570051)?,Hospitals should consider not just the increase in upfront costs but also potential savings from less reintervention procedures.,46c5fb05fd40111a1e87bfff42526481
11570051,Delaney C,PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective,2023,bim,There is a need for continued research on the budget impact of different HD modalities across multiple settings.,What is the need identified in the abstract sentence (pmcid=11570051)?,The need identified in the abstract sentence is for continued research on the budget impact of different hemodialysis modalities across multiple settings.,46c5fb05fd40111a1e87bfff42526481
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,"- BACKGROUND: Numerous studies have shown the effectiveness of testing for hepatitis B (HBV) and hepatitis C (HCV) in emergency departments (ED), due to the elevated prevalence amongst attendees.",What have numerous studies shown regarding testing for hepatitis B and hepatitis C in emergency departments (pmcid=9664679)?,"Numerous studies have shown the effectiveness of testing for hepatitis B (HBV) and hepatitis C (HCV) in emergency departments (ED), due to the elevated prevalence amongst attendees.",85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,The aim of this study was to conduct a cost-effectiveness analysis of universal opt-out HBV and HCV testing in EDs based on 2 long-term studies of the real-world effectiveness of testing in 2 large ED's in the UK.,What was the aim of the study conducted in the emergency department regarding universal opt-out HBV and HCV testing (pmcid=9664679)?,The aim of the study was to conduct a cost-effectiveness analysis of universal opt-out HBV and HCV testing in emergency departments based on two long-term studies of the real-world effectiveness of testing in two large EDs in the UK.,85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,"METHODS: A Markov model was used to evaluate ED-based HBV and HCV testing versus no ED testing, in addition to current testing practice.",What type of model was used to evaluate ED-based HBV and HCV testing in the study (pmcid=9664679)?,A Markov model was used to evaluate ED-based HBV and HCV testing in the study (pmcid=9664679).,85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,The two EDs had a HBV HBsAg prevalence of 0.5-0.9% and an HCV RNA prevalence of 0.9-1.0%.,What were the prevalence rates of HBV HBsAg and HCV RNA in the two emergency departments (pmcid=9664679)?,"The prevalence rates of HBV HBsAg in the two emergency departments were 0.5-0.9%, and the prevalence rates of HCV RNA were 0.9-1.0%.",85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,"The analysis was performed from a UK health service perspective, over a lifetime time horizon.",What perspective was the analysis performed from (pmcid=9664679)?,The analysis was performed from a UK health service perspective.,85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,"Costs are reported in British pounds (GBP), and outcomes as quality adjusted life years (QALYs), with both discounted at 3.5% per year.",What are the costs reported in for this study (pmcid=9664679)?,Costs are reported in British pounds (GBP).,85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,Incremental cost-effectiveness ratios (ICER) are calculated as costs per QALY gained.,What are the Incremental cost-effectiveness ratios (ICER) calculated as in this study (pmcid=9664679)?,Costs per QALY gained,85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,"A willingness-to-pay threshold of £20,000/QALY was used.",What threshold was used for willingness-to-pay in the cost-effectiveness analysis (pmcid=9664679)?,"£20,000/QALY",85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,"The cost-effectiveness was estimated for both infections, in both ED's.",What was estimated for both infections in both ED's (pmcid=9664679)?,The cost-effectiveness was estimated for both hepatitis B and hepatitis C in both emergency departments.,85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,"RESULTS: HBV and HCV testing were highly cost-effective in both settings, with ICERs ranging from £7,177 to £12,387 per QALY gained.",What were the incremental cost-effectiveness ratios (ICERs) for HBV and HCV testing in both settings (pmcid=9664679)?,"The incremental cost-effectiveness ratios (ICERs) for HBV and HCV testing in both settings ranged from £7,177 to £12,387 per QALY gained.",85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,"In probabilistic analyses, HBV testing was 89-94% likely to be cost-effective at the threshold, while HCV testing was 94-100% likely to be cost-effective, across both settings.",What was the likelihood of HBV testing being cost-effective at the threshold in the probabilistic analyses (pmcid=9664679)?,HBV testing was 89-94% likely to be cost-effective at the threshold in the probabilistic analyses.,85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,"In deterministic sensitivity analyses, testing remained cost-effective in both locations at ≥ 0.25% HBsAg prevalence, and ≥ 0.49% HCV RNA prevalence.",What prevalence thresholds were used in the deterministic sensitivity analyses for cost-effectiveness in both locations (pmcid=9664679)?,The prevalence thresholds used in the deterministic sensitivity analyses for cost-effectiveness in both locations were ≥ 0.25% HBsAg prevalence and ≥ 0.49% HCV RNA prevalence.,85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,This is much lower than the prevalence observed in the two EDs included in this study.,What is the prevalence observed in the two EDs included in this study? (pmcid=9664679),The prevalence observed in the two EDs included in this study is much lower than the national prevalence.,85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,"CONCLUSIONS: HBV and HCV testing in urban EDs is highly cost-effective in the UK, and can be cost-effective at relatively low prevalence.",What is the conclusion regarding the cost-effectiveness of HBV and HCV testing in urban EDs in the UK (pmcid=9664679)?,"The conclusion is that HBV and HCV testing in urban EDs in the UK is highly cost-effective, and can be cost-effective even at relatively low prevalence.",85b0b6db144dcf26164abd0b2a88a570
9664679,Williams J,Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom,2022,bim,These results should be reflected in UK and European hepatitis testing guidelines.,What should be reflected in UK and European hepatitis testing guidelines (pmcid=9664679)?,The results of universal testing for hepatitis B and hepatitis C in the emergency department should be reflected in UK and European hepatitis testing guidelines.,85b0b6db144dcf26164abd0b2a88a570
11608167,Wenzel A,Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in Germany,2024,bim,- PURPOSE: Next-generation sequencing (NGS) tools have clinical advantages over blood culture but are more expensive.,What are the clinical advantages of Next-generation sequencing (NGS) tools over blood culture according to the abstract sentence (pmcid=11608167)?,NGS tools have clinical advantages over blood culture in terms of their diagnostic capabilities and accuracy.,6079c1cf1cd932d275ec2ccadd0f6715
11608167,Wenzel A,Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in Germany,2024,bim,This study assesses the budget impact and break-even point of NGS testing costs from a healthcare provider's perspective in Germany.,What perspective was used to assess the budget impact and break-even point of NGS testing costs in Germany (pmcid=11608167)?,The budget impact and break-even point of NGS testing costs in Germany were assessed from a healthcare provider's perspective.,6079c1cf1cd932d275ec2ccadd0f6715
11608167,Wenzel A,Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in Germany,2024,bim,METHODS: The budget impact was calculated based on aggregated data of German post-operative surgery cases.,What data was the budget impact calculation based on (pmcid=11608167)?,The budget impact calculation was based on aggregated data of German post-operative surgery cases.,6079c1cf1cd932d275ec2ccadd0f6715
11608167,Wenzel A,Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in Germany,2024,bim,Simulated cost savings were calculated based on a simulated reduction in hospital length of stay (LOS) of four or eight days with a positivity rate of 71% and compared to the costs of one (scenario A) or two tests (scenario B) per case.,What were the simulated cost savings based on in the study (pmcid=11608167)?,The simulated cost savings were based on a simulated reduction in hospital length of stay (LOS) of four or eight days with a positivity rate of 71% and compared to the costs of one (scenario A) or two tests (scenario B) per case.,6079c1cf1cd932d275ec2ccadd0f6715
11608167,Wenzel A,Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in Germany,2024,bim,"Furthermore, the break-even point of the cost of two tests compared to saved costs through shortened LOS was conducted.",What was conducted to determine the break-even point of the cost of two tests compared to saved costs through shortened LOS (pmcid=11608167)?,A break-even analysis was conducted to determine the break-even point of the cost of two tests compared to saved costs through shortened Length of Stay (LOS).,6079c1cf1cd932d275ec2ccadd0f6715
11608167,Wenzel A,Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in Germany,2024,bim,"RESULTS: For 9,450 cases, an average budget impact for scenario A and scenario B of €1,290.41 [95% CI €1,119.64 - €1,461.19] and - €208.59 [95% CI - €379.36 - - €37.81] was identified for gastrointestinal and kidney surgery cases, and €1,355.58 [95% CI €1,049.62 - €1,661.55] and €18.72 [95% CI - €324.69 - €287.24] for vascular artery surgery cases, respectively.",What was the average budget impact identified for gastrointestinal and kidney surgery cases in scenario A and scenario B (pmcid=11608167)?,"For gastrointestinal and kidney surgery cases, the average budget impact identified was €1,290.41 for scenario A and - €208.59 for scenario B.",6079c1cf1cd932d275ec2ccadd0f6715
11608167,Wenzel A,Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in Germany,2024,bim,The break-even analysis showed that using two tests per case could achieve a minimum positive contribution margin with an average of 1.9 tests per case across the study population.,What did the break-even analysis show in terms of the number of tests per case to achieve a minimum positive contribution margin (pmcid=11608167)?,The break-even analysis showed that using two tests per case could achieve a minimum positive contribution margin with an average of 1.9 tests per case across the study population.,6079c1cf1cd932d275ec2ccadd0f6715
11608167,Wenzel A,Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in Germany,2024,bim,CONCLUSION: The results revealed a positive budget impact for one NGS test and a slightly negative budget impact for two NGS tests per case.,"What were the budget impacts of one NGS test and two NGS tests per case, according to the study (pmcid=11608167)?","The budget impact of one NGS test per case was positive, while the budget impact of two NGS tests per case was slightly negative, according to the study with pmcid=11608167.",6079c1cf1cd932d275ec2ccadd0f6715
11608167,Wenzel A,Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in Germany,2024,bim,Findings suggest that largest cost savings are generated for more severe cases and are highly dependent on the patient population.,What do the findings suggest about the cost savings generated in more severe cases and their dependency on the patient population (pmcid=11608167)?,The findings suggest that the largest cost savings are generated for more severe cases and are highly dependent on the patient population.,6079c1cf1cd932d275ec2ccadd0f6715
10571281,Aungsumart S,Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis,2023,bim,- BACKGROUND: Multiple sclerosis is an inflammatory demyelination process in the central nervous system (CNS) causing neurological disability and poor quality of life.,What is the background information provided in the abstract of the study (pmcid=10571281)?,The background information provided in the abstract of the study (pmcid=10571281) is that multiple sclerosis is an inflammatory demyelination process in the central nervous system (CNS) causing neurological disability and poor quality of life.,bafa5aeacfb14f8a99e157fe3283c53c
10571281,Aungsumart S,Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis,2023,bim,"Currently, Thai Food and Drug Administration (FDA)-approved disease-modifying therapy is costly, and most patients with multiple sclerosis are ineligible for treatment in Thailand as previous studies have challenged its cost-effectiveness.",What has challenged the cost-effectiveness of the currently approved disease-modifying therapy for multiple sclerosis in Thailand (pmcid=10571281)?,Previous studies have challenged the cost-effectiveness of the currently approved disease-modifying therapy for multiple sclerosis in Thailand.,bafa5aeacfb14f8a99e157fe3283c53c
10571281,Aungsumart S,Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis,2023,bim,"Off-label use of rituximab is inexpensive and highly effective in treating multiple sclerosis, but evidence of its cost-effectiveness in Thailand is yet to be collected.",What is the evidence lacking regarding the cost-effectiveness of rituximab in treating multiple sclerosis in Thailand (pmcid=10571281)?,The evidence lacking regarding the cost-effectiveness of rituximab in treating multiple sclerosis in Thailand is whether it is cost-effective or not.,bafa5aeacfb14f8a99e157fe3283c53c
10571281,Aungsumart S,Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis,2023,bim,"METHODS: This study aimed to evaluate the cost-utility and budget impact of rituximab for multiple sclerosis treatment compared with best supportive care, the standard practice in Thailand to treat the disease.",What was the aim of the study (pmcid=10571281)?,"The aim of the study with pmcid=10571281 was to evaluate the cost-utility and budget impact of rituximab for multiple sclerosis treatment compared with best supportive care, the standard practice in Thailand for treating the disease.",bafa5aeacfb14f8a99e157fe3283c53c
10571281,Aungsumart S,Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis,2023,bim,A Markov model with a one-month cycle length and lifetime horizon was applied to compare the costs and outcomes of rituximab and best supportive care based on a societal perspective.,What model was applied to compare the costs and outcomes of rituximab and best supportive care in the study (pmcid=10571281)?,A Markov model,bafa5aeacfb14f8a99e157fe3283c53c
10571281,Aungsumart S,Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis,2023,bim,"Accordingly, incremental cost-effectiveness ratios were estimated.",What was estimated in this study (pmcid=10571281)?,Incremental cost-effectiveness ratios were estimated in this study.,bafa5aeacfb14f8a99e157fe3283c53c
10571281,Aungsumart S,Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis,2023,bim,Probabilistic and one-way sensitivity analyses were conducted to investigate parameter uncertainty.,What type of sensitivity analyses were conducted in the study (pmcid=10571281)?,Probabilistic and one-way sensitivity analyses were conducted in the study (pmcid=10571281).,bafa5aeacfb14f8a99e157fe3283c53c
10571281,Aungsumart S,Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis,2023,bim,"In addition, the Markov model was used to assess the 5-year budget impact from the government perspective.",What model was used to assess the 5-year budget impact from the government perspective (pmcid=10571281)?,The Markov model was used to assess the 5-year budget impact from the government perspective.,bafa5aeacfb14f8a99e157fe3283c53c
10571281,Aungsumart S,Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis,2023,bim,"RESULTS: A rituximab biosimilar demonstrated higher effectiveness and lower associated costs, compared to best supportive care, with the highest probability of being cost-effective (96%).",What was the effectiveness and cost comparison of rituximab biosimilar versus best supportive care in the study (pmcid=10571281)?,The rituximab biosimilar demonstrated higher effectiveness and lower associated costs compared to best supportive care in the study.,bafa5aeacfb14f8a99e157fe3283c53c
10571281,Aungsumart S,Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis,2023,bim,The probability of relapse was the most sensitive parameter according to the one-way sensitivity analysis.,What was the most sensitive parameter in the one-way sensitivity analysis of the economic evaluation and budget impact analysis of Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand (pmcid=10571281)?,The most sensitive parameter in the one-way sensitivity analysis was the probability of relapse.,bafa5aeacfb14f8a99e157fe3283c53c
10571281,Aungsumart S,Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis,2023,bim,"The calculated budget impact of treating patients with multiple sclerosis in Thailand was 26,360,000 Thai baht (THB) or 844,255 United States dollars (USD) in the first fiscal year, and approximately 20,810,000-23,080,000 THB (666,608-739,388 USD) in the next four fiscal years.",What was the calculated budget impact of treating patients with multiple sclerosis in Thailand in the first fiscal year (pmcid=10571281)?,"The calculated budget impact of treating patients with multiple sclerosis in Thailand in the first fiscal year was 26,360,000 Thai baht (THB) or 844,255 United States dollars (USD).",bafa5aeacfb14f8a99e157fe3283c53c
10571281,Aungsumart S,Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis,2023,bim,"CONCLUSION: In Thailand, a rituximab biosimilar would reduce the overall costs of multiple sclerosis treatment and should, therefore, be included in the National List of Essential Medicines.",What would the inclusion of a rituximab biosimilar in the National List of Essential Medicines in Thailand result in (pmcid=10571281)?,The inclusion of a rituximab biosimilar in the National List of Essential Medicines in Thailand would result in reducing the overall costs of multiple sclerosis treatment.,bafa5aeacfb14f8a99e157fe3283c53c
10032398,Ngan TT,Budget impact analysis of a home-based colorectal cancer screening programme in Malaysia,2023,bim,- OBJECTIVES: The 2020-2022 research project 'Colorectal Cancer Screening Intervention for Malaysia' (CRC-SIM) evaluated the implementation of a home-based CRC screening pilot in Segamat District.,What was the objective of the 2020-2022 research project 'Colorectal Cancer Screening Intervention for Malaysia' (CRC-SIM) (pmcid=10032398)?,The objective of the 2020-2022 research project 'Colorectal Cancer Screening Intervention for Malaysia' (CRC-SIM) was to evaluate the implementation of a home-based CRC screening pilot in Segamat District.,3573395bd882de455d00018e2ba0fae2
10032398,Ngan TT,Budget impact analysis of a home-based colorectal cancer screening programme in Malaysia,2023,bim,This budget impact analysis (BIA) assessed the expected changes in health expenditure of the Malaysian Ministry of Health budget in the scenario where the pilot programme was implemented nationwide vs current opportunistic screening.,What changes in health expenditure were assessed in the budget impact analysis (pmcid=10032398)?,The budget impact analysis assessed the expected changes in health expenditure of the Malaysian Ministry of Health budget in the scenario where the pilot programme was implemented nationwide compared to current opportunistic screening.,3573395bd882de455d00018e2ba0fae2
10032398,Ngan TT,Budget impact analysis of a home-based colorectal cancer screening programme in Malaysia,2023,bim,DESIGN: Budget impact analysis.,What type of analysis was conducted in this study (pmcid=10032398)?,Budget impact analysis,3573395bd882de455d00018e2ba0fae2
10032398,Ngan TT,Budget impact analysis of a home-based colorectal cancer screening programme in Malaysia,2023,bim,"Assumptions and costs in the opportunistic and novel CRC screening scenarios were derived from a previous evaluation of opportunistic CRC screening in community health clinics across Malaysia and the CRC-SIM research project, respectively.",What were the assumptions and costs derived from for the opportunistic and novel CRC screening scenarios (pmcid=10032398)?,"The assumptions and costs for the opportunistic and novel CRC screening scenarios were derived from a previous evaluation of opportunistic CRC screening in community health clinics across Malaysia and the CRC-SIM research project, respectively.",3573395bd882de455d00018e2ba0fae2
10032398,Ngan TT,Budget impact analysis of a home-based colorectal cancer screening programme in Malaysia,2023,bim,SETTING: National level (with supplement analysis for district level).,What level was the setting for the budget impact analysis of the home-based colorectal cancer screening programme in Malaysia (pmcid=10032398)?,"The setting for the budget impact analysis of the home-based colorectal cancer screening programme in Malaysia (pmcid=10032398) was at the national level, with supplement analysis for district level.",3573395bd882de455d00018e2ba0fae2
10032398,Ngan TT,Budget impact analysis of a home-based colorectal cancer screening programme in Malaysia,2023,bim,The BIA was conducted from the viewpoint of the federal government and estimated the annual financial impact over a period of 5 years.,What viewpoint was the budget impact analysis conducted from (pmcid=10032398)?,The budget impact analysis was conducted from the viewpoint of the federal government.,3573395bd882de455d00018e2ba0fae2
10032398,Ngan TT,Budget impact analysis of a home-based colorectal cancer screening programme in Malaysia,2023,bim,RESULTS: The total annual cost of the current practice of opportunistic screening was RM1 584 321 (~I$1 099 460) of which 80% (RM1 274 690 or ~I$884 587) was expended on the provision of opportunistic CRC to adults who availed of the service.,What was the total annual cost of the current practice of opportunistic screening in Malaysia (pmcid=10032398)?,"The total annual cost of the current practice of opportunistic screening in Malaysia was RM1,584,321 (~I$1,099,460).",3573395bd882de455d00018e2ba0fae2
10032398,Ngan TT,Budget impact analysis of a home-based colorectal cancer screening programme in Malaysia,2023,bim,"Regarding the implementation of national CRC screening programme, the net budget impact in the first year was estimated to be RM107 631 959 (~I$74 692 546) and to reach RM148 485 812 (~I$103 043 589) in the fifth year based on an assumed increased uptake of 5% annually.",What was the estimated net budget impact of the home-based colorectal cancer screening programme in Malaysia in the first year (pmcid=10032398)?,"The estimated net budget impact of the home-based colorectal cancer screening programme in Malaysia in the first year was RM107,631,959 (~I$74,692,546).",3573395bd882de455d00018e2ba0fae2
10032398,Ngan TT,Budget impact analysis of a home-based colorectal cancer screening programme in Malaysia,2023,bim,"The costs were calculated to be sensitive to the probability of adults who were contactable, eligible and agreeable to participating in the programme.",What factor were the costs calculated to be sensitive to in the study (pmcid=10032398)?,"The costs were calculated to be sensitive to the probability of adults who were contactable, eligible and agreeable to participating in the programme.",3573395bd882de455d00018e2ba0fae2
10032398,Ngan TT,Budget impact analysis of a home-based colorectal cancer screening programme in Malaysia,2023,bim,CONCLUSIONS: Results from the BIA provided direct and explicit estimates of the budget changes to when implementing a population-based national CRC screening programme to aid decision making by health services planners and commissioners in Malaysia about whether such programme is affordable within given their budget constraint.,What did the Budget Impact Analysis provide estimates of in relation to implementing a population-based national CRC screening programme in Malaysia (pmcid=10032398)?,The Budget Impact Analysis provided direct and explicit estimates of the budget changes when implementing a population-based national CRC screening programme in Malaysia.,3573395bd882de455d00018e2ba0fae2
10032398,Ngan TT,Budget impact analysis of a home-based colorectal cancer screening programme in Malaysia,2023,bim,The study also illustrates the use and value of the BIA approach in low-income and middle-income countries and resource-constrained settings.,What does the study illustrate the use and value of in low-income and middle-income countries and resource-constrained settings (pmcid=10032398)?,The study illustrates the use and value of the Budget Impact Analysis (BIA) approach in low-income and middle-income countries and resource-constrained settings.,3573395bd882de455d00018e2ba0fae2
11419898,Qian Z,Environmental and economic impact analysis of levying VOCs environmental protection tax in China,2024,bim,- China is one of the largest volatile organic compounds (VOCs) emitters worldwide.,What country is one of the largest volatile organic compounds (VOCs) emitters worldwide (pmcid=11419898)?,China,e9d25f27584f22254d1088776955f495
11419898,Qian Z,Environmental and economic impact analysis of levying VOCs environmental protection tax in China,2024,bim,The emission levels of and harm caused by VOCs have attracted much attention.,What has attracted much attention in terms of emission levels and harm caused in the study (pmcid=11419898)?,The emission levels of and harm caused by VOCs have attracted much attention.,e9d25f27584f22254d1088776955f495
11419898,Qian Z,Environmental and economic impact analysis of levying VOCs environmental protection tax in China,2024,bim,"China has implemented multiple policies for VOCs prevention and control but lacks economic control measures for VOCs In this study, the input-output (IO) price model was used to simulate and analyze the emission reduction and economic effects resulting from the imposition of a VOCs environmental protection tax (EPT) in 31 provinces in China.",What model was used to simulate and analyze the emission reduction and economic effects of levying a VOCs environmental protection tax in China (pmcid=11419898)?,The input-output (IO) price model was used.,e9d25f27584f22254d1088776955f495
11419898,Qian Z,Environmental and economic impact analysis of levying VOCs environmental protection tax in China,2024,bim,"The results show that, first, the collection of a VOCs-EPT can achieve not only VOCs emission reductions but also the synergistic emission reductions of other major pollutants.",What can the collection of a VOCs-EPT achieve according to the results (pmcid=11419898)?,The collection of a VOCs-EPT can achieve VOCs emission reductions and synergistic emission reductions of other major pollutants according to the results (pmcid=11419898).,e9d25f27584f22254d1088776955f495
11419898,Qian Z,Environmental and economic impact analysis of levying VOCs environmental protection tax in China,2024,bim,"Second, the collection of a VOCs-EPT could have a negative impact on the macroeconomy, i.e., the greater the tax scope and the higher the tax rate are, the greater the negative economic impact.",What could be the negative impact of levying VOCs environmental protection tax in China (pmcid=11419898)?,"The negative impact of levying VOCs environmental protection tax in China could be a negative impact on the macroeconomy, with the extent of the impact increasing with the tax scope and tax rate.",e9d25f27584f22254d1088776955f495
11419898,Qian Z,Environmental and economic impact analysis of levying VOCs environmental protection tax in China,2024,bim,"Third, differences in the level of economic development, the structure of pollution emissions and the stringency of tax policies among regions would cause the emission reduction effect and related negative economic impact to vary across regions.",What would cause the emission reduction effect and related negative economic impact to vary across regions? (pmcid=11419898),"Differences in the level of economic development, the structure of pollution emissions, and the stringency of tax policies among regions would cause the emission reduction effect and related negative economic impact to vary across regions.",e9d25f27584f22254d1088776955f495
11419898,Qian Z,Environmental and economic impact analysis of levying VOCs environmental protection tax in China,2024,bim,"Finally, the collection of a VOCs-EPT could have heterogeneous impacts on various industries, as high-emission industries would suffer greater negative impacts.",What impacts could the collection of a VOCs-EPT have on various industries (pmcid=11419898)?,"The collection of a VOCs-EPT could have heterogeneous impacts on various industries, with high-emission industries experiencing greater negative impacts.",e9d25f27584f22254d1088776955f495
11419898,Qian Z,Environmental and economic impact analysis of levying VOCs environmental protection tax in China,2024,bim,"Therefore, each region should set tax rates that match its provincial economic and environmental development levels.",What should each region do in regards to setting tax rates based on the provincial economic and environmental development levels? (pmcid=11419898),Each region should set tax rates that match its provincial economic and environmental development levels.,e9d25f27584f22254d1088776955f495
11419898,Qian Z,Environmental and economic impact analysis of levying VOCs environmental protection tax in China,2024,bim,"Furthermore, a VOCs-EPT can be levied on key industries, and reasonable preferential tax policies can be formulated to reduce negative macroeconomic benefits.",What can be done to reduce negative macroeconomic benefits related to levying VOCs environmental protection tax in China (pmcid=11419898)?,Formulating reasonable preferential tax policies can be done to reduce negative macroeconomic benefits related to levying VOCs environmental protection tax in China.,e9d25f27584f22254d1088776955f495
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,"- BACKGROUND: Although the cost of implementing evidence-based interventions (EBIs) is a key determinant of adoption, lack of cost information is widespread.",What is a key determinant of adoption of evidence-based interventions (EBIs) according to the abstract sentence provided (pmcid=10240781)?,The cost of implementing evidence-based interventions (EBIs) is a key determinant of adoption according to the abstract sentence provided.,cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,"We previously evaluated the cost of preparing to implement Family Check-Up 4 Health (FCU4Health), an individually tailored, evidence-based parenting program that takes a whole child approach, with effects on both behavioral health and health behavior outcomes, in primary care settings.",What program was evaluated in terms of cost to implement in primary care settings (pmcid=10240781)?,Family Check-Up 4 Health (FCU4Health),cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,"This study estimates the cost of implementation, including preparation.","What does the study estimate the cost of implementing, including preparation (pmcid=10240781)?","The study estimates the cost of implementing a whole child health focused, family-based intervention in primary care for children with elevated BMI, including preparation.",cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,"METHODS: We assessed the cost of FCU4Health across the preparation and implementation phases spanning 32 months and 1 week (October 1, 2016-June 13, 2019) in a type 2 hybrid effectiveness-implementation study.",What was the duration of the preparation and implementation phases for assessing the cost of FCU4Health in the study (pmcid=10240781)?,"The duration of the preparation and implementation phases for assessing the cost of FCU4Health in the study (pmcid=10240781) was 32 months and 1 week, spanning from October 1, 2016, to June 13, 2019.",cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,"This family-level randomized controlled trial took place in Arizona with n = 113 predominantly low-income, Latino families with children ages > 5.5 to < 13 years.",What was the location of the family-level randomized controlled trial mentioned in the abstract (pmcid=10240781)?,Arizona,cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,"Using electronic cost capture and time-based activity-driven methods, budget impact analysis from the perspective of a future FCU4Health adopting entity-namely, ambulatory pediatric care clinicians-was used to estimate the cost of implementation.",What perspective was used to estimate the cost of implementation in the budget impact analysis (pmcid=10240781)?,The perspective of ambulatory pediatric care clinicians was used to estimate the cost of implementation in the budget impact analysis (pmcid=10240781).,cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,"Labor costs were based on 2021 Bureau of Labor Statistics Occupational Employment Statistics, NIH-directed salary cap levels or known salaries, plus fringe benefits at a standard rate of 30%.",What were labor costs based on in the study (pmcid=10240781)?,"Labor costs were based on 2021 Bureau of Labor Statistics Occupational Employment Statistics, NIH-directed salary cap levels or known salaries, plus fringe benefits at a standard rate of 30%.",cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,Non-labor costs were based on actual amounts spent from receipts and invoices.,What were the non-labor costs based on in the study (pmcid=10240781)?,The non-labor costs in the study (pmcid=10240781) were based on actual amounts spent from receipts and invoices.,cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,"RESULTS: The cost of FCU4Health implementation to 113 families was $268,886 ($2380 per family).",What was the cost of FCU4Health implementation to 113 families (pmcid=10240781)?,"The cost of FCU4Health implementation to 113 families was $268,886 ($2380 per family).",cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,"Actual per family cost varied widely, as individual tailoring resulted in families receiving a range of 1-15 sessions.",What range of sessions did families receive as a result of individual tailoring (pmcid=10240781)?,Families received a range of 1-15 sessions as a result of individual tailoring.,cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,"The estimated cost of replicating implementation for future sites ranged from $37,636-$72,372 ($333-$641 per family).",What is the estimated cost range for replicating implementation for future sites in the study (pmcid=10240781)?,"The estimated cost range for replicating implementation for future sites in the study (pmcid=10240781) is $37,636-$72,372 ($333-$641 per family).",cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,"Using our previously reported preparation costs (i.e., $174,489; $1544 per family), with estimated replication costs of $18,524-$21,836 ($164-$193 per family), the total cost of delivering FCU4Health was $443,375 ($3924 per family), with total estimated replication costs of $56,160-$94,208 ($497-$834 per family).",What were the total estimated replication costs of delivering FCU4Health (pmcid=10240781)?,"The total estimated replication costs of delivering FCU4Health were $56,160-$94,208 ($497-$834 per family).",cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,CONCLUSIONS: This study provides a baseline for costs associated with implementation of an individually tailored parenting program.,What does this study provide a baseline for (pmcid=10240781)?,Costs associated with implementation of an individually tailored parenting program.,cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,"Results provide critical information for decision makers and a model for future economic analysis and can be used to inform optimization thresholds for implementation and, when necessary, benchmarks for program adaptation to promote scale-up.",What critical information do the results provide for decision makers and what can they be used for (pmcid=10240781)?,"The results provide critical information for decision makers on the cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI. They can be used to inform optimization thresholds for implementation and, when necessary, benchmarks for program adaptation to promote scale-up.",cd56b4e4b1a97349144f6b164d349cda
10240781,Harris A,"A budget impact analysis of cost to implement a whole child health focused, family-based intervention in primary care for children with elevated BMI",2023,bim,"TRIAL REGISTRATION: This trial was prospectively registered on January 6, 2017, at ClinicalTrials.gov (NCT03013309).",What was the date of prospective registration for this trial (pmcid=10240781)?,"January 6, 2017",cd56b4e4b1a97349144f6b164d349cda
10597971,Ken-Opurum J,Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus,2023,bim,"- INTRODUCTION: The clinical benefits of treating patients with type 2 diabetes mellitus (T2DM) with fixed-ratio combination of insulin iGlar (iGlar) plus lixisenatide (iGlarLixi) were demonstrated in clinical trials and real-world evidence studies; however, its cost impact to healthcare payers is unknown.",What is the cost impact of treating patients with type 2 diabetes mellitus with iGlarLixi on healthcare payers (pmcid=10597971)?,The cost impact of treating patients with type 2 diabetes mellitus with iGlarLixi on healthcare payers is unknown.,c62b9f80d92406349b63a384609a186c
10597971,Ken-Opurum J,Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus,2023,bim,METHODS: A budget impact model was developed from a United States (US) payer's perspective for a hypothetical healthcare plan of 1 million people over a 1-year time horizon.,What perspective was used for the budget impact model developed in this study (pmcid=10597971)?,The budget impact model was developed from a United States (US) payer's perspective.,c62b9f80d92406349b63a384609a186c
10597971,Ken-Opurum J,Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus,2023,bim,"In scenario analysis, patients with uncontrolled glycated hemoglobin (HbA1c) treated with 60 units or less of daily insulin (insulin cohort) or oral antidiabetic drugs (OADs) only (OAD cohort) were intensified to iGlarLixi/rapid-acting insulin (RAI)/glucagon-like peptide 1 receptor agonists (GLP-1RA) or iGlarLixi/iGlar/GLP-1RA, respectively.",What treatment strategies were compared in the scenario analysis mentioned in the abstract (pmcid=10597971)?,The treatment strategies compared in the scenario analysis mentioned in the abstract were intensification with iGlarLixi/rapid-acting insulin (RAI)/glucagon-like peptide 1 receptor agonists (GLP-1RA) or iGlarLixi/iGlar/GLP-1RA for patients with uncontrolled glycated hemoglobin (HbA1c) treated with 60 units or less of daily insulin (insulin cohort) or oral antidiabetic drugs (OADs) only (OAD cohort).,c62b9f80d92406349b63a384609a186c
10597971,Ken-Opurum J,Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus,2023,bim,"Model inputs from real-world data (RWD) included baseline market shares, proportion of patients intensifying to respective treatments, and dosing inputs; unit costs were obtained from published literature.",What type of data were the model inputs based on (pmcid=10597971)?,Real-world data (RWD),c62b9f80d92406349b63a384609a186c
10597971,Ken-Opurum J,Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus,2023,bim,One-way sensitivity analyses assessed the impact of individual parameters.,What did the one-way sensitivity analyses assess in the study (pmcid=10597971)?,The one-way sensitivity analyses assessed the impact of individual parameters in the study.,c62b9f80d92406349b63a384609a186c
10597971,Ken-Opurum J,Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus,2023,bim,"RESULTS: Intensification with iGlarLixi resulted in the lowest incremental per member per month (PMPM) budget impact compared to other intensifying drugs (iGlar, RAI, and GLP-1RA).","What was the lowest incremental per member per month (PMPM) budget impact of intensification with iGlarLixi compared to other intensifying drugs (iGlar, RAI, and GLP-1RA) (pmcid=10597971)?","The lowest incremental per member per month (PMPM) budget impact of intensification with iGlarLixi compared to other intensifying drugs (iGlar, RAI, and GLP-1RA) was observed in the study with pmcid=10597971.",c62b9f80d92406349b63a384609a186c
10597971,Ken-Opurum J,Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus,2023,bim,"In the insulin cohort, the incremental PMPM cost for intensification with iGlarLixi ($0.03) was the lowest among intensifying drugs; GLP-1RA ($72.20) and RAI ($4.81).",What was the incremental PMPM cost for intensification with iGlarLixi compared to alternative treatment strategies among patients with Type 2 Diabetes Mellitus (pmcid=10597971)?,The incremental PMPM cost for intensification with iGlarLixi compared to alternative treatment strategies among patients with Type 2 Diabetes Mellitus was $0.03.,c62b9f80d92406349b63a384609a186c
10597971,Ken-Opurum J,Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus,2023,bim,"Similarly, the incremental PMPM cost for intensification with iGlarLixi was the lowest ($1.25) in the OAD cohort among intensifying drugs; GLP-1RA ($321.65) and iGlar ($114.82).",What was the incremental PMPM cost for intensification with iGlarLixi in the OAD cohort among intensifying drugs (pmcid=10597971)?,The incremental PMPM cost for intensification with iGlarLixi in the OAD cohort among intensifying drugs was $1.25.,c62b9f80d92406349b63a384609a186c
10597971,Ken-Opurum J,Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus,2023,bim,"In scenario analyses, when equal market intensification shares for iGlarLixi and GLP-1RA were explored, the incremental PMPM cost for iGlarLixi ($0.03) remained lower than GLP-1RA ($2.28) and RAI ($10.44) in the insulin cohort.","What were the incremental PMPM costs for iGlarLixi, GLP-1RA, and RAI in the insulin cohort in scenario analyses (pmcid=10597971)?","In scenario analyses, the incremental PMPM cost for iGlarLixi was $0.03, for GLP-1RA was $2.28, and for RAI was $10.44 in the insulin cohort.",c62b9f80d92406349b63a384609a186c
10597971,Ken-Opurum J,Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus,2023,bim,"CONCLUSIONS: Intensification with iGlarLixi was associated with lower costs compared to other treatment intensifications, as well as overall budget reductions compared to pre-intensification when considering cost savings attributable to reduction in HbA1c; therefore, its inclusion for the treatment of T2DM would represent a budget saving.",What were the overall budget reductions associated with intensification with iGlarLixi compared to other treatment strategies for patients with Type 2 Diabetes Mellitus (pmcid=10597971)?,Intensification with iGlarLixi was associated with overall budget reductions compared to other treatment strategies for patients with Type 2 Diabetes Mellitus.,c62b9f80d92406349b63a384609a186c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,"- BACKGROUND: Given growing demand for hip and knee arthroplasty and unsustainable resource requirements, safe and efficient models of care are critical.",What is the background information provided in the abstract of the study (pmcid=11616323)?,The background information provided in the abstract of the study (pmcid=11616323) is about the growing demand for hip and knee arthroplasty and the need for safe and efficient models of care due to unsustainable resource requirements.,bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,This study aims to determine the impact on healthcare costs of implementing an enhanced short-stay model of care (ESS-MOC) for arthroplasty at a national level.,What is the aim of this study (pmcid=11616323)?,The aim of this study is to determine the impact on healthcare costs of implementing an enhanced short-stay model of care (ESS-MOC) for arthroplasty at a national level.,bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,METHODS: A budget impact analysis was conducted for the years 2023-2030 in the setting of Australian publicly and privately funded hospitals performing hip or knee arthroplasty.,What years were included in the budget impact analysis for the implementation of an enhanced recovery pathway for primary hip or knee arthroplasty in Australian hospitals (pmcid=11616323)?,The budget impact analysis for the implementation of an enhanced recovery pathway for primary hip or knee arthroplasty in Australian hospitals included the years 2023-2030.,bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,"The model considered population-based future arthroplasty projections, published data on healthcare costs and resource utilisation, and aggregate health insurer claims data related to minor complexity elective hip or knee arthroplasty for osteoarthritis.",What data sources were considered in the model for this study (pmcid=11616323)?,"The data sources considered in the model for this study (pmcid=11616323) were population-based future arthroplasty projections, published data on healthcare costs and resource utilization, and aggregate health insurer claims data related to minor complexity elective hip or knee arthroplasty for osteoarthritis.",bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,The ESS-MOC assigned a conservative hypothesized 30% of eligible patients to an enhanced recovery from surgery (ERAS) pathway which comprised a shortened acute ward stay (average 2 days versus 4 days with current care) and outpatient rehabilitation.,What percentage of eligible patients were assigned to an enhanced recovery from surgery (ERAS) pathway in the study (pmcid=11616323)?,30%,bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,"The primary outcome was total healthcare cost savings post-ESS-MOC implementation, stratified by joint (knee/hip) and healthcare sector (public/private).","What was the primary outcome of the study post-ESS-MOC implementation, and how was it stratified (pmcid=11616323)?",The primary outcome of the study post-ESS-MOC implementation was total healthcare cost savings. It was stratified by joint (knee/hip) and healthcare sector (public/private). (pmcid=11616323),bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,"Return on investment (ROI) ratio, measuring the return for each dollar invested in implementation, and hospital bed days utilized, were also estimated.",What was estimated in addition to the return on investment ratio in the study (pmcid=11616323)?,Hospital bed days utilized,bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,"Costs are presented in Australian dollars (AUD), at 2023 prices.",What currency are the costs presented in for this study (pmcid=11616323)?,The costs are presented in Australian dollars (AUD).,bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,"RESULTS: Estimated cost savings for 2023-2030 from implementing the ESS-MOC pathway were AUD641 million (95% CI: AUD99 million to AUD1250 million), corresponding to a ROI ratio of AUD8.88 (AUD1.3 to AUD17.9).",What were the estimated cost savings for 2023-2030 from implementing the ESS-MOC pathway (pmcid=11616323)?,"The estimated cost savings for 2023-2030 from implementing the ESS-MOC pathway were AUD641 million (95% CI: AUD99 million to AUD1250 million), corresponding to a ROI ratio of AUD8.88 (AUD1.3 to AUD17.9).",bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,"Total implementation costs for the ESS-MOC were estimated at AUD38 million and AUD34 million for the private and public sectors, respectively.",What were the total implementation costs estimated for the ESS-MOC in the private and public sectors (pmcid=11616323)?,Total implementation costs for the ESS-MOC were estimated at AUD38 million for the private sector and AUD34 million for the public sector.,bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,Savings would be 8-fold higher in the private sector (AUD571 million vs.,What would be the 8-fold higher savings in the private sector compared to the public sector? (pmcid=11616323),Savings would be 8-fold higher in the private sector compared to the public sector.,bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,"AUD70 million in the public sector), primarily attributable to the > 80,000 rehabilitation bed days saved annually in this sector.",What is the primary reason for the cost savings in the public sector mentioned in the abstract (pmcid=11616323)?,"The primary reason for the cost savings in the public sector mentioned in the abstract is the >80,000 rehabilitation bed days saved annually.",bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,"For the period 2023-2030, an estimated 337,000 (261,000 to 412,000) acute bed days could be saved (private sector 262,000 [200,000 to 324,000]; public sector 74,000 [57,000 to 92,000]).",How many acute bed days could be saved for the period 2023-2030 according to the abstract sentence (pmcid=11616323)?,"337,000 (261,000 to 412,000) acute bed days could be saved.",bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,Less than 10% of eligible patients would need to move into the ERAS pathway to realise cost savings.,What percentage of eligible patients would need to move into the ERAS pathway to realize cost savings? (pmcid=11616323),Less than 10% of eligible patients would need to move into the ERAS pathway to realize cost savings.,bed0690b008422d927bf9174ac1bba2c
11616323,Lloyd M,Implementing an enhanced recovery from surgery pathway to reduce hospital length of stay for primary hip or knee arthroplasty: a budget impact analysis,2024,bim,"CONCLUSIONS: Implementation of an enhanced short-stay model of care for eligible arthroplasty patients in Australia would generate significant cost and resource savings, particularly for the private hospital sector.",What would be the impact of implementing an enhanced short-stay model of care for eligible arthroplasty patients in Australia (pmcid=11616323)?,"The impact of implementing an enhanced short-stay model of care for eligible arthroplasty patients in Australia, as discussed in the study with pmcid=11616323, would result in significant cost and resource savings, particularly for the private hospital sector.",bed0690b008422d927bf9174ac1bba2c
11801450,Gong CL,Budget Impact Analysis of Integrative Medicine Practices for Pediatric Patients With Chronic Pain,2025,bim,- OBJECTIVES: Chronic pain is a leading cause of morbidity in children and adolescents globally but can be managed with a combination of traditional Western medicine and integrative medicine (IM) practices.,What is a leading cause of morbidity in children and adolescents globally that can be managed with a combination of traditional Western medicine and integrative medicine practices (pmcid=11801450)?,Chronic pain,96222903f342dd07bdfd04b0c09d9d84
11801450,Gong CL,Budget Impact Analysis of Integrative Medicine Practices for Pediatric Patients With Chronic Pain,2025,bim,"This combination has improved various critical health outcomes, such as quality of life, sleep, pain, anxiety, and health care utilization.",What critical health outcomes have been improved by the combination mentioned in the abstract (pmcid=11801450)?,"Quality of life, sleep, pain, anxiety, and health care utilization.",96222903f342dd07bdfd04b0c09d9d84
11801450,Gong CL,Budget Impact Analysis of Integrative Medicine Practices for Pediatric Patients With Chronic Pain,2025,bim,"These IM practices include acupuncture, yoga, biofeedback, massage, mindfulness, or any combination of these modalities.",What are some of the integrative medicine practices included in the budget impact analysis for pediatric patients with chronic pain (pmcid=11801450)?,"Some of the integrative medicine practices included in the budget impact analysis for pediatric patients with chronic pain are acupuncture, yoga, biofeedback, massage, mindfulness, or any combination of these modalities.",96222903f342dd07bdfd04b0c09d9d84
11801450,Gong CL,Budget Impact Analysis of Integrative Medicine Practices for Pediatric Patients With Chronic Pain,2025,bim,The current article﻿ developed a budget impact model to estimate the institutional costs of implementing these practices among adolescents.,What did the current article develop a budget impact model for (pmcid=11801450)?,The current article developed a budget impact model to estimate the institutional costs of implementing integrative medicine practices for pediatric patients with chronic pain among adolescents.,96222903f342dd07bdfd04b0c09d9d84
11801450,Gong CL,Budget Impact Analysis of Integrative Medicine Practices for Pediatric Patients With Chronic Pain,2025,bim,METHODS: A decision tree was used to estimate the reduction in hospitalizations and emergency department (ED) use based on a previously published retrospective analysis of children receiving IM practices comparing utilization rates 1-year pre-implementation and post-implementation of IM services (Figure 1).,What type of analysis was used to estimate the reduction in hospitalizations and emergency department use in pediatric patients with chronic pain (pmcid=11801450)?,A decision tree analysis was used to estimate the reduction in hospitalizations and emergency department use in pediatric patients with chronic pain.,96222903f342dd07bdfd04b0c09d9d84
11801450,Gong CL,Budget Impact Analysis of Integrative Medicine Practices for Pediatric Patients With Chronic Pain,2025,bim,"Costs associated with implementing each modality were based on hourly compensation rates for licensed professionals administering each service and equipment associated with delivery (eg, acupuncture needles, biofeedback equipment, and sensors).",What costs were considered in the budget impact analysis of integrative medicine practices for pediatric patients with chronic pain (pmcid=11801450)?,"Costs associated with implementing each modality were considered in the budget impact analysis of integrative medicine practices for pediatric patients with chronic pain. This includes hourly compensation rates for licensed professionals administering each service and equipment associated with delivery, such as acupuncture needles, biofeedback equipment, and sensors.",96222903f342dd07bdfd04b0c09d9d84
11801450,Gong CL,Budget Impact Analysis of Integrative Medicine Practices for Pediatric Patients With Chronic Pain,2025,bim,The cost of each hospitalization and ED visit was derived from the literature.,What was the source of the cost data for each hospitalization and ED visit (pmcid=11801450)?,The cost data for each hospitalization and ED visit was derived from the literature.,96222903f342dd07bdfd04b0c09d9d84
11801450,Gong CL,Budget Impact Analysis of Integrative Medicine Practices for Pediatric Patients With Chronic Pain,2025,bim,"In addition, cost savings were estimated based on government-contracted and commercial-contracted reimbursement rates for each service.",What were the cost savings estimated based on for each service? (pmcid=11801450),The cost savings were estimated based on government-contracted and commercial-contracted reimbursement rates for each service.,96222903f342dd07bdfd04b0c09d9d84
11801450,Gong CL,Budget Impact Analysis of Integrative Medicine Practices for Pediatric Patients With Chronic Pain,2025,bim,"RESULTS: Cost savings were approximated to range from $1344 to $3439 per patient, with even greater cost savings of up to $6000 and $4132 when accounting for governmental and commercial payer reimbursement, respectively.",What were the approximate cost savings per patient in the budget impact analysis of integrative medicine practices for pediatric patients with chronic pain (pmcid=11801450)?,The approximate cost savings per patient in the budget impact analysis of integrative medicine practices for pediatric patients with chronic pain were estimated to range from $1344 to $3439.,96222903f342dd07bdfd04b0c09d9d84
11801450,Gong CL,Budget Impact Analysis of Integrative Medicine Practices for Pediatric Patients With Chronic Pain,2025,bim,"DISCUSSION: IM leads to improved pain relief when combined with traditional medicine and yields significant cost savings, thus supporting the routine implementation of IM alongside traditional medicine in health care settings.","What leads to improved pain relief when combined with traditional medicine and yields significant cost savings, thus supporting routine implementation in health care settings (pmcid=11801450)?","Integrative Medicine (IM) leads to improved pain relief when combined with traditional medicine and yields significant cost savings, thus supporting the routine implementation of IM alongside traditional medicine in health care settings.",96222903f342dd07bdfd04b0c09d9d84
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,- High rates of unplanned pregnancies persist despite pharmacological developments and advancements in contraceptive methods.,What persists despite pharmacological developments and advancements in contraceptive methods? (pmcid=10977723),High rates of unplanned pregnancies,1e7fa768584c24f89a679ae3646fac2d
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,"Here, we demonstrate that the etonogestrel-releasing subdermal contraceptive implant (IMP-ETN) may be an appropriate and cost-effective alternative to levonorgestrel-releasing intrauterine systems (LNG-IUSs) for women in Brazil.",What may be an appropriate and cost-effective alternative to levonorgestrel-releasing intrauterine systems for women in Brazil (pmcid=10977723)?,The etonogestrel-releasing subdermal contraceptive implant (IMP-ETN),1e7fa768584c24f89a679ae3646fac2d
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,"For our pharmacoeconomic analysis, we reviewed the literature on IMP-ETN regarding its acceptance, eligibility criteria, choice, relations with age, adverse events and, finally, the unmet need in the fee-for-service private healthcare sector.",What aspects of IMP-ETN were reviewed for the pharmacoeconomic analysis (pmcid=10977723)?,"The aspects of IMP-ETN that were reviewed for the pharmacoeconomic analysis in the study with pmcid=10977723 included its acceptance, eligibility criteria, choice, relations with age, adverse events, and the unmet need in the fee-for-service private healthcare sector.",1e7fa768584c24f89a679ae3646fac2d
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,We considered qualitative observations in combination with quantitative analysis and performed a deterministic sensitivity analysis to investigate whether this technology can be self-sustainable over a period of five years.,What type of analysis was performed to investigate the self-sustainability of the technology over a period of five years (pmcid=10977723)?,A deterministic sensitivity analysis was performed to investigate the self-sustainability of the technology over a period of five years in the study with pmcid=10977723.,1e7fa768584c24f89a679ae3646fac2d
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,"The target population for this analysis comprised 158,696 women.",What was the target population for this budget impact analysis (pmcid=10977723)?,"The target population for this budget impact analysis was 158,696 women.",1e7fa768584c24f89a679ae3646fac2d
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,"Compared with the continued use of LNG-IUSs, adopting the IMP-ETN can result in a cost avoidance of $ 7.640.804,02 in the first year and $ 82,455,254.43 in five years.",What cost avoidance can be achieved by adopting the IMP-ETN compared to the continued use of LNG-IUSs in the first year and over five years (pmcid=10977723)?,"In the first year, adopting the IMP-ETN can result in a cost avoidance of $7,640,804.02. Over five years, the cost avoidance would be $82,455,254.43.",1e7fa768584c24f89a679ae3646fac2d
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,Disseminating information among physicians will promote this change and strengthen the potential cost avoided by private health system payers.,What will promote the change and strengthen the potential cost avoided by private health system payers? (pmcid=10977723),Disseminating information among physicians.,1e7fa768584c24f89a679ae3646fac2d
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,These savings can be used to improve other healthcare programs and strategies.,What can the savings from the etonogestrel-releasing subdermal contraceptive implant be used for in the Brazilian private healthcare system (pmcid=10977723)?,The savings from the etonogestrel-releasing subdermal contraceptive implant can be used to improve other healthcare programs and strategies in the Brazilian private healthcare system.,1e7fa768584c24f89a679ae3646fac2d
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,"Moreover, the principles of care can be promoted by improving and adapting healthcare systems and expanding treatment and follow-up strategies.",What can be promoted by improving and adapting healthcare systems and expanding treatment and follow-up strategies (pmcid=10977723)?,The principles of care,1e7fa768584c24f89a679ae3646fac2d
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,This would also provide support to women's reproductive rights and improve their quality of life.,What would the provision of the etonogestrel-releasing subdermal contraceptive implant support and improve for women (pmcid=10977723)?,The provision of the etonogestrel-releasing subdermal contraceptive implant would support women's reproductive rights and improve their quality of life.,1e7fa768584c24f89a679ae3646fac2d
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,Our results suggest that the IMP-ETN has a favorable cost-effectiveness profile.,What does the cost-effectiveness profile of the IMP-ETN suggest (pmcid=10977723)?,The cost-effectiveness profile of the IMP-ETN suggests that it is favorable.,1e7fa768584c24f89a679ae3646fac2d
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,"Given all its advantages and negative incremental cost impact over a period of five years, the IMP-ETN may be a more favorable alternative to LNG-IUSs.",What may be a more favorable alternative to LNG-IUSs based on the budget impact analysis in the Brazilian private healthcare system (pmcid=10977723)?,The Etonogestrel-releasing subdermal contraceptive implant (IMP-ETN) may be a more favorable alternative to LNG-IUSs based on the budget impact analysis in the Brazilian private healthcare system.,1e7fa768584c24f89a679ae3646fac2d
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,"Therefore, it should be offered to beneficiaries with a private healthcare plan.",What beneficiaries should the etonogestrel-releasing subdermal contraceptive implant be offered to based on the budget impact analysis (pmcid=10977723)?,The etonogestrel-releasing subdermal contraceptive implant should be offered to beneficiaries with a private healthcare plan based on the budget impact analysis.,1e7fa768584c24f89a679ae3646fac2d
10977723,Lopes da Silva Filho A,Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system,2024,bim,"This analysis overcomes previous barriers to the use of cost-benefit models, and our results may help balance decision-making by policymakers, technical consultants, and researchers.",What may the results of this analysis help balance decision-making for (pmcid=10977723)?,"The results of this analysis may help balance decision-making for policymakers, technical consultants, and researchers.",1e7fa768584c24f89a679ae3646fac2d
11772286,Permsuwan U,Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand,2025,bim,- OBJECTIVE: This study aimed to assess the financial impact of different adoption rates of insulin glargine (IGlar) treatment compared to isophane protamine (neutral protamine hagedorn [NPH]) insulin treatment for patients with type-2 diabetes (T2D) and severe hypoglycemia in Thailand from the payer's perspective.,What was the objective of the study (pmcid=11772286)?,The objective of the study with pmcid=11772286 was to assess the financial impact of different adoption rates of insulin glargine (IGlar) treatment compared to isophane protamine (neutral protamine hagedorn [NPH]) insulin treatment for patients with type-2 diabetes (T2D) and severe hypoglycemia in Thailand from the payer's perspective.,7649bf7a8eb5ec4a498f1efee36183f7
11772286,Permsuwan U,Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand,2025,bim,METHODS: The budget impact analysis (BIA) model over a period of 5 years was used to estimate the net budget impact (NBI) of IGlar treatment by comparing the total budget expenditures under two scenarios: scenario 1 involved only NPH insulin and scenario 2 included the introduction of IGlar.,What model was used to estimate the net budget impact of insulin glargine treatment in patients with type-2 diabetes and severe hypoglycemia in Thailand (pmcid=11772286)?,The budget impact analysis (BIA) model was used to estimate the net budget impact of insulin glargine treatment in patients with type-2 diabetes and severe hypoglycemia in Thailand (pmcid=11772286).,7649bf7a8eb5ec4a498f1efee36183f7
11772286,Permsuwan U,Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand,2025,bim,The total budget included either the cost of insulin or a combination of the costs of insulin and the expense related to severe hypoglycemia.,What was included in the total budget analysis (pmcid=11772286)?,The total budget analysis included either the cost of insulin or a combination of the costs of insulin and the expense related to severe hypoglycemia.,7649bf7a8eb5ec4a498f1efee36183f7
11772286,Permsuwan U,Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand,2025,bim,Scenario 2 started at 20% uptake of IGlar and a yearly increase of 20%.,What was the starting uptake percentage of IGlar in Scenario 2 (pmcid=11772286)?,20%,7649bf7a8eb5ec4a498f1efee36183f7
11772286,Permsuwan U,Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand,2025,bim,NBI was calculated as the difference between the total budgets of scenarios 1 and 2.,What was calculated as the difference between the total budgets of scenarios 1 and 2 (pmcid=11772286)?,The Net Budget Impact (NBI) was calculated as the difference between the total budgets of scenarios 1 and 2.,7649bf7a8eb5ec4a498f1efee36183f7
11772286,Permsuwan U,Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand,2025,bim,NBI and one-way sensitivity analyses were conducted for evaluation.,What analyses were conducted for evaluation in the study (pmcid=11772286)?,NBI and one-way sensitivity analyses were conducted for evaluation.,7649bf7a8eb5ec4a498f1efee36183f7
11772286,Permsuwan U,Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand,2025,bim,"RESULTS: Considering only the cost of insulin, the use of IGlar for patients with T2D and severe hypoglycemia resulted in a yearly average NBI of 174.9 million Thai baht (THB) (5.1 million USD).",What was the yearly average Net Budget Impact (NBI) of using IGlar for patients with T2D and severe hypoglycemia (pmcid=11772286)?,The yearly average Net Budget Impact (NBI) of using IGlar for patients with T2D and severe hypoglycemia in Thailand was 174.9 million Thai baht (THB) or 5.1 million USD.,7649bf7a8eb5ec4a498f1efee36183f7
11772286,Permsuwan U,Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand,2025,bim,"However, when the cost related to severe hypoglycemia was included, the total budget incurred from scenario 2 was less than that of scenario 1, leading to a negative NBI or cost savings.",What was the total budget incurred from scenario 2 compared to scenario 1 when the cost related to severe hypoglycemia was included (pmcid=11772286)?,"The total budget incurred from scenario 2 was less than that of scenario 1 when the cost related to severe hypoglycemia was included, leading to a negative NBI or cost savings.",7649bf7a8eb5ec4a498f1efee36183f7
11772286,Permsuwan U,Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand,2025,bim,"CONCLUSION: The NBI of IGlar adoption would be substantial when considering only the cost of insulin; however, the significant benefit of IGlar in terms of a lower rate of severe hypoglycemia compared with NPH insulin would clearly offset the additional cost of IGlar.",What would offset the additional cost of IGlar compared to NPH insulin (pmcid=11772286)?,The lower rate of severe hypoglycemia compared with NPH insulin would offset the additional cost of IGlar.,7649bf7a8eb5ec4a498f1efee36183f7
10445371,Reyes-Urueña J,Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis,2023,bim,"- OBJECTIVES: To perform a budget impact analysis of the HepClink test-and-treat strategy in which community health agents offer hepatitis C virus (HCV) testing, diagnosis and treatment to the Pakistani population living in Catalonia compared with the current practice of the Catalan health system (without targeted screening programmes).",What is the objective of the budget impact analysis mentioned in the abstract (pmcid=10445371)?,"The objective of the budget impact analysis mentioned in the abstract is to evaluate the HepClink test-and-treat strategy, where community health agents offer hepatitis C virus testing, diagnosis, and treatment to the Pakistani population living in Catalonia, compared to the current practice of the Catalan health system without targeted screening programs.",1f5c0e826a098734cd4e7b7f84ba4543
10445371,Reyes-Urueña J,Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis,2023,bim,"METHODS: We estimated the population of adult Pakistani migrants registered at the primary care centres in Catalonia by means of the Information System for the Development of Research in Primary Care (n=37 972 in 2019, Barcelona health area).",What was the population of adult Pakistani migrants registered at the primary care centres in Catalonia in 2019 (pmcid=10445371)?,"The population of adult Pakistani migrants registered at the primary care centres in Catalonia in 2019 was estimated to be 37,972.",1f5c0e826a098734cd4e7b7f84ba4543
10445371,Reyes-Urueña J,Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis,2023,bim,This cohort was followed for a time period of 10 years after HCV diagnosis (2019-2028).,What was the time period of follow-up for the cohort in this study (pmcid=10445371)?,"The time period of follow-up for the cohort in this study (pmcid=10445371) was 10 years after HCV diagnosis, from 2019 to 2028.",1f5c0e826a098734cd4e7b7f84ba4543
10445371,Reyes-Urueña J,Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis,2023,bim,The statistical significance of the differences observed in the anti-HCV positivity rate between screened and non-screened was confirmed (α=0.05).,What was confirmed regarding the statistical significance of the differences observed in the anti-HCV positivity rate between screened and non-screened individuals (pmcid=10445371)?,The statistical significance of the differences observed in the anti-HCV positivity rate between screened and non-screened individuals was confirmed at a significance level of α=0.05.,1f5c0e826a098734cd4e7b7f84ba4543
10445371,Reyes-Urueña J,Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis,2023,bim,The budget impact was calculated from the perspective of the Catalan Department of Health.,What perspective was the budget impact calculated from in this study (pmcid=10445371)?,The budget impact was calculated from the perspective of the Catalan Department of Health.,1f5c0e826a098734cd4e7b7f84ba4543
10445371,Reyes-Urueña J,Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis,2023,bim,"Sensitivity analyses included different levels of participation in HepClink: pessimistic, optimistic and maximum.",What were the different levels of participation in the HepClink program included in the sensitivity analyses (pmcid=10445371)?,"The different levels of participation in the HepClink program included in the sensitivity analyses were pessimistic, optimistic, and maximum.",1f5c0e826a098734cd4e7b7f84ba4543
10445371,Reyes-Urueña J,Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis,2023,bim,RESULTS: The HepClink scenario screened a higher percentage of individuals (69.8%) compared with the current scenario of HCV care (39.7%).,What percentage of individuals were screened in the HepClink scenario compared to the current scenario of HCV care (pmcid=10445371)?,69.8% of individuals were screened in the HepClink scenario compared to 39.7% in the current scenario of HCV care.,1f5c0e826a098734cd4e7b7f84ba4543
10445371,Reyes-Urueña J,Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis,2023,bim,"Viraemia was lower in the HepClink scenario compared with the current scenario (1.7% vs 2.5%, respectively).",What was the viraemia rate in the HepClink scenario compared to the current scenario (pmcid=10445371)?,1.7% vs 2.5%,1f5c0e826a098734cd4e7b7f84ba4543
10445371,Reyes-Urueña J,Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis,2023,bim,The budget impact of the HepClink scenario was €884 244.42 in 10 years.,What was the budget impact of the HepClink scenario over 10 years (pmcid=10445371)?,"The budget impact of the HepClink scenario over 10 years was €884,244.42.",1f5c0e826a098734cd4e7b7f84ba4543
10445371,Reyes-Urueña J,Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis,2023,bim,CONCLUSIONS: Scaling up the HepClink strategy to the whole Catalan territory infers a high budget impact for the Department of Health and allows increasing the detection of viraemia (+17.8%) among Pakistani migrants ≥18 years.,What does scaling up the HepClink strategy to the whole Catalan territory infer in terms of budget impact for the Department of Health (pmcid=10445371)?,Scaling up the HepClink strategy to the whole Catalan territory infers a high budget impact for the Department of Health.,1f5c0e826a098734cd4e7b7f84ba4543
10445371,Reyes-Urueña J,Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis,2023,bim,"To achieve a sustainable elimination of HCV by improving screening and treatment rates, there is room for improvement at two levels.",What is the room for improvement identified in the study by Reyes-Urueña et al. regarding the sustainable elimination of HCV (pmcid=10445371)?,The room for improvement identified in the study by Reyes-Urueña et al. regarding the sustainable elimination of HCV is improving screening and treatment rates.,1f5c0e826a098734cd4e7b7f84ba4543
10445371,Reyes-Urueña J,Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis,2023,bim,"First, taking advantage of the fact that 68.08% of the Pakistani population had visited their primary care physicians to reinforce targeted screening in primary care.",What percentage of the Pakistani population visited their primary care physicians to reinforce targeted screening in primary care? (pmcid=10445371),68.08%,1f5c0e826a098734cd4e7b7f84ba4543
10445371,Reyes-Urueña J,Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis,2023,bim,"Second, to use HepClink at the community level to reach individuals with reluctance to use healthcare services.",What is the purpose of using HepClink at the community level (pmcid=10445371)?,The purpose of using HepClink at the community level is to reach individuals with reluctance to use healthcare services.,1f5c0e826a098734cd4e7b7f84ba4543
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,"- INTRODUCTION: Cytomegalovirus (CMV), a prevalent human herpes virus, has long periods of latency.",What is the prevalence of Cytomegalovirus (CMV) mentioned in the abstract (pmcid=11718931)?,The prevalence of Cytomegalovirus (CMV) is mentioned as being prevalent in the abstract (pmcid=11718931).,cc34dce3ce2e40e6727e3bdaea46c4b9
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,It can reactivate following immunosuppression causing diverse clinical manifestations.,What can cause diverse clinical manifestations following immunosuppression (pmcid=11718931)?,Cytomegalovirus infection,cc34dce3ce2e40e6727e3bdaea46c4b9
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,"In immunocompetent individuals, CMV infections are usually asymptomatic.",What is the usual presentation of CMV infections in immunocompetent individuals (pmcid=11718931)?,"In immunocompetent individuals, CMV infections are usually asymptomatic.",cc34dce3ce2e40e6727e3bdaea46c4b9
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,"However, in immunosuppressed individuals, such as patients with human immunodeficiency virus, CMV infections can cause serious complications.",What can CMV infections cause in immunosuppressed individuals (pmcid=11718931)?,"CMV infections can cause serious complications in immunosuppressed individuals, such as patients with human immunodeficiency virus.",cc34dce3ce2e40e6727e3bdaea46c4b9
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,"Antiviral treatment is crucial for minimizing health risks and preventing severe outcomes, such as retinitis and colitis, in this population.",What is crucial for minimizing health risks and preventing severe outcomes in immunosuppressed patients in Brazil (pmcid=11718931)?,Antiviral treatment,cc34dce3ce2e40e6727e3bdaea46c4b9
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,METHODS: A cost-effectiveness analysis was conducted using a decision tree model to estimate the incremental cost-effectiveness ratio (ICER) of ganciclovir (1 mg/mL) for people with acquired immunodeficiency syndrome (AIDS) affected by CMV-related retinitis or colitis.,What type of analysis was conducted to estimate the incremental cost-effectiveness ratio of ganciclovir for people with AIDS affected by CMV-related retinitis or colitis (pmcid=11718931)?,A cost-effectiveness analysis was conducted.,cc34dce3ce2e40e6727e3bdaea46c4b9
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,"The model compared ganciclovir therapy to no ganciclovir, with the outcome being progression of CMV disease.","What did the model compare ganciclovir therapy to, with the outcome being progression of CMV disease (pmcid=11718931)?","The model compared ganciclovir therapy to no ganciclovir, with the outcome being progression of CMV disease.",cc34dce3ce2e40e6727e3bdaea46c4b9
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,Budget impact was considered over a five-year time frame with 100 percent diffusion among patients with AIDS and CMV-related colitis.,What time frame was considered for the budget impact analysis in the study (pmcid=11718931)?,Budget impact was considered over a five-year time frame.,cc34dce3ce2e40e6727e3bdaea46c4b9
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,"RESULTS: In patients with AIDS and CMV-related retinitis, use of ganciclovir incurred an incremental cost of BRL29,378.95 (USD5,188.70) with an incremental effectiveness of 0.51 in the therapeutic response rate and an ICER of BRL57,605.79 (USD10,173.93).",What was the incremental cost and effectiveness of using ganciclovir in patients with AIDS and CMV-related retinitis (pmcid=11718931)?,"The incremental cost of using ganciclovir in patients with AIDS and CMV-related retinitis was BRL29,378.95 (USD5,188.70), and the incremental effectiveness was 0.51 in the therapeutic response rate.",cc34dce3ce2e40e6727e3bdaea46c4b9
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,"For those with AIDS and CMV-related colitis, ganciclovir incurred an incremental cost of BRL10,040.71 (USD1,773.32), with an incremental effectiveness of 0.26 and an ICER of BRL38,618.11 (USD6,820.45).",What was the incremental cost of ganciclovir for those with AIDS and CMV-related colitis (pmcid=11718931)?,"The incremental cost of ganciclovir for those with AIDS and CMV-related colitis was BRL10,040.71 (USD1,773.32) (pmcid=11718931).",cc34dce3ce2e40e6727e3bdaea46c4b9
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,"The estimated cumulative budget impact, considering 100 percent ganciclovir diffusion over five years, was BRL1,124,800,751.17 (USD198,654,342.23) and BRL571,223,309.75 (USD100,885,415.26) for patients with AIDS CMV-related retinitis and colitis, respectively.",What was the estimated cumulative budget impact for patients with AIDS CMV-related retinitis and colitis over five years (pmcid=11718931)?,"The estimated cumulative budget impact for patients with AIDS CMV-related retinitis over five years was BRL1,124,800,751.17 (USD198,654,342.23), and for patients with colitis was BRL571,223,309.75 (USD100,885,415.26).",cc34dce3ce2e40e6727e3bdaea46c4b9
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,CONCLUSIONS: The application of economic evaluation and budget impact tools is crucial for maintaining health system sustainability.,What is crucial for maintaining health system sustainability (pmcid=11718931)?,The application of economic evaluation and budget impact tools.,cc34dce3ce2e40e6727e3bdaea46c4b9
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,Introducing treatments with high ICERs and budget impact can jeopardize the health system and access to treatments.,What can jeopardize the health system and access to treatments? (pmcid=11718931),Introducing treatments with high ICERs and budget impact can jeopardize the health system and access to treatments.,cc34dce3ce2e40e6727e3bdaea46c4b9
11718931,Alvernaz dos Santos BR,PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil,2025,bim,"Upholding criteria, such as the willingness-to-pay threshold, is essential for ensuring the sustainability and continuity of health care.",What is essential for ensuring the sustainability and continuity of health care according to the abstract sentence provided (pmcid=11718931)?,"Upholding criteria, such as the willingness-to-pay threshold, is essential for ensuring the sustainability and continuity of health care.",cc34dce3ce2e40e6727e3bdaea46c4b9
10961941,Danielson EC,Implementation Preparation Costs of Virtual Reality Job Interview Training in Prisons: A Budget Impact Analysis,2023,bim,- Virtual Reality Job Interview Training (VR-JIT) has increased employment rates for returning citizens when added to a successful prison-based employment readiness program.,What has Virtual Reality Job Interview Training (VR-JIT) been shown to increase for returning citizens when added to a successful prison-based employment readiness program (pmcid=10961941)?,Employment rates,6cd5e34969065e839f5c02c4728adb92
10961941,Danielson EC,Implementation Preparation Costs of Virtual Reality Job Interview Training in Prisons: A Budget Impact Analysis,2023,bim,"However, implementation preparation cost-expenses prior to offering VR-JIT to intended recipients-is unknown.",What is unknown regarding the implementation preparation cost-expenses prior to offering VR-JIT to intended recipients (pmcid=10961941)?,The implementation preparation cost-expenses prior to offering VR-JIT to intended recipients are unknown.,6cd5e34969065e839f5c02c4728adb92
10961941,Danielson EC,Implementation Preparation Costs of Virtual Reality Job Interview Training in Prisons: A Budget Impact Analysis,2023,bim,"We estimated the cost of implementation preparation activities (e.g., organizing workflow) for two prisons to deliver VR-JIT.",What did the study estimate the cost of for two prisons to deliver VR-JIT (pmcid=10961941)?,"The study estimated the cost of implementation preparation activities (e.g., organizing workflow) for two prisons to deliver VR-JIT.",6cd5e34969065e839f5c02c4728adb92
10961941,Danielson EC,Implementation Preparation Costs of Virtual Reality Job Interview Training in Prisons: A Budget Impact Analysis,2023,bim,We conducted a budget impact analysis and enumerated the labor costs incurred during this important stage of implementation.,What costs were enumerated during the budget impact analysis (pmcid=10961941)?,The labor costs were enumerated during the budget impact analysis in the study with pmcid=10961941.,6cd5e34969065e839f5c02c4728adb92
10961941,Danielson EC,Implementation Preparation Costs of Virtual Reality Job Interview Training in Prisons: A Budget Impact Analysis,2023,bim,"Labor costs were approximately $8,847 per prison.",How much were the labor costs per prison for the implementation preparation of virtual reality job interview training? (pmcid=10961941),"Labor costs were approximately $8,847 per prison.",6cd5e34969065e839f5c02c4728adb92
10961941,Danielson EC,Implementation Preparation Costs of Virtual Reality Job Interview Training in Prisons: A Budget Impact Analysis,2023,bim,"Our sensitivity analysis estimated the labor costs to replicate this effort in a new prison to range from $2,877 to $4,306 per prison.",What did the sensitivity analysis estimate the labor costs to range from in a new prison (pmcid=10961941)?,"The sensitivity analysis estimated the labor costs to range from $2,877 to $4,306 per prison in a new prison.",6cd5e34969065e839f5c02c4728adb92
10961941,Danielson EC,Implementation Preparation Costs of Virtual Reality Job Interview Training in Prisons: A Budget Impact Analysis,2023,bim,"Thus, VR-JIT may be an affordable tool for prison-based employment readiness programs to improve gainful employment.",What tool may be affordable for prison-based employment readiness programs to improve gainful employment (pmcid=10961941)?,VR-JIT,6cd5e34969065e839f5c02c4728adb92
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,- BACKGROUND AND AIMS: Risperidone is used in autism spectrum disorder (ASD) to manage aggressive behavior.,What is risperidone used for in autism spectrum disorder (ASD) (pmcid=10721756)?,Risperidone is used in autism spectrum disorder (ASD) to manage aggressive behavior.,91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,"Budget impact analysis (BIA) assists managers in promoting more sustainable health systems; however, it is unclear whether BIAs underestimate or overestimate the estimates derived from real-world data.",What does budget impact analysis assist managers in promoting (pmcid=10721756)?,Budget impact analysis (BIA) assists managers in promoting more sustainable health systems.,91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,This study aimed to compare the estimated BIA values of risperidone use and the monitoring of adverse events in ASD using theoretical and real data.,What did the study aim to compare regarding risperidone use and adverse event monitoring in ASD (pmcid=10721756)?,The study aimed to compare the estimated budget impact analysis (BIA) values of risperidone use and the monitoring of adverse events in Autism Spectrum Disorder (ASD) using theoretical and real data.,91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,METHODS: Analyses were conducted based on the clinical protocol and the Brazilian therapeutic guidelines for ASD.,What were the analyses conducted based on in this study (pmcid=10721756)?,The analyses were conducted based on the clinical protocol and the Brazilian therapeutic guidelines for Autism Spectrum Disorder (ASD).,91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,"The perspective adopted was that of the Unified Health System (SUS), considering a time horizon of 5 years.",What perspective was adopted in the budget impact analysis of risperidone use and adverse event monitoring in autism spectrum disorder in Brazil (pmcid=10721756)?,"The perspective adopted in the budget impact analysis of risperidone use and adverse event monitoring in autism spectrum disorder in Brazil (pmcid=10721756) was that of the Unified Health System (SUS), considering a time horizon of 5 years.",91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,Three possible scenarios were considered based on the maximum daily dose of risperidone.,What were the three possible scenarios considered based on the maximum daily dose of risperidone in the study (pmcid=10721756)?,Three possible scenarios considered based on the maximum daily dose of risperidone in the study were not explicitly mentioned in the provided context information.,91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,Expenses related to the acquisition of risperidone and the monitoring of adverse events were taken into account using health databases in Brazil.,What expenses were taken into account in the analysis conducted in Brazil (pmcid=10721756)?,Expenses related to the acquisition of risperidone and the monitoring of adverse events were taken into account in the analysis conducted in Brazil.,91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,"For the calculation based on theoretical data, the prevalence of ASD was estimated using information from the scientific literature and the Brazilian demographic census.",What was the prevalence of ASD estimated based on in the calculation using theoretical data (pmcid=10721756)?,The prevalence of ASD was estimated using information from the scientific literature and the Brazilian demographic census.,91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,The model calculated from real data was obtained by analyzing the linear trend of the number of users assisted in the SUS from 2017 to 2021.,What trend was analyzed to obtain the model calculated from real data (pmcid=10721756)?,The trend of the number of users assisted in the SUS from 2017 to 2021 was analyzed to obtain the model calculated from real data in the study with pmcid=10721756.,91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,RESULTS: The population estimated by the theoretical model compared with the model calculated from the real data was higher.,What was the population estimated by the theoretical model compared with the model calculated from the real data (pmcid=10721756)?,The population estimated by the theoretical model compared with the model calculated from the real data was higher.,91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,"Likewise, the 5-year budgetary impact of the theoretical model versus the model calculated from the real data was higher, with statistical significance in all scenarios (p < 0.001).",What was the comparison made in terms of budgetary impact in the study (pmcid=10721756)?,"The comparison made in terms of budgetary impact in the study with pmcid=10721756 was between the theoretical model and the model calculated from real data. The study found that the 5-year budgetary impact of the theoretical model was higher than the model calculated from real data, with statistical significance in all scenarios.",91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,"In the real data model, the most economically advantageous scenarios were Scenario 1 for children (International dollars [I$] 7,630,040.73) and Scenario 3 for adults (I$60,329,288.17).",What were the most economically advantageous scenarios in the real data model for children and adults (pmcid=10721756)?,"In the real data model, the most economically advantageous scenarios were Scenario 1 for children (International dollars [I$] 7,630,040.73) and Scenario 3 for adults (I$60,329,288.17).",91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,Estimated expenditures for monitoring adverse events ranged from 17 to 74% in children and from 50% to 63% in adults.,What were the estimated expenditures for monitoring adverse events in children and adults (pmcid=10721756)?,Estimated expenditures for monitoring adverse events ranged from 17 to 74% in children and from 50% to 63% in adults.,91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,CONCLUSIONS: The data revealed significant differences in population and cost estimation between theoretical data and real-world data.,What did the data reveal significant differences in between theoretical data and real-world data (pmcid=10721756)?,The data revealed significant differences in population and cost estimation between theoretical data and real-world data.,91e1ba09fb1d2df855475e30a0359dde
10721756,Lopes LP,Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data,2023,bim,The expenses associated with monitoring adverse events represented a substantial expenditure estimate for the SUS.,What represented a substantial expenditure estimate for the SUS (pmcid=10721756)?,The expenses associated with monitoring adverse events represented a substantial expenditure estimate for the SUS.,91e1ba09fb1d2df855475e30a0359dde
11187468,Tang T,Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis,2024,bim,- Background Levalbuterol is a short-acting β(2)-agonist (SABA) indicated for treating or preventing asthma exacerbation.,What is Levalbuterol indicated for treating or preventing (pmcid=11187468)?,Levalbuterol is indicated for treating or preventing asthma exacerbation.,3840cefd7065f39a45d2716456ad2956
11187468,Tang T,Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis,2024,bim,It was included in the 2020 Chinese National Reimbursement Drug List (NRDL).,What drug was included in the 2020 Chinese National Reimbursement Drug List (pmcid=11187468)?,Levalbuterol,3840cefd7065f39a45d2716456ad2956
11187468,Tang T,Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis,2024,bim,This study estimates the economic impact of levalbuterol's status change within and withdrawal from the NRDL in treating pediatric asthma from a publicly funded medical insurance perspective.,What perspective was used to estimate the economic impact of levalbuterol's status change within and withdrawal from the NRDL in treating pediatric asthma (pmcid=11187468)?,The economic impact was estimated from a publicly funded medical insurance perspective.,3840cefd7065f39a45d2716456ad2956
11187468,Tang T,Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis,2024,bim,Methodology A prevalence-based budget impact model was developed.,What type of budget impact model was developed in this study (pmcid=11187468)?,A prevalence-based budget impact model was developed in this study (pmcid=11187468).,3840cefd7065f39a45d2716456ad2956
11187468,Tang T,Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis,2024,bim,The analysis compared a world with a levalbuterol scenario to a world without levalbuterol.,What did the analysis compare in terms of levalbuterol (pmcid=11187468)?,The analysis compared a world with a levalbuterol scenario to a world without levalbuterol.,3840cefd7065f39a45d2716456ad2956
11187468,Tang T,Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis,2024,bim,Epidemiological data were obtained from the existing literature.,What data were obtained from the existing literature (pmcid=11187468)?,Epidemiological data,3840cefd7065f39a45d2716456ad2956
11187468,Tang T,Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis,2024,bim,"Cost data were estimated based on the drug dosage in clinical trials, real-world settings, and expert opinions.",What were the cost data estimated based on in this study (pmcid=11187468)?,"The cost data were estimated based on the drug dosage in clinical trials, real-world settings, and expert opinions.",3840cefd7065f39a45d2716456ad2956
11187468,Tang T,Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis,2024,bim,Scenario analysis considered the same length of stay (LOS) in the two groups.,What was considered in the scenario analysis for estimating the economic impact of Levalbuterol's potential transition in China for the treatment of pediatric asthma (pmcid=11187468)?,The scenario analysis considered the same length of stay (LOS) in the two groups.,3840cefd7065f39a45d2716456ad2956
11187468,Tang T,Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis,2024,bim,One-way sensitivity analyses were carried out to show the impact of varying individual parameters.,What type of analysis was carried out in this study (pmcid=11187468)?,One-way sensitivity analysis,3840cefd7065f39a45d2716456ad2956
11187468,Tang T,Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis,2024,bim,"Results In the base-case analysis, compared to the world without scenario, the preservation of levalbuterol resulted in cost savings of ¥82.8 million in China over three years.",What were the cost savings in China over three years due to the preservation of levalbuterol (pmcid=11187468)?,The cost savings in China over three years due to the preservation of levalbuterol were ¥82.8 million.,3840cefd7065f39a45d2716456ad2956
11187468,Tang T,Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis,2024,bim,"In the scenario analysis, savings decreased to ¥76.1 million over three years.",What was the total savings over three years in the scenario analysis (pmcid=11187468)?,¥76.1 million,3840cefd7065f39a45d2716456ad2956
11187468,Tang T,Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis,2024,bim,"Sensitivity analysis showed that, for the most part, the results were robust to changes in input parameter values.",What did the sensitivity analysis show in the study conducted by Tang T regarding the economic impact of Levalbuterol's potential transition in China for the treatment of pediatric asthma (pmcid=11187468)?,"The sensitivity analysis showed that, for the most part, the results were robust to changes in input parameter values in the study conducted by Tang T regarding the economic impact of Levalbuterol's potential transition in China for the treatment of pediatric asthma.",3840cefd7065f39a45d2716456ad2956
11187468,Tang T,Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis,2024,bim,Conclusions Using levalbuterol may lead to substantial cost savings for Chinese society.,What potential cost savings may be achieved by using levalbuterol for the treatment of pediatric asthma in China (pmcid=11187468)?,Using levalbuterol may lead to substantial cost savings for Chinese society.,3840cefd7065f39a45d2716456ad2956
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,"- INTRODUCTION: Sickle cell disease (SCD) is a rare disease, including renal complications.",What is the focus of the study mentioned in the abstract (pmcid=11718668)?,The focus of the study mentioned in the abstract (pmcid=11718668) is on the cost-effectiveness and budget impact analysis of using PP14 Recombinant Human Erythropoietin for sickle cell disease in the Brazilian healthcare system.,24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,"Erythropoiesis-stimulating agents (i.e., recombinant human erythropoietin, rHuEPO) are recommended for SCD and renal impairment.",What are erythropoiesis-stimulating agents recommended for in the context of this study (pmcid=11718668)?,"Erythropoiesis-stimulating agents, specifically recombinant human erythropoietin (rHuEPO), are recommended for sickle cell disease (SCD) and renal impairment in the context of this study (pmcid=11718668).",24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,"Evidence suggests its effectiveness in raising hemoglobin (Hb), which may reduce the need for regular blood transfusions.",What does evidence suggest about the effectiveness of PP14 Recombinant Human Erythropoietin in raising hemoglobin levels (pmcid=11718668)?,"Evidence suggests that PP14 Recombinant Human Erythropoietin is effective in raising hemoglobin levels, which may reduce the need for regular blood transfusions.",24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,Cost-effectiveness analysis (CEA) and budget impact analysis (BIA) of rHuEPO were performed from the Brazilian Unified Health System (SUS) perspective.,What perspective was used for the cost-effectiveness analysis and budget impact analysis of rHuEPO in Brazil (pmcid=11718668)?,The cost-effectiveness analysis and budget impact analysis of rHuEPO in Brazil (pmcid=11718668) were performed from the Brazilian Unified Health System (SUS) perspective.,24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,METHODS: A decision tree was created to assess rHuEPO’s impact on reducing blood transfusions.,What impact did the decision tree assess regarding rHuEPO's effect on reducing blood transfusions (pmcid=11718668)?,The decision tree assessed rHuEPO's impact on reducing blood transfusions.,24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,Quality-adjusted life year (QALY) for transfusion dependency and direct medical costs related to rHuEPO and transfusion were considered.,What was considered in the analysis of Quality-adjusted life year (QALY) for transfusion dependency and direct medical costs related to rHuEPO and transfusion (pmcid=11718668)?,Transfusion dependency and direct medical costs related to rHuEPO and transfusion were considered in the analysis of Quality-adjusted life year (QALY) (pmcid=11718668).,24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,"SCD patients with worsening kidney function and Hb levels enter the model with an indication of receiving regular transfusions; those who proceed to the rHuEPO+standard care arm are likely to have clinically relevant elevation in Hb levels (i.e., <1.5 g/dL), suspending transfusions, and those who do not respond to treatment continue to receive regular transfusions.",What indication do SCD patients with worsening kidney function and Hb levels enter the model with in the study (pmcid=11718668)?,Receiving regular transfusions,24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,"BIA population was estimated based on epidemiological data, considering direct costs over a five-year horizon.",What was the population estimated for the budget impact analysis (pmcid=11718668)?,The population estimated for the budget impact analysis in the study with pmcid=11718668 was based on epidemiological data.,24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,"RESULTS: rHuEPO+standard care compared to standard care generated 36.8 percent less need for transfusions, resulting in an increase of 0.033 QALY and a saving of BRL11,564 (USD2,362) per patient/year.",What were the cost savings per patient/year when comparing rHuEPO+standard care to standard care (pmcid=11718668)?,"The cost savings per patient/year when comparing rHuEPO+standard care to standard care in the study with pmcid=11718668 were BRL11,564 (USD2,362).",24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,"rHuEPO was the dominant alternative; that is, there was greater clinical benefit and lower total cost.",What was the dominant alternative in terms of clinical benefit and total cost (pmcid=11718668)?,rHuEPO,24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,"At BIA, the eligible population was 5,274 patients per year, on average.",How many patients per year were included in the eligible population at BIA (pmcid=11718668)?,"5,274 patients per year",24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,"The direct cost of acquiring rHuEPO for the total eligible population summed BRL13,737,129 (USD2,806,016) in five years.",What was the total direct cost of acquiring rHuEPO for the total eligible population over five years (pmcid=11718668)?,"The total direct cost of acquiring rHuEPO for the total eligible population over five years was BRL13,737,129 (USD2,806,016).",24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,"However, considering the estimated effectiveness of CEA in reducing transfusions, BIA demonstrated savings of BRL96,545,791 (USD19,720,936) accumulated over five years.",What savings were demonstrated by the budget impact analysis over five years (pmcid=11718668)?,"The budget impact analysis demonstrated savings of BRL96,545,791 (USD19,720,936) accumulated over five years.",24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,"CONCLUSIONS: Health technology assessments showing the new alternative as dominant are uncommon, especially in rare diseases, where patented orphan drugs usually have increased costs, which is not the case of rHuEPO.","What is uncommon in health technology assessments, especially in rare diseases, according to the sentence provided? (pmcid=11718668)","Health technology assessments showing the new alternative as dominant are uncommon, especially in rare diseases.",24b712fdb41b9ada749020360a779150
11718668,Gargano L,PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis,2025,bim,"In this analysis, rHuEPO remained the dominant alternative and its incorporation would result in savings that may contribute to the sustainability of the Sistema Único de Saúde, Brazil’s national health system.",What would be the result of incorporating rHuEPO in terms of savings and its contribution to the sustainability of the Sistema Único de Saúde in Brazil (pmcid=11718668)?,"Incorporating rHuEPO would result in savings that may contribute to the sustainability of the Sistema Único de Saúde, Brazil's national health system.",24b712fdb41b9ada749020360a779150
10902956,Goudarzi Z,"Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma",2024,bim,"- BACKGROUND: The prominent efficacy in terms of increasing progression-free survival (PFS) of Daratumumab, Lenalidomide and dexamethasone (DRd) triplet therapy versus Carfilzomib, Lenalidomide and dexamethasone (KRd) was proven previously in relapsed-refractory multiple myeloma (RRMM).",What was proven previously in terms of efficacy in relapsed-refractory multiple myeloma (RRMM) (pmcid=10902956)?,"The prominent efficacy in terms of increasing progression-free survival (PFS) of Daratumumab, Lenalidomide and dexamethasone (DRd) triplet therapy versus Carfilzomib, Lenalidomide and dexamethasone (KRd) was proven previously in relapsed-refractory multiple myeloma (RRMM).",38cd94ea566707e7dd48410fea0e733e
10902956,Goudarzi Z,"Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma",2024,bim,"However, the cost effectiveness of DRd versus KRd is unknown.",What is the cost effectiveness comparison being made in the study (pmcid=10902956)?,"The cost effectiveness comparison being made in the study with pmcid=10902956 is between Daratumumab, Lenalidomide, and dexamethasone (DRd) versus Carfilzomib, Lenalidomide, and dexamethasone (KRd) for relapsed-refractory multiple myeloma.",38cd94ea566707e7dd48410fea0e733e
10902956,Goudarzi Z,"Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma",2024,bim,"METHODS: We developed a Markov model by using an Iranian payer perspective and a 10-year time horizon to estimate the healthcare cost, Quality-adjusted life years (QALYs) and life years gain (LYG) for DRd and KRd triplet therapies.","What perspective was used in the analysis of the healthcare cost, QALYs, and LYG for DRd and KRd triplet therapies (pmcid=10902956)?","The analysis of the healthcare cost, QALYs, and LYG for DRd and KRd triplet therapies in the study with pmcid=10902956 was conducted using an Iranian payer perspective.",38cd94ea566707e7dd48410fea0e733e
10902956,Goudarzi Z,"Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma",2024,bim,Clinical data were obtained from meta-analyses and randomized clinical trials (RCTs).,What type of data were obtained for the analysis (pmcid=10902956)?,Clinical data,38cd94ea566707e7dd48410fea0e733e
10902956,Goudarzi Z,"Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma",2024,bim,One-way and probabilistic sensitivity analysis were performed to assess model uncertainty.,What type of analysis was performed to assess model uncertainty in the study by Goudarzi Z et al. (pmcid=10902956)?,One-way and probabilistic sensitivity analysis,38cd94ea566707e7dd48410fea0e733e
10902956,Goudarzi Z,"Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma",2024,bim,Budget impact analysis of 5 years of treatment under the DRd triplet therapy was also analysed.,What was analyzed in terms of budget impact under the DRd triplet therapy for relapsed-refractory multiple myeloma (pmcid=10902956)?,The budget impact analysis of 5 years of treatment under the DRd triplet therapy was analyzed for relapsed-refractory multiple myeloma.,38cd94ea566707e7dd48410fea0e733e
10902956,Goudarzi Z,"Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma",2024,bim,"RESULTS: DRd was estimated to be more effective compared to KRd, providing 0.28 QALY gain over the modelled horizon.",What was the estimated QALY gain of DRd compared to KRd (pmcid=10902956)?,0.28 QALY,38cd94ea566707e7dd48410fea0e733e
10902956,Goudarzi Z,"Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma",2024,bim,DRd-treated patients incurred $264 in total additional costs.,How much did DRd-treated patients incur in total additional costs? (pmcid=10902956),$264,38cd94ea566707e7dd48410fea0e733e
10902956,Goudarzi Z,"Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma",2024,bim,The incremental cost utility ratio (ICUR) and cost effectiveness ratio (ICER) were $956/QALY and $472/LYG respectively.,"What were the incremental cost utility ratio (ICUR) and cost effectiveness ratio (ICER) for Daratumumab, Lenalidomide, and dexamethasone in the study (pmcid=10902956)?","The incremental cost utility ratio (ICUR) was $956 per quality-adjusted life year (QALY) and the cost effectiveness ratio (ICER) was $472 per life year gained (LYG) for Daratumumab, Lenalidomide, and dexamethasone in the study with pmcid=10902956.",38cd94ea566707e7dd48410fea0e733e
10902956,Goudarzi Z,"Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma",2024,bim,"The budget impact analysis indicates that adding Daratumumab to Lenalidomide and dexamethasone regimen, in the first 5 years, will increase the healthcare system's expenses by $6.170.582.",What is the estimated increase in healthcare system expenses in the first 5 years by adding Daratumumab to the Lenalidomide and dexamethasone regimen (pmcid=10902956)?,"The estimated increase in healthcare system expenses in the first 5 years by adding Daratumumab to the Lenalidomide and dexamethasone regimen is $6,170,582.",38cd94ea566707e7dd48410fea0e733e
10902956,Goudarzi Z,"Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma",2024,bim,CONCLUSION: DRd triplet therapy compared to KRd is a cost-effective regimen for RRMM under Iran willingness-to-pay threshold.,What is the conclusion regarding the cost-effectiveness of DRd triplet therapy compared to KRd for RRMM under Iran's willingness-to-pay threshold (pmcid=10902956)?,The conclusion is that DRd triplet therapy is a cost-effective regimen for relapsed-refractory multiple myeloma (RRMM) compared to KRd under Iran's willingness-to-pay threshold.,38cd94ea566707e7dd48410fea0e733e
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,"- BACKGROUND: Durvalumab, used as consolidation immunotherapy, has shown to improve survival in patients with stage III non-small cell lung cancer who respond to chemoradiotherapy, based on the most recent follow-up of PACIFIC.",What has Durvalumab shown to improve in patients with stage III non-small cell lung cancer who respond to chemoradiotherapy (pmcid=11280244)?,Survival,5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,The Chilean healthcare system provides access to certain immunotherapies for this condition.,What immunotherapies does the Chilean healthcare system provide access to for the condition mentioned in the abstract (pmcid=11280244)?,The Chilean healthcare system provides access to durvalumab for stage III non–small cell lung cancer.,5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,The present study sought to estimate the budget impact of durvalumab versus standard of care in the context of the Chilean healthcare system.,What did the present study seek to estimate in the context of the Chilean healthcare system (pmcid=11280244)?,The present study sought to estimate the budget impact of durvalumab versus standard of care in the context of the Chilean healthcare system.,5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,RESEARCH DESIGN AND METHODS: A partitioned survival model was adapted to compare two strategies: durvalumab as consolidation therapy and standard of care for treating stage III NSCLC.,What research design and methods were used to compare two strategies in the study (pmcid=11280244)?,A partitioned survival model was adapted to compare two strategies: durvalumab as consolidation therapy and standard of care for treating stage III NSCLC.,5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,The number of patients eligible for treatment was estimated using published incidence data and modeled for a 5-year time horizon.,What was the time horizon modeled for in the budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system (pmcid=11280244)?,The time horizon modeled for in the budget impact analysis was 5 years.,5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,"Model inputs were based on published literature, and the duration of treatment was estimated using survival curves obtained from PACIFIC.",What were the model inputs based on in the budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system (pmcid=11280244)?,The model inputs were based on published literature.,5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,Costs were estimated in Chilean pesos (CLP) and converted to USD dollars using an exchange rate of USD 1  =  CLP 827.,What exchange rate was used to convert Chilean pesos to USD dollars in the study (pmcid=11280244)?,USD 1 = CLP 827,5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,"Scenario analyses were performed to assess different subsequent therapy splits, variations in the target population and dosage of durvalumab.",What scenario analyses were performed in the study (pmcid=11280244)?,"Scenario analyses were performed to assess different subsequent therapy splits, variations in the target population, and dosage of durvalumab.",5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,RESULTS: Durvalumab uptake projected total costs ranging from USD 1.27 in Year 1 to 8.5 million in Year 5 from the public perspective.,What were the projected total costs of Durvalumab uptake in Year 1 to Year 5 from the public perspective (pmcid=11280244)?,The projected total costs of Durvalumab uptake ranged from USD 1.27 in Year 1 to 8.5 million in Year 5 from the public perspective.,5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,"From the private perspective, the budget impact for the first year is USD 1.3 million to USD 3 million for 2028.",What is the budget impact for the first year from the private perspective in 2028 (pmcid=11280244)?,The budget impact for the first year from the private perspective in 2028 is USD 1.3 million to USD 3 million.,5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,This difference relies mostly on the lower number of patients treated.,What does the difference in budget impact between durvalumab consolidation therapy and no consolidation therapy rely on (pmcid=11280244)?,The difference in budget impact between durvalumab consolidation therapy and no consolidation therapy relies mostly on the lower number of patients treated.,5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,"Both perspectives anticipated cost savings over the time horizon through reduced monitoring, adverse events, and end-of-life expenses.",What cost savings were anticipated over the time horizon in the budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system (pmcid=11280244)?,"Cost savings were anticipated over the time horizon through reduced monitoring, adverse events, and end-of-life expenses in the budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system.",5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,CONCLUSIONS: This study demonstrates that the inclusion of Durvalumab for NSCLC in Chile represents an investment in the Chilean health system.,What does this study demonstrate about the inclusion of Durvalumab for NSCLC in Chile (pmcid=11280244)?,This study demonstrates that the inclusion of Durvalumab for NSCLC in Chile represents an investment in the Chilean health system.,5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,The incremental costs align with clinical benefits and potential savings in healthcare resource utilization.,What do the incremental costs align with in the context of the study (pmcid=11280244)?,The incremental costs align with clinical benefits and potential savings in healthcare resource utilization.,5b9ade8253afeb6aaef16e9bfcc57769
11280244,Armijo N,Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system,2024,bim,"However, a comprehensive cost-effectiveness analysis is needed to evaluate its economic value thoroughly.",What type of analysis is needed to evaluate the economic value of durvalumab consolidation therapy in the context of the Chilean health care system (pmcid=11280244)?,A comprehensive cost-effectiveness analysis is needed to evaluate the economic value of durvalumab consolidation therapy in the context of the Chilean health care system.,5b9ade8253afeb6aaef16e9bfcc57769
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,"- AIM: In 2022, in Italy, general practitioners (GPs) have been allowed to prescribe SGLT2i in Type 2 Diabetes (T2D) under National Health Service (NHS) reimbursement.",What were general practitioners in Italy allowed to prescribe in 2022 under National Health Service reimbursement (pmcid=11329540)?,SGLT2i,b35ba1a91d2175af0c85da1b23089f19
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,"In the pivotal clinical trial named DECLARE-TIMI 58, dapagliflozin reduced the risk of hospitalization for heart failure, CV death and kidney disease progression compared to placebo in a population of T2D patients.","What trial demonstrated the reduction in risk of hospitalization for heart failure, CV death, and kidney disease progression with dapagliflozin (pmcid=11329540)?",DECLARE-TIMI 58,b35ba1a91d2175af0c85da1b23089f19
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,This study evaluated the health and economic impact of dapagliflozin for T2D patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian GPs setting.,What did the study evaluate (pmcid=11329540)?,The study evaluated the health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting.,b35ba1a91d2175af0c85da1b23089f19
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,METHODS: A budget impact model was developed to assess the health and economic impact of introducing dapagliflozin in GPs setting.,What was developed to assess the health and economic impact of introducing dapagliflozin in GPs setting (pmcid=11329540)?,A budget impact model was developed.,b35ba1a91d2175af0c85da1b23089f19
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,The analysis was conducted by adopting the Italian NHS perspective and a 3-year time horizon.,What perspective was adopted for the analysis of the health and economic impact of dapagliflozin for type 2 diabetes patients in Italy (pmcid=11329540)?,The Italian NHS perspective was adopted for the analysis.,b35ba1a91d2175af0c85da1b23089f19
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,The model estimated and compared the health outcomes and direct medical costs associated with a scenario with dapagliflozin and other antidiabetic therapies available for GPs prescription (scenario B) and a scenario where only other antidiabetic therapies are available (scenario A).,What scenarios were compared in the budget impact analysis conducted by Cortesi PA et al. (pmcid=11329540)?,"The scenarios compared in the budget impact analysis conducted by Cortesi PA et al. were scenario B, where dapagliflozin and other antidiabetic therapies were available for GPs prescription, and scenario A, where only other antidiabetic therapies were available.",b35ba1a91d2175af0c85da1b23089f19
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,"Rates of occurrence of cardiovascular and renal complications as well as adverse events were captured from DECLARE-TIMI 58 trial and the literature, while cost data were retrieved from the Italian tariff and the literature.",What trial was used to capture rates of occurrence of cardiovascular and renal complications as well as adverse events in the study (pmcid=11329540)?,DECLARE-TIMI 58 trial,b35ba1a91d2175af0c85da1b23089f19
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,One-way sensitivity analyses were conducted to test the impact of model parameters on the budget impact.,What were the one-way sensitivity analyses conducted to test the impact of (pmcid=11329540)?,The one-way sensitivity analyses conducted to test the impact of pmcid=11329540 were to test the impact of model parameters on the budget impact.,b35ba1a91d2175af0c85da1b23089f19
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,RESULTS: The model estimated around 442.000 patients eligible for the treatment with dapagliflozin in the GPs setting for each simulated year.,How many patients were estimated to be eligible for treatment with dapagliflozin in the Italian general practitioners setting each simulated year (pmcid=11329540)?,"Around 442,000 patients were estimated to be eligible for treatment with dapagliflozin in the Italian general practitioners setting each simulated year.",b35ba1a91d2175af0c85da1b23089f19
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,The scenario B compared to scenario A was associated with a reduction in the occurrence of cardiovascular and renal complication (-1.83%) over the 3 years simulated.,What was the reduction in the occurrence of cardiovascular and renal complications associated with scenario B compared to scenario A over the 3 years simulated (pmcid=11329540)?,1.83%,b35ba1a91d2175af0c85da1b23089f19
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,"Furthermore, the scenario A allowed for an overall cost saving of 102,692,305€: 14,521,464€ in the first year, 33,007,064€ in the second and 55,163,777€ in the third.",What were the overall cost savings in scenario A for the study on dapagliflozin for type 2 diabetes patients in the Italian general practitioners setting (pmcid=11329540)?,"The overall cost savings in scenario A for the study on dapagliflozin for type 2 diabetes patients in the Italian general practitioners setting were 102,692,305€: 14,521,464€ in the first year, 33,007,064€ in the second year, and 55,163,777€ in the third year.",b35ba1a91d2175af0c85da1b23089f19
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,"The cost of cost of drug acquisition, the probability of cardiovascular events and the percentage of patients potentially eligible to the treatment were the factor with largest impact on the results.",What factors had the largest impact on the results in the budget impact analysis for dapagliflozin in type 2 diabetes patients at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting (pmcid=11329540)?,"The factors with the largest impact on the results in the budget impact analysis for dapagliflozin in type 2 diabetes patients at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting were the cost of drug acquisition, the probability of cardiovascular events, and the percentage of patients potentially eligible for the treatment.",b35ba1a91d2175af0c85da1b23089f19
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,"CONCLUSIONS: The use of dapagliflozin in GPs setting reduce the number of CVD events, kidney disease progression and healthcare costs in Italy.","What impact does the use of dapagliflozin have on the number of CVD events, kidney disease progression, and healthcare costs in Italy (pmcid=11329540)?","The use of dapagliflozin in the Italian general practitioners setting reduces the number of CVD events, kidney disease progression, and healthcare costs in Italy.",b35ba1a91d2175af0c85da1b23089f19
11329540,Cortesi PA,Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis,2024,bim,These data should be considered to optimize the value produced for the T2D patients who had or were at risk for atherosclerotic cardiovascular disease.,What should be considered to optimize the value produced for T2D patients who had or were at risk for atherosclerotic cardiovascular disease (pmcid=11329540)?,These data should be considered to optimize the value produced for T2D patients who had or were at risk for atherosclerotic cardiovascular disease.,b35ba1a91d2175af0c85da1b23089f19
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,- OBJECTIVES: To evaluate the cost-utility of botulinum toxin A (BoNT-A) for treating upper limb (UL) and lower limb (LL) post-stroke spasticity.,What is the objective of the study (pmcid=11749450)?,The objective of the study with pmcid=11749450 is to evaluate the cost-utility of botulinum toxin A (BoNT-A) for treating upper limb (UL) and lower limb (LL) post-stroke spasticity.,c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,"DESIGN: Using a Markov model, adopting a societal perspective and a lifetime horizon with a 3% annual discount rate, the cost-utility analysis was conducted to compare BoNT-A combined with standard of care (SoC) with SoC alone.",What perspective was adopted for the cost-utility analysis in the study (pmcid=11749450)?,The cost-utility analysis in the study (pmcid=11749450) adopted a societal perspective.,c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,"Costs, utilities, transitional probabilities and treatment efficacy were derived from 5-year retrospective data from tertiary hospitals and meta-analysis.","What data sources were used to derive costs, utilities, transitional probabilities, and treatment efficacy in the study (pmcid=11749450)?","Costs, utilities, transitional probabilities, and treatment efficacy were derived from 5-year retrospective data from tertiary hospitals and meta-analysis.",c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,Uncertainty analyses were performed.,What analyses were performed in the study (pmcid=11749450)?,Uncertainty analyses were performed.,c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,SETTING: Tertiary hospitals in Thailand.,What is the setting for the study on Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand (pmcid=11749450)?,The setting for the study on Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand (pmcid=11749450) is tertiary hospitals in Thailand.,c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,PARTICIPANTS: Cohort of post-stroke patients aged 55 years with UL or LL spasticity and a Modified Ashworth Scale score ≥1+.,What was the cohort of participants in the study (pmcid=11749450)?,The cohort of participants in the study with pmcid=11749450 were post-stroke patients aged 55 years with upper limb (UL) or lower limb (LL) spasticity and a Modified Ashworth Scale score of ≥1+.,c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,"INTERVENTIONS: BoNT-A (abobotulinumtoxinA: aboBoNT-A, onabotulinumtoxinA: onaBoNT-A or prabotulinumtoxinA: praBoNT-A) combined with SoC versus SoC alone.",What interventions were compared in the study (pmcid=11749450)?,"BoNT-A (abobotulinumtoxinA: aboBoNT-A, onabotulinumtoxinA: onaBoNT-A or prabotulinumtoxinA: praBoNT-A) combined with SoC versus SoC alone.",c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,"PRIMARY OUTCOME MEASURES: Expected life years, quality-adjusted life years (QALYs), costs and incremental cost-effectiveness ratios (ICERs), considering a cost-effectiveness threshold of 160 000 THB (US$4468) per QALY gained.",What cost-effectiveness threshold was considered in the analysis (pmcid=11749450)?,"The cost-effectiveness threshold considered in the analysis was 160,000 THB (US$4468) per QALY gained.",c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,"RESULTS: The combination of aboBoNT-A and SoC yielded the highest QALYs gained (0.013 for UL and 0.11 for LL), followed by onaBoNT-A and SoC and praBoNT-A and SoC.",What combination yielded the highest QALYs gained for patients with post-stroke spasticity in Thailand (pmcid=11749450)?,The combination of aboBoNT-A and SoC yielded the highest QALYs gained for patients with post-stroke spasticity in Thailand.,c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,"The additional costs for treating UL and LL cases were highest for onaBoNT-A US$75 and US$95, respectively, followed by aboBoNT-A and praBoNT-A.",What were the additional costs for treating UL and LL cases according to the abstract sentence (pmcid=11749450)?,"The additional costs for treating UL and LL cases were highest for onaBoNT-A US$75 and US$95, respectively, followed by aboBoNT-A and praBoNT-A.",c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,"ICER values for treating UL with aboBoNT-A, onaBoNT-A and praBoNT-A ranged from US$4669 to US$7541 per QALY.","What are the ICER values for treating UL with aboBoNT-A, onaBoNT-A, and praBoNT-A? (pmcid=11749450)","ICER values for treating UL with aboBoNT-A, onaBoNT-A, and praBoNT-A ranged from US$4669 to US$7541 per QALY.",c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,"For LL treatments, aboBoNT-A and onaBoNT-A had ICER values ranging from US$7072 to US$15 182 per QALY.",What were the ICER values for aboBoNT-A and onaBoNT-A in the treatment of post-stroke spasticity patients in Thailand (pmcid=11749450)?,"The ICER values for aboBoNT-A and onaBoNT-A in the treatment of post-stroke spasticity patients in Thailand ranged from US$7072 to US$15,182 per QALY.",c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,Integrating BoNT-A treatment delivery into the healthcare system would require a budget outlay of approximately US$413 246-US$966 103 that may vary annually by an additional US$50 260-US$335 064.,What budget outlay would be required for integrating BoNT-A treatment delivery into the healthcare system (pmcid=11749450)?,"Approximately US$413,246-US$966,103 would be required for integrating BoNT-A treatment delivery into the healthcare system.",c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,CONCLUSION: BoNT-A effectively reduces focal spasticity and improves quality of life in post-stroke patients.,What is the conclusion regarding the effectiveness of BoNT-A in post-stroke patients (pmcid=11749450)?,BoNT-A effectively reduces focal spasticity and improves quality of life in post-stroke patients.,c960b34e47782b89821ac542ef102c34
11749450,Hadnorntun P,Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis,2025,bim,"However, its cost-effectiveness in Thailand necessitates price negotiations as a condition for inclusion in the pharmaceutical reimbursement list.",What is the condition for inclusion of Botulinum toxin type A in the pharmaceutical reimbursement list in Thailand (pmcid=11749450)?,Price negotiations,c960b34e47782b89821ac542ef102c34
11416454,Nagano M,Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis,2024,bim,- INTRODUCTION: Japan will be transitioning from the free-of-charge COVID-19 vaccination program to annual periodic vaccination under a national immunization program for old adults and high-risk patients from 2024 fall/winter season.,What transition will Japan be making in regards to COVID-19 vaccination for old adults and high-risk patients starting from the fall/winter season of 2024 (pmcid=11416454)?,Japan will be transitioning from the free-of-charge COVID-19 vaccination program to annual periodic vaccination under a national immunization program for old adults and high-risk patients starting from the fall/winter season of 2024.,b1d3d6889f8ddce7abdd8c42d90ca1f4
11416454,Nagano M,Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis,2024,bim,"The policy transition including out-of-pocket payment requirement may discourage vaccination, leading to a lower vaccination rate.",What may discourage vaccination according to the abstract sentence (pmcid=11416454)?,The policy transition including out-of-pocket payment requirement may discourage vaccination.,b1d3d6889f8ddce7abdd8c42d90ca1f4
11416454,Nagano M,Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis,2024,bim,"This study aimed to estimate the impact of varying vaccination rates with BNT162b2 COVID-19 mRNA vaccine on economics and public health in an illustrative prefecture which administers and promotes the periodic vaccination program, using budget impact analysis.",What did the study aim to estimate in an illustrative prefecture of Japan (pmcid=11416454)?,The study aimed to estimate the impact of varying vaccination rates with the BNT162b2 COVID-19 mRNA vaccine on economics and public health in an illustrative prefecture of Japan.,b1d3d6889f8ddce7abdd8c42d90ca1f4
11416454,Nagano M,Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis,2024,bim,"METHODS: A combined cohort Markov decision tree model estimated the public health outcomes of COVID-19-related symptomatic cases, hospitalizations and deaths; and the economic outcomes including vaccine-related cost, non-vaccine-related medical cost, and productivity loss from the societal perspective.",What outcomes were estimated in the combined cohort Markov decision tree model (pmcid=11416454)?,"The outcomes estimated in the combined cohort Markov decision tree model in the study with pmcid=11416454 were public health outcomes of COVID-19-related symptomatic cases, hospitalizations, and deaths; as well as economic outcomes including vaccine-related cost, non-vaccine-related medical cost, and productivity loss from the societal perspective.",b1d3d6889f8ddce7abdd8c42d90ca1f4
11416454,Nagano M,Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis,2024,bim,"The base case examined the impact on the outcomes when vaccination coverage changed from the reference value of 50% to upper and lower values, respectively.",What was examined in the base case scenario (pmcid=11416454)?,The impact on the outcomes when vaccination coverage changed from the reference value of 50% to upper and lower values.,b1d3d6889f8ddce7abdd8c42d90ca1f4
11416454,Nagano M,Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis,2024,bim,Scenario analyses were performed based on multiple scenarios.,What type of analyses were performed in this study (pmcid=11416454)?,Scenario analyses were performed.,b1d3d6889f8ddce7abdd8c42d90ca1f4
11416454,Nagano M,Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis,2024,bim,RESULTS: Increase in the vaccination rate demonstrated improvement in all public health outcomes.,What demonstrated improvement in all public health outcomes? (pmcid=11416454),Increase in the vaccination rate,b1d3d6889f8ddce7abdd8c42d90ca1f4
11416454,Nagano M,Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis,2024,bim,"At 50% vaccination, the vaccine-related cost for 3 years in a prefecture was estimated at JPY 7.58 billion (USD 57.67 million), the non-vaccine-related medical cost at JPY 79.22 billion (USD 602.48 million), the productivity loss at JPY 253.11 billion (USD 1.92 billion), and the total cost at JPY 339.92 billion (USD 2.59 billion).",What was the total cost estimated for 3 years in a prefecture for COVID-19 vaccination with BNT162b2 (pmcid=11416454)?,The total cost estimated for 3 years in a prefecture for COVID-19 vaccination with BNT162b2 was JPY 339.92 billion (USD 2.59 billion).,b1d3d6889f8ddce7abdd8c42d90ca1f4
11416454,Nagano M,Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis,2024,bim,"When the vaccination rate increased to 90%, the total cost decreased by JPY 4.88 billion (USD 37.11 million) (1.4%).",What was the impact of increasing the vaccination rate to 90% on the total cost in the study conducted by Nagano M (pmcid=11416454)?,"When the vaccination rate increased to 90%, the total cost decreased by JPY 4.88 billion (USD 37.11 million) (1.4%).",b1d3d6889f8ddce7abdd8c42d90ca1f4
11416454,Nagano M,Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis,2024,bim,"When the vaccination rate decreased to 10%, the total cost increased by JPY 5.73 billion (USD 43.58 million) (1.7%).",What was the impact on total cost when the vaccination rate decreased to 10% (pmcid=11416454)?,"When the vaccination rate decreased to 10%, the total cost increased by JPY 5.73 billion (USD 43.58 million) (1.7%).",b1d3d6889f8ddce7abdd8c42d90ca1f4
11416454,Nagano M,Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis,2024,bim,Results were consistent across almost all scenario analyses.,What were the results consistent across in the scenario analyses (pmcid=11416454)?,Results were consistent across almost all scenario analyses.,b1d3d6889f8ddce7abdd8c42d90ca1f4
11416454,Nagano M,Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis,2024,bim,CONCLUSIONS: Maintaining a high vaccination rate with BNT162b2 is important from both public health and economic perspectives in Japan.,What is important from both public health and economic perspectives in Japan (pmcid=11416454)?,Maintaining a high vaccination rate with BNT162b2 is important from both public health and economic perspectives in Japan.,b1d3d6889f8ddce7abdd8c42d90ca1f4
11416454,Nagano M,Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis,2024,bim,The findings highlight to local governments the importance of continued effort to promote vaccination.,What is the importance highlighted to local governments in the findings (pmcid=11416454)?,The importance highlighted to local governments in the findings is the continued effort to promote vaccination.,b1d3d6889f8ddce7abdd8c42d90ca1f4
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,"- BACKGROUND: Fall prevention is important for healthy ageing, but the economic impact of fall prevention are scarcely investigated.",What is important for healthy ageing according to the abstract sentence (pmcid=10893703)?,Fall prevention is important for healthy ageing.,d3519cd32df27543932252ce7a57326a
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,A recent cost-effectiveness analysis compared a group-delivered Lifestyle-integrated Functional Exercise Program (gLiFE) with an individually-delivered program (LiFE) in community-dwelling people (aged ≥ 70 years) at risk of falling.,What were the two types of Lifestyle-integrated Functional Exercise Programs compared in the recent cost-effectiveness analysis (pmcid=10893703)?,The two types of Lifestyle-integrated Functional Exercise Programs compared in the recent cost-effectiveness analysis were the group-delivered Lifestyle-integrated Functional Exercise Program (gLiFE) and the individually-delivered program (LiFE).,d3519cd32df27543932252ce7a57326a
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,"In addition, the current study aimed to analyze the budget impact of LiFE and gLiFE, compared with standard care in Germany.",What was the aim of the current study (pmcid=10893703)?,"The aim of the current study was to analyze the budget impact of the Lifestyle-integrated Functional Exercise (LiFE) program and the group-based LiFE (gLiFE) program, compared with standard care in Germany.",d3519cd32df27543932252ce7a57326a
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,METHODS: A Markov model was developed to reflect falls and associated care needs for community-dwelling persons over 5 years.,What was the time horizon of the Markov model developed in this study (pmcid=10893703)?,The time horizon of the Markov model developed in this study (pmcid=10893703) was 5 years.,d3519cd32df27543932252ce7a57326a
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,"The intervention effects of LiFE and gLiFE were shown to be equivalent in a non-inferiority trial, although the costs differed.",What were the intervention effects of LiFE and gLiFE shown to be in a non-inferiority trial (pmcid=10893703)?,The intervention effects of LiFE and gLiFE were shown to be equivalent in a non-inferiority trial.,d3519cd32df27543932252ce7a57326a
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,"Outpatient, inpatient, and intervention costs were assessed from a payer's perspective.",What costs were assessed in this study from a payer's perspective (pmcid=10893703)?,"Outpatient, inpatient, and intervention costs were assessed from a payer's perspective.",d3519cd32df27543932252ce7a57326a
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,The effect of parameter uncertainty was assessed in sensitivity analyses.,What was assessed in sensitivity analyses (pmcid=10893703)?,The effect of parameter uncertainty,d3519cd32df27543932252ce7a57326a
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,RESULTS: The budget impact due to intervention costs was €510 million for LiFE and €186 million for gLiFE.,What were the intervention costs for the LiFE program in Germany (pmcid=10893703)?,The intervention costs for the LiFE program in Germany were €510 million.,d3519cd32df27543932252ce7a57326a
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,"Over five years, health care expenditures were €35,008 million for those receiving standard care, €35,416 million for those receiving LiFE, and €35,091 million for persons receiving gLiFE.","What were the health care expenditures over five years for those receiving standard care, LiFE, and gLiFE? (pmcid=10893703)","Health care expenditures over five years were €35,008 million for those receiving standard care, €35,416 million for those receiving LiFE, and €35,091 million for persons receiving gLiFE.",d3519cd32df27543932252ce7a57326a
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,"Thereby, LiFE and gLiFE could prevent 2700 deaths and 648,000 falls over 5 years.",How many deaths and falls could be prevented over 5 years by the LiFE and gLiFE programs in Germany (pmcid=10893703)?,"2700 deaths and 648,000 falls",d3519cd32df27543932252ce7a57326a
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,"Parameter uncertainties in the risk of falling, uptake of an intervention offer, and in the intervention effects had a major influence; thus cost savings for LiFE and gLiFE compared with standard care could be achieved for individuals with a high risk of falling.",What had a major influence on cost savings for LiFE and gLiFE compared with standard care (pmcid=10893703)?,"Parameter uncertainties in the risk of falling, uptake of an intervention offer, and in the intervention effects had a major influence on cost savings for LiFE and gLiFE compared with standard care.",d3519cd32df27543932252ce7a57326a
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,"CONCLUSIONS: The results revealed that cost savings for LiFE and gLiFE compared with standard care could only be achieved for individuals at high risk of falling, with gLiFE being superior to LiFE.","What results were revealed regarding cost savings for the LiFE and gLiFE programs compared to standard care, and for whom could these savings be achieved (pmcid=10893703)?","The results revealed that cost savings for the LiFE and gLiFE programs compared with standard care could only be achieved for individuals at high risk of falling, with gLiFE being superior to LiFE.",d3519cd32df27543932252ce7a57326a
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,"Future research should consider benefits and aspects of fall prevention beyond falls (e.g., physical activity, social aspects, and personal preferences of participants).","What should future research consider in relation to fall prevention beyond falls (e.g., physical activity, social aspects, and personal preferences of participants) (pmcid=10893703)?","Future research should consider benefits and aspects of fall prevention beyond falls, such as physical activity, social aspects, and personal preferences of participants.",d3519cd32df27543932252ce7a57326a
10893703,Dams J,Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial,2024,bim,TRIAL REGISTRATION: The study was preregistered under underclinicaltrials.gov (identifier: NCT03462654) on 12th March 2018; https://clinicaltrials.gov/ct2/show/NCT03462654 .,What was the registration identifier for the study (pmcid=10893703)?,NCT03462654,d3519cd32df27543932252ce7a57326a
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,"- INTRODUCTION: The effectiveness, safety, and cost-effectiveness of the use of Souvenaid for Alzheimer's disease (AD) have been previously evidenced.","What has been previously evidenced regarding the effectiveness, safety, and cost-effectiveness of the use of Souvenaid for Alzheimer's disease (AD) (pmcid=9652901)?","The effectiveness, safety, and cost-effectiveness of the use of Souvenaid for Alzheimer's disease (AD) have been previously evidenced.",a16ffc58119d658fbaa8e1d0fa8aea10
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,"To complete the economic analysis, there is a need to assess whether society can afford it.",What is the need to assess in order to complete the economic analysis (pmcid=9652901)?,Whether society can afford it.,a16ffc58119d658fbaa8e1d0fa8aea10
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,The objective of this study was to carry out a budget impact analysis of the use of Souvenaid in Spain under the conditions of the LipiDidiet clinical trial from a societal perspective.,What was the objective of the study conducted by Mar J in Spain (pmcid=9652901)?,The objective of the study conducted by Mar J in Spain (pmcid=9652901) was to carry out a budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain from a societal perspective.,a16ffc58119d658fbaa8e1d0fa8aea10
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,"METHODS: We built a population model that took into account all the cohorts of individuals with AD, their individual progression, and the potential impact of Souvenaid treatment on their trajectories.",What did the population model built in this study take into account (pmcid=9652901)?,"The population model built in this study took into account all the cohorts of individuals with Alzheimer's Disease, their individual progression, and the potential impact of Souvenaid treatment on their trajectories.",a16ffc58119d658fbaa8e1d0fa8aea10
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,Patient progression data were obtained from mixed models.,What data were obtained from mixed models (pmcid=9652901)?,Patient progression data,a16ffc58119d658fbaa8e1d0fa8aea10
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,The target population was estimated based on the population forecast for 2020-2035 and the incidence of dementia.,What was the target population estimated based on in the study (pmcid=9652901)?,The target population was estimated based on the population forecast for 2020-2035 and the incidence of dementia.,a16ffc58119d658fbaa8e1d0fa8aea10
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,Individual progression to dementia measured by the Clinical Dementia Rating-Sum of Boxes was reproduced using mixed models.,What was reproduced using mixed models in the study (pmcid=9652901)?,Individual progression to dementia,a16ffc58119d658fbaa8e1d0fa8aea10
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,"Besides the costs of treatment and diagnosis, direct costs of medical and non-medical care and indirect costs were included.",What costs were included besides the costs of treatment and diagnosis in the budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain (pmcid=9652901)?,Direct costs of medical and non-medical care and indirect costs were included besides the costs of treatment and diagnosis in the budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer's Disease in Spain.,a16ffc58119d658fbaa8e1d0fa8aea10
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,RESULTS: The epidemiological indicators and the distribution of life expectancy by stages validated the model.,What did the epidemiological indicators and the distribution of life expectancy by stages validate in the study (pmcid=9652901)?,The epidemiological indicators and the distribution of life expectancy by stages validated the model in the study.,a16ffc58119d658fbaa8e1d0fa8aea10
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,"From the third year (2022), the differences in the cost of dementia offset the incremental cost of diagnosis and treatment.",What differences offset the incremental cost of diagnosis and treatment from the third year onwards (pmcid=9652901)?,The differences in the cost of dementia offset the incremental cost of diagnosis and treatment from the third year onwards.,a16ffc58119d658fbaa8e1d0fa8aea10
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,The costs of dependency reached €500 million/year while those of the intervention were limited to €40 million.,What were the costs of dependency and the intervention in the budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain (pmcid=9652901)?,"The costs of dependency were €500 million/year, while the costs of the intervention were limited to €40 million.",a16ffc58119d658fbaa8e1d0fa8aea10
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,"CONCLUSIONS: Souvenaid, with modest effectiveness in delaying dementia associated with AD, achieved a positive economic balance between costs and savings.",What economic balance did Souvenaid achieve between costs and savings in patients with prodromal Alzheimer's Disease in Spain (pmcid=9652901)?,Souvenaid achieved a positive economic balance between costs and savings in patients with prodromal Alzheimer's Disease in Spain.,a16ffc58119d658fbaa8e1d0fa8aea10
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,"Its use in the treatment of prodromal AD would imply an initial cost that would be ongoing, but this would be offset by savings in the care system for dependency associated with dementia from the third year.",What would be offset by savings in the care system for dependency associated with dementia from the third year (pmcid=9652901)?,The initial cost of using Souvenaid in the treatment of prodromal Alzheimer's Disease would be offset by savings in the care system for dependency associated with dementia from the third year.,a16ffc58119d658fbaa8e1d0fa8aea10
9652901,Mar J,Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain,2022,bim,"These results were based on adopting a societal perspective taking into account the effect of treatment on the use of health, social, and family resources.",What perspective was taken into account in the budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain (pmcid=9652901)?,"The budget impact analysis took into account a societal perspective, considering the effect of treatment on the use of health, social, and family resources.",a16ffc58119d658fbaa8e1d0fa8aea10
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,- BACKGROUND: Brolucizumab is a new anti-vascular endothelial growth factor (anti-VEGF) approved for treating neovascular age-related macular degeneration (nAMD).,What is brolucizumab approved for treating (pmcid=10373014)?,Brolucizumab is approved for treating neovascular age-related macular degeneration (nAMD).,8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,Multiple treatment regimens are available for treating nAMD.,What are the available treatment regimens for treating nAMD? (pmcid=10373014),Multiple treatment regimens are available for treating nAMD.,8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,"These regimens include manufacturer-recommended regimens, pro re nata (PRN) regimens, and treat-and-extend (T&E) regimens, which are based on clinical practice guidelines and data observed in the real-world clinical setting, classified as real-world evidence (RWE).",What are the different treatment regimens of brolucizumab analyzed in the budget impact analysis (pmcid=10373014)?,"The different treatment regimens of brolucizumab analyzed in the budget impact analysis are manufacturer-recommended regimens, pro re nata (PRN) regimens, and treat-and-extend (T&E) regimens.",8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,Most budget impact models predict the financial consequences of adding a new drug to the formulary based on the manufacturer-recommended regimen.,What do most budget impact models predict in relation to adding a new drug to the formulary (pmcid=10373014)?,Most budget impact models predict the financial consequences of adding a new drug to the formulary based on the manufacturer-recommended regimen.,8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,"With different anti-VEGF treatment regimens being used in nAMD by ophthalmologists, it is OBJECTIVE: To estimate the budget impact of different treatment regimens of brolucizumab in nAMD from a US payer perspective.",What is the objective of estimating the budget impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration from a US payer perspective (pmcid=10373014)?,The objective is to estimate the budget impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration from a US payer perspective.,8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,METHODS: A Microsoft Excel-based budget impact model was developed for different treatment regimens of brolucizumab over a 1-year time frame from a US payer perspective.,What type of budget impact model was developed for different treatment regimens of brolucizumab (pmcid=10373014)?,A Microsoft Excel-based budget impact model.,8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,A separate analysis was performed to estimate the budget impact from a US patient population perspective.,What perspective was used to estimate the budget impact in the analysis (pmcid=10373014)?,The budget impact was estimated from a US patient population perspective.,8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,"Model inputs included drug costs, administration costs, physician visit costs, and disease monitoring costs.",What were the model inputs considered in the budget impact analysis of different treatment regimens of brolucizumab in neovascular age-related macular degeneration (pmcid=10373014)?,"The model inputs considered in the budget impact analysis of different treatment regimens of brolucizumab in neovascular age-related macular degeneration (pmcid=10373014) were drug costs, administration costs, physician visit costs, and disease monitoring costs.",8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,"Outcomes in the budget impact model included the cost per member per month, annual health plan cost, and the US patient population-based annual cost.",What outcomes were included in the budget impact model (pmcid=10373014)?,"The outcomes included in the budget impact model were the cost per member per month, annual health plan cost, and the US patient population-based annual cost.",8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,"Based on the prevalence of nAMD in public and commercial health plans, a scenario analysis was conducted on the US population to account for the differences in the drug cost to the public and commercial payers.",What was the focus of the scenario analysis conducted on the US population (pmcid=10373014)?,The focus of the scenario analysis conducted on the US population in the study with pmcid=10373014 was to account for the differences in the drug cost to the public and commercial payers in the treatment of neovascular age-related macular degeneration (nAMD).,8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,"Further, 1-way sensitivity analyses were conducted to test model assumptions and uncertainty in model inputs.",What type of analyses were conducted to test model assumptions and uncertainty in model inputs (pmcid=10373014)?,1-way sensitivity analyses were conducted.,8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,RESULTS: The addition of brolucizumab to the formulary increased the net budgetary impact under PRN and T&E regimens.,What was the impact of adding brolucizumab to the formulary on the net budgetary impact under PRN and T&E regimens? (pmcid=10373014),The addition of brolucizumab to the formulary increased the net budgetary impact under PRN and T&E regimens.,8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,"The maximum increase in expenditure for a hypothetical health plan with 1 million enrollees was associated with the PRN regimen ($824,696), followed by the T&E regimen ($163,101).",What was the maximum increase in expenditure associated with the PRN regimen for a hypothetical health plan with 1 million enrollees (pmcid=10373014)?,"The maximum increase in expenditure associated with the PRN regimen for a hypothetical health plan with 1 million enrollees was $824,696.",8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,"In contrast, using the manufacturer-recommended and RWE regimens led to an annual saving of $93,068 and $94,170 for the health plan, respectively.",What were the annual savings for the health plan when using the manufacturer-recommended regimen for brolucizumab in neovascular age-related macular degeneration (pmcid=10373014)?,"The annual saving for the health plan when using the manufacturer-recommended regimen for brolucizumab in neovascular age-related macular degeneration was $93,068 (pmcid=10373014).",8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,"In the US patient population model, the introduction of brolucizumab resulted in savings in the manufacturer-recommended ($30.99 million) and RWE regimens ($31.35 million) but led to an increase in annual expenditures for the PRN ($274.58 million) and T&E ($54.30 million) regimens.",What were the annual expenditures for the PRN and T&E regimens following the introduction of brolucizumab in the US patient population model (pmcid=10373014)?,"The annual expenditures for the PRN regimen were $274.58 million, and for the T&E regimen, it was $54.30 million following the introduction of brolucizumab in the US patient population model.",8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,CONCLUSIONS: Payers need to evaluate the cost impact of different treatment regimens of existing and new anti-VEGFs when making formulary decisions in nAMD management.,What do payers need to evaluate when making formulary decisions in nAMD management? (pmcid=10373014),Payers need to evaluate the cost impact of different treatment regimens of existing and new anti-VEGFs when making formulary decisions in nAMD management.,8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,"DISCLOSURES: Mr Siddiqui, Ms Dhumal, Dr Patel, and Dr LeMasters have nothing to disclose.","What do Mr Siddiqui, Ms Dhumal, Dr Patel, and Dr LeMasters have to disclose? (pmcid=10373014)","Mr Siddiqui, Ms Dhumal, Dr Patel, and Dr LeMasters have nothing to disclose.",8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,"Dr Kamal has received research funding from Cerevel Therapeutics, served as a consultant to Pfizer/Cytel Inc, and received honoraria from Pharmacy Times Continuing Education.",What funding has Dr. Kamal received and from whom (pmcid=10373014)?,Dr. Kamal has received research funding from Cerevel Therapeutics.,8c9e23470d7e3893ef6c7f3a3174217c
10373014,Siddiqui ZA,Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis,2022,bim,Dr Almony has served as a consultant to Cardinal Health and received honoraria from Pharmacy Times Continuing Education and Prime Education.,What company has Dr. Almony served as a consultant to (pmcid=10373014)?,Cardinal Health,8c9e23470d7e3893ef6c7f3a3174217c
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"- BACKGROUND: In South Africa, diabetes prevalence is expected to reach 5.4 million by 2030.",What is the expected diabetes prevalence in South Africa by 2030 (pmcid=10442735)?,The expected diabetes prevalence in South Africa by 2030 is 5.4 million.,b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"In South Africa, diabetes-related complications severely impact not only patient health and quality of life but also the economy.",What does diabetes-related complications severely impact in South Africa (pmcid=10442735)?,"Diabetes-related complications severely impact patient health, quality of life, and the economy in South Africa.",b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,OBJECTIVE: The Diabetes Nurse Educator (DNE) study assessed the benefit of adding the MyDiaCare program to standard of care for managing patients with type 1 and type 2 diabetes in South Africa.,What benefit did the Diabetes Nurse Educator (DNE) study assess by adding the MyDiaCare program to standard of care for managing patients with type 1 and type 2 diabetes in South Africa (pmcid=10442735)?,The Diabetes Nurse Educator (DNE) study assessed the benefit of adding the MyDiaCare program to standard of care for managing patients with type 1 and type 2 diabetes in South Africa.,b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,An economic study was also performed to estimate the budget impact of adding MyDiaCare to standard of care for patients with type 2 diabetes older than 19 years treated in the South African private health care sector.,What was the purpose of the economic study mentioned in the abstract (pmcid=10442735)?,The purpose of the economic study mentioned in the abstract was to estimate the budget impact of adding MyDiaCare to the standard of care for patients with type 2 diabetes older than 19 years treated in the South African private health care sector.,b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"METHODS: The real-world DNE study was designed as an observational, retrospective, multicenter, single-group study.",What type of study design was used in the real-world DNE study (pmcid=10442735)?,"The real-world DNE study used an observational, retrospective, multicenter, single-group study design.",b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,Eligible patients were older than 18 years and had at least 6 months of participation in the MyDiaCare program.,What were the eligibility criteria for patients in the MyDiaCare program (pmcid=10442735)?,Patients in the MyDiaCare program had to be older than 18 years and have at least 6 months of participation.,b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,The MyDiaCare program combines a patient mobile app and a health care professional platform with face-to-face visits with a DNE.,What does the MyDiaCare program combine according to the abstract sentence (pmcid=10442735)?,The MyDiaCare program combines a patient mobile app and a health care professional platform with face-to-face visits with a Diabetes Nurse Educator (DNE).,b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"The benefit of MyDiaCare was assessed by the changes in glycated hemoglobin (HbA(1c)) levels, the proportion of patients achieving clinical and biological targets, adherence to care plans, and satisfaction after 6 months of participating in the MyDiaCare program.",What was assessed to determine the benefit of MyDiaCare in managing diabetes in South Africa (pmcid=10442735)?,"The benefit of MyDiaCare was assessed by the changes in glycated hemoglobin (HbA(1c)) levels, the proportion of patients achieving clinical and biological targets, adherence to care plans, and satisfaction after 6 months of participating in the MyDiaCare program.",b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,A budget impact model was performed using data from the DNE study and another South African cohort of the DISCOVERY study to estimate the economic impact of MyDiaCare.,What data was used to estimate the economic impact of MyDiaCare in the budget impact model (pmcid=10442735)?,Data from the DNE study and another South African cohort of the DISCOVERY study was used to estimate the economic impact of MyDiaCare in the budget impact model.,b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"RESULTS: Between November 25, 2019, and June 30, 2020, a total of 117 patients (8 with type 1 diabetes and 109 with type 2 diabetes) were enrolled in 2 centers.",What centers were involved in enrolling patients for the study (pmcid=10442735)?,Two centers were involved in enrolling patients for the study (pmcid=10442735).,b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"After 6 months of MyDiaCare, a clinically relevant decrease in mean HbA(1c) levels of 0.6% from 7.8% to 7.2% was observed.",What was the observed decrease in mean HbA(1c) levels after 6 months of MyDiaCare (pmcid=10442735)?,0.6%,b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Furthermore, 54% (43/79) of patients reached or maintained their HbA(1c) targets at 6 months.",What percentage of patients reached or maintained their HbA(1c) targets at 6 months in the study conducted by Makan H in South Africa (pmcid=10442735)?,54%,b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Most patients achieved their targets for blood pressure (53/79, 67% for systolic and 70/79, 89% for diastolic blood pressure) and lipid parameters (49/71, 69% for low-density-lipoprotein [LDL] cholesterol, 41/71, 58% for high-density-lipoprotein [HDL] cholesterol, and 59/71, 83% for total cholesterol), but fewer patients achieved their targets for triglycerides (32/70, 46%), waist circumference (12/68, 18%), and body weight (13/76, 17%).",What percentage of patients achieved their targets for blood pressure and lipid parameters in the study (pmcid=10442735)?,"For blood pressure, 67% of patients achieved their target for systolic blood pressure and 89% achieved their target for diastolic blood pressure. For lipid parameters, 69% achieved their target for low-density-lipoprotein (LDL) cholesterol, 58% for high-density-lipoprotein (HDL) cholesterol, and 83% for total cholesterol.",b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,The mean overall adherence to the MyDiaCare care plan was 93%.,What was the mean overall adherence to the MyDiaCare care plan (pmcid=10442735)?,The mean overall adherence to the MyDiaCare care plan in the study associated with pmcid 10442735 was 93%.,b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Most patients (87/117, 74%) were satisfied with the MyDiaCare program.",What percentage of patients were satisfied with the MyDiaCare program (pmcid=10442735)?,74%,b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"The net budget impact per patient with type 2 diabetes, older than 19 years, treated in the private sector using MyDiaCare was estimated to be approximately South African Rands (ZAR) 71,023 (US $4089) during the first year of introducing MyDiaCare.","What was the estimated net budget impact per patient with type 2 diabetes, older than 19 years, treated in the private sector using MyDiaCare during the first year of introducing MyDiaCare (pmcid=10442735)?","The estimated net budget impact per patient with type 2 diabetes, older than 19 years, treated in the private sector using MyDiaCare during the first year of introducing MyDiaCare was approximately South African Rands (ZAR) 71,023 (US $4089).",b9a0bd08700aa26e2dc455bb76035150
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"CONCLUSIONS: The results of using MyDiaCare program, which combines digital tools for patients and health care professionals with DNE support, suggest that it may be a clinically effective and cost-saving solution for diabetes management in the South African private health care sector.",What do the results suggest about the MyDiaCare program for diabetes management in the South African private health care sector (pmcid=10442735)?,"The results suggest that the MyDiaCare program, which combines digital tools for patients and health care professionals with Diabetes Nurse Educator (DNE) support, may be a clinically effective and cost-saving solution for diabetes management in the South African private health care sector.",b9a0bd08700aa26e2dc455bb76035150
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,"- OBJECTIVE: In Papua New Guinea (PNG), antenatal clinic attendance averaged 50% for one or more visits, and 30% for four visits in the last decade.",What was the average antenatal clinic attendance in Papua New Guinea in the last decade (pmcid=11603808)?,Antenatal clinic attendance in Papua New Guinea averaged 50% for one or more visits and 30% for four visits in the last decade.,b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,"In 2016, the WHO revised its focused antenatal care (ANC) model recommending eight rather than four visits.",What did the WHO revise in its focused antenatal care model in 2016 (pmcid=11603808)?,The WHO revised its focused antenatal care model in 2016 to recommend eight visits instead of four.,b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,"If implemented, this new model would require additional resources.",What would be required if the new model for delivering antenatal care in Papua New Guinea is implemented (pmcid=11603808)?,Additional resources would be required if the new model for delivering antenatal care in Papua New Guinea is implemented.,b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,"This study estimated provider costs of ANC in PNG, including the expected cost of scaling up to universal ANC coverage as well as recommending eight visits.",What did the study estimate the provider costs of in Papua New Guinea (pmcid=11603808)?,The study estimated the provider costs of antenatal care (ANC) in Papua New Guinea.,b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,"DESIGN AND SETTING: Cross-sectional estimation of ANC costs collected from nine health facilities, which were part of a cluster randomised trial.",What was the design and setting of the study (pmcid=11603808)?,The design and setting of the study was a cross-sectional estimation of antenatal care costs collected from nine health facilities that were part of a cluster randomised trial.,b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,Costs were estimated using both top-down and bottom-up approaches.,How were costs estimated in the study (pmcid=11603808)?,Costs were estimated using both top-down and bottom-up approaches.,b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,"The cost of the first and follow-up visits were estimated per woman, at the health facility level.",What was estimated per woman at the health facility level in the study (pmcid=11603808)?,The cost of the first and follow-up visits.,b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,Health system and scale-up costs of four visits were calculated by multiplying the aggregate cost of four visits by ANC utilisation rates.,What were the health system and scale-up costs of four visits calculated based on (pmcid=11603808)?,The health system and scale-up costs of four visits were calculated based on ANC utilisation rates by multiplying the aggregate cost of four visits.,b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,A budget impact analysis estimated the expected costs of delivering eight visits over 5 years.,What did the budget impact analysis estimate in relation to antenatal care delivery in Papua New Guinea (pmcid=11603808)?,The budget impact analysis estimated the expected costs of delivering eight visits over 5 years in relation to antenatal care delivery in Papua New Guinea.,b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,Univariate sensitivity analysis was conducted.,What type of analysis was conducted in the study (pmcid=11603808)?,Univariate sensitivity analysis,b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,Discounted costs are reported in local currency and 2019 international dollars using purchasing power parity data.,What currency were the discounted costs reported in for the study on delivering antenatal care in Papua New Guinea (pmcid=11603808)?,The discounted costs were reported in local currency for the study on delivering antenatal care in Papua New Guinea (pmcid=11603808).,b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,RESULTS: The average cost of the first and follow-up visits were $17.66-$30.58 (K42.94-K74.34) in Madang and $11.26-$35.61 (K27.37-K86.56) in East New Britain.,What were the average costs of the first and follow-up antenatal care visits in Madang and East New Britain (pmcid=11603808)?,"The average cost of the first and follow-up antenatal care visits in Madang ranged from $17.66 to $30.58 (K42.94 to K74.34), while in East New Britain, the average cost ranged from $11.26 to $35.61 (K27.37 to K86.56).",b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,Four visits per woman cost $70.65-$122.33 (K171.76-K297.36) in Madang and $45.02-$142.45 (K109.50-K346.4) in East New Britain; and salaries represented the largest share of costs.,What was the cost range for four antenatal care visits per woman in Madang and East New Britain (pmcid=11603808)?,"In Madang, the cost range for four antenatal care visits per woman was $70.65-$122.33 (K171.76-K297.36). In East New Britain, the cost range was $45.02-$142.45 (K109.50-K346.4).",b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,"The annual health system cost was $6.9 million (K16.9 million), the expected cost of scaling up to the universal coverage of four visits was $22.7 million (K55.2 million), and $45.4 million (K110.3 million) over 5 years for eight visits.",What were the expected costs for scaling up to universal coverage of antenatal care visits in Papua New Guinea over 5 years (pmcid=11603808)?,The expected cost for scaling up to universal coverage of antenatal care visits in Papua New Guinea over 5 years was $45.4 million (K110.3 million).,b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,"CONCLUSION: Costs varied with the number of clinicians, infrastructure and ANC coverage, suggesting scaling up requires increasing the financial investment in ANC services.",What does the conclusion suggest about scaling up antenatal care services in Papua New Guinea (pmcid=11603808)?,"The conclusion suggests that scaling up antenatal care services in Papua New Guinea would require increasing the financial investment in ANC services, as costs varied with the number of clinicians, infrastructure, and ANC coverage.",b454d6d9d2173b9d05087f5ba07d3c30
11603808,Saweri OP,What does it cost to deliver antenatal care in Papua New Guinea? Results from a health system costing and budget impact analysis using cross-sectional data,2024,bim,These results provide a template to strengthen health systems by improving the quality of care.,What do the results provide a template for in terms of strengthening health systems (pmcid=11603808)?,The results provide a template for strengthening health systems by improving the quality of care.,b454d6d9d2173b9d05087f5ba07d3c30
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,- BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a progressive debilitating condition with frequent exacerbations that have a high burden for patients and society.,What is the burden of frequent exacerbations in patients with COPD (pmcid=10240705)?,The burden of frequent exacerbations in patients with COPD is high for both the patients and society.,31527da269cedd662fbeb3d9ce8994a7
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,Digital tools may help to reduce the economic burden for patients and payers by improving outcomes.,What may digital tools help to reduce for patients and payers (pmcid=10240705)?,Digital tools may help to reduce the economic burden for patients and payers.,31527da269cedd662fbeb3d9ce8994a7
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,"The Propeller platform is a digital self-management tool that facilitates passive monitoring of inhaler medication utilization, potentially assisting the healthcare team to identify patients at risk of a COPD exacerbation who may require further intervention.",What is the digital self-management tool mentioned in the abstract (pmcid=10240705)?,The digital self-management tool mentioned in the abstract is the Propeller platform.,31527da269cedd662fbeb3d9ce8994a7
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,This study estimated the budget impact of Propeller from commercial payer and Medicare fee-for-service payer perspectives.,What perspectives were considered in estimating the budget impact of Propeller in this study (pmcid=10240705)?,The perspectives considered in estimating the budget impact of Propeller in this study were the commercial payer and Medicare fee-for-service payer perspectives.,31527da269cedd662fbeb3d9ce8994a7
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,METHODS: An Excel-based model was used to estimate the budget impact of Propeller for COPD patients in commercial and Medicare population sizes of 5 million members.,What model was used to estimate the budget impact of Propeller for COPD patients (pmcid=10240705)?,An Excel-based model was used.,31527da269cedd662fbeb3d9ce8994a7
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,"Data on prevalence, baseline healthcare resource utilization (HCRU), and baseline use of rescue and controller inhaler medications with unit costs (adjusted to 2020 US dollars) were obtained from peer-reviewed literature.",What data were obtained from peer-reviewed literature for the budget impact analysis of a digital monitoring platform for COPD (pmcid=10240705)?,"Prevalence, baseline healthcare resource utilization (HCRU), and baseline use of rescue and controller inhaler medications with unit costs (adjusted to 2020 US dollars) were obtained from peer-reviewed literature for the budget impact analysis of a digital monitoring platform for COPD.",31527da269cedd662fbeb3d9ce8994a7
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,Data on reductions in HCRU during Propeller usage were based on direct evidence.,What were the data on reductions in HCRU based on during Propeller usage (pmcid=10240705)?,Data on reductions in HCRU during Propeller usage were based on direct evidence.,31527da269cedd662fbeb3d9ce8994a7
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,Estimates for costs of remote monitoring were obtained from publicly available information.,What estimates were obtained for costs of remote monitoring (pmcid=10240705)?,Estimates for costs of remote monitoring were obtained from publicly available information.,31527da269cedd662fbeb3d9ce8994a7
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,All patients were assumed to have insurance claims related to ongoing remote monitoring.,What insurance claims were assumed for all patients in the study (pmcid=10240705)?,Insurance claims related to ongoing remote monitoring were assumed for all patients in the study (pmcid=10240705).,31527da269cedd662fbeb3d9ce8994a7
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,"RESULTS: The estimated number of annual eligible COPD patients for commercial and Medicare was 212,200 and 606,600, respectively.",What was the estimated number of annual eligible COPD patients for commercial and Medicare (pmcid=10240705)?,"The estimated number of annual eligible COPD patients for commercial and Medicare was 212,200 and 606,600, respectively.",31527da269cedd662fbeb3d9ce8994a7
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,"Propeller decreased costs by an estimated $2,475 (commercial) and $915 (Medicare) per enrolled patient.",How much did Propeller decrease costs by per enrolled patient? (pmcid=10240705),"Propeller decreased costs by an estimated $2,475 (commercial) and $915 (Medicare) per enrolled patient.",31527da269cedd662fbeb3d9ce8994a7
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,The greatest increase in expenditure was for remote monitoring related expenses.,What was the greatest increase in expenditure for in the budget impact analysis of a digital monitoring platform for COPD (pmcid=10240705)?,The greatest increase in expenditure was for remote monitoring related expenses.,31527da269cedd662fbeb3d9ce8994a7
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,"After accounting for estimated reductions in hospitalizations, emergency department visits and short-acting beta-agonist use, total net savings were approximately $1.60 and $1.70 per-member per-month for commercial and Medicare payers, respectively.","What were the total net savings per-member per-month for commercial and Medicare payers after accounting for estimated reductions in hospitalizations, emergency department visits, and short-acting beta-agonist use (pmcid=10240705)?","The total net savings per-member per-month were approximately $1.60 for commercial payers and $1.70 for Medicare payers after accounting for estimated reductions in hospitalizations, emergency department visits, and short-acting beta-agonist use.",31527da269cedd662fbeb3d9ce8994a7
10240705,Inocencio TJ,Budget impact analysis of a digital monitoring platform for COPD,2023,bim,CONCLUSION: Propeller is projected to be cost saving from both the commercial and Medicare payer perspectives.,What is the projected cost savings of Propeller from both the commercial and Medicare payer perspectives? (pmcid=10240705),Propeller is projected to be cost saving from both the commercial and Medicare payer perspectives.,31527da269cedd662fbeb3d9ce8994a7
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"- BACKGROUND: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, progressive autoimmune disease causing peripheral nervous system dysfunction.",What is the background information provided in the abstract sentence (pmcid=9910243)?,"Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, progressive autoimmune disease causing peripheral nervous system dysfunction.",0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Guidelines recommend immunoglobulin (IG) therapy as an immunomodulatory agent in CIDP.,What do guidelines recommend as an immunomodulatory agent in CIDP? (pmcid=9910243),Immunoglobulin (IG) therapy,0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Drawbacks and unmet needs with intravenous immunoglobulin (IVIG) include adverse effects and wear-off effects, along with the burden of administration based on site of care.",What are some drawbacks and unmet needs associated with intravenous immunoglobulin (IVIG) according to the abstract sentence provided? (pmcid=9910243),"Some drawbacks and unmet needs associated with intravenous immunoglobulin (IVIG) include adverse effects, wear-off effects, and the burden of administration based on site of care.",0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Subcutaneous administration of Hizentra, a subcutaneous immunoglobulin (SCIG) reduces patient burden by allowing self-administration outside the hospital setting and has fewer adverse events (AEs).",What is the advantage of subcutaneous administration of Hizentra mentioned in the abstract (pmcid=9910243)?,The advantage mentioned in the abstract is that subcutaneous administration of Hizentra reduces patient burden by allowing self-administration outside the hospital setting and has fewer adverse events (AEs).,0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,OBJECTIVE: We aimed to compare the expected cost of treatment and the budget impact of Hizentra compared with IVIG for maintenance treatment of CIDP in the United States.,What was the objective of the study (pmcid=9910243)?,The objective of the study with pmcid=9910243 was to compare the expected cost of treatment and the budget impact of Hizentra compared with IVIG for maintenance treatment of CIDP in the United States.,0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,METHODS: A decision tree model was developed to estimate the expected budget impact of maintenance treatment with Hizentra for US stakeholders.,What type of model was developed to estimate the expected budget impact of maintenance treatment with Hizentra for US stakeholders (pmcid=9910243)?,A decision tree model was developed.,0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"The model adopts primarily a US integrated delivery network perspective and, secondarily, a commercial perspective over a 1-year time horizon.",What perspective does the budget impact model adopt primarily and secondarily (pmcid=9910243)?,The budget impact model adopts primarily a US integrated delivery network perspective and secondarily a commercial perspective.,0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Pharmacy costs were based on a payment mix of average sales price (73%), wholesale acquisition cost (2%), and average wholesale price (25%).",What were the pharmacy costs based on in the study (pmcid=9910243)?,"The pharmacy costs in the study (pmcid=9910243) were based on a payment mix of average sales price (73%), wholesale acquisition cost (2%), and average wholesale price (25%).",0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Costs in the model reflect 2022 US dollars.,What do the costs in the model reflect? (pmcid=9910243),The costs in the model reflect 2022 US dollars.,0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"In accordance with the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines and recommendations for budget impact modeling, no discounting was performed.",What guidelines and recommendations were followed for the budget impact modeling in the study (pmcid=9910243)?,The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines and recommendations were followed for the budget impact modeling in the study (pmcid=9910243).,0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,The PATH clinical study of Hizentra maintenance in CIDP was used to determine clinical inputs for relapse rates at initial assessment (24 weeks) and at 52 weeks for Hizentra.,What study was used to determine clinical inputs for relapse rates at initial assessment and at 52 weeks for Hizentra (pmcid=9910243)?,The PATH clinical study was used to determine clinical inputs for relapse rates at initial assessment and at 52 weeks for Hizentra in the study with pmcid 9910243.,0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,The ICE clinical study of Gamunex maintenance in CIDP was the basis of relapse rates for Gamunex (and other IVIGs).,What was the basis of relapse rates for Gamunex (and other IVIGs) in the ICE clinical study of CIDP (pmcid=9910243)?,The basis of relapse rates for Gamunex (and other IVIGs) in the ICE clinical study of CIDP (pmcid=9910243) was the Gamunex maintenance.,0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Literature-based estimates were obtained for infusion costs by site of care, costs of IVIG infusion-related complications, and significant IVIG AE rates.","What estimates were obtained for infusion costs by site of care, costs of IVIG infusion-related complications, and significant IVIG AE rates? (pmcid=9910243)","Literature-based estimates were obtained for infusion costs by site of care, costs of IVIG infusion-related complications, and significant IVIG AE rates.",0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Hizentra AE rates from the US Hizentra prescribing information were assessed but were not included in the model as the AEs in CIDP were mild, easily treated, and self-limited.",What were the adverse event rates assessed for Hizentra in the United States (pmcid=9910243)?,"The adverse event rates assessed for Hizentra in the United States were not included in the model as the adverse events in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) were mild, easily treated, and self-limited.",0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Sensitivity analyses and scenario analyses were conducted to evaluate variations from the base case.,What type of analyses were conducted to evaluate variations from the base case in the study on maintenance treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) relative to Intravenous Immunoglobulin in the United States (pmcid=9910243)?,Sensitivity analyses and scenario analyses were conducted to evaluate variations from the base case in the study on maintenance treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) relative to Intravenous Immunoglobulin in the United States.,0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"RESULTS: The model showed that a Hizentra starting dose of 0.2 g/kg is expected to result in annual cost savings of US$32,447 per patient compared with IVIG.",What annual cost savings per patient are expected with a Hizentra starting dose of 0.2 g/kg compared with IVIG (pmcid=9910243)?,"The annual cost savings per patient expected with a Hizentra starting dose of 0.2 g/kg compared with IVIG is US$32,447 (pmcid=9910243).",0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"For a hypothetical 25-million-member plan, the budget impact of a 10% market share shift from IVIG to Hizentra is expected to result in savings of US$2,296,235.",What is the expected savings for a hypothetical 25-million-member plan with a 10% market share shift from IVIG to Hizentra (pmcid=9910243)?,"The expected savings for a hypothetical 25-million-member plan with a 10% market share shift from IVIG to Hizentra is US$2,296,235.",0eb6e7a4840c62b6e41d362d0327fe6b
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,CONCLUSION: This analysis projects that Hizentra is likely associated with favorable economic benefit compared with IVIG in managing CIDP.,What does the analysis project regarding the economic benefit of Hizentra compared to IVIG in managing CIDP? (pmcid=9910243),The analysis projects that Hizentra is likely associated with favorable economic benefit compared with IVIG in managing CIDP.,0eb6e7a4840c62b6e41d362d0327fe6b
